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Abstract 
 
Growth factors are important signalling molecules in regenerative medicine and tissue 
engineering, but their inherent instability, lasting only minute to hours in vivo, presents an 
obstacle to sustained and controlled delivery. This is particularly difficult to achieve in the 
brain, where the blood brain barrier (BBB) prevents systemic delivery. For this reason, much 
research is currently directed at incorporating growth factors into supportive tissue 
engineering materials that mimic the natural extracellular matrix (ECM). In this case 
temporally controlled and sequential delivery must come from selectively delaying the release 
of some growth factors from the material. Here, we aim to develop novel growth factor 
delivery systems to provide temporally controlled growth factor delivery from self-
assembling peptide (SAP) hydrogel materials specifically. 
We use minimalist and tissue-specific Fmoc-SAP hydrogels, a novel class of material 
designed around biologically recognisable peptide sequences, engineered to self-assemble at 
physiological conditions into supportive nanofibres. We demonstrate the biocompatibility of 
three distinct sequences in vivo with cell grafts into an intact brain, as well as the tissue-
specificity of the materials, with the brain protein laminin derived SAPs showing superior 
performance. We also demonstrate their ability to improve cell graft treatment efficacy in an 
ischemic brain injury in rats, showing improved sensorimotor recovery, increased neuronal 
differentiation, and reduced cortical atrophy compared to the unsupported cell graft 
treatment.  
We demonstrate that these materials stabilise growth factors to provide sustained delivery, 
with release detected out to 6 weeks. Sustained delivery of growth factors is a common goal 
in growth factor delivery, and here we go beyond that by providing novel systems for 
temporally controlled delivery, allowing the sequential delivery of multiple growth factors 
vi 
required to achieve their full therapeutic potential. We have successfully demonstrated 
systems to provide a short delay of 4 hours, a long delay of 6 days, and stimuli-responsive 
control of the delivery profiles. Covalent attachment of the polysaccharide chitosan to the 
growth factor increased physical associations with the SAP nanofibres, delaying its release by 
4 hours. Using emulsion electrospinning to create polymer nanofibres loaded with growth 
factor, we then cut short fibres to mix into the SAP hydrogel. The polymer provided an 
additional barrier to diffusion, delaying the release from the hydrogel by 6 days. Covalent 
attachment of growth factor to UV-sensitive nanoparticles allowed for counter-intuitive 
control over growth factor delivery, with UV exposure reducing the growth factor released. 
We were also able to use this system to tune the shape of the temporal release profile to 
provide a constant dose delivery with no initial burst. These novel systems demonstrate an 
improved level of control of growth factor delivery without sacrificing the tissue engineering 
material properties, and represent a significant contribution to the field of tissue engineering. 
vii 
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1.1 Background 
Regenerative medicine, or tissue engineering, relies on the formation of new tissue from 
exogenous or endogenous cells. To encourage this new growth within damaged tissue, tissue 
engineering scaffold materials are used to support the cells and provide physical, chemical, 
and biological cues to guide cell growth and differentiation. These cues are designed to mimic 
the extracellular matrix (ECM) environment of healthy tissue, which provides support and 
guidance to cells in healthy tissue. 
1.1.1 The Extracellular Matrix (ECM) 
The extracellular matrix is a complex aqueous environment surrounding and connecting 
cells. It is composed of water, proteins, and polysaccharides and structurally speaking the 
two major components are cellularly secreted fibrous proteins and proteoglycan hydrogels.1 
The ECM interacts dynamically with cells, with each affecting the other.1 As such, the exact 
nature of the ECM is different in different tissues, and reciprocally the tissue specific 
properties of the ECM affect cell behaviour. When using tissue engineering materials as a 
synthetic ECM, tuning these properties can be used to can direct cell fate. Stiffness is an 
excellent example of the tissue-specificity of the ECM and of how ECM properties can direct 
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cell fate. It is obvious that different tissue types have different stiffnesses, with bone tissue, 
for example, being much stiffer/harder than brain tissue, which is comparatively soft. Naïve 
mesenchymal stem cells (MSCs) grown on similar materials varying only in stiffness were 
effectively directed into neurogenic, myogenic, and osteogenic cell types.2 Similarly cells 
grown in 3D environments compared to traditional 2D culture plates show more in vivo like 
behaviour,3 with the specific morphology/topography capable of improving or directing cell 
growth, for instance with parallel aligned nanofibres to promote neurite extension via contact 
guidance.4 And of course, the ECM also provides biological signals specific to the individual 
tissue and to regulate processes required for morphogenesis or homeostasis.1 Early in this 
thesis the effect on cell fate of distinct biological epitopes from different tissue specific 
proteins is investigated, while the goal of this thesis is to engineer methods for controlling 
the delivery of growth factors, which are used within the ECM to allow intercellular 
communication, initiating signal transduction and regulating gene transcription.1  
1.1.2 Tissue Engineering Materials 
There are many types of tissue engineering materials currently being explored and 
developed, all with pros and cons. Natural materials can provide more biological cues and 
mimicry, while synthetic materials are more easily controlled and customised. In all cases 
mimicking the nature of the ECM is desired, and as such nanofibrous materials and hydrogels 
(mimicking the two major structural components of the ECM) are very common. 
Electrospinning is a popular approach for the development of nanofibrous materials due to 
its simplicity, low cost, and versatility.5 The method produces a sheet of overlapping 
nanofibres, providing a 3D microenvironment for cells despite macroscopically appearing as 
a 2D sheet, and are therefore well suited for bandaging and wrapping applications. Hydrogels 
provide an aqueous environment analogous to that of the ECM and their flexible 3D 
structure makes them suited for implantation in 3D voids or injury sites. Many hydrogel 
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materials also undergo shear-thinning,6  meaning that they can flow readily through a needle 
and reform in situ to perfectly fit a void and fully interface with surrounding tissue.  
The materials used throughout this thesis, self-assembling peptide (SAP) hydrogels, are a 
semi-synthetic material presenting nanofibrous structures within a fluid hydrogel 
environment. Most hydrogel materials are formed from an interconnected network of 
hydrated molecular chains. In SAP hydrogels, however, the network forms between 
comparatively large supramolecular assemblies rather than individual molecules, meaning 
that the interconnecting fibres exist on a biologically structurally relevant scale (~10 nm 
diameter).7-9 The material provides the nanofibre morphology, while also providing an 
aqueous hydrogel environment with shear-thinning capability to allow it to fill an irregular 
3D void or injury site. Specifically, SAP materials designed around biologically relevant 
peptide sequences are used here to provide the biomimicry of natural materials. The specific 
peptide composition makes the material inherently biocompatible, with biocompatible 
degradation by-products.8 Meanwhile, the minimalist bottom-up fabrication of the materials, 
consisting of a specific peptide molecule synthesised from individual amino acids, makes 
their material composition and properties controllable like synthetic materials.  
1.1.3 Growth Factors in Regenerative Medicine  
Growth factors are natural proteins and important signalling molecules in regenerative 
medicine. They exist in the ECM, either bound to other ECM proteins or soluble within the 
aqueous environment, to bind to receptors on the cell surface to initiate biological 
processes.10 In regenerative medicine they encourage growth of new tissues and specific cell 
types. Unlike the tissue engineering materials, which provide constant support, growth 
factors can be used to encourage different activities at different stages of regeneration. For 
example, for angiogenesis, first vascular endothelial growth factor (VEGF), fibroblast growth 
factor (FGF), and angiopoietin-2 can be used to provide disrupt pre-existing blood vessels 
and induce migration to form new ones, then angiopoietin-1 and platelet derived growth 
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factor BB (PDGF-BB) can be used to stabilise newly formed blood vessels.11 Biological 
processes require growth factors not just in a specific order, but with specific timing as well. 
For example, demyelination involves many growth factors with different temporal 
presentation profiles in the cortex, including initial presentation lasting 2 weeks for glial cell 
line derived neurotrophic factor (GDNF), initial and sustained presentation of FGF-2, and 
delayed presentation starting after 1 week for transforming growth factor beta-1 (TGF-β1).12 
However, growth factors are inherently short-lived, and in vivo enzymatic degradation results 
in very short growth factor half-lives, as low as 3 min for basic fibroblast growth factor 
(bFGF)13 and 45 min for nerve growth factor (NGF).14 
1.1.4 Drug (including Growth Factor) Delivery in the Brain  
Neurotrophic growth factors have demonstrated great potential for neural tissue 
regeneration, where these is limited capacity for healing, in both promoting regeneration and 
delaying disease progression.15,16 Brain-derived neurotrophic factor (BDNF),17 nerve growth 
factor (NGF),18 and GDNF19 have all been used in vivo to support cells and slow the 
progression of neurodegenerative disorders. The use of growth factors can also prevent 
secondary degeneration after injury or stroke by protecting the surrounding parenchyma.15 
However, growth factor delivery to brain tissue is particularly challenging.  
Systemic drug delivery to the brain is hampered by the blood brain barrier (BBB), a 
selective membrane that prohibits most drugs in the bloodstream from entering the brain 
based on chemical structure and size.20 Strategies do exist to overcome this obstacle, such as 
the use of prodrugs, a modified form of the drug being delivered with chemical properties 
(i.e.: lipophilicity) at all it to pass through the selective BBB and then undergo reactions into 
the active form of the drug on the other side.20 This allows drugs to bypass the chemical 
specificity of the BBB, but not the size exclusivity. Growth factors are protein molecules and 
comparatively large (e.g.: 27 kDa for BDNF) relative to standard pharmaceutical drug 
molecules like the prodrug L-DOPA (0.197 kDa). There are also methods of disrupting the 
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BBB, such as with pulsed lasers,21 but this removes all selectivity, preventing the BBB from 
performing its useful function. In both cases, the delivery occurs from the bloodstream, 
meaning there is time for growth factor degradation to occur and the chance for off target 
side effects.10 Currently direct delivery is achieved with implanted mechanical micro pumps 
or indwelling cannulas, which are highly invasive.22 While these methods are not well suited 
for regenerative medicine applications focusing on natural tissue growth to repair, they do 
all offer a high degree of temporal control, as drugs can be administered sequentially or 
devices programmed for different delivery patterns. That level of temporal control is highly 
desirable, and tissue engineering materials will not be able to operate fully independently until 
they can provide a similar level of control. For this reason, temporally controlled growth 
factor delivery from tissue engineering materials is a growing research field, with a focus on 
achieving complex delivery patterns (i.e.: multiple growth factors delivered with distinct 
delivery profiles from the same material).22 Current techniques of incorporating drug delivery 
into tissue engineering materials, examined in detail in Literature Review (Chapter Two) of 
this thesis, generally rely on modifying the tissue engineering material to control release. This 
approach limits their ability to deliver multiple independently controlled drugs and potentially 
detracts from their material function as ECM mimics.  
1.2 Thesis Outline 
1.2.1 Hypothesis 
We hypothesize that SAP hydrogels can be used to provide a greater degree of temporal 
control of growth factor delivery. This thesis investigates SAP material properties and their 
interactions with other chemicals to design improved growth factor delivery systems. 
Specifically, we hypothesise that these systems will be able to provide distinct options for 
temporally controlling the delivery of growth factors beyond the stabilised and sustained 
delivery common in the field while maintaining the biomimetic properties of the SAP 
hydrogels.  
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1.2.2 Thesis Aims 
This thesis describes work investigating SAP materials and strategies to use them to 
provide temporally controlled delivery of growth factors. The work focuses on applications 
in brain tissue repair, where growth factor delivery is particularly challenging. The overall aim 
is to increase the diversity of growth factor delivery/release profiles options from SAP 
materials, and for this thesis delivery strategies for three distinct modified profiles have been 
developed, in addition to the sustained delivery achieved from unmodified growth factor 
mixed with unmodified SAP hydrogel: 
Short (Hours) Delay 
Growth factor release from the SAP hydrogel is delayed for a short time, several hours, 
relative to the unmodified growth factor. To achieve this a polysaccharide molecule, chitosan, 
is covalently attached to the growth factor to create a bulkier growth factor with increased 
interactions with the SAP fibres causing it to remain in hydrogel longer before diffusing out. 
This achievement is discussed in full in Chapter Six. 
Long (Days) Delay 
Growth factor release from the SAP hydrogel is delayed for a long time, several days, 
relative to the unmodified growth factor. To achieve this the growth factor was mixed into 
electrospun nanofibres via emulsion electrospinning, and the electrospun scaffold was cut 
into short loose fibres that were mixed into the SAP hydrogel. The growth factor in the 
electrospun fibres was extensively delayed due to the time required to first diffuse from the 
fibres into the SAP hydrogel environment, and only then from the SAP hydrogel into the 
surrounding environment. This achievement is discussed in full in Chapter Eight. 
Stimuli Responsive 
The temporal profile of growth factor release from the SAP hydrogel is controlled by 
external stimulation in a counter-intuitive way. To achieve this the growth factor was 
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covalently attached to titanium dioxide (TiO2) nanoparticles via a UV-sensitive coating. The 
nanoparticle bound growth factor displayed a unique release profile relative to that of free 
growth factor regardless of UV stimulation, and by controlling UV exposure the release 
profile was also controlled. The nanoparticles diffused out of the hydrogel irrespective of 
UV exposure, but the UV exposure affected the amount of growth factor that remained 
bound to and therefore was release with the nanoparticles. The UV caused the growth factor 
to leave the nanoparticle and become free to interact with and physically adsorb to the SAP 
nanofibres, with that adsorption slowing their release. For this reason, UV exposure 
decreased the growth factor released rather than increasing it, as is the normal approach for 
photo-triggered drug delivery. This system was also used to tune the shape of the release 
profile rather than delaying it. The increasing release rate observed from the nanoparticles 
was adjusted via UV exposure to a constant rate of delivery with no initial burst. This 
achievement is discussed in full in Chapter Nine. 
1.2.3 Thesis Structure 
Chapter Two-Chapter Four provide background information. Chapter Two comprises a 
literature review of common tissue engineering materials and current methods of 
incorporating growth factor and other drug delivery strategies.  In writing this review I was 
able to identify common themes in delivery strategies as well as the areas currently lacking, 
specifically achieving temporal control beyond sustained delivery while maintaining material 
properties of the base tissue engineering material. Chapter Three covers all the methods used 
for the work discussed through this thesis, and Chapter Four discusses work to which I 
contributed evaluating the SAP materials for their biocompatibility and efficacy in treatments 
in vivo.  
The heart of the novelty and advancement of the field described in this thesis is covered 
in Chapter Six, Chapter Eight, and Chapter Nine, which cover the research led by me to 
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develop innovate methods of temporally controlled growth factor delivery from SAP 
hydrogels, achieving short delay, long delay, and stimuli responsive delivery respectively.  
Chapter Five and Chapter Six discuss the work done to achieve temporally controlled 
growth factor delivery in the form of a short (hours) delay in release from the SAP hydrogel, 
as well as the unmodified delivery profile obtained from unmodified growth factors diffusing 
out of an unmodified SAP hydrogel. Chapter Six discusses this achievement itself, while 
Chapter Five discusses projects in which I was involved that provided the insights to achieve 
the work done in Chapter Six, investigating physical associations between SAP nanofibres 
and other, non-growth factor therapeutic agents. Chapter Six also includes a discussion on 
improved presentation of drug delivery data, focusing on release rates rather than cumulative 
release, which is done throughout this thesis. 
Chapter Seven and Chapter Eight discuss work done to achieve temporally controlled 
growth factor delivery in the form of a long (days) delay in release from the SAP hydrogel. 
Chapter Eight discusses this achievement itself, while Chapter Seven discusses projects in 
which I was involved working on growth factor incorporation into electrospun materials that 
allowed for a composite material to be developed for the growth factor delivery described in 
Chapter Eight.  
Chapter Nine discusses the work done to achieve stimuli-responsive temporal control of 
growth factor delivery. This work is fully contained in one chapter. 
Finally, Chapter Ten discusses the overall conclusions from the thesis as well as future 
perspectives for this work and the field. The appendices include supplementary information 
for Chapter Six (Appendices A), as well as full published works to which I have contributed, 
including work discussed only briefly in this thesis (Appendices B-E) and additional work 
combining different sequence SAP hydrogels not discussed in this thesis (Appendix F). 
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2.1 Chapter Details 
This chapter provides a review of current approaches to drug delivery, and specifically 
growth factor delivery, from tissue engineering materials. This chapter is also a review article 
manuscript in preparation.   
2.2 Abstract 
Tissue engineering scaffolds are designed to mimic physical, chemical, and biological 
features of the extracellular matrix (ECM), thereby providing a constant static support that 
is crucial to improved regenerative medicine outcomes. Beyond mechanical and structural 
support, the next generation of these materials must also consider the dynamic presentation 
and delivery of drugs or growth factors to guide new and regenerating tissue development. 
These two aspects have been explored expansively separately, but they must interact 
synergistically to achieve optimal regeneration. This review explores common tissue 
engineering materials types, electrospun polymers and hydrogels, and strategies used for 
incorporating drug delivery systems into these scaffolds. 
Chapter Two 
Literature Review 
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2.3 Introduction 
The goal of tissue engineering for regenerative medicine is to stimulate the growth of new, 
healthy tissue. Strategies to achieve this include encouraging the activation of host cells for 
the repair of damaged tissue or tissue replacement with new cells via cell replacement therapy 
(CRT).23 In either case, specifically designed tissue engineering materials or scaffolds are used 
to mimic the natural extracellular matrix (ECM) and provide an intermediate supportive 
environment. The material degrades away as it is replaced by new, healthy ECM from 
regenerating tissue.  
The ECM is an incredibly complex aqueous environment that connects individual cells 
within a tissue, both structurally and functionally. Nanofibrous structural proteins are a major 
component of the ECM,1 and cell behaviours are heavily influenced by cues from the 
surrounding microenvironment, provided by the tissue-specific ECM.24 These cues vary 
widely, including physical, chemical, and biological properties. For cells to behave as they 
would in healthy ECM, the synthetic scaffolds must be as mimetic as possible of the desired 
tissue’s ECM.25 
Much research has been done investigating and optimising one material property at a time 
to mimic the ECM. For example, extensive work has been done tuning material stiffness2,26 
and the nano-/microscale morphology,27 and these properties have both been shown to 
significantly affect cell differentiation and proliferation.28,29 While tuning an individual 
biochemical or physical cue can enable study of its effect in isolation and enhance material 
performance, multiple biomimetic cues often have a synergistic effect, such that the overall 
benefit is greater than the combined individual benefits.29,30 This makes it important to 
include and optimise as many aspects of the ECM as synthetically possible to achieve the 
greatest therapeutic benefit.  
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While tissue engineering materials are designed with degradation in mind, this can be over 
a relatively long timescale (months to years) so in the context of drug delivery the long-term 
materials can be considered static compared to growth factors and other drugs. They provide 
a constant, static, environment that is mimetic of the ECM and supportive of new tissue 
growth and regeneration. Another important factor in directing cell growth and behaviour is 
the more dynamic presentation of secreted, soluble growth factors into the ECM.24 Growth 
factors are protein signalling molecules that have an important role in determining cell fate 
and behaviour, and they are inherently short-lived10 in the order of minutes to hours.31 
Different growth factors are needed at different stages of tissue growth/regeneration, and 
the order and timing of their delivery is important.11 For example, for angiogenesis, 
angiopoietin-1 and platelet derived growth factor BB (PDGF-BB) stabilise newly formed 
blood vessels after vascular endothelial growth factor (VEGF), fibroblast growth factor 
(FGF), and angiopoietin-2 provide the disruption of pre-existing vessels and migration to 
form new immature vessels.11 Furthermore, in neuroscience applications epidermal growth 
factor (EGF), which increases proliferation of neural stem/progenitor cells (NSPs), is best 
delivered initially for 7 days, followed by erythroprotein (EPO) to protect and reduce 
apoptosis in the new cells.22 In addition to the order of delivery, different growth factors 
require different durations. The demyelination process, for example, involves many growth 
factors with different temporal presentation profiles in the cortex, including: initial 
presentation lasting 2 weeks for glial cell line derived neurotrophic factor (GDNF), initial 
sustained presentation for FGF-2, and delayed presentation starting after 1 week for 
transforming growth factor beta-1 (TGF-β1).12 While designing static ECM mimetic 
materials focuses on ongoing presentation of biological cues, here a variety of presentation 
or delivery profiles is required to create the optimal dynamic environment for tissue 
regeneration.   
To provide this dynamic environment, growth factors, and other drugs, are being 
incorporated into tissue engineer materials. When developing drug delivery strategies, there 
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are several important issues that need to be considered. Drugs, including growth factors, 
function best at doses within a therapeutic window; concentrations above this window can 
be toxic or produce harmful side effects, while lower concentrations can be ineffective.10,32 
This means a design consideration needs to be the control of the timing and rate of the drug 
delivery, whilst being mindful of its in situ properties. In particular, protein growth factors 
require sustained presentation, yet are unstable in a physiological environment and degrade 
within minutes to hours.14,31,33 in vivo, enzymatic degradation results in very short growth 
factor half-lives, as low as 3 min for basic fibroblast growth factor (bFGF)13 and 45 min for 
nerve growth factor (NGF).14 It is also important to consider the delivery or release profile; 
most commonly a sustained release is desirable34 but sometimes a burst release is required 
for immediate response or a pulsatile release is required to mimic natural processes.32 The 
delivery site is another major consideration, as drugs can have negative side effects to non-
target tissues.20  
In an effort to control drug dosage, maximise delivery, and reduce cytotoxicity, the 
targeted delivery of drugs to the site of therapeutic need is an area of intense research focus.20 
Delivery and targeting methods are becoming increasingly specific; for example, in cancer 
treatment, shielded cytotoxic chemotherapy drugs that are detrimental to the surrounding 
healthy tissue, can be introduced globally into the blood stream where they undergo localised 
and selective release only around cancerous cells.35 Localisation of drug delivery can also be 
achieved simply by incorporating the drug delivery system into a tissue engineering material, 
as we are discussing here. The tissue engineering material must be implanted at the specific 
injury or disease site, providing a base for highly localised drug delivery. This is particularly 
advantageous for regeneration of tissues shielded from the bloodstream, such as the brain, 
which is protected from systemic drug delivery by a highly selective membrane called the 
blood brain barrier (BBB).20 Sustained and controlled delivery to the brain can be achieved 
using intracerebroventricular (ICV) infusion or micropumps, however, this is very invasive 
and causes significant tissue damage as well as the chance of potentially fatal infection so 
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much research has focused on using tissue engineering scaffolds as growth factor delivery 
vehicles as well.22,36 
Tissue engineering materials can be used as a reservoir for sustained and controlled drug 
delivery as they are minimally invasive (small implants or injections) and their 
biodegradability means they require no additional surgery for removal. Note that when using 
a reservoir, temporally controlled delivery must be achieved via controlled delay in release 
from the reservoir. This review discusses methods of incorporating drugs into tissue 
engineering materials and efforts to control their delivery/presentation. We will discuss a 
variety of drug delivery systems, with a particular focus on growth factor delivery. We will 
explore methods in the two most common classes of tissue engineering materials, 
electrospun materials and hydrogels, including brief contextual explanations of the 
fabrication and material properties of these materials themselves. Drug delivery systems will 
be evaluated based on their applicability with growth factors, ability to provide temporally 
controlled delivery of multiple distinct drugs, and their effect on the properties of the tissue 
engineering material.  
2.4 Electrospun Materials 
Electrospinning produces a scaffold in the form of a mesh of nano- to microscale polymer 
fibres, either randomly oriented or aligned in parallel.37 The final material is a sheet that is 3-
dimensional (3D) at the micro scale and provides a structural mimic of the fibrous structural 
proteins abundant in the ECM.38  
To produce these materials, a high voltage is applied between a collection plate and 
spinneret (metal needle) from which a polymer solution is slowly dispensed (Figure 2.1). This 
method is simple and versatile; it can be used with any materials that can be dispersed in the 
spinning solution enough to pass through the spinneret. The competing forces of surface 
tension holding the solution in place and electrostatic attraction, pulling the charged solution 
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towards the collection plate deform the solution droplet at the end of the spinneret into a 
Taylor cone shape with charge concentrated at the peak.5 The concentrated charge allows 
the electrostatic forces to finally overcome the surface tension and a very thin stream of the 
spinning solution is drawn out towards the collection plate.5 The spinning solution consists 
of the final scaffold material, generally a natural or synthetic polymer, dissolved in volatile 
solvents. The volatility of the solvents is such that they are lost to the atmosphere between 
the spinneret and collection plate, so that only thin fibres of the scaffold material are 
collected.5 
 
Figure 2.1: Scheme of the electrospinning system with major components.5 A high voltage is applied 
between the needle of the spinning solution and the collecting plate, which causes a charge build up at the 
solution surface and the formation of a Taylor cone. Fibres of the spinning solution are pulled toward the 
collector to form a fibrous polymer scaffold. (© IOP Publishing. Reproduced with permission. All rights 
reserved) 
The operating parameters (applied voltage, working distance between spinneret and 
collector, solution flow rate) and solution properties (solvents, scaffold material 
concentration, additional surfactants or other additives) can be adjusted and optimised to 
tune fibre diameter, porosity, fibre consistency, and final scaffold thickness.5 Fibre alignment 
can be controlled by changing the collector type. Randomly aligned fibres accumulate on a 
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stationary collection plate, while a rapidly rotating collection drum forces fibre alignment 
because it collects fibres like winding a spool of thread.37  
Electrospinning can be used with natural or synthetic scaffold materials and can 
accommodate many additives, including living cells.37,39 The tissue response to electrospun 
nanofibrous scaffolds along with methods of tuning their surface and bulk properties, have 
been well explored and reviewed.5,37,38,40-42 On the micro-scale, the nanofibrous structure can 
be used to promote specific cell growth, such as neurite extension, via contact guidance.4 
The 2D nature of these materials makes them ideal for wrapping or bandaging applications 
where additional support or a barrier is required from the scaffold. One major drawback of 
these materials is their inability to fill voids, which limits their ability to fully interface with 
the healthy tissue surrounding an irregularly shaped disease/injury site, and therefore inhibits 
its full therapeutic potential.43  
2.4.1 Emulsion Electrospinning 
When creating an electrospun scaffold material, the polymer used to form the scaffold is 
first dissolved to create the spinning solution. As the polymer initially exists in solution, it is 
possible, via emulsion electrospinning, to add drugs or other active agents directly into this 
solution to produce a homogeneously loaded scaffold material.44 With electrospun materials 
being suited for bandaging applications, drug loaded electrospun mats have been prepared 
for wound dressings, such as antibacterial tetracycline hydrochloride loaded poly-ε-
caprolactone (PCL)/polylactic acid (PLA) blend electrospun materials.45 These materials 
showed superior performance to commercial Comfeel wound dressings, with improved 
water-uptake capacity, 600% vs. 100% respectively, as well as adding effective antibacterial 
properties, showing continuous release of tetracycline hydrochloride over 48 hours and 
effectively killing all E. coli and S. aureus in agar plates.45  
This approach can be used for protein growth factors, whose large size and instability can 
be an obstacle for delivery from the blood stream across size-selective membranes such as 
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the BBB. Human β-nerve growth factor (NGF), in the presence of the stabilising carrier 
protein bovine serum albumin (BSA), has been successfully electrospun with PCL dissolved 
in chloroform (CHCl3)46 and PCL/poly-ε-caprolactone ethyl ethylene phosphate (PCLEEP) 
blend in dichloromethane (DCM).47 The materials demonstrated a sustained, continuous 
release for 2846 to 90 days47 with bioactivity unaffected by the harsh solvents confirmed by 
neurite outgrowth from PC12 cells in vitro.47 Both brain derived neurotrophic factor (BDNF) 
and ciliary neurotrophic factor (CNTF) have been simultaneously loaded into electrospun 
silk fibroin/poly(ethylene oxide) (PEO) blend, which showed a greater increase in the axonal 
growth of rat retinal ganglion cells (RGCs) compared to fibres loaded with just one growth 
factor or fibres alone.48 
This method is effective for achieving a single, sustained release profile of growth factors, 
and while it can be used to deliver multiple growth factors concurrently, it does not offer 
control over the release or temporal distinction between multiple loaded drugs. To achieve 
more control of the release properties, more individually customisable methods must be 
used.  
2.4.2 Radially Layered Fibres 
Coaxial electrospinning uses concentric spinnerets with distinct spinning solutions in 
order to produce radially layered fibres.49 This method can be used to shield a drug loaded 
core with a degradable or porous outer sheath in order to delay and control the release of 
the drug.49 Similar to the wound dressing mats discussed above, biodegradable poly(lactide-
co-glycolide) (PLGA) nanofibrous mats have been prepared with tetracycline hydrochloride 
in the core of each fibre.49 Optimal mats were produced using a smaller amount of drug in 
the sheath as well, and these mats provided sustained release for 10 days with a reduction in 
the initial burst release (defined as the percentage of total release achieved in the first hour) 
from 62 to 44% compared to blended single-layer fibres.49  
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The coaxial method can also be used to layer different drugs to provide successive release 
of multiple agents.50 Han and Steckl developed a model electrospun material with three 
distinct radial layers to deliver multiple drugs with distinct release profiles (Figure 2.2).50 
Using colour dyes as model drugs the dye in the hygroscopic outer sheath layer displayed a 
burst release, while the dye in the core showed sustained release for 50 hours as it was slowed 
by an intermediate hydrophobic layer and the other sheath.50 This method could be employed 
for any active agent stable in the electrospinning solution, and can also provide a non-solvent 
layer for active agents unstable in the volatile electrospinning solution. 
 
Figure 2.2: Triaxial electrospinning of radially layered fibres.50 Three concentric needles are used to 
dispense separate spinning solutions to create fibres with three distinct radial layers. Dye added to the other 
layer displayed a burst release while the dye in the core displayed a sustained release after travelling through the 
intermediate sheath layer. (Reprinted with permission from Han, D. & Steckl, A.J. ACS Appl. Mater. Interfaces, 
5, 8241-8245 (2013). Copyright 2013 American Chemical Society.) 
2.4.3 Immobilisation onto Electrospun Materials 
Drugs can be immobilised permanently onto an electrospun scaffold by attaching them 
using strong covalent bonds (preferably formed through bonding of an otherwise inactive 
site on the drug molecule). Immobilised drugs can be detected by surrounding cells but not 
consumed; making this approach applicable to mimic the delivery of secreted, extracellularly 
active intercellular signalling molecules such as some protein growth factors. Growth factors 
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play an important role in cellular activity, and function as a mechanism for rapid 
communication between surrounding cells in other parts of the tissue. However, due to this 
transient signalling role, growth factors naturally degrade rapidly under normal physiological 
conditions, lasting only minutes to hours when introduced in vivo in soluble form.31 For the 
growth factor to have prolonged effectiveness a sustained delivery system, such as covalent 
immobilisation to an electrospun scaffold, is required. 
Click chemistry has be used to chemically immobilise therapeutic agents, including 
cyclodextrins,51 and bioactive peptide sequences,52,53 to the surface of electrospun materials. 
Growth factors can be covalently chemically immobilised through direct reactions with 
amine or carboxylic acid moieties present in their protein structure.54 Alternatively, 
commercially available crosslinking molecules, such as succinimidyl-4-(N-maleimidomethyl) 
cyclohexane-1-carboxylate (SMCC),31,36,55 can be used to link two materials by reacting with 
specific functional groups present on each material. SMCC connects two different molecules 
between the amine groups of one and the thiol groups of the other, such as by connecting 
an aminolysed electrospun polymer surface to the thiol group of a free cysteine residue in a 
protein growth factor.36 This results in the alteration of one, relatively small chemical moiety 
on the protein. The immobilised growth factors therefore remain biologically active and their 
degradation depends on the degradation of the polymer scaffold, allowing them to be 
presented on the scaffold surface for orders of magnitude longer than soluble growth 
factors.31,36,55 
Our group has immobilised GDNF onto electrospun PCL scaffolds using SMCC and 
have shown that GDNF maintained its biofunctionality for at least 7 days in a neural 
progenitor cell culture and remained detectable by enzyme linked immunosorbent assay 
(ELISA) after 120 days of storage in PBS or artificial cerebrospinal fluid.31 The 
biofunctionality was confirmed by ongoing ErK phosphorylation in the neural stem line 
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SN4741 as well as improved viability and number of tyrosine hydroxylase immunoreactive 
(TH+) cells.31  
The covalent immobilisation method is not entirely efficient, and some unattached 
protein remains bound to the scaffold through physical interactions, and can therefore de-
absorb over time.36,55 It is possible that this combination of soluble and immobilised growth 
factor act synergistically, with the soluble component diffusing from the implanted scaffold 
to create a concentration gradient, an important aspect of growth factor function,10 directing 
nearby cells toward the electrospun material and the immobilised drug. Although 
unquantified, this could potentially mitigate the lack of void filling capacity of the electrospun 
scaffolds since the diffused soluble component spreads through the void to interact with the 
surrounding tissue, potentially encouraging the tissue-material interface to migrate toward 
the scaffold. Covalent immobilisation strategies are limited however, as they are only relevant 
to drugs that can be used by cells non-destructively, where only repeated surface recognition 
but not internalisation is required. This method is also static; it cannot be used to provide a 
temporally varied drug delivery profile. It can be used to allow materials to present ongoing 
biochemical cues in addition to the physical cues, either of drugs that are required indefinitely 
or to increase the biomimetic quality of the scaffold material by immobilising biological 
components of the ECM. The inherent properties of electrospun materials do put some 
limitations on their biomimicry, and this is one of the main reasons why hydrogel materials 
are often more suitable.  
2.5 Hydrogel Materials 
A cellularly secreted proteoglycan hydrogel is a major component of the ECM, meaning 
that hydrogels can be intrinsically biomimetic.1 Hydrogels consist of highly hydrated 
interconnected chains, connected through physical or chemical crosslinking, forming an 
aqueous matrix. Chemical crosslinking involves the formation of covalent bonds and is an 
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irreversible procedure resulting in a strong network that can only be degraded by breaking 
those bonds, typically via hydrolysis, enzymatic action, or a specific stimulus (such as photo-
degradable hydrogels56). Physical crosslinking, however, occurs reversibly through the 
secondary bonds between the chain molecules. As these forces are relatively weak, they allow 
the hydrogel to undergo shear thinning, where applied shear stress disrupts the physically 
bound network and breaks the continuous gel material into many small domains (Figure 
2.3).6 These smaller gel domains can easily move past and around one another, so that the 
bulk material flows with minimal resistance.6 When the stress is removed the domains 
interconnect again to recreate the structure allowing the gel to recover its initial stiffness.6 
 
Figure 2.3: Hydrogel shear thinning and recovery.6 Application of shear stress causes the hydrogel network 
to break into smaller domains, which flow easily around each other. When the stress is removed, the small 
domains reintegrate into a larger hydrogel network. (Reproduced with permission from The Royal Society of 
Chemistry) 
This is a very attractive property for tissue engineering applications as the engineered 
material can be injected directly to the site of therapeutic need via a minimally invasive needle 
rather than surgically implanted. Shear-thinning also increases their void filling ability, as the 
thinned hydrogel flows throughout the entire injury site before the domains reassemble and 
the material returns to its more solid-like gel state to create a perfectly fitted implant.57 The 
true ECM is a dynamic environment, constantly changing and undergoing stress,1 so 
materials based on reversible and reformable physical interactions can potentially provide a 
more adaptable and appropriate scaffold. 
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An important class of physically formed hydrogels for biomedical applications are those 
that mimic the natural fabrication of the ECM, exploiting the spontaneous self-assembly of 
bioinspired amphiphilic molecules (such as synthetic polymers, proteins, peptides, 
polysaccharides, and their derivatives) into higher order structures.42,57-60 Self-assembly occurs 
when there is a balance between the intermolecular repulsive and solvating forces, which 
drive the material towards a homogeneous solution, and attractive forces and insolubility, 
which drive the material towards precipitation or separation. The intermolecular interactions 
can include hydrophobic interactions, hydrogen bonds, π-π stacking of aromatic groups, and 
charge-charge interactions.57 A stimulus is usually applied to reduce the solvation and 
promote intermolecular attractions, allowing the molecules to organise into interconnected 
network structures under thermodynamic or kinetic control. Starting from a state of 
overpowering repulsive and/or solvating forces is preferable, as this provides a 
homogeneous distribution of nucleation points throughout the solution. The stimulus must 
be presented as uniformly as possible to ensure homogeneity, and the rate at which the 
stimulus is applied must be adjusted to promote ordered structures and avoid uncontrolled 
aggregation or precipitation.61 The extent and nature of the stimulus can have an effect on 
the final material properties. Adjusting pH affects the charge on free amine or carboxylic 
acid groups present,57 increasing salt concentration in the aqueous medium shields surface 
charges and reduces their effect,57 and hydrophobic interactions are strengthened by 
increased temperature.57 The catalytic action of enzymes has also been used to modify these 
interactions due to the formation/cleavage of bonds. For biological applications it is 
important that the molecular assembly occurs under physiological conditions (pH 7.4, salt 
concentration 150 mM, temperature 37 °C) to ensure the desirable hydrogel structure is 
retained in vivo.62 For more information relating the cellular response to synthetic and natural 
hydrogels, particularly in the central nervous system, the interested reader is directed to our 
review.37 
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2.5.1 Direct Addition of Drugs into Hydrogels 
The self-organising and shear thinning nature of physical hydrogels makes direct 
incorporation into the gel material much simpler than with electrospun materials. Soluble 
additives that interact with the structures can be co-assembled into the material as it forms, 
or can be mixed into the aqueous component of the hydrogel post assembly by simply 
applying minimal shear stress to thin the gel temporarily without destroying/disrupting the 
beneficial structures (e.g.: with a bench top vortex mixer), and then allowing the gel to 
reform.63 NGF was mixed into the self-assembling diblock copolypeptide hydrogels K180L20 
and E180L20 and showed ongoing bioactive effect for at least 4 weeks in vivo in mice. This 
study demonstrated prolonged hypertrophy and a larger region of effect compared to NGF 
injected in a buffer solution.64 Although the loading is simple, the release profile of drugs and 
growth factors from hydrogels is dependent on interactions between the two materials. From 
MAX8 peptide hydrogels for example, positively charged proteins diffuse out while 
negatively charged proteins adsorb to the hydrogel showing little diffusion.65 While the 
electrostatic properties of different growth factors inherently result in different release 
profiles, so as with electrospun materials controlling the release profile again requires more 
involved methods. Unmodified diffusion of growth factor from hydrogels can occur very 
rapidly,66 so for growth factors in particular, for which rapid degradation means sustained 
delivery is required, just slowing the diffusion to provide more long-term delivery is an 
important goal. 
2.5.2 Immobilisation of Drugs in Hydrogels 
Non-covalent affinity interactions can be used to either permanently or non-permanently 
immobilise growth factors within a hydrogel. Thesis systems are particularly applicable to 
growth factors, as many natural growth factors have known binding partners, biological 
molecules with known affinities for the target growth factor.54,67 For example, biotin tagged 
interferon-γ (IFN-γ) and platelet derived growth factor AA (PDGF-AA) have been 
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immobilised to a streptavidin functionalised methacrylamide chitosan (MAC) hydrogel via 
the well-known biotin-streptavidin conjugation.68 These materials showed improved neural 
regeneration in vivo in spinal cord injury in rats, showing increased neuron count relative to 
treatment with the hydrogel material alone.68 Similar immobilised IFN-γ in chitosan hydrogel 
materials were tested with NSCs.69 When cultured in hydrogels functionalised with either 
immobilised or soluble IFN-γ, both conditions resulted in a similar improvement in neuronal 
differentiation compared to medium alone, but the immobilised drug showed fewer semi-
committed and immature neurons, indicated by the lower co-presentation of nestin and βIII 
tubulin.69 The binding pairs can be used individually, or as one link in a chain. For example, 
collagen hydrogels have been modified with epidermal growth factor (EGF) covalently 
attached to a peptide designed to bind to collagen, which was observed to improve 
proliferation and neuronal differentiation of neural stem cells (NSCs).70  
Delayed release can be achieved by covalent immobilisation to the hydrogel material of a 
molecule with a weaker affinity for the drug being released. The drug is not fully immobilised 
to the scaffold, but held in place by a strong affinity through reversible physical bonds. This 
has been achieved for heparin-binding drugs by first immobilising heparin within the 
hydrogel.71 In this work, a bi-domain peptide was covalently bound to a fibrin matrix through 
a transglutaminase substrate on the N-terminus, and a heparin-binding domain on the C-
terminus was used to electrostatically immobilise heparin to the matrix.71 The heparin-
binding drug, basic fibroblast growth factor (bFGF), was in turn semi-immobilised through 
its electrostatic interaction with heparin, and its release from the hydrogel was delayed.71 This 
approach is widely applicable to heparin binding growth factors, and has also been adapted 
for some non-heparin-binding factors. NGF is non-heparin binding, but its C-terminus 
contains several basic residues surrounded by hydrophobic residues, which is similar to a 
heparin-binding domain.66 Using a high molar excess of immobilised heparin, the release of 
NGF was slowed from the fibrin matrix, allowing a continuous release over 15 days 
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compared to 1 day from fibrin alone and resulting in a 100% improvement in neurite growth 
compared to fibrin and NGF alone.66  
This heparin binding domain system is diverse, with 15 binding proteins identified so far 
from the platelet-derived growth factor (PDGF)/VEGF, FGF, transforming growth factor 
beta (TGT-β), and neurotrophin families.72 This variety shows versatility of this controlled 
release method for delaying the release of individual proteins, but it also highlights a 
significant drawback of this technique: the release profile cannot be tailored for one drug 
without affecting the release profile of other loaded heparin-binding drugs. Also, this method 
is dependent on chemical modification of the hydrogel scaffold itself, which could alter some 
of the specifically engineered scaffold properties, particularly stiffness, a property that plays 
a major role in driving cell differentiation.2,26 This could mean that control of the dynamic 
environment is attained at the expense of control of the static environment. 
Many affinity binding pairs occur naturally, including the commonly explored heparin 
binding affinity discussed above that can be used with many growth factors. Natural affinity 
binding pairs can occur in the form of: ECM-integrin, receptor-ligand, protein-protein, and 
antibody-antigen.67 These non-covalent linkages are a requirement of the dynamic nature 
biological processes. New binding partners can be discovered via screening against 
peptide/protein libraries, or else new partners can be evolved in vitro through random 
mutagenesis or in silico using computational models to directly design binding structures.       
A similar delivery effect has been achieved with enzyme sensitive linkages. Therapeutic 
peptide sequences flanked with matrix metalloproteinase (MMP) enzyme degradable 
sequences were chemically crosslinked to a PEG hydrogel structure, such that host MMP 
cleaved the bonds holding the therapeutic peptide in place resulting in a sustained delivery.73 
This method has been confirmed in vivo in mice with proangiogenic SPARC sequences 
promoting increased vascularisation.73 This system is interesting as it allows drug delivery 
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dependent on local conditions, but being dependent on gel degradation for delivery it again 
does not fully utilise the potential of the hydrogel material as a biomimetic structural scaffold.   
2.5.3 Spatial Control of Multiple Drugs in Hydrogels 
Fine 3D spatial control over drug incorporation in hydrogel materials is possible using 2-
photon technology to attach molecules.74,75 In this method lasers are used to precisely 
determine where in the 3D hydrogel photochemical reactions occur to chemically immobilise 
therapeutic or binding agents. Immobilisation of a single therapeutic agent, the peptide 
sequence glycine-arginine-aspartic acid-serine (GRDGS) containing the RGD integrin 
binding sequence from fibronectin, has been used to spatially guide neurite outgrowth.76 This 
method has been adapted to provide independent control over multiple therapeutic agents 
via protein binding agents.75 Multiple protein binding agents can be immobilised first, before 
washing the hydrogel material with the appropriate protein solutions to allow the physical 
association with the binding agent to hold them in place (Figure 2.4).75 The nature of this 
procedure means that all reactive chemistry is performed before any sensitive proteins are 
introduced into the material.75 The method is also widely applicable to other proteins, 
requiring only a common biotin or barstar modification.75 The number of spatially distinct 
regions is limited to the number of biotin-streptavadin style binding pairs can be 
incorporated. Combining this technique with work being done on injectable preformed 
hydrogel materials with shape memory77 might lead to fine spatial control of drugs within an 
injectable hydrogel matching an irregularly shaped injury site. However, this method does 
not offer advances in the way of temporally controlled delivery.  
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Figure 2.4: Method for the simultaneous immobilisation of (sonic hedgehog) SHH and CNTF.75 Two-
photon irradiation is provided sequentially to chemically bind one half of each binding pair. The entire hydrogel 
is immersed in the material but fine spatial control of the two-photon irradiation limits the immobilisation 
reaction. Once all the first halves are bound individually, a final wash off all the binding proteins combined is 
used to lock them in place only where the relevant binding pair has been immobilised. (Reproduced with 
permission from Nature Publishing Group) 
2.5.4 Bioactive Sequences in Self-Assembling Peptide (SAP) Hydrogels 
SAP hydrogels are growing in popularity as tissue engineering materials, they offer some 
uniquely attractive properties as well as the option to use desired bioactive signals directly as 
the material structure. SAPs exist in the semi-synthetic middle ground of tissue engineering 
materials. While all the individual amino acids used are natural materials, the peptide 
sequences are synthetically manufactured. The stepwise synthesis of the sequence of amino 
acid residues in the SAP means it is completely controllable, with no variation and high 
purity.  However, because they are made from biocompatible natural materials SAP 
hydrogels have a very high level of biodegradability and biocompatability.78 
Physical intermolecular interactions under the right conditions drive self-assembly into 
supramolecularly organised fibril structures much thicker than the single molecule polymer 
chains comprising the matrix of traditional hydrogels.6,57 This fibrillar nature allows SAPs to 
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occupy a structural middle zone as well, displaying advantageous structural properties of both 
hydrogels and electrospun materials. As physical hydrogels, SAPs are highly hydrated, 
completely 3D, undergo shear thinning (so are injectable), and display void-filling behaviour, 
while also acting similarly to electrospun materials by providing supportive fibrous structures 
mimetic of the ECM structural proteins.8  
Commercially available SAPs consisting of long repetitive peptides, such as RADA16 and 
MAX8, are biocompatible, but do not provide the ECM-mimetic biochemical signals that 
natural protein and polysaccharide gels provide. To address this, these systems are typically 
functionalised by adding bioactive sequences as pendant groups.79 However, SAPs can also 
be formed from short biologically relevant sequences, thereby incorporating a biochemical 
cue directly into the self-assembled fibril structures.8,9 Those long sequence peptides are 
designed specifically to undergo self-assembly, with correspondingly attracted regions to 
encourage the formation of β-sheets. When the peptide sequence is instead chosen for its 
biological significance, and too short to naturally fold into sheets, additional self-assembling 
motifs are used to drive the formation of the nanofibrillar structures. The bioactive peptide 
sequence can be capped with aromatic groups, such as naphthalene or 
fluorenylmethyloxycarbonyl chloride (Fmoc). These groups encourage the self-assembly of 
the supramolecular fibrils though π-π stacking of aromatic groups in addition to the β-sheet 
formation between the short peptide chains (Figure 2.5).7,9 Additional aromatic peptide 
residues can be used to further enhance self-assembly through additional π-π stacking 
interactions78 while acidic or basic residues can be added to shift the pH at which the net 
molecular charges favour self-assembly, ensuring self-assembly at physiological pH.9 
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Figure 2.5: Self-assembling peptide fibril formation.78 A: Fmoc peptide sequences. B: Fmoc groups engage 
in aromatic π-π stacking with peptide chains in alternating directions. The peptide chains interleave forming β-
sheets between lines of stacked Fmoc moieties. The resulting sheets roll into hollow fibrils, which interact most 
strongly longitudinally, forming bundles of fibrils which then form the nanofibrous hydrogel network. 
(Reproduced with permission from John Wiley and Sons) 
The arginine-glycine-aspartate (RGD) peptide is a bioactive sequence presented by the 
ubiquitous ECM protein fibronectin that encourages integrin activation and cell attachment. 
In a short sequence Fmoc-SAP, such as the RGD containing Fmoc-FRGDF, the biological 
cues (i.e.: the bioactive peptide sequence) are presented at a high density on the surface of 
the fibrils, and thereby throughout the hydrogel, improving the biological environment of 
the otherwise structurally biomimetic, but biologically inert material. The effectiveness of 
this presentation was demonstrated by the 3D culture of human mammary fibroblast cells 
(hMFCs), where the RGD SAPs showed significantly improved viability over a scaffold that 
was identical in bulk physical and chemical properties, but displayed a biologically inactive 
sequence, DGR.78 
The incorporation of bioactive sequences into the hydrogel structure mimics the static 
presentation of biological molecules. To provide dynamic control of drug release from a SAP 
hydrogel, methods like those described above for traditional hydrogels may be used. For 
example, including enzyme sensitive moieties within long chain SAPs, as well as SAP-drug 
complexes, results in fibrils that gradually degrade as the chains are broken down, providing 
a sustained release of the drug.80 However, when the intrinsic hydrogel matrix plays an active 
role in the drug release mechanism, it affects the gel properties and the static support 
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environment over time, especially in this case where the material must degrade to provide 
controlled drug delivery. Ideal tissue engineering materials must be designed with both drug 
delivery and material properties in mind. For more information regarding the cellular 
response to SAP scaffolds, the interested reader is directed to our previous review.8 
2.5.5 Responsive Hydrogels 
As long as stimuli can reach the material, then in situ modulation of gel properties is 
possible, allowing for the engineering of stimuli-responsive hydrogel materials. Hydrogels 
can be engineered to respond to external stimuli such as changes in temperature, pH, electric 
fields, light, and enzymes.81,82 Photodegradable hydrogels offer easy external control, such as 
poly(ethylene glycol)-tetrathiol (PEG4SH) hydrogels, which can be degraded with only 120 
seconds of low intensity UV light exposure (10 mW/cm2, 365 nm).82 Here the hydrogel 
degradation is irreversible, meaning that once the material is degraded to release any loaded 
drugs it can no longer offer the same structural support. 
Perhaps the most promising stimuli-responsive mechanisms for targeted drug delivery are 
the antigen responsive hydrogels. These can be tailored to respond to stimuli found at the 
site of therapeutic need; for example, hydrogels that swell in the presence of a specific disease 
associated antigen can be created by modifying the polymer chains with paired antibodies 
and antigens (Figure 2.6).83 In the absence of free antigen, the bound antibodies and antigens 
interact, creating more crosslinking points in the gel and essentially keeping the matrix very 
tight. When free antigen is present, some of the antibody-antigen interactions within the 
hydrogel are disrupted in favour of interactions with the free antigen, which lowers the degree 
of crosslinking and essentially loosens the gel. This process is reversible83 and since the degree 
of crosslinking in a hydrogel is directly linked to its permeability84 this system can provide 
pulsatile release of active agents responding to changing free concentrations of the antigen.83 
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Figure 2.6: Antigen responsive hydrogel.83 Antibodies and corresponding antigens are bound to the 
hydrogel chains, and increase the interconnectivity of the hydrogel network when they pair. Free antigen in the 
surrounding environment reduces the number of bound antibody-antigen pairs and decreases the 
interconnectivity of the hydrogel. (Reproduced with permission from Nature Publishing Group) 
Interestingly, this approach can be used to respond to externally controlled signals, or to 
automatically react to naturally arising cues. When foreign antigens, such as fluorescein 
isothiocyanate (FITC),85 or rabbit IgG,83 are used as trigger molecules, the release profile can 
be controlled independently of any ongoing biological processes. These materials are not 
naturally occurring in the body, so drug release can only be triggered by the controlled 
introduction (such as via injection) of the foreign antigen. The highly specific nature of 
antibody interactions means that even very similar antigens will not trigger release83 so 
complete and independent control of the release profile is retained. Alternatively, hydrogels 
can be designed to respond to predefined natural cues and automatically release the 
appropriate therapeutic agent. This approach also offers a potential way around the issues 
involved with the large size of protein growth factors, such as bypassing the blood brain 
barrier. A molecule that can cross the BBB can be selected as the trigger, such that systemic 
delivery can be used to trigger release of growth factors if not to deliver them.  
Glucose responsive hydrogels have been engineered to act as an artificial pancreas to 
provide automatic pulsatile release of insulin as needed.86 Several systems have been explored 
for glucose responsive insulin delivery. Lectin proteins that bind to carbohydrates have been 
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used in a similar system to the antigen-antibody interactions described above.87 Other 
systems incorporate reactive agents into the hydrogel mesh that affect charge changes in the 
presence of glucose and swell the gel via increased electrostatic repulsion between polymer 
chains.86 Glucose oxidase immobilised onto the polymer chains converts glucose to gluconic 
acid, which can in turn protonate tertiary amines on appropriate hydrogelating polymers, 
such as dimethylaminoethyl methacrylate (DMA), thereby swelling the hydrogel via 
electrostatic repulsion between chains.86 A non-enzymatic system based on phenylboronic 
acid (PBA) complexes with glucose and other 1,2 or 1,3-cis-diols to form an anionic 
group.81,87 The PBA approach is less specific, but offers improved longevity over systems 
dependant on proteins that degrade over time.87 
Responsive swelling gels are only applicable for the release of entrapped large molecules, 
such as proteins, whose transport depends on the hydrogel mesh size and permeability.85 The 
approach can be adapted for smaller drugs by covalently attaching the small drug molecule 
to larger gelling molecules by a cleavable linker.88 This also adds a second stage to the 
mediation of the drug release, as linkers can be selected that are susceptible to proteases 
expressed by disease cells to increase targeting efficiency.88 A common theme among stimuli-
responsive hydrogels is the alteration of gel properties to facilitate release. Even if temporary, 
this is still undesirable in tissue engineering materials where the hydrogel properties have 
been optimised to provide optimal static cues to the surrounding cells. Ideal tissue 
engineering materials must be designed to concurrently provide a static structurally 
supportive environment and provide controlled drug delivery. 
2.6 Independent Drug Delivery Vehicles 
A common theme in the dynamic control of drug delivery from tissue engineering 
materials is to use material degradation or alteration, which inherently requires the static 
material environment to change. This makes independent control of both the static 
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environment and drug delivery impossible. A combination of dynamically controlled drug 
release and static biomimetic tissue engineering materials will be required for optimised 
regenerative medicine strategies. Combining these two features, without compromise, is the 
goal, and perhaps the best strategy to achieving this independent control is to focus temporal 
control mechanisms on the drug-end rather than within material modifications. Modifying 
the tissue engineering material not only disrupts its (carefully) optimised properties, but also 
hinders independent control of multiple releases since changes to the scaffold material will 
affect all incorporated agents. Sophisticated techniques exist to control the targeting and 
release of drugs introduced systemically, most notably in the form of functionalised 
nanoparticle delivery vehicles, which can be incorporated directly into tissue engineering 
materials in the same way as soluble drugs. 
2.6.1 Nanoparticles in Tissue Engineering Materials 
Drug encapsulation in nanoparticles is a simple shielding procedure that allows for diverse 
functionalisation. Polymer materials with excellent biocompatibility and biodegradability can 
be used to create the nanoparticles, which can then be made to incorporate fluorescent or 
radioactive tags for diagnostic imaging, targeting moieties for location specific delivery, and 
delayed or stimuli-responsive release mechanisms.89 Once encapsulated, drugs can be 
incorporated directly into hydrogels22 or electrospinning solutions.90 Encapsulation also 
provides shielding to protect the drug from interactions with solvents used in electrospinning 
and harsh chemicals such as acids and bases used to induce gelation, making nanoparticles 
attractive for delivery of sensitive or reactive drugs. 
Using this approach, epidermal growth factor (EGF) and erythropoietin (EPO) have been 
presented sequentially to stimulate endogenous NSPCs to heal after stroke.22 EGF 
encapsulated in polylactic-co-glycolic acid (PLGA) nanoparticles and EPO encapsulated in 
PLGA and further coated in polysebacic acid (PSA) were incorporated in a hyaluronan 
methylcellulose (HAMC) hydrogel to provide sequential delayed release.22 EGF release was 
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observed from days 4-11, while EPO release was observed from days 11-25.22 When tested 
in vivo with mice, this functionalised nanoparticle and hydrogel system showed similar results 
in terms of cell differentiation and proliferation when compared to a standard mechanical 
pump system used to control drug delivery from implanted reservoirs, demonstrating state 
of the art drug delivery control from a minimally invasive and biodegradable material.22 
Similarly, nanoparticle loaded growth factors can also be loaded into electrospun materials 
to provide sequential delivery, with the nanoparticle loaded growth factor being delayed. 
Wound dressings have been prepared by electrospinning a chitosan/PEO blend loaded with 
free VEGF, which showed a burst release, and PLGA nanoparticles loaded with PDGF-BB, 
which showed a sustained ongoing release.91 
There is a vast array of stimuli responsive nanoparticle drug delivery vehicles92 and often 
these can be incorporated into tissue engineering materials to essentially achieve the same 
stimuli-responsive control of drug delivery discussed above without disrupting material 
properties. Silica nanoparticles have been modified with photo-sensitive attachment of small 
molecules drugs and then mixed into a PEG hydrogel to demonstrate photo-triggered drug 
release from a hydrogel.93 Nanoparticle systems also offer stimuli responsive behaviour not 
available otherwise, such as magnetically controlled delivery. Superparamagnetic Fe3O4 
nanoparticles have been incorporated into a poly(N-isopropylacrylamide) (PNIPAAm) 
hydrogel, which is reverse temperature responsive, to provide remote triggered drug 
delivery94 and pulsatile on-off delivery95 upon application of an alternating magnetic field. 
However, in this system the drug was loaded into the hydrogel, and once again the control 
of delivery depended on altering the material properties of the hydrogel, in this case by using 
the magnetically responsive nanoparticles to increase the temperature in the thermally 
responsive hydrogel,94,95 making it useful as a controllable drug reservoir but not as a general 
method for drug delivery from tissue engineering materials. 
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2.7 Conclusion 
Many techniques used to provide drug delivery systems from tissue engineering materials 
use the material as a biodegradable depot, which is definitely preferable to invasive 
micropumps,22 but is not achieving the full potential of drug delivery tissue engineering 
materials. Both the static environment, the physical, chemical, and biological cues mimicking 
a healthy ECM, and dynamic temporally controlled drug/growth factor delivery are 
important considerations in tissue engineering and they affect each other. Truly optimised 
tissue engineering systems need to consider both of these topics in their design. A common 
limitation with these current methods is incompatibility with multiple delivery profiles 
simultaneously. While many adaptable methods exist that could be used for a variety of drugs 
or growth factors, when the delivery method relies on adjusting properties of the tissue 
engineering material itself it can only be adjusted for a single delivery profile. There is also a 
tendency, especially with passive diffusion, affinity controlled release, and immobilisation 
delivery strategies, to adjust delivery timing only in terms of the duration of delivery but not 
delays to the start time. This is a vital consideration for achieving sequential delivery.  
The broad nature of research in this field, investigating individual aspects of tissue 
engineering material properties and diverse drug delivery systems, presents many options for 
potentially synergistic combination. Indeed, while one single universally controllable delivery 
system has not been established, the broad selection and adaptability of current methods may 
solve that problem. This thesis provides a collection of distinct delivery systems, each 
controllable within a different temporal range, working with the same tissue engineering 
material. These novel systems are based on the existing methods and materials described 
here, designed with both material properties and drug delivery in mind to provide optimal 
therapeutic performance.    
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3.1 Materials 
Fmoc protected amino acids, Hydroxybenzotriazole (HOBt), O-Benzotriazole-
N,N,N’,N’-tetramethyl-uronium-hexafluoro-phosphate (HBTU) and Wang resins were 
purchased from GL Biochem (China). Dimethylformamide (DMF) was dried using 4 Å 
molecular sieves for a minimum of 2 hr prior to use. Custom Fmoc capped and desalted 
peptides were purchased from Pepmic (China) for work done in Chapter Eight-Chapter 
Nine. BDNF and GDNF proteins, ELISA supplies (capture, primary and secondary 
antibodies; and the color reagent pack) and DuoSet GDNF ELISA Kits were purchased 
from R&D Systems (USA). Poly(lactic acid) (PLA) a.k.a. Poly(L-lactic acid) (PLLA) was 
purchased from Absorbable Polymers, Inc (AL, USA). All other chemicals were purchased 
from Sigma-Aldrich unless otherwise stated. Dialysis membranes were purchased from 
Spectra/Por (USA). 
Chapter Three 
Methods 
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3.2 Material Preparation 
3.2.1 Solid Phase Peptide Synthesis (SPPS) 
Peptides were manually synthesised for the work in Chapter Four-Chapter Six as 
previously described.9 The N-terminus Fmoc-capped peptides were synthesised by addition 
of individual Fmoc-capped amino acids one at a time, synthesising from the C-terminus to 
the N-terminus, starting with the C-terminal amino acid in resin bound form (with an N-
terminus Fmoc cap and linked to a resin bead at the C-terminus). All reactions were 
conducted in a rotating reaction vessel. 0.4 mmol of resin was swelled in 8 mL DMF for 15 
min. In series, the protecting Fmoc groups were removed by reaction with 5 mL of 20% 
piperidine in DMF for 20 minutes, and the next amino acid in the sequence coupled by 
reaction with a 2 mmol solution of the amino acid in 8 mL of DMF with HOBt (2 mmol), 
HBTU (1.92 mmol), and DIPEA (0.8 mL) for 60 minutes. In between each reaction the resin 
was washed with DMF to remove the reaction solution and then with dichloromethane 
(DCM) to perform a Kaiser test/ninhydrin reaction to confirm reaction progress based on 
the presence or absence of free amine groups before washing again with DMF. The final 
peptide resin was washed with ethanol and stored under vacuum for at least 2 days before 
cleaving the peptide from the resin in trifluoroacetic acid (TFA) containing 2.5% (v/v) 
triethylsilane (TES) and 2.5% (v/v) deionised water. The peptide was recovered by filtration 
through glass wool, and excess TFA was removed under gently flowing nitrogen gas. The 
remaining solution was precipitated and washed in dry ice-cooled ether and separated by 
centrifugation. This product was dried under vacuum for at least 2 days before being ground 
into a fine white powder and dried for a further 7 days before use. 
3.2.2 Self-Assembled Peptide (SAP) Hydrogel Preparation and Loading 
The SAP hydrogels were prepared as previously described9. Briefly, peptide powder was 
suspended in deionised water (DI H2O) and dissolved by minimal addition of 0.5 – 1 M 
sodium hydroxide (NaOH). The self-assembly was induced by a pH switch caused by the 
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dropwise addition of 0.1 – 0.2 M hydrochloric acid (HCl), then made up to volume with PBS. 
Hydrogels were prepared at a peptide concentration of 20 mg/mL (Chapter Four-Chapter 
Six) or 15 mg/mL (Chapter Eight-Chapter Nine). Hydrogels used in biological testing were 
made up to volume using Hank’s buffered saline solution (HBSS) (Gibco) instead of PBS 
and diluted 1:1 with cell media/suspension when used in biological testing. Loading with 
growth factor materials was done immediately before the commencement of release profile 
experiments to minimise degradation. Loading was performed by adding growth 
factor/short fibre solution via micropipette directly to the hydrogel and vortexing to mix. 
3.2.2.1 Growth Factor Loading (Chapter Six) 
After formation, hydrogels were loaded with BDNF or modified BDNF-Chitosan at a 
concentration of 865 ng/mL. GDNF was loaded at a concentration of 1000 ng/mL.  
3.2.2.2 Growth Factor Loading (Chapter Eight) 
After formation, hydrogels were loaded with short fibres and/or growth factor solutions 
as required. GDNF solution was loaded at a final concentration in the hydrogel of 1000 
ng/mL. Short fibres were loaded for final concentrations in the gel of 0.2 – 5 mg/mL, using 
5 mg/mL in release profiles (resulting in a final concentration in the hydrogel of 806 ng/mL 
GDNF from 0.0156% (w/w) loaded mGDNF short fibres). 
3.2.2.3 Growth Factor Loading (Chapter Nine) 
After formation, hydrogels were loaded with nanoparticles and growth factors as required. 
Nanoparticles were loaded at a final concentration in the hydrogel of 0.085 mg/mL. GDNF 
was loaded at a final concentration in the hydrogel of 1000 ng/mL. All nanoparticle 
containing gel containers were wrapped in aluminium foil to minimise light exposure. 
3.2.3 Xyloglucan-PDL Hydrogel Preparation and Loading 
For in vitro application, xyloglucan (3% (w/v)) was dissolved in PBS and stored below 4 
°C to prevent gelation. Composite scaffolds were generated by mixing PLLA short fibres 
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(SF, 0.25% (w/v)) into xyloglucan (at 4 °C) prior to its gelation. For cell culturing, 100 μL of 
xyloglucan (± SF) was used to coat glass coverslips, placed into the bottom of the culture 
wells (24-well plate). The plate was stored at 37 °C for 30 min prior to seeding of cells, and 
maintained at 37 °C for the duration of the study to ensure preservation of the integrity of 
the gel.  For in vivo application, the xyloglucan was prepared at 4.5% (w/v) in Hanks Buffered 
Saline Solution (HBSS, Gibco), and subsequently diluted with cells at a ratio of 2:1 (i.e. final 
concentration of 3% (w/v)) at the time of implantation. All gels for in vivo delivery were 
stored on ice to prevent gelation prior to implantation. 
3.2.4 SMCC Crosslinking – Covalent Attachment to Growth Factor 
The SMCC crosslinker used here for covalent attachment to growth factors refers to 
sulfo-SMCC (the water soluble form): 4-(N-maleimidomethyl)cyclohexane-1-carboxylic acid 
3-sulfo-N-hydroxysuccinimide ester sodium salt. The SMCC solution used in all attachments 
was prepared at 2.5 mg/mL in PBS, and mixed for 1 hr with gentle oscillation on an 
oscillating rocker table, and then filtered through a 0.2 µm filter. In all cases this SMCC 
solution was reacted with the amine moiety only for 2 hours with gentle oscillation, washed 
if applicable, then reacted overnight at 4 °C with the growth factor at ≥ 4 μg/mL. Both the 
BDNF and GDNF growth factors, as well as other members of the NGF and GDNF 
families, contain the cystine knot motif,96,97 a cysteine rich structure that has been shown to 
include the free unpaired cysteine residues necessary for SMCC crosslinking.98 
3.2.4.1 Chitosan-Growth Factor Attachment 
3.5 mL of filtered SMCC solution was reacted with 26 mg methacrylated chitosan for 2 
hr at room temperature on an oscillating rocker table. BDNF protein (in 25 µg/mL solution) 
was added to the SMCC-chitosan solution at a 35:100 volume ratio of BDNF to SMCC-
Chitosan and allowed to react overnight at 4 °C before being transferred to −20 °C for 
storage. 
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3.2.4.2 Electrospun Fibre-Growth Factor Attachment 
Intact scaffolds or short fibres were first aminolyzed in 0.5% (v/v) ethylenediamine (ED) 
in isopropanol (IPA) (Caledon Laboratories, Canada) for 15 min to provide amine groups 
on the fibre surface. For biological testing in Chapter Seven the materials were sterilised with 
70% (v/v) ethanol. All materials were washed in sterile deionised water. The materials were 
immersed in the filtered SMCC solution for 2 hours at room temperature, prior to being 
transferred to a solution containing growth factor at 4 μg/mL overnight at 4 °C. The 
vortexed scaffolds described in section 7.4 were vortexed for several minutes after this 
procedure.  
3.2.4.3 Nanoparticle-Growth Factor Attachment 
Amine coated TiO2 nanoparticles prepared as previously described, with predominant 
(87%) anatase phase and a smaller component of rutile phase(13%),99 were obtained. 1.5 mL 
of filtered SMCC was reacted with 17 mg of amine coated TiO2 nanoparticles for 2 hr at 
room temperature on an oscillating rocker table, then washed 3 times in ~45 mL DI H2O 
mixed using a vortex mixer and separated by centrifugation for 30 min at 4000 rpm. 1.5 mL 
of 4 µg/mL BDNF protein solution was added to the SMCC-nanoparticle solution and 
allowed to react overnight at 4 °C before using centrifugation to remove the BDNF solution 
from the nanoparticles and immediately commencing the UV exposure and washing 
experimentation. All nanoparticle reaction containers were wrapped in aluminium foil to 
minimise light exposure.  
3.2.5 Chitosan Methacrylation for Water Solubility 
Chitosan was treated to become water soluble using previously published methods100. 
Briefly, 3% (w/v) chitosan (190,000-310,000 Da) was dissolved in 2% (v/v) acetic acid 
overnight then reacted with 7.45 mmol methacrylic anhydride for 3 h. The solution was 
dialyzed using 12-14 kDa molecular weight cut-off (MWCO) membranes and lyophilised to 
recover the methacrylated chitosan. This product was subsequently re-dissolved in water, 
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with all insoluble material removed, leaving only the demonstrably water soluble chitosan to 
be re-lyophilised and used in the attachment. 
3.2.6 Xyloglucan-PDL Preparation and Gelation 
Poly-D-Lysine (PDL) was coupled to xyloglucan as previously described.101  Briefly, 54 
mg poly-D-lysine (PDL) and 58 mg 4-azidoaniline were covalently bound using 155 mg N-
(3-dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDAC) in 140 mL DI H2O 
in an ice bath for 4 hr without light exposure. The solution was dialyzed in DI H2O through 
a 500 Da MWCO cellulose ester membrane for 48 hr and lyophilised. 110 mg of this 
photosensitive intermediate product was recovered and reacted with 201 mg xyloglucan 
(Dainippon Sumitomo Pharma, Japan) in 6 mL PBS under 100 W 365 nm UV light 
(Spectroline SB-100P/FA) for 150 s at 5 cm from the source and the product was lyophilised.     
3.2.7 Electrospinning 
A custom built electrospinning setup was used consisting of a syringe pump (KD-100, 
KD Scientific, Holliston, USA) and an adjustable DC voltage power supply (Model RR 50-
1.25R/230/DDPM, Gamma High Voltage Research, Ormond Beach, FL, USA) and a 13 
cm diameter grounded metal rotating mandrel to collect the fibres. A solution of 0.1 g/mL 
PLA (a.k.a. PLLA) in 3:1 chloroform to acetone was stirred to dissolution. For growth factor 
loaded fibres GDNF was mixed with the PLA solution at a ratio of 135 μL GDNF stock 
solution (at 100 μg/mL) added to 865 μL PLA solution (at 0.1 g/mL) for a theoretical 
concentration of 0.0156% (w/w) GDNF. The solution was loaded into a syringe fitted with 
a metal drawing up needle, and dispensed at a rate of 2 mL/h while charged to 7.5 kV at a 
working distance of 5 cm. Unmodified PLA was charged to 20 kV at a 12 cm working 
distance onto a rotating collector (1000 rpm).  
For Chapter Seven, The PLLA solution used the solution also contained 1 mM 
Dodeoyltrimethyl-ammonium bromide (DTAB), and was spun using a 21 G needle, 22 kV, 
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1.0 mL/h, 10 cm working distance with a rotating collector (2000 rpm). Polycaprolactone 
(PCL) scaffolds were prepared similarly in a 3:1 solution of chloroform to methanol, using a 
21 G needle, 20 kV, 2 mL/h, 13 cm working distance onto a rotating collector The collected 
scaffolds were dried in a vacuum oven (Labec) overnight at 30 °C.  
3.2.8 Short Fibre Cutting 
Short fibres were cut on a Leica microtome, using dry ice to freeze small pieces of the 
intact scaffolds in an upright position embedded in cryo-mounting media (TissueTek OCT, 
Fisher Scientific, USA). Short fibres were cut and using an appropriate step size 2 – 10 μm 
(Chapter Seven) or 20 μm (Chapter Eight) and collected in DI H2O. After cutting, short 
fibres were washed with DI water 3 times to remove the tissue mounting media, recovering 
the short fibres by centrifugation at for 30 min at 4000 rpm (Chapter Eight). For Chapter 
Seven the short fibres were 5 times by centrifugation and also washed in an ultrasonic bath. 
3.2.9 Nanoparticle Preparation 
37 mg of TiO2 nanoparticles (Degussa P25) were added to 90 mL of 0.1 M HCl and then 
ultrasonicated for 3 min. 7.5 mg of L-lysine was dissolved in 10 mL of 0.1 M HCl and added 
to the nanoparticle suspension. The reaction mixture was stirred continuously over 24 hr at 
room temperature in dark conditions, then washed 3 times in ~ 40 mL DI H2O using 
centrifugation for 40 min at 4000 rpm followed by sonication for 3 min.  
3.3 Material Characterisation 
3.3.1 Transmission Electron Microscopy (TEM) 
Transmission electron microscopy (TEM) was performed on a Hitachi H7100FA electron 
microscope using a 100 kV beam with a LaB6 cathode. Formvar coated copper grids were 
glow-discharged for 30 s at 15 mA. Hydrogel samples were negatively stained with 0.75% 
(w/v) uranyl formate (UF): after glow discharge the grids were gently immersed in the sample 
for 30 s, then briefly immersed in two consecutive drops of deionised water, then two drops 
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of the UF negative stain solution staying in the second drop for 20 s. The grids were gently 
blotted dry between immersions. Nanoparticle samples were imaged without staining: drops 
of nanoparticle solutions in DI water were air dried on glow discharged grids. 
3.3.2 Scanning Electron Microscopy (SEM) 
Scanning electron microscopy (SEM) was performed on a Zeiss UltraPlus electron 
microscope using a 3.0 kV beam, 7.5 μm aperture, and an in lens detector. Samples were 
affixed to double sided carbon tape before being sputter coated with platinum for 20 – 60 s 
at 20 mA. Hydrogel samples first were snap frozen in liquid nitrogen and lyophilised for at 
least 24 hours before being affixed to the carbon tape. Short fibre solution droplets were 
allowed to air dry on the carbon tape before being platinum coated. 
3.3.3 Rheology 
Rheological analysis was performed using a Kinexus Pro+ Rehometer (Malvern) using 
flat plate geometries with a solvent trap (Upper Geometry: PU20 SR1351 SS, Lower 
Geometry: PLS55 C0177 SS). A gap of 0.2 mm was used, with temperature maintained at 37 
°C and frequency sweeps were performed from 0.1 – 30 Hz at 0.1 or 0.5% strain. Isothermal 
rheology (Chapter Seven) was performed at 37 °C and 0.1 Hz on samples initially loaded at 
4 °C to determine the induction time of gelation.  
3.3.4 Spectroscopy 
Fourier Transform Infrared (FTIR) spectroscopy was conducted with an Alpha Platinum 
ATR FTIR (Bruker Optics) on 10 μL hydrogel samples, collecting up to 200 scans of each. 
The samples were allowed to dehydrate for 20-30 min to distinguish the SAP spectra from 
that of water, or else allowed to sit for 5 min using a background scan of DI H2O to 
distinguish the spectra.  
Circular dichroism (CD) was conducted with a Chirascan CD Spectrometer (Applied 
Photophysics Limited), scanning from 350 to 170 nm at a step size of 1 and 1 nm bandwidth 
43 
using a deionised water background scan. SAP hydrogels were diluted at 1:200 in deionised 
water, or 1:21 in Chapter Six. 
X-ray photochemical spectroscopy (XPS) analysis and peak assignment, used to confirm 
the presentation of PDL on the xyloglucan in Chapter Seven, was performed externally at 
CSIRO. The high-resolution spectra obtained were curve fitted to determine the 
contributions from chemically different C and N species (C1 – C4, N1 - N2).  
3.3.5 Surface Area Analysis 
Brunauer-Emmett-Teller (BET) surface area analysis was performed using a 
micromeritics TriStar II surface area and porosity instrument to determine the surface area 
of the scaffolds, and subsequently the amount of GDNF tethered onto the PCL surface. 45 
mg of untreated polymer scaffold was loaded into a dry 0.95 cm diameter sample tube and 
degassed under vacuum (0.15–0.3 mbar) at room temperature for 7 days on a micromeritics 
VacPrep 061 sample degas system. The degassed sample mass was determined to be 43 mg. 
The sample tube was then loaded into the instrument for adsorption analysis of nitrogen gas 
in a liquid nitrogen bath. The specific surface area was determined to be 3.0050 m2/g. The 
weight of the punch biopsies (0.6 cm in diameter) on which GDNF was attached, and cells 
cultured, was 0.80 mg so the absolute surface area was 0.0008 g × 3.0050 m2/g = 0.0024 m2 
= 24 cm2. 
3.4 Release Profiles 
3.4.1 Degradation and Release Profiles 
For BDNF degradation triplicate 200 µL samples of 1000 ng/mL solution of BDNF in 
PBS were added to wells of a 96-well plate for each time point. For the release profiles, 100 
µL samples of growth factor loaded hydrogel were added to 3 wells (Chapter Six) or 4 wells 
(Chapter Eight-Chapter Nine) each in 96-well plates. Dually loaded gels were loaded into 
double the number of wells to allow samples to be collected and tested for each growth 
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factor. Intact scaffold pieces ~7 mm2 (average 1.3 mg/piece for mGDNF, 6.6 mg/piece for 
iBDNF) were added to 5 wells each. The hydrogel was allowed to settle for ~5 min to reform 
into a gel before 200 µL of PBS was gently added on top of the hydrogels and/or scaffold 
pieces, marking the start point of the release profile. The sample plates were incubated at 37 
°C at 5% CO2. 150 µL samples were taken at appropriate time points and 150 µL of 
replacement PBS was added after removing each sample. The collected samples were stored 
at −20 °C (Chapter Six) or −80 °C (Chapter Eight-Chapter Nine).  
Nanoparticle loaded hydrogel plates were wrapped in aluminium foil to minimise light 
exposure. The “initial UV” plate was exposed before adding the first 200 μL of PBS, the 
“midway UV” plate was treated after 6 hr, after removing the 6 hr time point samples and 
before adding the replacement PBS.  
3.4.2 Lentiviral Release Profile and ELISA 
To determine successful immobilisation of the mCherry lentivirus, release of mCherry 
lentivirus from the two Fmoc-SAP hydrogels was compared. 100 μL samples of Fmoc-SAP 
hydrogels at 20 mg/mL were mixed with 1 μL of mCherry lentivirus (titre at 9.28 x 1010 
copies/mL; GeneCopoeia) and placed in a 96 well plate. 200 μL of PBS was placed on top 
of the gel and the plate placed in an incubator (37 °C, 5 % CO2). The PBS was then collected 
and replaced with fresh PBS every 24 hours for 5 days. The PBS supernatant was stored in a 
freezer until ready for analysis by an enzyme linked immunosorbent assay (ELISA). A HIV 
Type 1 p24 Antigen ELISA 2.0 kit (ZeptoMetrix) was used to measure the amount of 
mCherry released. The ELISA was performed as per the manufacturer’s instructions. 
3.4.3 Enzyme Linked Immunosorbent Assay (ELISA) 
Enzyme linked immunosorbent assay (ELISA) was used to quantify the protein present 
in degradation and release profile samples, as well as the growth factor bound nanoparticle 
suspension and supernatant samples. GDNF was quantified using a DuoSet ELISA kit 
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(R&D Systems) following the manufacturer’s instructions as well as our previously described 
ELISA method also used for BDNF.102 96-well plates were incubated with 100 µL/well 
capture antibody (R&D Systems: MAB848 for BDNF, MAB212 for GDNF) solution at 4.0 
μg/mL in PBS at room temperature overnight, then incubated for 1 hr at 37 °C with 200 
µL/well 2.5% (w/v) gelatin blocking solution. 100 µL/well samples and standard solutions 
(0.1-200 ng/mL) were incubated for 2 hr at room temperature, followed by 100 µL/well of 
primary antibody (R&D Systems: BAM648 for BDNF, AF-212-NA for GDNF) solution at 
1.0 μg/mL in 5% (v/v) donkey serum for 2 hr at 37 °C, then 100 µL/well secondary antibody 
(R&D Systems: HAF018 for BDNF, HAF109 for GDNF) solution diluted 1:40000 for 
BDNF or 1:20000 for GDNF in 2% (v/v) donkey serum for 1 hr at 37 °C. 100 µL/well of 
color reagent (R&D Systems: DY999) solution was allowed to react for 20 min at room 
temperature before being stopped by the addition of 30 µL/well 1 M HCl. Absorbance at 
450 nm was measured by a Tecan plate reader spectrophotometer and a calibration curve of 
standard solutions used to quantify protein present. The plate was washed 3 times by addition 
of a solution of 0.05% (v/v) Tween20 in PBS and 10 min of gentle oscillation after each 
incubation period, and this solution was used as the diluent for the gelatin, primary antibody, 
and secondary antibody solutions. The plates were wrapped in aluminium to minimise light 
exposure after the introduction of the secondary antibody solution until the end of the 
procedure.  
ELISAs on scaffold materials were performed on cut pieces of scaffold incubating in 
solutions in the 96-well plates. In these cases, the procedure started with the primary antibody 
incubation, and washing steps were done using vortexing of the scaffolds in the wash 
solution in separate vials. The scaffolds were removed from the 96-well plates after the colour 
change reactions were completed, leaving only the coloured solution in the well plates to be 
measured.   
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3.4.4 Hydrogel Washing (Chapter Five and Chapter Eight)  
100 μL portions of the different short fibre loaded DDIKVAV hydrogels, or fucoidan-
GNP loaded FRGDF hydrogels, were added to wells of a 96-well plate and 200 μL of DI 
H2O was gently added on top after letting the gels settle and reform ~5 min. The plate was 
placed on an oscillating rocker table to gently rinse the hydrogels, and the water was changed 
(175 μL removed, 175 μL fresh water added) at 1, 3.25, 5.5, and 7.5-hour time points ±10 
min, with no fresh water added at the final time point.  
3.4.5 Nanoparticle UV Exposure and Washing 
40 mL of DI H2O was added to the nanoparticles, followed by vortex mixing, making 
them up to a 0.425 mg/mL suspension. Triplicate 1 mL samples were taken for UV exposure, 
and another triplicate for untreated control samples. The UV exposure samples were treated, 
then 100 μL portions of all six nanoparticle suspension samples were taken. Then the 
suspension samples were centrifuged for 30 min at 4000 rpm and 200 μL portions of all six 
supernatants were taken. These portions were immediately stored at −80 °C until later 
analysis. Meanwhile, the original nanoparticle suspension was also centrifuged to separate 
the now once washed nanoparticles and refilled with DI H2O to 34 mL to maintain the 
nanoparticle concentration in the suspension. This process was repeated for 5 washed. All 
nanoparticle containers and samples were covered with aluminium foil to minimise light 
exposure. UV exposure was performed under 100 W 365 nm UV light (Spectroline SB-
100P/FA) for 2 min at a distance of 7 cm from the source. 
3.5 Biological Testing 
3.5.1 Animal and Cell Culture Conditions 
3.5.1.1 Animal Ethics 
All procedures were conducted in accordance with the Australian National Health and 
Medical Research Council’s published Code of Practice for the Use of Animals in Research, 
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and approved by the Florey Neuroscience Institute animal ethics committee or the ANU 
Animal Care and Use Committee. Mice and athymic nude rats were housed on a 12 hr 
light/dark cycle with ad libitum access to food and water. Cells used for in vitro culturing and 
transplantation were obtained from mice that were time mated overnight, with visualization 
of a vaginal plug on the following morning taken as embryonic day (E) 0.5.  
3.5.1.2 Ventral Midbrain (VM) Primary Cell Culture (Chapter Seven) 
Except for Section 7.4, Ventral midbrain (VM) tissue was isolated from Swiss mice at 
E12.5 as previously described.103,104 Cells were seeded at a density of 350,000 cells/well (37 
°C, 5% CO2) for 72 hours prior to fixation with 4% (v/v) paraformaldehyde. Culture 
substrates included: PDL-coated coverslips (PDL), xyloglucan coated coverslips (XYLO), 
xyloglucan + short fibres (XYLO+SF), xyloglucan + soluble GDNF (XYLO+sGDNF), 
xyloglucan + blended GDNF (XYLO+bGDNF), xyloglucan + short fibres with 
immobilised GDNF (XYLO+SF-iGDNF).  
In Section 7.4, VM tissue was isolated from C57BL/6 mice. Pregnant mice (E11.5) were 
anesthetised with isoflurane prior to cervical dislocation. The collected embryos were 
immersed in chilled L15 medium (Invitrogen), the brains removed and ventral midbrain 
microdissected. Subsequently, the tissue fragments were incubated in 0.1% (v/v) DNase and 
0.05% (v/v) trypsin (in magnesium and calcium free Hank’s buffered saline solution (HBSS)) 
for 15 min followed by three gentle washes in HBSS. Finally, the tissue fragments were 
dissociated in N2 media consisting of a 1:1 mixture of F12 (Invitrogen) and MEM 
(Invitrogen) supplemented with 15 mM HEPES buffer (Invitrogen), 1 mM glutamine 
(Invitrogen), 6 mg/ml glucose (Sigma-Aldrich), 1.5 mg/ml bovine serum albumin 
(Invitrogen), and 1% (v/v) N2 supplement (Invitrogen). Cells were seeded at a density of 
175,000 cells/cm2 onto either PDL-coated coverslips (in the presence or absence of soluble 
GDNF, 30 ng/ml) or PCL scaffolds (± immobilised GDNF) and incubated at 37 °C in 5% 
CO2 for 3 and 7 days. After 3 days and 7 days, the cells were fixed with 4% (v/v) 
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paraformaldehyde for 20 min, washed, and stored in PBS containing 0.025% (v/v) sodium 
azide until the time of immunocytochemistry. 
3.5.1.3 Neuron Primary Cell Culture (Chapter Eight) 
Isolation and culture of primary cells was performed as previously described105 unless 
otherwise noted. Briefly, mice were obtained from the Australian Phenomics Facility (APF) 
having been time- At E14.5 the pregnant mouse was sacrificed by cervical dislocation (CD) 
to collect the fetuses for cortical dissection for cortices without hindbrain, olfactory bulb, 
and meninges under sterile conditions. The cortices were trypsinised by 1x 0.25% (v/v) 
trypsin (Gibco), 1x DNAase (Gibco) in Hank’s balanced salt solution (HBSS) (Invitrogen) 
for 20 min in the incubator at 37 °C, 5% CO2. After digestion, cells were washed with HBSS 
three times. MEM solution with 10% (v/v) FBS was added to dissociate tissue into dispersed 
cells, which were counted with a haemocytometer and trypan blue.  
Cortical neurones were seeded at 2.5 × 105 cell/mL in 0.1 mL of MEM with 10% (v/v) 
FBS in 96-well plate wells. After 2 hours for attachment, the media was changed to primary 
culture media containing Neurobasal medium (Gibco), 1% (v/v) B27 serum-free 
Supplement (Gibco), 5 mM glutamine (Gibco) and 10 μg/mL gentamicin (Sigma) and cells 
were maintained for 3-5 days.  
The 96-well plates were prepared in advance with a poly-D-Lysine (PDL) coating. 
10ug/mL PDL was added into the wells to cover the surfaces of wells and stored in an 
incubator overnight. The next day the excess PDL removed by washing with PBS 3 times 
and the plates were returned to the incubator. 
3.5.1.4 Preparation of Primary Cortical Cells for Transplantation (Chapter Four) 
Adult female C57BL/6 mice were used as graft recipients while donor tissue for 
transplantation was obtained from time mated mice expressing green fluorescent protein 
(GFP) under the β-actin promoter. Embryos at E14.5 were collected in chilled L15 media. 
GFP+ embryos were selected, their brains removed and the cortices dissected to isolate 
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GFP+ cortical primary tissue. The cortices were incubated for 20 minutes in 0.1% (v/v) 
DNase and 0.05% (v/v) trypsin in magnesium and calcium HBSS. The tissue was then 
washed gently 3 times with HBSS. The tissue was then dissociated and the cells re-suspended 
in HBSS with 0.1% (v/v) DNAse at 200,000 cells/mL.  
3.5.1.5 Differentiation of Human Embryonic Stem Cells (hESCs) 
The human ESC line, HES3-ENVY, that constitutively expresses GFP under the human 
β-actin promoter,106 was cultured and differentiated using the dual Smad, dorsal forebrain 
differentiation protocol, as previously described.107 In brief, day 7 hESC colonies were 
manually dissected and transferred to organ culture dishes coated with 1 mg/mL laminin and 
grown in neural basal media (NBM: Neurobasal Media with 1% (v/v) N2 supplement, 1% 
(v/v) ITS-A, 2% (v/v) B27 without vitamin A, 0.5% (v/v) penicillin-streptomycin, 1% (v/v) 
Glutamax). Neural induction (day 0-4) was achieved by dual SMAD-inhibition using 500 
ng/mL human recombinant noggin (PeproTech) and 10uM SB-431542. From day 4, media 
was supplemented with 20 ng/mL FGFb and EGF (R&D Systems), to promote neural 
precursor proliferation and maintenance. At day 10 thick central cores of neural precursor 
colonies were manually isolated and pieces transferred to low attachment 96-well plates to 
generate neurospheres for a further 7days. Spheres were either cryopreserved (4% (v/v) 
paraformaldehyde, 7min; followed by 20% (w/v) sucrose in PBS) and sectioned for 
immunohistochemical analysis or dissociated (Accutase, Invitrogen; 37oC for 10 minutes,) to 
provide a single cell suspension (100,000 cells/μL) for the purpose of transplantation. At the 
time of implantation, cells were diluted 1:1 in SAP gels or HBSS media. 
3.5.1.6 Cell Lines and Culture Conditions (Section 5.3) 
The human tongue squamous cell carcinoma cell line (SCC25) cultures were obtained 
verified from ATCC and were maintained in DMEM-F12 complete medium containing 10% 
(v/v) FBS and 400 ng/mL hydrocortisone and penicillin/streptomycin. The human 
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mammary fibroblast cell line (hMFC) cultures were maintained as described previously.78 Cell 
line cultures were maintained at 37 °C with 5% CO2. 
3.5.1.7 Endothelin-1 Lesioning and Transplantation in Rats 
Surgeries were performed under general anaesthetic using 2% isoflurane inhalation 
(Baxter; Deerfield, IL, USA). To model focal ischemia, 81 rats received unilateral injections 
(2 × 1 µL) of the vasoconstrictor endothelin-1 (400 pmol/μL) into the sensorimotor cortex 
at the following co-ordinates: 0.5 and 2.0 mm anterior, 2.5 mm lateral relative to bregma, and 
at depths of 0.0 and 2.0 mm below the dural surface. An additional 12 rats were used as 
unlesioned controls. At 6 days or 3 weeks after lesioning, animals received two intracortical 
injections (1 µL/injection) of hESC-derived cortical progenitor and/or SAP gels into the 
lesion site (0.5 and 2.0 mm anterior, 2.5 mm lateral relative to bregma, and at depths of 1.5 
mm below the dural surface). Where relevant, the final concentration of implanted SAP gels 
was 10 mg/mL and the total number of transplanted cells was 100,000/animal.  
3.5.1.8 6-Hydroxydopamine Lesions and Transplantation (Chapter Seven) 
For in vivo studies, adult female Swiss mice were used as graft recipients while tyrosine 
hydroxylase-green fluorescent protein (TH-GFP) mice 108 were used to generate embryos as 
a source of donor tissue for transplantation. The use of TH-GFP donor tissue enabled 
identification of graft (GFP+) verses host (GFP-) derived TH+ dopamine neurons in vivo. 
All surgeries were performed under general anaesthetic using 2% isoflurane inhalation 
(Baxter; Deerfield, IL, USA). To model Parkinson’s disease, mice received partial lesions of 
the VM DA neurons by unilateral injection of the selective catecholamine neurotoxin 6-
hydroxydopamine (6-OHDA, 3.2 μg) into the SNpc, as previously described.109 Using 
previously described methods, 3 weeks after lesioning, host animals received ectopic 
intrastriatal grafts of a single cell VM suspension.103 The cell suspension (150,000 cells/μL) 
was diluted 1:2 in either: HBSS, xyloglucan (±GDNF), or xyloglucan+PLLA short fibres 
(±GDNF) to give a final concentration of 50,000 cells/μL. The various cell suspensions 
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were stereotaxically injected (2 μL, i.e. 100,000 cells) into the denervated host striatum at the 
following co-ordinates relative to bregma: anterior 1.0 mm, lateral 2.3 mm, and 3.1 mm below 
the dural surface. Ten weeks after transplantation animals were killed by an overdose of 
sodium pentobarbitone (100 mg/kg) and their brain processed as previously described.19 
3.5.1.9 Implantation (Chapter Four) 
Mice received implants of cells in the presence or absence of Fmoc-SAPs (Fmoc-
DIKVAV; Fmoc-FRGDF; Fmoc-DYIGSRF), n = 6 per group. Mice were anaesthetised 
with 5% isoflurane, and the level of anesthesia maintained at 2% for the duration of the 
surgery. Mice were placed in a stereotaxic frame, midline incisions were made in the scalp 
and craniotomies were performed overlying the striatum. Cells were mixed at a 1:1 ratio with 
HBSS or Fmoc-SAP prior to implantation into the striatum. A total of 2 mL (200,000 cells) 
were injected, using a fine glass capillary, at the following co-ordinates: 1.0 mm anterior and 
2.5 mm lateral relative to bregma, and at a depth of 3.2 mm below the dural surface. After 
28 days, mice were delivered a terminal dose of barbiturate and were transcardially perfused 
with warm saline followed by 4% (v/v) paraformaldehyde (PFA). Brains were removed and 
post-fixed for 2 hours in 4% (v/v) PFA before overnight cryo-preservation in 30% (w/v) 
sucrose solution. The brains were then coronally sectioned at 40 mM in 12 series before free-
floating immunohistochemistry was performed. 
3.5.1.10 Implantation of m-Cherry virus 
Adult Swiss mice received stereotaxic implants of mCherry lentivirus alone (n = 6) or 
mCherry virus in the presence of Fmoc-DDIKVAV (n = 6) or Fmoc-DDIKVAVK (n = 6). 
5% isoflurane was used to induce anaesthesia. 2% isoflurane was maintained for the duration 
of surgery. Mice were placed into a stereotaxic frame and a craniotomy performed for 
microinjections into the underlying striatum (co-ordinates: anterior +1.0 mm and lateral -2.3 
mm, relative to Bregma). A fine pulled micropipette coupled to a Hamilton syringe was used 
to inject virus or virus with Fmoc-SAP at a depth of 3.2 mm below the dura surface. For 
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control animals, 1 μL of mCherry (109 UI/mL) was diluted in 1 μL sterile PBS and the total 
2 μL suspension implanted. Alternatively, the virus was mixed at a 1:1 ratio with the Fmoc-
SAP.  
3.5.1.11 Sample Preparation (Chapter Seven) 
For in vitro culturing, GDNF was delivered: (i) directly into the culture media (soluble 
GDNF, sGDNF; 30 ng/mL), (ii) blended into xyloglucan gels prior to casting into culture 
plates (blended GDNF, bGDNF, 150 ng/mL gel, 100 μL gel per coverslip/well) or 
alternatively (iii) covalently immobilised onto PLLA short fibres that were delivered in 
xyloglucan gel (immobilised GDNF, iGDNF, with 100μl of gel including PLLA short fibres 
per coverslip/well). All conditions were cultured in 24-well culture plates in the presence of 
0.5 mL of media—hence the total dose of sGDNF and bGDNF was 15 ng/well.  
For in vivo delivery, GDNF was delivered within the cell preparation (Cell + sGDNF, 1 
μg/injection), blended into the xyloglucan at the time of delivery with cells (Cells + XYLO-
bGDNF, 1 μg/injection), delivered by immobilization of short fibres (Cells + XYLO + SF-
iGDNF) or a combination of blended and immobilised (Cells + XYLO-bGDNF +SF-
iGDNF). 
3.5.2 Biological Assessment 
3.5.2.1 Assessment of Grafts in Rats (Chapter Four) 
Atrophy and neuronal cell loss within the host cortex were quantified in ET1 lesioned 
rats, immuno-labelled with NeuN, at 36 weeks after cell and/or SAP implants. Six sections 
from a 1:12 series, spanning from bregma to 2.5 mm rostral, were analysed. Cortical area, 
ipsilateral to the infarct, was delineated based on anatomical landmarks and expressed as a 
percentage of the intact (saline-injected) brain. The cortical area boundaries were established 
via the corpus collosum and limited ventrally by the piriform cortex. Volumetric assessment 
across the rostro-caudal axis was performed according to Cavalieri’s principle using 
StereoInvestigator Software (MicroBrightfields, USA). 
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NeuN cell loss within the cortex was estimated from the two sections adjacent to the 
lesion core.  The atrophied area delineated, was used to estimate NeuN cell density from 
lesioned and intact animals. Stereological counts within the area were made at regular pre-
determined intervals (200 × 200 μm) within a defined counting frame (40 × 40 μm), 
according the optical fractionator principles110 and previously described methods,109 and 
density determined according to the volume sampled. 
Human ESC-derived grafts were identified by GFP-labelling within the cortex, with 
volumetric assessments, cell counts (DAPI, NeuN and TBR1) and cell densities, performed 
stereologically. Counts were made at the following pre-determined intervals (DAPI: 500 × 
500 μm; NeuN: 400 x 400um; TBR1 & BRN2: 280 x 280um) using unbiased counting frames 
of known areas (DAPI: 10 × 10 μm; NeuN: 20 × 20 μm; TBR1 & BRN2: 30 x 30um). For 
all counts, the co-efficient of error (CE) coefficient of variance (CV) were calculated as 
estimates of precision, and values of less than 0.1 were accepted.111 
3.5.2.2 Assessment of Grafts in Mice (Chapter Four) 
Grafted cells, and the extent of their innervation were discernible by the presence of 
GFP+ staining. For all animals, total number of GFP+ cells, density (GFP+ cells/mm3) and 
volume of innervation (mm3) were quantified. Optical intensity was measured at two fields 
of view (FOV) for comparison of innervation between each group. This technique was also 
used for assessment of inflammation. ImageJ was used to determine the optical intensity of 
the fluorophore (488 for GFP; 550 for GFAP and 649 for CD11b) in each image at each 
FOV. This provides a relative comparison for the extent of innervation or elicited 
inflammatory response induced in each group. 
3.5.2.3 Cell Counting and Assessment of Neurite Growth (Chapter Seven) 
For in vitro assessment, neuronal differentiation and neurite morphology were analysed 
from cultures using previously described methods.104 In brief, TH+, TUJ+ and DAPI 
labelled cells were quantified from 10 sampling sites/well and 3 technical replicates (i.e. wells) 
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performed per experimental condition. For assessment of neurite morphology, 30 TH+ cells 
were quantified. Photomicrographs of each DA neuron (identified by TH+) were taken using 
a 20x objective (Olympus IX71) and measurements of total neurite length obtained using 
NeuronJ software (ImageJ, NeuronJ plugin, NIH). 
The inflammatory response of the host brain to the implants was assessed at 
predetermined sites adjacent to the graft core for each graft (Figure 7.7C). Leica LAS Image 
Analysis LAS Software (Leica) was used to estimate GFAP and CD11b density from images 
captured at 20x on a Leica 6000 microscope. The area covered by GFAP+ fibres or CD11b+ 
cells was expressed as a percentage of total area. 
For in vivo assessment of the graft, the number of grafted dopamine (DA) neurons within 
each animal was quantified based upon GFP+ labelling.112 The volume of the graft core (area 
delineated exclusively around the grafted GFP+ cell bodies) was used to estimate cell density 
within the grafts and total volume on GFP+ innervation was assessed by delineation of 
densely stained GFP+ fibre innervation of the striatum.  Density of innervation within the 
striatum was examined at a predetermined location, directly adjacent to the graft core.19 Leica 
LAS Image Analysis Software was used to estimate fibre density from images captured at 
40x magnification on a Leica 6000 microscope.  
3.5.2.4 Immunoblotting 
The dopaminergic (DA) neural stem cell line, SN4741, was cultured in DMEM, 10% (v/v) 
FBS, L-glutamine (2 mM), penicillin/streptomycin (50 units/mL), and glucose (0.6% (w/v)). 
For analysis of intracellular GDNF signalling, 100,000 cells were seeded onto 12-well plates 
or PCL scaffolds. At 70% confluency the cells were changed into serum-free media with or 
without GDNF (soluble or immobilised). A standard curve of GDNF treatment (0, 3, 10, 
30, 100 ng/ml), using the same cell line, was performed in parallel to quantify the levels of 
GDNF activity. Cells were stimulated with soluble GDNF (sGDNF, 30 ng/ml) for 60 min 
or 3 days, and tethered GDNF (iGDNF) for 1 day or 3 days prior to being lysed in ice-cold 
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buffer containing 20 mM Tris-Cl, pH 7.5, 150 mM NaCl, 1% (v/v) Triton X-100, 1% (v/v) 
protease inhibitor mixture, 50mM NaF, and 0.2mM Na3VO4 for 20 min. Lysates were 
centrifuged at 14,000 rpm for 20 min at 4 °C to collect supernatants. Protein was quantified 
using the bicinchoninic acid assay kit (Pierce) using bovine serum albumin standards. 
Protein (50 μg) was electrophoresed through 12.5% SDS-polyacrylamide gels and 
transferred to Immobilon PVDF-FL membrane (Millipore). Membranes were blocked with 
5% (v/v) skim milk in Tris-buffered saline with Tween-20 (TBST), pH 8.0, for 30 min and 
incubated with mouse pErk1,2 (1:2000, #9106, Cell Signaling Technology) and rabbit total 
Erk1,2 (1:1000, #9102, Cell Signaling Technology) antibodies in 3% (w/v) BSA in TBST 
overnight at 4 °C. Blots were washed 3x in TBST for 10 min and incubated with IRDYe 680 
and 800CW-conjugated secondary antibodies (1:10000) followed by 3 washes in TBST for 
10 min and detected using the Odyssey Classic infrared imaging system. Membranes were 
then stripped and re-probed with mouse anti β-actin (1:5000, Sigma). Blots were quantified 
by taking the ratio of pErk/Erk bands and subtracting background intensity 
intensity. 
3.5.2.5 Immunocytochemistry and Immunohistochemistry  
Procedures were performed as previously described.112 Primary antibodies and dilution 
factors used were: mouse anti-βIII-tubulin (TUJ1, 1:1500, Promega), rabbit anti-tyrosine 
hydroxylase (TH, 1:800; PelFreez), chicken anti-GFP (GFP, 1:1000, Abcam), rabbit anti-
GFP (1:20000; Abcam), rabbit anti-GFAP (GFAP, 1:800, DAKO), and mouse anti-CD11b 
(1:100, Serotec). The secondary antibodies used for direct detection were DyLight 488 
donkey anti-mouse, DyLight 549 anti-chicken, DyLight 649 anti-rabbit, DyLight 550 donkey 
anti-rabbit, and DyLight 649 donkey anti-mouse (Jackson ImmunoResearch) used at dilution 
of 1:200 for immunohistochemistry; and Dylight 488 donkey anti-rabbit and Dylight 549 
donkey anti-mouse (Jackson ImmunoResearch) used at a dilution of 1:300 for 
immunocytochemistry. The secondary antibodies used for indirect detection were biotin 
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conjugated donkey anti-rabbit (1:500; Jackson ImmunoResearch) followed by peroxidase 
conjugated streptavidin (Vectastain ABC kit, Vector laboratories) or 649 conjugated 
streptavidin (1:200; Jackson ImmunoResearch). All in vitro cultures were additionally 
counterstained with Hoechst (Life Technologies) at 1:5000 for immunohistochemistry and 
1:1000 for immunocytochemistry. All fluorescent images were captured using a Zeiss Axio 
Observer.Z1 or Leica CTR6000 microscope whilst bright and dark-field images were 
obtained using a Leica DM6000 upright microscope.  For the long-term study in Chapter 
Four, at 36 weeks post-implantation (gels and/or cells) animals were killed by an overdose 
of sodium pentobarbitone (100 mg/kg) and their brain processed for immunohistochemistry 
as previously described.112 
3.5.2.5.1 mCherry Staining (Section 5.4) 
After 21 days, mice were killed by an overdose of sodium pentobarbitone (100 mg/kg) 
and transcardially perfused with warm saline followed by 4% (v/v) paraformaldehyde (PFA). 
After removal, mouse brains were post-fixed for 2 hours in 4% (v/v) PFA. Following 
fixation, brains were cryo-preserved in a 30% (w/v) sucrose solution overnight. The brains 
were coronally sectioned (40 μm at a 1:12 series) and immunohistochemistry against red 
fluorescent protein (rabbit anti-RFP, 1:1000, Rockland, USA) was performed to amplify the 
mCherry signal, using previously described methods.112 Cell counts for mCherry virally 
infected cells (mCherry+), transduction volume and density measurements were carried out 
on a Leica CTR6000 microscope using LAS software. 
3.5.2.5.2 NFκB and CEP55 Staining (Section 5.3) 
SCC25 cells were treated without and with fucoidan (2 mg/mL) for 48 h. Cells were fixed 
with paraformaldehyde and permeabilised with 0.1% (v/v) triton-X-100. For Annexin V cells 
were stained with the Alexa Fluor® 488 annexin V/Dead Cell ApoptosisKit (Life 
Technologies) and counter-stained with Hoechst dye to stain the live cells. For NFκB and 
CEP55 cells were blocked with 1% (w/v) bovine serum albumin (BSA) in PBS for 1 hr at 
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room temperature and further treated with primary antibody rabbit polyclonal NFκB p65 
(Abcam) or rabbit monoclonal CEP55 antibody (Abcam) overnight at 4 °C. Cells were 
further incubated with anti-rabbit Alexa Fluor 488 secondary conjugates for 1 hr at room 
temperature. Following several washes cells were visualised under fluorescence microscope 
(Nikon Eclipse Ti-S). 
3.5.2.6 Reverse Transcription and Quantitative Polymerase Chain Reaction 
(QPCR) 
Total RNA was reverse-transcribed to generate complimentary DNA using Superscript 
III (Invitrogen) following the manufacturer's protocol. To challenge fucoidan, cells were 
stimulated with LPS at a concentration of 10 μg/mL in the complete media. cDNA of 30 ng 
was used to perform quantitative real time PCR in a 20 μL reaction using SYBR Green 
(Biorad) on a CFX connectTM Real Time PCR detection system (Biorad). Primer 
oligosequences were designed using Primer3 PCR prime design tool (Whitehead Institute for 
Biomedical Research, Cambridge, MA, USA) and the gene specificity was checked using the 
National Center for Biotechnology Information nucleotide database. Steps followed during 
QPCR to generate amplification curves included an initial denaturing step for 3 min at 95 
°C, followed by 40 cycles of 95 °C for 10 s, 60 °C for 30 s, and 72 °C for 30 s. The expression 
of each gene in terms of fold change was normalised to the housekeeping gene ACTB. 
3.5.2.7 Functional Recovery/Behavioural Testing 
The staircase test was performed as previously described,113 using 1 week post-lesioning 
as the untreated starting point and additional tests after treatment implants at 4, 8, 16, 24, 
and 36 weeks post-lesioning. Briefly, animals were placed on a food-restricted diet 
(maintained at 85% of pre-test free-feed weight) for the duration of the 7-day test period. 
Each day rats were placed in the staircase apparatus where each forepaw had unilateral access 
to sugar pellets positioned on ascending steps. The total number of pellets (maximum 50) 
retrieved and eaten for each forelimb was reordered in a 20 min test period. The number of 
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pellets eaten was recorded and averaged for the last 3 days of the test period Retrievals made 
with the impaired paw (left) were expressed as a percentage of total retrievals, (%L/L+R). 
The cylinder test was performed at 36 weeks post implantation as previously described.114 
Animals were placed in a glass cylinder (20 cm diameter) and weight-bearing forepaw 
contacts with the glass wall in response to exploratory behaviour were recorded. A total of 
20 paw contacts were recorded per animal and expressed as a percentage of left (impaired 
paw) touches/total touches. 
The stepping test was performed as previously described.115 Rats were restrained by the 
experimenter and allowed to make unilateral forepaw weight-bearing contact with the bench. 
Rats were assessed for their ability to make stepping adjustments with their weight-bearing 
forepaw when moved laterally over a distance of 1 m. The number of steps made by the paw 
was recorded in both the forehand and backhand direction with testing repeated 3 times/day 
over 5 consecutive days.  
The rotarod performance test was conducted in rats at 36 weeks following treatment 
implantation. Animals were placed on a horizontally suspended rotating rod and the time on 
the rod before falling (maximum 300s) was recorded. Each animal received 3 consecutive 
trials. 
3.5.2.8 MTT Assays 
Primary cells were incubated overnight to adhere before commencing. Cell media was 
removed and cells were replaced with 100 μL of fresh media containing growth factor 
samples, including: growth factor solution at a final concentration in the media of 1000 
ng/mL, scaffold segments approximately 4 mm square with average masses of 1.4 mg for 
the iBDNF scaffolds and 1.6 mg for the mGDNF scaffolds submerged in media, and short 
fibres solutions at 9.1 mg/mL in media (for a theoretical maximum concentration of 1.4 
μg/mL GDNF from 0.0156% (w/w) loaded mGDNF short fibres, noting that release data 
suggests this would not be completely released over the 3-day incubation). Samples were 
59 
incubated with the cells for 3 days, after which the samples were removed, the cells washed 
with PBS, and the MTT assay conducted. MTT Assays were performed using a Vybrant 
MTT Cell Proliferation Assay Kit (V-13154) following the manufacturer’s instructions using 
the DMSO quick method. Cells were visually assessed by light microscopy before and after 
the MTT assay to confirm healthy neuron growth. 
3.5.2.9 Statistical Analysis 
One-way ANOVAs with Tukey post-hoc tests were used to identify statistically significant 
changes between groups. Statistical significance was set at a level of P < 0.05. Data represents 
mean ± standard error of the mean (SEM), or data ± standard deviation (SD) in Section 7.4. 
For the intact brain biocompatibility studies in Chapter Four the data was also transformed 
in order to obtain equal variance and the tests repeated, however, this had no effect on the 
statistical information obtained. For Chapter Seven, all in vitro studies were performed on 3 
technical replicates per condition per experiment and repeated on 3-5 independent VM 
primary cultures. A total of 74 animals received cell transplants ± scaffolds, with 9-11 animals 
assigned per treatment group. For assessments of cell viability and differentiation, 10 fields 
of view per coverslip or scaffold were imaged using a Zeiss200 inverted microscope (images 
captured at 20x magnification). 
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4.1 Chapter Details 
The work in this thesis was aimed at achieving temporal control of the delivery of growth 
factors from self-assembling peptide (SAP) hydrogels, making SAP hydrogels a critical 
component. This chapter briefly discusses work to which I have contributed to confirm the 
biocompatibility of the SAP hydrogels used before moving on to the incorporation of growth 
factor delivery into the materials. The work includes the primary SAP sequences used 
throughout this thesis (FRGDF, DDIKVAV, and DIKVAV) as well as another 
neurologically relevant sequence (DYIGSRF). All sequences were tested in vivo, with the 
FRGDF, DIKVAV, and DYIGSRF sequence hydrogels tested for their biocompatibility 
with cell grafts in an intact brain in mice and the DDIKVAV assessed separately in a more 
extensive long-term study for their ability to provide cell graft support to aid recovery in an 
ischemic (stroke) brain injury in rats.  
The biocompatibility testing in intact brains section of this chapter briefly describes work 
published in the research article listed below, and included in full in Appendix B: 
Chapter Four 
SAP Hydrogels in vivo 
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A. Rodriguez, T. Wang, K. Bruggeman, C. Horgan, R. Li, R. Williams, C. Parish, D. 
Nisbet, “in vivo assessment of grafted cortical neural progenitor cells and host response 
to functionalised self-assembling peptide hydrogels and the implications for tissue 
repair”, Journal of Materials Chemistry B, 2014, vol. 2, pp. 7771-7778 - Reproduced by 
permission of The Royal Society of Chemistry (http://www.rsc.org/) 
The ischemic brain study section of this chapter briefly describes work from a manuscript 
in preparation. 
4.2 Abstract 
Tissue engineering materials that can mimic the physical, chemical, and biological 
properties of the natural extracellular matrix (ECM) are of great interest in regenerative 
medicine. Self-assembling peptide (SAP) hydrogel materials are of particular interest for their 
inherent biocompatibility and ability to be engineered with biologically relevant and tissue-
specific sequences, which are then presented at a high density in a nanofibrous environment 
structurally mimetic of the ECM. Here SAP hydrogels designed from a range of biological 
peptide sequences were tested in vivo for their biocompatibility delivered with cell grafts into 
an intact brain (in mice). Additionally, a brain tissue specific hydrogel, designed from the 
common brain ECM protein laminin, was tested for its efficacy in supporting cell grafts in 
treatment of ischemic brain injury (stroke) in a protected 9-month study (in rats). All 
hydrogels tested show non-cytotoxicity, and the tissue-specific hydrogel significantly 
improved the cell graft results in treating the ischemic brain, showing improvements in 
sensorimotor behavioural analysis, specific neuronal differentiation, and reduction in 
secondary degeneration/cortical atrophy of the host tissue. 
4.3 Introduction 
Three-dimensional (3D) ECM mimicking materials have demonstrated their potential to 
provide cellular support in vitro and in vivo.116 Materials designed with a “bottom up” 
approach, particularly nanofibrous SAP materials, are gaining interest62,117 and being 
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investigated for their ability to promote endogenous repair of support cell transplantation.8 
The ECM itself includes tissue-specific proteins that initiate cell pathways via integrin 
activation,9 and specific sequences within these proteins are known to influence intracellular 
processes including adhesion, proliferation, differentiation, and migration.118 Research has 
shown that incorporating these peptide sequences into multicomponent materials can direct 
intracellular signalling and control cell fate.119,120  Commercial SAPs consist of long sequences 
engineered for self-assembly and inherent biocompatibility, and these have been additionally 
modified to include biologically relevant peptide sequences as pendant groups to add an 
element of biological signalling/mimicry to the materials.79 The design of Fmoc-capped 
minimalist SAP materials simplifies the process by using the bioactive sequence directly as 
the SAP, engineered with small additions to the sequence in order to ensure self-assembly 
under physiological conditions.9 In addition to the inherent biocompatibility of a peptide 
material, the use of peptide self-assembly to incorporate biological cues means that those 
biochemical and biomechanical cues are presented to cells in a manner similar to that of 
natural cues from the natural ECM,121 increasing the biomimicry of the material.  
Biological testing of these minimalist Fmoc-capped SAPs has focused on the in vitro cell 
culture using short di- or tri-peptide or the arginine-glycine-aspartic acid (RGD) sequence 
from fibronectin.7,122-124 The specific design of the peptide sequence to allow the inclusion of 
larger 5-amino acid sequences is relatively new,9 and these materials have not been fully 
investigated in vivo. Here we focus on in vivo investigation of laminin derived SAPs, designed 
for tissue-specific application in the brain by using the sequences from the ECM protein 
common in brain tissue. Both isoleucine-lysine-valine-alanine-valine (IKVAV) and tyrosine-
isoleucine-glycine-serine-arginine (YIGSR) sequences from laminin have been incorporated 
into minimalist Fmoc-SAPs, and are tested for biocompatibility as a cell graft support 
material in an intact brain in mice along with an RGD derived sequence for comparison and 
confirmation of the benefit of tissue-specific materials. The IKVAV sequence is further 
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investigated as a cell graft support material in repairing brain tissue in an ischemic brain injury 
model in rats. 
Biomaterials have been shown to be very useful in regenerative medicine125 including 
supporting neural cells for central nervous system (CNS) repair.23 In the case of stroke or 
ischemic brain injury, much of the dysfunction is caused by the loss of neurons in the cerebral 
cortex as well as secondary degeneration in the surrounding penumbra.126,127 However, 
clinical trials in cell transplantation for stroke have not focused on neuron replacement, but 
rather on penumbral protection or controlling angiogenesis or inflammation.128-132 Studies 
have shown that pluripotent stem cells (PSCs) survive when transplanted into an ischemic 
brain, and increase neuron numbers and partially alleviate functional deficits.133-141 However, 
cells injected alone into ischemic brain lesion cavities have poor survival rates as they migrate 
from that hostile host environment to the adjacent parenchyma, indicating the need for 
adjuvant scaffolds to provide a supportive environment at the lesion site to improve the 
effectiveness of cell transplantation treatments. These tissue engineering materials could 
essentially bridge the cavity and provide a substratum for the grafted cells and their axons. 
Polymer-based tissue engineering materials have been well explored in this supportive role 
for cell grafts into ischemic brains,142-149 and the work described here represents the first 
protracted (~9 months) assessment of human stem cell-derived neural progenitor cell grafts 
with SAP hydrogels.  
4.4 Results and Discussion 
The π-β self-assembly mechanism of Fmoc-SAPs has been previously investigated and 
explained.7 π-π stacking of the aromatic Fmoc groups and formation of β-sheet structures 
between peptide sequences together form slightly twisted sheets that create a cylindrical 
structure.7  Following this assembly mechanism (Figure 4.1A-G), the minimalist Fmoc-
capped self-assembling peptide (SAP) sequences used here have several important features. 
The aromatic Fmoc capping groups engage in π-π stacking (Figure 4.1B), one of the driving 
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forces of the self-assembly process. The self-assembly also involves hydrogen bonding and 
charge-charge interactions between the peptide sequences themselves, forming β-sheet 
structures (Figure 4.1C). Because these interactions depend on charges, and the charges 
present in peptide molecules are dependent on pH, the self-assembly process is pH driven. 
This has been considered in the peptide sequence design.  
 
Figure 4.1: Self-assembling peptides. A-G: Self-assembly mechanism: molecular structure of Fmoc-
DIKVAV (A), π-π stacking between aromatic Fmoc groups (B), additional anti-parallel β-sheet interactions 
between peptide sequences resulting in sheets (C) that wrap around into hollow nanofibres (D) and associate 
longitudinally in bundles (E), and TEM micrograph (F) and photo (G) of resulting nanofibrous hydrogel. Scale 
bar represents 100 nm. H-J: Molecular structures of other self-assembling peptide sequences: Fmoc-
DDIKVAV (H), Fmoc-DYIGSRF (I), and Fmoc-FRGDF (J). 
All the sequences studied here include biologically recognisable epitopes (Figure 4.1A,H-
J), IKVAV or YIGSR from laminin, or RGD from fibronectin, both ECM proteins. The 
sequences also contain additional amino acid residues to engineering the molecules to allow 
self-assembly under physiological conditions. The additional aspartic acid (D) residues shift 
the pKa of the overall molecule, affecting the charges on the sequence such that self-
assembly occurs at a lower pH (as the IKVAV sequence alone self-assembled under very 
basic conditions).9 The additional aromatic phenylalanine (F) residues aid the self-assembly 
by engaging in additional π-π stacking.78 All the sequences studied here do self-assemble at 
physiological pH, forming nanofibres that physically associate longitudinally with each other 
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due to surface interactions, and form into bundles of nanofibres and a nanofibrous hydrogel 
network (Figure 4.1D-F). Unlike some commercial SAP sequences, the minimalist Fmoc 
SAPs used here all present a high density of biologically relevant cues on the surface of the 
nanofibres.  
Working first with the DIKVAV, DYIGSRF, and FRGDF sequences the material 
properties of the hydrogels were assessed. The TEM micrographs showed nanofibrous 
networks for all hydrogels (Figure 4.2A-C). Rheological analysis confirmed the viscoelastic 
properties of a hydrogel in all cases, with the storage modulus (G’) greater than the loss 
modulus (G’’) and both mostly independent of frequency (Figure 4.2D-F).9 The DIKVAV 
sequence was stiffer than the other two, with G’ ~ 30 kPa, compared to ~100 Pa and ~200 
Pa for the FRGDF and DYIGSRF sequences. These values all fall in the range appropriate 
to various soft tissues (0.1 – 40 kPa),2 and while the ideal range for brain tissue is 0.1 – 1 
kPa,2 the exact stiffness for each sequence can be adjusted by changing the peptide 
concentration in the hydrogel. The spectroscopic analysis confirmed the intermolecular 
interactions, with FTIR major and minor peaks around 1630 cm-1 and 1690 cm-1 respectively 
indicative of β-sheets (Figure 4.2G).9 The CD spectroscopy showed transitions in the in the 
180-220 nm range indicative of anti-parallel β-sheets, and another in the 230-270 nm range, 
indicative of supramolecular ordering (Figure 4.2H).9  
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Figure 4.2: Material properties of SAP hydrogels. A-C: TEM micrographs of the SAP nanofibres. Scale 
bars represent 100 nm. D-F: Rheological analysis of SAP hydrogels showing storage modulus (G’) (black circles) 
and loss modulus (G’’) (black squares). G-H: Spectroscopic FTIR (G) and CD (H) analysis of the SAP 
hydrogels. Fmoc-DIKVAV (A, D, solid line), Fmoc-FRGDF (B, E, dashed line), and Fmoc-DYIGSRF (C, F, 
dotted line). 
The SAP hydrogels were tested biologically as carriers for use in cell replacement therapy 
(CRT), injected with GFP+ neural progenitor cells from embryonic mice (Section 3.5.1.4, 
3.5.1.9). After 28 days, we assessed the graft (Section 3.5.2.2), looking at the overall graft 
region, the region permeated by GFT+ cells, as well as the graft core, with the highest density 
of implanted GFP+ cells (respectively, the brown and dark/black regions seen in the brain 
hemisphere (Figure 4.3D)). The overall graft innervation volume, as well as the number of 
GFP+ cells and GFP+ cell density in the core of the graft (Figure 4.3A-C), all showed no 
statistically significant difference between any of the hydrogels or the cell graft alone, 
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indicating that the materials are non-cytotoxic. Although not statistically significant, the 
FRGDF sequence did show lower GFP+ cell number, volume, and density. This supports 
the idea of designing tissue-specific SAP hydrogels, as the bioactive RGD portion of the 
sequence is from fibronectin rather than laminin. Laminin is a major constituent of the ECM 
of the brain and is known to modulate neural differentiation and neurite extension.150 Fibre 
innervation specifically was assessed at 2 pre-determined locations starting at the edge of the 
graft and moving outward (Figure 4.3D-J). Again, there was no statistically significant 
difference between the groups, indicating that neurite outgrowth from the grafted cells was 
not impeded. This is particularly important as integration of transplanted cells and 
reinnervation of damaged tissue are key goals in cell replacement therapy required for last 
repair of neural circuitry.151  
 
Figure 4.3: Cell grafts with SAP hydrogels. A: Total innervation volume. B-C: cell number (B) and cell 
density (C) of GFP+ cells in the graft core implanted into mouse brains alone and with the 3 SAP hydrogels 
studied. D: Locations within single brain hemisphere of field of view (FOV) 1 (white box) and FOV2 (black 
box), starting at the edge of the graft and moving outwards. E-F: Fibre density within FOV1 (E) and FOV2 
(F). G-J: Images from FOV2 used to measure fibre density and to show innervation. Data represent mean ± 
SEM. 
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Another important concern with injuries in the CNS specifically is the formation of a glial 
scar, which is formed by reactive astrocyte and microglia cells forming a fibrotic scare and 
secreting inhibitory proteins.152-154 For this reason, we also assessed the astrocyte and 
microglia response to the SAP hydrogel cell grafts among the host (GFP-) cells (Figure 4.4). 
Here the same trends continued, the DIKVAV was not treated as a foreign material, while 
the DYISRF sequence showed only minimal microglia response after 28 days. The FRGDF 
sequence showed significantly more microglia present as well as a non-statistically significant 
increase in astrocytes, indicating that although results above confirm its non-cytotoxicity, the 
fibronectin based sequence is not suitable for applications in the brain.   
 
Figure 4.4: Astrocyte and microglia response to transplants. A-B: Astrocyte (A) and microglia (B) present 
at the edge of the grafts measured by fluorescence optical density. Data represent mean ± SEM, * p < 0.05, ** 
p < 0.01, ***(*) p < 0.0001. C-R: images of transplanted neural progenitor cells (GFP, green), astrocytes 
(GFAP, red), and microglia (CD11b, blue). 
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Fmoc-DDIKVAV was studied separately in a long-term 36-week (~9-month) study of 
transplantations of GFP+ human embryonic stem cells (hESCs) (Section 3.5.1.5) into a 
stroke model ischemic lesion (induced via injection of endothelin-1 (ET1) into the 
sensorimotor cortex) in rats (Section 3.5.1.7). First the material properties of this hydrogel 
were assessed (Figure 4.5) and found to be similar to the hydrogels studied above, concurrent 
with the self-assembly mechanism (Figure 4.1). Note that the hydrogel used here displayed a 
stiffness ~ 1000 Pa (Figure 4.5D), which is within the range of rat brain tissue stiffness of ~ 
100-1000 Pa.155 This sequence also contains the IKVAV sequence from laminin, and 
therefore appropriate for tissue-specific support in the brain. 
 
Figure 4.5: Material characterisation of Fmoc-DDIKVAV hydrogel. A-B: Spectroscopic FTIR (A) and 
CD (B) analysis. C: TEM micrograph. Scale bar represents 100 nm. D: Rheological analysis of viscoelastic 
properties showing storage modulus (G’) (black circles) and loss modulus (G’’) (open circles). Grey region 
indicates stiffness range of rat brain tissue.  
This more extensive study in rats allowed behavioural assessment (Section 3.5.2.7) of the 
treatment over 36 weeks as well as assessment of the SAP alone transplants. The staircase 
test was performed at several time points over 36 weeks to assess functional recovery, 
measuring the proportion of food pellets eaten from the stroke-affected left side (Figure 
4.6A).  The cell treatment alone resulted in a statistically significant improvement after 36 
weeks, while the cells + SAP treatment saw significant improvement after only 16 weeks, 
with continual improvement out to 36 weeks surpassing that of the cells alone treatment. 
This shows that the SAP scaffold improves both the speed and degree of functional recovery. 
The cylinder (Figure 4.6B) and adjusted stepping (Figure 4.6C-D) tests showed similar results 
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after 36 weeks, with the cells + SAP treatment showing the most functional recovery 
followed by cells alone. Cells + SAP treatment showed a statistically significantly increase in 
the number of left (stroke-affected) paw touches in the cylinder test compared to the lesion 
untreated and treated with SAP alone (Figure 4.6B). In the adjusted stepping tests the cells 
+ SAP treatment showed statistically significantly more forehand touches than all the other 
lesioned groups (Figure 4.6C), and was the only group with no statistically significant 
difference from the intact rats in backhand touches (Figure 4.6D). The Rotarod test revealed 
showed no statistically significant difference between any groups tested (Figure 4.6E), 
indicating no significant gross motor deficient impairing the rats’ ability to remain on the 
rotating rod. These results altogether demonstrate the effectiveness of the SAP hydrogel in 
supporting and improving the success of transplanted cell grafts for neural recovery; while 
the SAPs alone treatment shows little to no positive effect on recovery, the SAP was able to 
significantly improve on the recovery seen with cells alone when used to support the cell 
graft. 
 
Figure 4.6: Behavioural assessment of cell and SAP transplantation. Staircase (A), cylinder (B), adjusted 
stepping (C-D), and rotarod (E) tests of untreated intact rats (n = 12) and right-side lesioned rats untreated 
(ET1) (n = 20) and treated with SAP (n = 8), cells (n = 12), and cells + SAP (n = 13). Data represent mean ± 
SEM, * p < 0.05, ** p < 0.01, *** p < 0.001. 
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Post-mortem analysis 36 weeks after treatment allowed detailed assessment of the cell 
grafts (Section 3.5.2.1). Staining of GFP+ cells highlighted the difference between cell alone 
and cell + SAP treatments in photomicrographs, with the cells + SAP graft being visibly 
larger and more integrated (Figure 4.7A-B). Quantitative assessment showed that the cells + 
SAP treatment resulted in significantly larger graft volume (Figure 4.7C) and cell number 
(Figure 4.7D) than the cells alone treatment, while the cell density was not significantly 
different between the two treatment groups (Figure 4.7E). Importantly, the inclusion of the 
SAP hydrogel within the material also resulted in an increased proportion of neurons in the 
graft (Figure 4.7F), indicating that not only does the SAP support graft cell survival, but also 
encourages neuronal differentiation.  
 
Figure 4.7: Assessment of cells alone and cells + SAP GFP+ graft transplants after 36 weeks. A-B: 
representative photomicrographs providing a coronal view of GFP+ (red) grafts within the cortex of cells alone 
(A) and cells + SAP (B) treatment of lesioned rats. C-F: Graft volume (C), cell (DAPI+) number (D), cell 
density (E), and proportion of neuron cells (NeuN+) after treatment with cells alone (white) and cells + SAP 
(black). Data represent mean ± SEM, * p < 0.05, ** p < 0.01, *** p < 0.001. 
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Cortical atrophy (determined as decrease in cortical volume) was also assessed, in animals 
who received acute treatment 6 days after the lesion and those who received delayed 
treatment 3 weeks after the lesion, to determine if the transplants would protect against 
secondary degeneration of the host tissue (Figure 4.8A). The untreated lesion appears as a 
large necrotic cavity after 1 week (Figure 4.8E) and without treatment resulted in a high 
degree of cortical atrophy (Figure 4.8A, F). Treatment with cells alone or cells + SAP 
significantly decreased the amount of cortical atrophy observed, consistent with results above 
of graft assessment. Regression shows a strong (r2 = 0.858) inverse linear correlation between 
cortical atrophy and sensorimotor function as measured by the staircase test above, showing 
the incremental improvements from cells alone, then cells + SAP approaching the non-
lesioned state (Figure 4.8B). Assessment of cortical atrophy also highlights the effect of acute 
vs. delayed treatment. While all treatment groups showed a trend for reduced atrophy with 
the acute treatment, the effect was most pronounced and only statistically significant for the 
cell + SAP treatment (Figure 4.8A, I, L), indicating that SAP supported cell grafts in 
particular should be administered early for the best results. The neuron (NeuN+) density 
was not affected by treatment timing, although it was affected by the treatment group, with 
cells and cells + SAP being the only groups to show a statistically significant increase in 
neuron density (Figure 4.8C). The lesion itself did not affect neurons disproportionately, so 
did not affect the neuron density compared to non-lesioned rats. The photomicrographs of 
NeuN+ staining for neurons show the degree of atrophy 36 weeks after treatment (Figure 
4.8G-L) compared to intact (Figure 4.8D) and untreated lesioned (Figure 4.8F) brains, with 
the acute cells + SAP treatment showing the least atrophy and therefore the best ability to 
protect against secondary degeneration of host tissue.  
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Figure 4.8: Acute implantation improves graft performance. A: Cortical atrophy of lesioned rats. B: 
Regression analysis of cortical atrophy and staircase test behavioural assessment for lesions alone (white) and 
treated with cells alone (light grey) or cells + SAP (dark grey), and non-lesioned/intact brain (black) rats. C: 
Neuron density in non-lesioned and lesioned rats. Results for treatments performed at 6 days (striped) and 3 
weeks (solid) after lesion. Data represent mean ± SEM, * p < 0.05, ** p < 0.01, *** p < 0.001. D-L: 
Photomicrographs of NeuN+ staining for neurons 36 weeks after SAP (G, J), cells (H, K), and cells + SAP (I, 
L) treatments injected 3 weeks (G-I) and 6 days (J-L) after lesion. Comparative images of non-lesioned brain 
(D) and lesioned (ET1) brain after 1 week (E) and 36 weeks (F).  
4.5 Conclusion 
The work done here confirms the biocompatibility of the FRGDF, DYIGSRF, 
DIKVAV, and DDIKVAV sequence SAP hydrogels in vivo, as well as confirming the 
effectiveness of the DDIKVAV sequence in particular as a cell support material in cell graft 
treatment of ischemic brain injury. The work also confirms the validity of the tissue-specific 
design approach, engineering SAP hydrogels with peptide sequences relevant to the specific 
74 
tissue environment to achieve the best biological response. With this new evidence 
supporting previous in vitro studies, the potential of these minimalist and tissue-specific Fmoc 
SAP hydrogels as a supportive tissue engineering material is clear. While the materials did 
significantly improve the efficacy of cell transplantation treatment, they did not provide total 
recovery and so there is need to further improve these materials. The next step in their 
material development is the incorporation of additional therapeutic agents such as growth 
factors to improve the dynamic, trophic environment the materials provide. 
 
75 
 
5.1 Chapter Details 
Having established the biocompatibility of our minimalist SAP hydrogel materials, the 
next step in material development was to incorporate drug delivery. While this thesis focuses 
on providing temporally controlled delivery of growth factors from the SAP hydrogels, there 
are many non-growth factor therapeutic agents that can be beneficial to incorporate. As 
previously discussed in Chapter Two, a broad system-wide view of tissue engineering 
materials is required for maximum therapeutic advantage. Additionally, engineering SAP 
hydrogels for the presentation of non-growth factor therapeutic agents can provide both 
delivery strategies adaptable to growth factors and insights about the material potentially 
applicable to growth factor delivery systems. This chapter describes work done on projects 
for delivery of two distinct non-growth factor therapeutics, viral vectors and an anti-
inflammatory polysaccharide, and their applicability to growth factor delivery.  
The fucoidan section of this chapter briefly describes work published in the research 
article listed below, and included in full in Appendix C: 
Chapter Five 
Non-Growth Factor Delivery 
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Rui Li, Sivapriya Pavuluri, Kiara Bruggeman, Benjamin M. Long, Andrew J. Parnell, 
Anne Martel, Steven R. Parnell, Frederick M. Pfeffer, Andrew J.C. Dennison, Kevin 
R. Nicholas, Colin J. Barrow, David R. Nisbet, Richard J. Williams, “Coassembled 
nanostructured bioscaffold reduces the expression of proinflammatory cytokines to 
induce apoptosis in epithelial cancer cells”, Nanomedicine: Nanotechnology, Biology and 
Medicine, 2016, vol. 12, pp. 1397-1407 – Reproduced with permission from Elsevier 
The viral particle section of this chapter describes work published in the research article 
listed below, and included in full in Appendix D: 
Alexandra L. Rodriguez, Ting-Yi Wang, Kiara F. Bruggeman, Rui Li, Richard J. 
Williams, Clare L. Parish, David R. Nisbet, “Tailoring minimalist self-assembling 
peptides for localised viral vector gene delivery”, Nano Research, 2016, vol. 9, pp. 674-
684 – Reproduced with permission from Springer 
5.2 Abstract 
Two distinct therapeutic agents, the polysaccharide fucoidan and viral vectors, were 
incorporated into SAP hydrogels to provide sustained presentation. In both cases the 
physical interactions with the peptide nanofibres were fundamental to successful 
presentation of the therapeutic. While working with fucoidan, a novel gold nanoparticle 
tagging method was developed to allow visualisation via electron microscopy of the 
interactions with the nanofibres. Experiments confirmed that fucoidan formed strong 
physical associations with the nanofibres, keeping it immobilised in the hydrogel while 
maintaining anti-cancer bioactivity demonstrated by selective inhibition of cancer cells in 
vitro. To immobilise viral vectors to the peptide nanofibres, the peptide sequence itself was 
re-engineered with a terminal lysine residue to provide free positive charges for electrostatic 
interactions with the negatively charge surface of viral capsids, and this immobilisation was 
used to successfully localise virus transfection in vivo. Both cases have parallels with growth 
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factor delivery and highlight interactions with the peptide nanofibres that can be used to 
further develop delivery systems from SAP hydrogels.   
5.3 Fucoidan 
5.3.1 Background 
Fucoidan refers to any of a group of a sulphated polysaccharides found in seaweed, and 
they are currently being explored as non-steroidal therapeutics in cancer treatment for their 
anti-inflammatory and anti-mitogenic properties in addition to biocompatibility.156-159 This is 
particularly applicable to endothelial cancers (e.g.: oral, pancreatic, and colon), where 
epidemiological studies have shown chronic inflammation to be a causative factor for 
cancer.160-162 Studies have also shown fucoidan’s ability to halt cell progression and induce 
apoptosis in cancer cell lines.163 One of the major obstacles to fucoidan treatment is its high 
solubility, which effectively prevents sustained presentation in vivo.164,165 In this way fucoidan 
is very similar to growth factors, although with growth factors it is enzymatic degradation 
that limits the sustained presentation of soluble factors.  
Here we aimed to provide sustained presentation of fucoidan via incorporation with a 
SAP hydrogel, which would itself provide a stable microenvironment to promote healthy 
tissue following surgical excision.166 To do this, we first investigated the interactions between 
the polysaccharide fucoidan and the SAP nanofibre structures. While SAP nanofibre 
visualisation via electron microscopy is established, single molecule solubilised fucoidan is 
too small and too atomically lightweight to be observed alone or using staining. To visualise 
their interactions, we adapted a method of gold nanoparticle synthesis to create gold 
nanoparticle tagged fucoidan, to provide a discrete and electron dense location indicator for 
fucoidan as it interacted with SAP nanofibres. This allowed the investigation of interactions 
between SAP nanofibres and the polysaccharide fucoidan, as well as with inorganic 
nanoparticles.  
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5.3.2 Results and Discussion 
Gold nanoparticles are commonly produced from solution via reduction under reflux.167 
An aqueous solution of gold from hydrogen tetrachloroaurate (III) under reflux with a 
reducing agent yields solid gold according to the chemical half reaction described in Figure 
5.1A. Maintaining dispersed nanoparticles, as opposed to large agglomerations, requires a 
stabilising agent. The surfaces of the solid metal nanoparticles have some inherent solubility, 
resulting in a layer of positive charge around the nanoparticles. A stabilising agent with 
negative charge forms a layer on the surface of the particles, creating a negative zeta potential 
and preventing their agglomeration. Often the reducing agent itself can act as a stabiliser, as 
is the case with the most common citrate reduced method,168 and fucoidan can also be used 
as a reducing and stabilising agent.167 Here, using fucoidan, the sulphate groups on the long 
polysaccharide fucoidan from Undaria pinnatifida (Figure 5.1B) act as a reducing agent and 
provide the opposing negative charge layer as they electrostatically bind to the gold 
nanoparticles (Figure 5.1C), essentially providing gold nanoparticle (GNP) labelled fucoidan. 
 
Figure 5.1: Fucoidan stabilised gold nanoparticle synthesis. A: Half reaction of the reduction of gold from 
solution to solid. B: Chemical structure of fucoidan polysaccharide and diagrammatic representation of main 
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chain (black) and negatively charged sulphate groups (blue). C: Diagrammatic representation of fucoidan 
stabilised gold nanoparticles, cutaway shows the solid gold interior of the nanoparticles and charged layer of 
positive ions (to demonstrate the nature of interaction only, not to scale).  
In this work the minimalist Fmoc peptide sequence FRGDF, containing RGD from the 
common ECM protein fibronectin, was used. The fucoidan was mixed with the dry peptide 
powder and co-assembled into the nanofibrous SAP hydrogel. The GNP labelled fucoidan 
was used to visualise the interactions between the SAP nanofibres and fucoidan via TEM. 
To avoid potential ambiguity, samples were observed without the use of the normal uranyl 
formate negative stain. This limited image quality, as organic peptide molecules are not 
electron rich, but ensured that the gold nanoparticles were the only source of electron dense 
material present in the samples, allowing black dots to be identified confidently as gold 
nanoparticles. Under these conditions, the GNP labelled fucoidan was observed to closely 
associate with the SAP nanofibres (Figure 5.2A). The nanoparticles visible on the nanofibre 
surface indicate that the fucoidan is associating closely with the peptide. To test the strength 
of this association, we subjected the gel to gentle washing in water (Section 3.4.4) and the 
GNP labelled fucoidan retained its association with the peptide nanofibres (Figure 5.2B-C), 
indicating a strong association between the fucoidan and the peptide nanofibres. This 
strength of association was not observed after washing SAP hydrogels prepared with separate 
GNP and unlabelled fucoidan (Figure 5.2E), nor those prepared with independent GNP 
alone (Figure 5.2F), indicating that the association is caused by interactions with the fucoidan 
not the GNP.  
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Figure 5.2: TEM micrographs of GNP labelled fucoidan and SAP nanofibres. A-C: GNP labelled 
fucoidan shows co-localization along peptide fibrils before (A) and after (B-C) washing of the hydrogel. D: 
GNP labelled fucoidan alone. E: Hydrogel co-assembled with unlabelled fucoidan and independent GNP 
shows no residual GNP post-washing. F: Hydrogel co-assembled only with independent GNP shows no 
residual GNP post-washing. Scale bars represents 100 nm. 
This strong association can be explained by the similar chemical structures of the peptide 
and fucoidan materials, with the charged sulphate groups interacting with charged amine 
groups present in the peptide sequence (from the arginine (R) residues). These results also 
suggest that similar materials (i.e. polysaccharide chains with charged groups) might 
associated with the peptide nanofibres as well, a relationship that will be explored and 
exploited in the next chapter. In this work, the fucoidan material was further characterised 
and the biological effectiveness was assessed. The key results are discussed below, and the 
full work is included in Appendix C. 
The SAP gels were tested with and without fucoidan with both healthy and cancerous cell 
lines, human mammary fibroblast cells (hMFCs) and human tongue squamous cell carcinoma 
cell line SCC25 respectively (Section 3.5.2.5.2). Testing cell viability over 3 days the healthy 
cells remained highly viable on both materials while the fucoidan loaded material resulted in 
significant decrease in viability of the cancer cells only (Figure 5.3A). The different responses 
from the two cell lines demonstrate the specific anti-cancer effect of fucoidan, as opposed 
to general cytotoxicity. Specifically, the fucoidan was found to have anti-inflammatory and 
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anti-mitogenic effects on the cancer cell line. Fucoidan loaded materials induced significant 
downregulation of genes involved in the NFκβ pro-inflammatory pathway (interleukins: IL-
1α, IL-1β; and tissue necrotic factor (TNF))169 and CEP55, a cytokinesis promoter and 
marker for the uncontrolled C2 to M cell cycle progression seen in oral cancer169 (Figure 
5.3C, Section 3.5.2.5.2, 3.5.2.6). Lipopolysaccharide (LPS), known to induce inflammation, 
was used to challenge the cells and while that did cause upregulation of all tested genes on 
the unloaded control hydrogel, the fucoidan loaded hydrogel negated the effect of LPS, 
resulting in little to no upregulation of the pro-inflammatory cytokine genes studied. 
 
Figure 5.3: Confirmed biological effectiveness of fucoidan loaded in SAP hydrogel. A: Cell viability of 
cancer (SCC25) and healthy (hMFC) cell lines grown on fucoidan loaded (2RGD) and control SAP hydrogel. 
B: Mitogenic and pro-inflammatory gene expression profiles in LPS stimulated and non-stimulated cancer 
(SCC25) cells as determined by qPCR. *P = 0.05, **P = 0.01, ***P = 0.001, ****P = 0.0001. 
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5.4 Viral Vectors 
5.4.1 Background 
Viral vectors are another therapeutic agent with great potential. They are used for gene 
delivery in treatments being developed for cancer, autoimmune diseases, and 
neurodegenerative diseases.170,171 They are particularly interesting in a drug delivery context 
because they allow decoupling between the agent being delivered and the drug being 
received. For growth factor delivery, specifically, instead of delivering the protein directly a 
virus is delivered to transfect local cells with the genetic material required to produce the 
desired protein.172-176 This removes the need for high concentrations required for growth 
factors to achieve therapeutic benefit because it bypasses many of the obstacles inherent to 
the growth factors, such short half-lives, susceptibility to enzyme degradation, and inability 
to permeate selective barriers like the blood brain barrier.177 Additionally, many growth factor 
delivery strategies are limited to a subset of growth factors based on their specific binding 
sites66 or charge,178 and different electrostatic and material properties between growth factors 
can effect individual delivery characteristics,65 making the delivery systems inconsistent 
between different growth factors. Using viral vectors eliminates that variation, as the same 
viral vector can be used to deliver genetic material for different growth factors.     
The use of viral vectors does have its own challenges and limitations. Currently viral 
vector therapies can experience spreading of the virus to non-target locations, neutralisation 
by the host immune system, and low transduction efficiencies.170 Research is being done 
using biomaterials to deliver viral vectors in order to alleviate these problems using strategies 
common in drug delivery, including encapsulation in nanoparticles and microspheres,179,180 
incorporation into biocompatible hydrogels,181,182 and immobilisation.183-185 Tissue 
engineering biomaterials designed for biocompatibility provide some protection from the 
host immune response while also potentially improving the localisation of the delivery.  
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Here, once again using SAP hydrogels, we aimed to mix viral vectors with the hydrogel 
to provide localised delivery based on electrostatic interactions with the peptide nanofibres. 
Recently, non-minimalist SAPs have been demonstrated to effectively deliver genetic 
material to human mesenchymal stem cells in culture via recombinant adeno-associated 
virus.186 Research has also been done using amine moieties, which exist physiologically as 
positively charged groups (NH3+), to immobilise viral vectors, which have a negatively 
charged viral capsid to a surface and found improved transduction efficiency.187 Here we 
combine these findings, engineering a minimalist SAP hydrogel to provide increased 
localisation of viral vector delivery. 
5.4.2 Results and Discussion 
To optimise the peptide for viral vector immobilisation we adjusted an established peptide 
sequence with the addition of a terminal lysine (K) residue to provide available amine groups, 
and therefore positive charge, to immobilise the viral particles (Figure 5.4). The minimalist 
peptide Fmoc-DDIKVAV has previously been established as an appropriately 
biocompatible sequence for neural tissue application and was developed around the IKVAV 
sequence found in the ECM protein laminin, which is common in the brain.9 The additional 
aspartic acid (D) residues were included in the rational design of the peptide to tune the pKa 
properties of the molecule to ensure that the pH driven self-assembly occurred under 
physiological conditions.9 Here we synthesised the new sequence Fmoc-DDIKVAVK. Since 
the Fmoc is an N-terminal group, the amine groups of the amino acid backbones are 
unavailable. Additionally, while the IKVAV sequence itself does include a K residue, this is 
not true for all minimalist SAP sequences, and in any case, the C-terminal position was 
selected as the ideal location for the viral immobilising K as it would be less restricted and 
more able to interact with the viral capsids. 
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Figure 5.4: Schematic of terminal lysine driven viral vector immobilisation. Terminal lysine residues 
provide positive charges on the peptide nanofibre surface, which interact with negatively charged viral capsids, 
immobilising them to the fibres. Inserts show the proposed diffusive release from unmodified peptide 
nanofibres and TEM micrograph of viral capsids within the peptide nanofibre network (viral capsids false 
coloured for identification, scale bar represents 200 nm). 
The modified peptide sequence was tested to ensure that it still underwent self-assembly 
into a nanofibrous hydrogel and that the material properties were maintained. The 
DDIKVAVK sequence did form a hydrogel visually comparable to that of DDIKVAV 
(Figure 5.5A) and rheological analysis confirmed no change in the hydrogel stiffness (Figure 
5.5B-C). Titration was performed to investigate the pKa properties of the two sequences, and 
the addition of the basic lysine group did slightly increase the gelation point, the effective 
pKa observed as a plateau in the titration curve, from ~7.0 to ~7.8 (Figure 5.5). This was 
expected based on previous work using acidic D groups to decrease it.9 The shift was minimal 
however, and the peptide was able to form a gel at physiological pH. Spectroscopic analysis 
confirmed the self-assembly mechanism via FTIR (Figure 5.5E) and CD (Figure 5.5F). The 
FTIR spectra show that the large and small peaks at 1630 cm-1 and 1690 cm-1 respectively are 
maintained, indicative of β-sheets.61 The large dip in the CD spectra is also maintained and 
indicative of β-sheets.61 Together these results confirm that the addition of a terminal K 
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residue does not interfere with the formation of a hydrogel and has only a minor effect the 
hydrogel’s pH-responsive properties. 
 
Figure 5.5: Material properties of SAP hydrogel with and without terminal lysine. A: Photos of inverted 
hydrogels from DDIKVAV and DDIKVAVK peptides. B-C: Rheological analysis of DDIKVAV (B) and 
DDIKVAVK (C) hydrogels, showing storage moduli G’ (closed circles) and loss moduli G’’ (open circles). D: 
Titration curve for DDIKVAV (open circles) and DDIKVAVK (closed circles) showing a slight shift in pKa 
(DDIKVAV – dashed line; DDIKVAVK – solid line). E-F: FTIR (E) and CD (F) spectroscopic analysis of 
DDIKVAV (solid line) and DDIKVAVK (dashed line).   
AFM and TEM imaging confirm the presence of nanofibres in both hydrogels formed 
(Figure 5.6A-B, E-F), although the additional K residue did result in increased bundling of 
fibres. This increased bundling, increased supramolecular ordering, also explains the slightly 
larger dip observed for the DDIKVAVK sequence in the CD spectroscopy above (Figure 
5.5F). Lentivirus particles loaded into both hydrogels (Figure 5.6C, G) appear embedded in 
the nanofibrous network, so to determine the ability of each hydrogel to immobilise and 
retain the viral particles the loaded hydrogels were incubated in PBS over 5 days to allow 
non-immobilised viral particle to diffuse out (Section 3.4.2). The unmodified DDIKVAV 
hydrogel showed substantial and ongoing release of the viral particles, while the 
DDIKVAVK hydrogel retained the viral particles within the hydrogel, with minimal 
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amounts detectable in the PBS (Figure 5.6D). This result is key to the project and 
demonstrates the success of the terminal K in viral particle immobilisation within the 
hydrogel. 
 
Figure 5.6: Virus loading in SAP hydrogels. AFM (A, E) and TEM (B, F) micrographs of DDIKVAV (A-
C) and DDIKVAVK (E-G), including TEM micrographs of virus loaded hydrogels (C, G). Insert shows viral 
particles alone. Scale bars represent 1 μm for AFM and 200 nm for TEM. Viral vectors false coloured for 
identification. D: Cumulative release profile of viral vectors from DDIKVAV (open circles) and DDIKVAVK 
(closed circles).  
With the immobilisation method confirmed, and hydrogel material properties maintained, 
the materials were tested in vivo for their biological efficacy and ability to specifically transfect 
only a highly localised environment. mCherry lentivirus was injected into mouse brain 
(striatum) alone and loaded into the two hydrogels (Section 3.5.1.10), and the transfection 
was assessed after 3 weeks (Section 3.5.2.5.1). The mCherry infected cell number (Figure 
5.7A) and striatal volume (Figure 5.7B) showed the same trend, with the most transfection 
achieved from the virus alone, followed by the unmodified gel, and significantly lower 
transfection when using the lysine modified hydrogel. These results indicate that the hydrogel 
material and K modification successfully localised the transfection, preventing spreading of 
the virus to off-target tissue. The cell densities remained similar in all groups (Figure 5.7C), 
indicating that neither the hydrogel nor the K modification affect the nature of the 
transfection, only it’s localisation. Chromogenic staining mCherry+ cells gave a clear 
visualisation of the effective localisation achieved using the K modified hydrogel (Figure 
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5.7D-F). These results together confirm that the hydrogel system does not impede the 
bioactivity of the virus, and that the K modification method is able to highly localise 
transfection. This is a promising development with the potential to achieve more targeted 
therapeutic viral delivery and to avoid off-target side effects.   
 
Figure 5.7: Biological efficacy and localisation of viral transfection 3 weeks post injection. mCherry+ 
cell number (A), infected striatal volume (B), and cell density (C). Data represent mean + SEM. *P < 0.05, **P 
< 0.01. Chromgoenic stain of mCherry+ cells in mouse brains treated with virus alone (D), virus in DDIKVAV 
hydrogel (E), and virus in DDIKVAVK hydrogel (F) at 5x (top) and 20x (bottom) magnification.  
5.5 Conclusion 
Working with fucoidan, the cell response confirmed the maintained presentation and 
bioactivity of fucoidan when loaded into the SAP hydrogel, overcoming the solubility 
obstacle that normally prevents sustained delivery. The specific investigation of the material 
component interactions suggests that the charged polysaccharide fucoidan physically 
associates strongly with the peptide nanofibres. Together these results indicate that simple 
loading could provide prolonged presentation of similar therapeutic agents, but without any 
temporal control. 
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Similarly, working with viral particles, electrostatically driven immobilisation was used to 
achieve highly localised presentation of viral particles, significantly reducing the infected 
volume relative to other delivery methods. As a means of growth factor delivery, viral vectors 
inherently provide a permanent or very long-term source of the protein. Again, this method 
would overcome the issues of short half-lives and degradation preventing sustained delivery, 
but again this method offers no significant temporal control.  
Achieving sustained delivery is the first obstacle to overcome in achieving finer temporal 
control of delivery, and both systems explored here represent interesting additions to the 
broader field of drug delivery and tissue engineering material design. Also, both systems rely 
on and highlight the electrostatic interactions that occur between peptide nanofibres and 
other materials loaded into the hydrogel network. These specific material interactions will be 
explored and exploited in the next chapter to achieve the desired temporal control of 
delivery. 
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6.1 Chapter Details 
Using interactions explored in Chapter Five, this chapter describes the successful 
development of the first temporally controlled growth factor delivery system from a tissue-
specific SAP hydrogel, achieving a short delay in the release of growth factors. This chapter 
has been published as the research article listed below: 
Kiara F Bruggeman, Alexandra L Rodriguez, Clare L Parish, Richard J Williams, David 
R Nisbet, “Temporally controlled release of multiple growth factors from a self-
assembling peptide hydrogel”, Nanotechnology, 2016, 27 – © IOP 
Publishing.  Reproduced with permission.  All rights reserved.  
6.2 Abstract 
Protein growth factors have demonstrated great potential for tissue repair, but their 
inherent instability and large size prevents meaningful presentation to biologically protected 
nervous tissue. Here, we create a nanofibrous network from a self-assembling peptide (SAP) 
hydrogel to carry and stabilize the growth factors. We significantly reduced growth factor 
degradation to increase their lifespan by over 40 times. To control the temporal release 
profile, we covalently attached polysaccharide chitosan molecules to the growth factor to 
Chapter Six 
Delivery System: Short (Hours) Delay 
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increase its interactions with the hydrogel nanofibres and achieved a 4-hour delay, 
demonstrating the potential of this method to provide temporally controlled growth factor 
delivery. We also describe release rate based analysis to examine the growth factor delivery 
in more detail than standard cumulative release profiles allow and show that the chitosan 
attachment method provided a more consistent release profile with a 60% reduction in 
fluctuations. To prove the potential of this system as a complex growth factor delivery 
platform we demonstrate for the first time temporally distinct release of two growth factors 
from a single tissue specific SAP hydrogel: a significant goal in regenerative medicine. 
 
6.3 Introduction 
Growth factors play important roles as short lived and fast acting signals, influencing cell 
fate and promoting survival for improved tissue repair. However, their high cost and inherent 
instability in physiological environments presents a challenge for long-term, sustained, 
therapeutic delivery.31 Systemic growth factor delivery into the bloodstream carries 
overwhelming cost and risk of off-target side effects. Within the central nervous system 
(CNS) there are additional challenges involved in transporting such large molecules across 
the blood brain barrier (BBB).20 Therefore, to ensure therapeutic benefit, growth factors 
must be directly introduced into the CNS. Current sustained delivery strategies involve 
indwelling cannulas and infusion pumps, which cause additional trauma. Thus, there is 
pressing need for minimally invasive strategies that can also provide sustained growth factor 
delivery. A significant obstacle to this goal is the short half-lives of neurotrophic growth 
factors. For example, brain derived neurotrophic factor (BDNF) and glial-cell derived 
neurotrophic factor (GDNF), have short half-lives of approximately 45 minutes in vivo, as 
they are susceptible to enzyme degradation.14,33 To provide an ideal environment for the 
regeneration of CNS tissue, a delivery system is required that prevents growth factor 
degradation, whilst providing consistent, localised delivery over prolonged periods; all from 
a single injection. 
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Here we demonstrate an effective mechanism for improved delivery of BDNF, a growth 
factor that plays an important role in neuronal differentiation and proliferation, by loading it 
into a tissue specific self-assembling peptide (SAP) hydrogel. The CNS provides a proof of 
concept model for this broadly applicable growth factor delivery system that can be tailored 
using different tissue specific SAP hydrogels. These are sophisticated biomaterials designed 
with recognisable peptide sequences from tissue specific extracellular matrix (ECM) proteins 
to biochemically mimic the ECM while also providing nanofibrous structural support.8,9 
Importantly for a delivery vehicle, SAP hydrogels are formed via physical interactions, 
allowing the material to undergo reversible shear thinning. Thus, the material can flow readily 
when injected and will then interface with the entire surface area of irregularly shaped injury 
sites as it reforms into a stiffer gel,6 providing a more customised and less invasive material 
than surgical implantation. Once reformed in situ, these hydrogels retain their mechanical 
properties and biomimetic nanoscale morphology.8,9 Self-assembly of nanoscale fibres is 
driven by secondary bonds or physical interactions, including aromatic stacking, 
hydrophobicity, polarity, and charge-charge interactions between different amino acids of 
the SAP peptide sequence.7,188 We have previously engineered minimalist (< 7 amino acids) 
N-fluorenylmethyloxycarbonyl (Fmoc) peptides that self-assemble under physiological 
conditions to present a high density of bioavailable and biofunctional peptide sequences to 
promote cell interactions.9,78 To tailor the hydrogel to CNS tissue, we used the peptide 
sequence isoleucine-lysine-valine-alanine-valine (IKVAV), a recognizable peptide sequence 
from laminin, a protein abundant in the ECM of the brain where it is involved in neural 
adhesion, migration, proliferation, and differentiation.150 To tailor material properties of the 
hydrogel, we used aspartic acid (D) residues to alter the pKa of the peptide molecule and 
therefore pH of self-assembly. The minimalist SAP Fmoc-DDIKVAV forms a hydrogel 
under physiological conditions with the shortest possible peptide sequence, and we have 
shown these peptides to be biocompatible in vivo.31  
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A key aspect of the hydrogel formation is the longitudinal alignment of individual fibrils 
through surface mediated supramolecular associations to form intertwined bundles that form 
the interconnected nanofibrous network.57,62 We predicted that such interactions would 
occur between the peptide chains on the nanofibre surface and the peptide chains of protein 
growth factors. We have shown that permanent immobilisation of growth factors to a 
scaffold stabilised growth factors for prolonged presentation and bioactivity,31 and 
hypothesised that this temporary immobilisation through reversible adsorption of growth 
factors to the SAP nanofibres would also stabilise them for prolonged delivery. This system 
presents an option for prolonged but non-permanent growth factor delivery with potential 
to control the delivery profile by adjusting the increasing or decreasing the fibre-growth 
factor interactions. This method also provides inherent control over the localisation of 
delivery, because growth factors are only stabilised in the presence of the stationary SAP 
hydrogel, unlike nanoparticle delivery systems, in which the stabilising nanoparticle carrier 
can diffuse away. 
6.4 Results and Discussion 
To test the ability of SAPs to provide prolonged growth factor delivery, we loaded Fmoc-
DDIKVAV hydrogel with BDNF and examined its release into surrounding phosphate 
buffered saline (PBS). In PBS alone, free BDNF quickly degraded, with an approximate half-
life of 5 hours (Figure 6.1 (a)) and no detectable BDNF after 24 hours. In stark contrast, 
BDNF loaded into the SAP hydrogel (Section 3.2.2.1, 3.4.1) showed continued delivery of 
stabilised BDNF into the surrounding solution all the way to the 6-week time point (Figure 
6.1 (b)), representing an increase in BDNF lifespan of over 40 times compared to the 
degradation profile in PBS alone. These data show a distinct improvement in the longevity 
of BDNF within a SAP. Next we investigated growth factor release rates using daily and 
hourly sampling intervals, as growth factor concentration in the surrounding solution affects 
its diffusion from the gel (Figure 6.1 (c)). Because growth factors exhibit such short half-lives 
of minutes to hours in vivo,14,31,33 an hourly sampling interval mimics the rate at which the 
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growth factor would be removed from the surrounding environment in vivo. We also 
examined the changing release rate, in addition to the cumulative release profile standard in 
the field. This approach allowed us to better observe changes in growth factor delivery over 
time. Using this method, we observed that using the more frequent (daily and hourly) 
sampling intervals, the release of BDNF was less consistent, with the actual release rate 
fluctuating significantly between consecutive time points. 
 
 
Figure 6.1: BDNF degradation and sustained release. (a) BDNF degradation profile in PBS at 37 °C. (b) 
Weekly cumulative release profiles from Fmoc-DDIKVAV hydrogel showing the absolute amount of BDNF 
released since the beginning of the experiment. (c) Hourly (i), daily (ii) and weekly (iii) release rate profiles 
showing the BDNF released in individual samples/intervals. Data represent mean ± standard error. 
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The therapeutic window is an important consideration for drug delivery.  Dosage should 
be adequate to stimulate intracellular responses while remaining well below toxic thresholds. 
Burst release drug delivery can exceed the therapeutic window, resulting in toxic side effects. 
Preparations are usually most effective when delivered at a consistent concentration,34 thus 
optimization requires minimizing bursts and fluctuations in the release. Timing is also 
important.189 An ideal drug delivery system would allow temporally distinct delivery of more 
than one drug. From an implanted SAP hydrogel, this would mean delaying the release of 
some drugs. 
In order to simultaneously achieve both temporal control and consistent growth factor 
release rate, we investigated the effects of chemical modification on interactions with the 
nanofibre scaffold. However, in addition to a short half-life in physiological environments, 
protein activity is destroyed by extremes of heat, acidity, and basicity,190 conditions frequently 
employed during chemical modification. Previously, we have shown indefinitely sustained 
presentation of growth factors when covalently cross-linked to electrospun biocompatible 
polymer scaffolds via a succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate) 
(SMCC) crosslinking molecule.31,55 SMCC includes N-hydroxysuccinimide (NHS) ester and 
maleimide moieties that, at neutral pH in an aqueous environment, react with amine and 
sulfhydryl groups respectively. To minimize protein denaturation, the sulfhydryl containing 
protein is not reacted until the final step of the cross-linking process, after the amine 
containing attachment material has been functionalised with SMCC.31,36 We have previously 
demonstrated that SMCC attachment does not impede growth factor bioactivity, confirming 
bioactivity in vitro with BDNF,36 and in vivo with GDNF,31,191 and Interleukin-10 (IL-10).192 In 
the current study, we adapted this immobilization method (Figure 6.2 (a), Section 3.2.5, 
3.2.4.1) to investigate a more tuneable approach that can provide both sustained and delayed 
growth factor delivery. We attached the polysaccharide chain chitosan, which has D-
glucosamine and N-acetyl-D-glucosamine repeating units suitable for crosslinking with 
SMCC. Chitosan is also biocompatible, and is used extensively in tissue engineering.193 
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Figure 6.2: BDNF modification and temporally controlled release profiles. (a) SMCC crosslinking 
between chitosan polysaccharide amine group and BDNF sulfhydryl group. (b) Weekly (i), daily (ii), and hourly 
(iii) release profiles of BDNF (blue) and modified BDNF-Chitosan (red) from Fmoc-DDIKVAV hydrogels. 
(c) Hourly, simultaneous release profiles of GDNF (purple) and modified BDNF-Chitosan (red) from the same 
Fmoc-DDIKVAV hydrogels. Cumulative release profiles (top) show the absolute amount of growth factor 
released since the beginning of the experiment. Release rate profiles (bottom) show the growth factor released 
in individual samples/time intervals. Data represents mean ± standard error. 
Electrostatic interactions can delay release of proteins from a β-peptide system.65 BDNF 
is positively charged178 with a high isoelectric point (pI) of ~9-10,194 whereas the Fmoc-
DDIKVAV molecule is negatively charged with a low pI of 0.72, as calculated by 
Innovagen’s Peptide Property Calculator.195 We proposed that functionalizing BDNF (27 
kDa) with chitosan (190 – 310 kDa) would increase its interaction with the SAP fibres, 
keeping the BDNF adsorbed to the material longer, and resulting in a  bulkier BDNF-
Chitosan molecule that is therefore slower to diffuse out of the hydrogel matrix once 
desorbed. The release profile for BDNF-Chitosan demonstrated that the modified growth 
factor retained the sustained 6-week release, but showed notably improved consistency in its 
release rates in terms of the delivered dose at consecutive time points (Figure 6.2 (b)). 
Fluctuations between consecutive time points were reduced by 65 ± 5% in the hourly profile 
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(see supplementary data). The underlying cause of this reduced fluctuation was not 
investigated. We propose that it may be the result of steric hindrance becoming a more 
dominant factor in determining release characteristics for the bulkier BDNF-Chitosan. It 
could also be that the electrostatic interactions chitosan has with the SAP nanofibres are 
more constant that those of the less stable BDNF molecule.  
These findings also highlight the usefulness of examining the release rate vs. the standard 
cumulative release profile when assessing drug delivery; the cumulative profiles hide 
inconsistency in release rate. The modified and unmodified BDNF release rates have 
markedly different consistencies in the delivered dose, despite both groups displaying a 
smooth cumulative profile. This analytical method could be applied across the field of drug 
delivery to better analyse the dynamic nature of drug delivery and ensure dose remains within 
the therapeutic window. 
Chitosan modification also delayed the release profiles compared to unmodified BDNF 
(Figure 6.2 (b) ii, iii). The extent of the delay was dependent on the nature of the release 
profile sampling, with greater effects in more dynamic release profiles. In the most dynamic 
(hourly) profile that most closely mimics the in vivo environment, the modified BDNF release 
was delayed by 4 hours.  
Finally, for maximum therapeutic benefit, an ideal delivery system would accommodate 
more than one drug.196 Here, we evaluated the temporal release characteristics of a dual 
system by simultaneously loading hydrogel with BDNF-Chitosan and unmodified GDNF, a 
growth factor that promotes neuronal survival and neurite outgrowth.55 The hourly release 
profile for the dual system showed more consistent release of modified BDNF than the 
unmodified GDNF (Figure 6.2 (c)). While release of both growth factors continued beyond 
12 hours, unmodified GDNF peaked at 3-5 hours and BDNF-Chitosan at 12 hours.  As 
expected, BDNF-Chitosan release was delayed, with no significant levels detected in the first 
3 hours. Importantly, profiles from dually loaded material were similar as expected to those 
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of modified and unmodified BDNF alone. This demonstrates independent control of the 
delivery of more than one growth factor without affecting the release of others. The temporal 
distinction in delivery means that this system could be employed to deliver multiple factors 
each at their own most beneficial time. For example, BDNF could be delivered initially to 
promote neural progenitor proliferation and/or survival, whilst delayed GDNF release 
would enhance survival and promote neurite growth in regenerating tissue. 
To ensure loading with a growth factor does not alter the established optimised properties 
of SAP hydrogels, we characterised unloaded, BDNF loaded, and BDNF-Chitosan loaded 
hydrogels. Transmission electron microscopy (TEM) micrographs showed consistent SAP 
fibre structure in all cases. As expected, there were more bundles and inter-fibre interactions 
in BDNF-Chitosan loaded SAP hydrogels (Figure 6.3 (a-c)). In all cases, the images show 
tubular fibrils approximately 10-20 nm in diameter, consistent with morphology expected of 
this SAP class. Matrix stiffness has been shown to have a major effect on stem cell 
differentiation, with differentiation promoted towards tissues of matching stiffness.2 SAP 
hydrogels change mechanically with rate of assembly, concentration of SAP, and the 
presence of macromolecules.61,62 Rheological analysis showed that growth factor loading did 
not disrupt the hydrogel nature; in all cases the elastic component of the storage modulus 
(G’), exceeded the loss modulus (G”), and the moduli were mostly independent of frequency 
(Figure 6.3 (d-f)), displaying the standard SAP rheological properties.9,61 Importantly, all 
hydrogels exhibited similar stiffness, in the range of 1-6 kPa, within the range relevant for 
soft tissue applications.2 Spectroscopic analysis confirmed the π-β mode of assembly9 was 
conserved in all samples (Figure 6.3 (g-h)). Fourier transform infrared spectroscopy (FTIR) 
analysis showed the distinct anti-parallel β-sheet signal (a major peak at ~1630 cm-1 and 
minor peak at ~1690 cm-1).9 CD analysis also confirmed supramolecular ordering and the 
presence of β-sheets. These spectra all presented a chirality transition between small peaks 
of opposite orientation around 275 nm, indicative of supramolecular ordering, and a large 
peak around 220 nm, indicative of β-sheets.9  Overall, the data confirm neither BDNF 
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loading nor chitosan attachment disrupt the optimal morphology or mechanical properties 
of the resultant hydrogels. 
 
Figure 6.3: Hydrogel characterisation. Characterisation of Fmoc-DDIKVAV SAP hydrogels alone (a,d), 
loaded with BDNF (b, e) and loaded with modified BDNF-Chitosan (c, f). (a-c) TEM images with 200 nm 
scale bar. (d-f) Rheological analysis showing storage modulus (G’) (solid line) and loss modulus (G’’) (dotted 
line). (g-h) FTIR (g) and CD (h) spectroscopic analysis of hydrogel alone (solid green line), loaded with BDNF 
(dashed blue line), and loaded with modified BDNF-chitosan (dotted red line). 
6.5 Conclusion 
In summary, here we demonstrate a new and sophisticated method for sustained, 
localised, consistent dose and temporally controlled delivery of multiple protein growth 
factors from a novel biomimetic tissue engineering material. We show independent control 
of the release of two growth factors from a single SAP hydrogel, while maintaining the 
previously optimised mechanical properties of the tissue specific SAP material. We also 
demonstrate the improved utility of release rate based analysis compared to standard 
cumulative release profiles. Our findings have significant implications for regenerative 
medicine, where long-term and controlled delivery of multiple, trophic proteins is required.  
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7.1 Chapter Details 
As discussed in Chapter Two, electrospun materials are another very popular class of 
tissue engineering material. This chapter discusses work done using electrospun materials to 
present immobilised growth factors for neural regeneration applications. The chapter 
encompasses the work of two projects, first testing the bio-functionality of growth factors 
immobilised to electrospun materials in vivo, then adapting those materials for incorporation 
into a non-SAP hydrogel material and testing in vivo in a Parkinson’s disease model. The 
techniques used here represent important progress for the combination of growth factors 
and tissue engineering materials, while also providing the framework for the temporally 
controlled delivery mechanism from SAP hydrogels discussed in the next chapter.    
This chapter has been published as the research article listed below: 
Ting-Yi Wang*, Kiara F Bruggeman* (co first author), Jessica A Kauhausen, 
Alexandra L Rodriguez, David R Nisbet, Clare L Parish, “Functionalized composite 
scaffolds improve the engraftment of transplanted dopaminergic progenitors in a 
mouse model of Parkinson's disease”, Biomaterials, 2016, vol. 74, pp. 89-98 – 
Reproduced with permission from Elsevier 
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This chapter also contains an excerpt (Section 7.4), briefly describing work published in 
the research article listed below and included in full in Appendix E: 
Ting-Yi Wang, Kiara AF Bruggeman, Rebecca K Sheean, Bradley J Turner, David R 
Nisbet, Clare L Parish, “Characterization of the Stability and Bio-functionality of 
Tethered Proteins on Bioengineered Scaffolds IMPLICATIONS FOR STEM CELL 
BIOLOGY AND TISSUE REPAIR”, Journal of Biological Chemistry, 2014, vol. 289, pp. 
15044-15051 – Reproduced with permission from Elsevier 
7.2 Abstract 
With the brain’s limited capacity for repair there is a need for new and innovative therapies 
to promote regeneration. Stem/progenitor cell transplantation has received increasing 
attention, and whilst clinical trials demonstrating functional integration exist, inherent 
variability between patients has hindered development of this therapy. Variable outcomes 
have largely been attributed to poor survival and insufficient reinnervation of target tissues 
due in part to the suboptimal host environment. Here we examined whether improving the 
physical properties of the host milieu, by way of bioengineered scaffolds, may enhance 
engraftment. We developed a composite scaffold, incorporating electrospun poly(L-lactic 
acid) short nanofibres embedded within a thermo-responsive xyloglucan hydrogel, which 
could be easily injected into the injured brain. Furthermore, to improve the trophic properties 
of the host brain, glial derived neurotrophic factor (GDNF), a protein known to promote 
cell survival and axonal growth, was blended into and/or covalently attached onto the 
composite scaffolds to provide controlled delivery. in vitro we confirmed the ability of the 
scaffolds to support ventral midbrain (VM) dopamine progenitors, and provide sustained 
delivery of GDNF - capable of eliciting effects on cell survival and dopaminergic axon 
growth. In Parkinsonian mice, we show that these composite scaffolds, whilst having no 
deleterious impact on the host immune response, enhanced the survival of VM grafts and 
reinnervation of the striatum, an effect that was augmented through the scaffold delivery of 
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GDNF. Taken together, these functionalised composite scaffolds provide a means to 
significantly improve the milieu of the injured brain, enabling enhanced survival and 
integration of grafted neurons.    
7.3 Introduction 
Damage to the central nervous system (CNS), as a consequence of disease or trauma, can 
have devastating consequences due to its limited capacity for repair. With a notable lack of 
therapies, the transplantation of stem cells and neural progenitors has received increasing 
attention. Proof of principle studies in animals and clinical trials have demonstrated that new 
neurons are capable of functionally integrating into the injured brain; however, hindering the 
development of these therapies has been the inherent variability in treatment outcomes. Key 
challenges facing neural transplants in the CNS have been variable graft survival, as well as 
inadequate integration and reinnervation of the host tissue.197,198 In part, this has been 
attributed to the non-conducive environment of the adult brain – failing to provide adequate 
physical and trophic support for the graft, and highlighting the need for strategies to improve 
the host milieu.  
Several lines of evidence support the importance of physical scaffolding for the growth 
and connectivity of new axons. In neural development, ‘pioneer axons’ have been observed 
to establish precise targeting and establish scaffolds along which later-developing axons 
grow.199,200 Additionally, the presence of a number of extracellular matrix (ECM) and 
associated adhesion molecules in the developing brain provide critical anchoring to cells 
within their appropriate location and support axonal extension.201,202 Within the injured brain, 
founding work by Aguayo and colleagues demonstrated that CNS axons were capable of 
growing over distances in the adult brain when they were placed into the permissive 
environment of a peripheral nerve graft,203,204 work that was also demonstrated in the support 
of dopaminergic neural grafts,205 and complimented by studies using alternate support cells 
such as Schwann and olfactory ensheathing cells to enhance graft integration.206 Furthermore, 
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in more recent years, grafted neurons have been demonstrated to grow their axons along 
residual host axons within the designated pathway, or alternate axonal tracts, using these host 
axons as natural scaffolds.19,207 Combined, this knowledge suggests that efforts to improve 
the physical support of grafted neurons could enhance integration.  
One such strategy to optimize graft support is to engineer biomaterials for implantation.208 
In this regard, electrospun nanofibres provide some of the best examples of simulation of 
the brain’s 3-dimensional (3D) in vivo environment—whereby scaffold fibres can support cell 
adhesion and axon extension. A number of our previous studies have demonstrated that 
electrospun scaffolds can influence cell proliferation, neural differentiation and axon 
extension in vitro, whilst also influencing survival and plasticity of both host- and grafted-
derived neurons in the intact brain.36,55,105,209-211 Despite these encouraging findings, the 
bulkiness of electrospun scaffolds renders them less attractive for repair of the brain and 
more appropriate for spinal cord or peripheral nerve injury where they can be functionalised 
and used to ensheath axon bundles. Consequently, increasing attention has been paid to the 
potential of hydrogels—particularly thermo-responsive gels that can be designed to (i) be 
liquid at 4°C (enabling easy injection) yet rapidly form gels in situ at 37°C and (ii) match the 
modulus of the host tissue.40,212,213 This is appealing in the current context as cells can be 
mixed into the liquid prior to implantation. We have previously demonstrated that xyloglucan 
(polysaccharide) hydrogels can support the survival of neural cells in vitro, promote neurite 
growth of host neurons following implantation into the intact brain, and additionally 
suppress local reactive astrocytes101,214—all critical attributes for cell transplantation. 
In addition to the physical support necessary for transplanted neurons, numerous studies 
have highlighted the capacity of trophic proteins and guidance cues to enhance graft survival 
and integration.19,207,215-217 During embryonic development, establishment of neural circuits 
relies on the precise temporal and spatial expression of axonal growth and guidance cues. 
Following establishment of circuitry many of these cues are down regulated, with this loss of 
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expression believed to be one of the major contributors to the adult brain’s poor regenerative 
capacity. Re-expression of these trophic cues can greatly increase the survival and integration 
of residual host and newly transplanted neurons. This has been most notably demonstrated 
through the delivery of various neurotrophins known to promote neuronal survival and 
axonal plasticity.215,218 However, to date, delivery of trophic proteins into the brain relies on 
implantation of cells that over-express the protein, invasive pumps for protein infusion in 
situ, or injection of viral constructs to induce local cells to produce proteins. Each of these 
approaches is clinically problematic and new efforts for providing a prolonged, yet 
controllable, trophic environment to promote the integration of grafted cells is required. 
Using biomaterials, we have recently developed methods to prolong the presentation of 
proteins in vitro and in the intact brain.31,36,55 Covalent tethering of proteins onto biomaterials 
prolongs their presentation by preventing endocytosis. Previously we have demonstrated that 
prolonged presentation of brain derived neurotrophic factor (BDNF) or GDNF onto 
electrospun fibres resulted in improved survival, proliferation, differentiation, and neurite 
growth of cells in vitro and in vivo following implantation into the uninjured brain.31,36,55 
In recent years, several studies have examined the potential of biomaterials to deliver 
GDNF and/or cells in an effort to improve graft integration. This has included the use of 
various hydrogels to deliver stem cells including those over-expressing GDNF,219,220 as well 
as microcarriers/spheres to deliver GDNF with and without foetal progenitors.221,222 
Unfortunately, the success of these approaches have been largely suboptimal due to the 
bulkiness of the biomaterials together with cells, and duration of peak GDNF dose delivery. 
Resultant outcomes have positively described no change or reduced host inflammatory 
responses yet only modest increase in graft survival, and little to no improvement in graft 
plasticity.   
In the present study, we sought to develop a more sophisticated composite scaffold, 
demonstrating the benefits of electrospun scaffolds delivered as short nanofibres within a 
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thermo-sensitive xyloglucan hydrogel. These composite scaffolds were further functionalised 
to prolong the delivery of the GDNF, thereby providing an improved physical and trophic 
niche environment for the survival and engraftment of new neurons. As a feasibility and 
efficacy study, we elected to examine the potential of these biomaterials in a rodent model 
of Parkinson’s disease, a neurodegenerative disorder characterised by the loss of dopamine 
neurons, that has shown the greatest progress in the field of neural transplantation.197,198 The 
goal is to reverse the progression of the disease by promoting the growth of new 
dopaminergic neurons. The use of biodegradable tissue engineering materials means that no 
additional surgery is required to remove the implanted materials. 
7.4 Results from Previous Material Development 
While testing the stability and bio-functionality of growth factors chemically immobilised 
to electrospun scaffolds via SMCC, polycaprolactone (PCL) scaffolds were used with 
immobilised GDNF. To confirm the growth factor immobilisation technique PCL scaffolds 
were prepared alone (PCL), immersed in the growth factor solution to allow adsorption of 
soluble growth factor only (PCL_sGDNF), with immobilised growth factor via SMCC 
(PCL_iGDNF), and with immobilised growth factor and extensive washing in a vortex mixer 
to remove non-immobilised growth factor (PCL_iGDNF(v)). The vortex mixing provides 
significant mechanical Quantification of the growth factor present on the scaffolds by ELISA 
(Figure 7.1A) showed significantly more growth factor on the immobilised scaffolds, with 
only a slight decrease and no statistically significant change after vortexing. The very large 
difference between the amount of growth factor attached through adsorption 
(PCL_sGDNF) and via immobilisation indicates that the SMCC method is effective at 
tethering growth factor to the scaffold, while the relatively small decrease observed after 
vortexing indicates that the majority of growth factor present on the immobilised scaffolds 
is strongly chemically attached. BET analysis was used to determine the available surface area 
within the nanofibrous electrospun scaffold, and this area combined with quantification of 
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growth factor from ELISA was used to calculate the density of growth factor presentation 
as 41 pg/cm2 (Section 3.3.5).  
 
Figure 7.1: Growth factor attachment and stabilisation on electrospun scaffolds. A: GDNF on PCL 
scaffolds alone, with absorbed GDNF, and with immobilised GDNF with and without vortex washing. B-C: 
GDNF on immobilised scaffolds (B) without vortexing (black bars) and with vortexing (white bars) after 
incubation in PBS and in the corresponding incubation supernatant (C) D: GDNF on scaffolds with and 
without proteolytic trypsin treatment. All GDNF quantified by ELISA. Data represent mean ± SEM, * p < 
0.05, ** p < 0.01, *** p < 0.001, one-way ANOVA with Tukey post-hoc test. 
Immobilised scaffolds with and without vortexing were incubated in PBS over 120 and 
14 days respectively to test the long-term stability of the immobilisation, and no significant 
change in detectable growth factor was found (Figure 7.1B). The undiminished presence of 
growth factor at all time points tested suggests that growth factor presentation timeframe 
will be limited by the scaffold material degradation and should therefore remain present in 
culture for over 12 months.223 The PBS incubation supernatants were also tested (Figure 
7.1C) and the results corroborate the strength of the SMCC attachment. Some growth factor 
was found released from the non-vortexed scaffolds after 24 hours, comparable to the 
difference between vortexed and non-vortexed scaffolds, meaning that the scaffold 
preparation results in some loosely adsorbed growth factor that can be removed with 
washing or over time in solution. The vortexed scaffolds did not release any detectable 
growth factor into the solution, indicating that the remaining growth factor was strongly 
bound so the scaffold. No supernatants held any growth factor after 24 hours, indicating the 
unattached growth factor was fully removed after 24 hours, and that that released growth 
factor had fully degraded by 3 days. The immobilised growth factor on the scaffolds did not 
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experience that degradation, and neither was it susceptible to proteolysis, as indicated by a 
lack of effect of trypsin treatment on the immobilised scaffold (Figure 7.1D), indicating 
increased growth factor stability after attachment.  
To confirm the bioactivity of the immobilised growth factor immunoblotting was 
performed focusing on the GDNF-ErK signalling pathway, specifically the phosphorylation 
of ErK1 and ErK2. Testing was done with SN4741 cells were used as they are known to 
express the GDNF receptors c-ret and GFRa1. Non-phosphorylated ErK was found in 
comparable levels on both the control PCL scaffold and the immobilised scaffold (PCL + 
iGDNF), but the phosphorylated counterparts (pErK1 and pErK2) were significantly 
increased with the immobilised scaffold, showing a 4.4 times increase in the ratio of 
phosphorylated to total ErK (Figure 7.2A-B). This confirms that the immobilised GDNF 
retained its bioactivity, as it was still capable of mediating intracellular signalling. The 
motivation behind growth factor immobilisation is to sustain presentation beyond the 
normally very short active lifespan of the soluble factor. To confirm this, further 
immunoblotting was performed comparing the immobilised GDNF to a GDNF solution (at 
30 ng/mL) over 3 days (Figure 7.2C-D). Both the GDNF solution and immobilised scaffold 
demonstrated bioactivity initially via increased ErK phosphorylation, only the immobilised 
scaffold showed continued bioactivity after 3 days. 3 days after treatment with GDNF 
solution the cells had returned to phosphorylation levels comparable to the basal levels of 
the control group. These results confirm not only that the immobilisation method retains 
bioactivity, but that it is successfully achieves a prolonged lifespan of growth factor efficacy.  
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Figure 7.2: Long-term biofunctionality of immobilised GDNF confirmed based on phosphorylation 
of intracellular ErK. Immunoblotting (A, C) and band densities (B, D) of the ErK and phosphorylated pErK 
from SN4741 neural cells. A-B: Comparison of PCL scaffold alone and with immobilised GDNF. C-D: 
Comparison of GDNF solution and immobilised GDNF over time. Data represent mean ± SEM, * p < 0.05, 
** p < 0.01, *** p < 0.001, student’s t test and one-way ANOVA. 
The bioactivity was further confirmed in vitro with neural progenitor cells from ventral 
midbrain (VM) tissue of embryonic mice. The cultures were tested at 3 and 7 days for cell 
viability (Figure 7.3A) and proportion of dopaminergic neurons indicated by tyrosine 
hydroxylase-immunoreactivity (TH+) (Figure 7.3B). Once again the PCL scaffold alone had 
no effect and the GDNF solution showed an initial effect only, with improved cell viability 
and increased dopaminergic neurons at 3 days but not at 7 days. The immobilised scaffold 
treatments, however, showed ongoing effect out to 7 days, confirming the long-term 
bioactivity of the immobilised growth factor. These results show that the immobilised 
GDNF, with or without vortexing, promotes cell viability and dopaminergic neuronal 
differentiation. This effect is also shown in the photomicrographs of the fluorescence 
staining for cells (Hoechst), neurons (Tuj), and dopaminergic neurons (TH) (Figure 7.3C-R).  
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Figure 7.3: GDNF immobilisation enhances cell viability and differentiation. A-B: Cell viability (A) and 
proportion of tyrosine hydroxylase-immunoreactive (TH+) cells (B) in ventral midbrain cultures with control 
conditions (PDL-coated plastic), GDNF solution, PCL scaffold alone, and immobilised scaffolds with and 
without vortexing after 3 days in vitro (DIV) (black bars) and 7 DIV (white bars). Data represent mean ± SEM, 
* p < 0.05, ** p < 0.01, *** p < 0.001, # p < 0.05, ## p < 0.01, one-way ANOVA with Tukey post-hoc test. 
C–R: Representative photomicrographs of Hoechst-labelled nuclei (C-F), TUJ+ neurons (G-J), TH+ 
dopaminergic neurons (K-N), and merged images (O-R) of VM cells cultured on PDL-coated plastic (control), 
PCL, PCL with immobilised GDNF (PCL_iGDNF), and PCL with immobilised GDNF and vortexed 
(PCL_iGDNF(v)).  
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7.5 Results 
7.5.1 Characterisation of Scaffolds 
Desirable for bioengineered scaffolds to support neural cells in vitro and in vivo is the 
confirmation of their previously described physical attributes, as well as assessment of the 
characteristic features of the novel composite scaffold. Scanning electron micrographs 
confirmed the macroporous 3-dimensional structure of xyloglucan hydrogel with the 
inclusion of PDL (Figure 7.5A). PDL was immobilised onto xyloglucan to promote cell 
adhesion and neurite elongation, as previously shown (Figure 7.4, Section 3.2.6, 3.2.3).101 In 
addition to SEM, the presence of PDL on xyloglucan was confirmed by XPS. The nitrogen 
to carbon ratio (1:0.043) indicated that there was 1.85 PDL molecules immobilised to each 
xyloglucan repeat unit. SEM images revealed that electrospun PLLA nanofibres showed 
aligned fibre orientation (Figure 7.5B), from which short fibres (Figure 7.5C) could be 
generated for the composite scaffold. The presence of these PLLA short fibres could be 
visualised within the xyloglucan gel of the composite scaffold (Figure 7.5D).  
 
Figure 7.4: PDL xyloglucan immobilisation mechanism 
Isothermal rheological experiments were conducted to determine the composition at 
which the elastic modulus of the xyloglucan hydrogels matched the modulus of the rodent 
brain (1.0-3.0 kPa224). At 37 °C the presence of the short fibres increased the elastic modulus 
of the xyloglucan-PDL (red line, Figure 7.5E) compared to xyloglucan-PDL without SF 
(purple line, Figure 7.5E), resulting in a biomaterial closer in shear stiffness to the host brain. 
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Scaffolds were functionalised with GDNF to promote cell survival and dopaminergic 
neurite extension. The presence of GDNF was validated using ELISA prior to in vitro 
culturing and in vivo implantation. In the absence of scaffolds, the presence of GDNF in the 
media diminished within 4 days (white bars, Figure 7.5G). The blending of GDNF into 
xyloglucan retarded the protein’s release from the gel, resulting in maintained expression in 
the media for 14 days, yet undetectable by 28 days (grey bars, Figure 7.5G). The 
immobilization of GDNF on PLLA fibres confirmed sustained expression for 28 days 
(striped bars, Figure 7.5G), with little GDNF (presumably absorbed, rather than covalently 
attached) released from the scaffolds during this period (black bars, Figure 7.5G). These 
findings of immobilised GDNF are in accordance with our previous findings, that 
demonstrated maintained neurotrophin expression on electrospun fibres for up to 120 days.31   
 
Figure 7.5: Synthesis and GDNF functionalization of bioengineered scaffolds. Scanning electron 
micrographs illustrating the architecture of (A) 3 wt% xyloglucan gel with photo-coupled PDL, (B) electrospun 
nanofibrous PLLA, (C) PLLA short fibres, and (D) the composite scaffolds, including PLLA short fibres within 
the xyloglucan gel. (E) Rheological measurements of the elastic (G’, closed symbols) shear moduli of 
xyloglucan-PDL and xyloglucan-PDL + SF under isothermic (37 °C) conditions. (F) Schematic illustration of 
GDNF immobilization onto PLLA nanofibres. (G) GDNF ELISA showing the presence of GDNF protein 
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over 28 days in the media following soluble delivery (sGDNF), GDNF released from xyloglucan gels 
(XYLO+bGDNF), GDNF release from PLLA scaffolds immobilised with GDNF (XYLO+iGDNF (release)), 
and the amount of GDNF tethered onto the scaffolds (XYLO+iGDNF (immobilised)). Data represents mean 
+ SEM. Scale bar: A-D: 5 µm. 
7.5.2 Survival, Differentiation, and Plasticity of Ventral Midbrain Neurons in 
vitro  
To assess the ability of the 3D bioengineered scaffold to support dopaminergic neurons 
and deliver functional GDNF, we cultured VM-derived cells on PDL-coated coverslips or 
xyloglucan (± SF ± GDNF) (Section 3.5.1.2, 3.5.1.11). Xyloglucan provided a superior 
substrate for the attachment and survival of VM cells compared to PDL (69.4% ± 3.2 and 
53.0% ± 3.3 viability, respectively), with the presence of PLLA short fibres resulting in no 
further improvement in survival (71.5% ± 4.9) (Figure 7.6A). The culture substrate (PDL, 
XYLO or XYLO+SF) had no effect on the proportion of neurons in culture, with > 80% 
of viable cells expressing the neuronal marker, TUJ1, under all conditions (Figure 7.6B).  
As anticipated, the presentation of GDNF in culture significantly improved cell viability 
to levels ≥ 83% (Figure 7.6A), as well as increasing the proportion of TH+ dopaminergic 
neurons in culture (Figure 7.6C) and their neurite length (Figure 7.6D). This was apparent 
whether GDNF was administered directly into the media (sGDNF), blended into the 
xyloglucan (bGDNF) or tethered onto short fibres in the gel (iGDNF). Whilst sGDNF 
increased the proportion of TH+ dopaminergic cells in culture compared to culturing on 
xyloglucan alone (3.2% ± 0.2 and 2.0% ± 0.2, respectively), the prolonged presentation of 
GDNF within the gel (bGDNF) resulted in a 2.5-fold increase in TH+ cells. This effect was 
not seen by immobilised GDNF, and is likely reflective of the amount of SF on the surface 
of the hydrogel and hence the subsequent amount of GDNF available to interact with the 
cultured neurons.  Figure 7.6E-J provides representative micrographs of cells cultured on 
PDL, XYLO and composite scaffolds, demonstrating the benefit on viability of the 
enhanced 3-dimensional physical support provided by biomaterials. Figure 7.6K-N illustrates 
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examples of dopaminergic neurons showing increased neurite length following GDNF 
delivery, and confirming the ability of scaffolds to deliver functional protein.  
 
Figure 7.6: Bioengineered scaffolds, incorporating GDNF, enhance cell viability and support 
dopaminergic neurons in vitro. Quantification of (A) the number of DAPI-labeled viable cells and, (B) 
proportion of TUJ+ neurons in culture. (C) Assessment of the proportion of TH+ dopamine neurons and, (D) 
neurite length in culture following GDNF administration. Representative photomicrographs illustrating (E-J) 
TUJ+ neurons and total DAPI labeled nuclei, and (K-N) TH+ dopaminergic neurons. Data represents mean 
+ SEM, * P < 0.05, ** P < 0.01, *** P < 0.001. 
7.5.3 Biocompatibility 
Given the ability of our scaffolds, including incorporated GDNF, to support VM-derived 
neurons in vitro, we next examined the potential of these scaffolds to support and promote 
the integration of transplanted VM progenitors in an animal model of Parkinson’s disease 
(Section 3.5.1.8, 3.5.1.11). Paramount for the utility of bioengineered scaffolds in tissue repair 
is their biocompatibility and impact on the host inflammatory response. At 10 weeks post-
implantation, we observed that neither xyloglucan nor the presence of PLLA short fibres at 
the graft site induced elevated levels of reactive astrocytes (GFAP+, Figure 7.7A,D-J) or 
microglia (CD11b+, Figure 7.7B,D’-J’), compared to cell implants alone.  
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Figure 7.7: Biomaterials bear no impact of the host immune system following implantation. (A) 
Assessment of GFAP+ astrocyte and, (B) CD11b+ microglia density surrounding the GFP+ graft 
demonstrates that the employed biomaterials, nor the incorporation of GDNF protein, impacted on the host 
inflammatory response, as compared to cell grafts alone (black bars). (C) Schematic, illustrating the region 
adjacent to the graft (boxed area) used to assess GFAP and CD11b density. (D-J) Representative 
photomicrographs of GFAP+ and (D’-J’) CD11b+ immunolabeling adjacent to the GFP+ graft core. Data 
represents mean + SEM. 
7.5.4 Dopaminergic (DA) Neurons in VM Grafts and Reinnervation of the 
Striatum 
The use of TH-GFP mice provided a valuable means to accurately measure graft-derived 
patterns of innervation of the host striatum, even in the presence of a residual level of 
innervation from host (GFP-) DA neurons. At the time of assessment (10 weeks post-
transplantation) (Section 3.5.2.3), TH immunohistochemistry confirmed robust ablation of 
the host midbrain DA neurons in lesioned mice (data not shown). GFP staining verified 
viable grafts, confined to the striatum in 68/74 (91%) of the mice. Quantification of GFP+ 
cells revealed that the presence of xyloglucan, but not PLLA short fibres, significantly 
increased graft volume, Figure 7.8A,D-J. Assessment of the volume of the graft core 
highlighted a proportionate increase for cells grafted in the presence of xyloglucan Figure 
7.8B, such that the overall density of cells within the graft core was not significantly different 
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from cell implants alone Figure 7.8C, and inferring that the presence of the scaffold did not 
retard the migration of neurons within the graft.   
 
Figure 7.8: Functionalised composite scaffolds support transplanted GFP+ dopamine neurons. (A) 
Exposure of VM fetal grafts to xyloglucan and/or GDNF increased the number of GFP+ dopaminergic 
neurons following implantation. Note the synergy of the composite material and dual delivery of GDNF 
(blended within the gel and immobilised onto short fibres). (B) The volume of the graft core commensurately 
increased with increased GFP+ cell numbers, resulting in (C) no significant difference in the density of GFP+ 
DA neurons in the graft and importantly demonstrating that the scaffolds did not impede cell migration. (D-J) 
Representative photomicrographs providing a coronal view of the GFP+ grafts within the striatum. Images 
depict grafts of GFP+ cells alone (D), GFP+ cells in the presence of scaffolds (E-F) and GFP+ cells in the 
presence of GDNF ± scaffolds (G-J). Data represents mean ± SEM, * P < 0.05, ** P < 0.01, *** P < 0.001. 
The use of TH-GFP donor tissue enabled not only improved visualization and assessment 
of GFP+ cells, but furthermore the extensive network of fibres emanating from these 
neurons. This allowed for quantitative comparisons of the total striatal area innervated by 
the graft (Figure 7.9A), innervation volume/grafted neuron (Figure 7.9B), and the density of 
grafted fibres in the striatum (Figure 7.9C). Commensurate to the increase in the number of 
GFP+ cells, XYLO implanted animals showed an increase in striatal innervation volume 
compared to cell grafts alone (2.67 mm3 ± 0.42 and 2.04 mm3 ± 0.36, respectively) (Figure 
7.9A-B,D-E). Interestingly the presence of PLLA short fibres had a negative impact on 
striatal innervation and innervation/GFP+ cells (Figure 7.9A-B,F), an effect likely explained 
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by the preference for graft derived GFP fibres to remain within the graft core and attach to 
the short fibres, rather than infiltrating the host striatal tissue. Despite these differences in 
volume of striatal territory innervated, the overall density of fibres within the innervated areas 
was not significantly different from cells alone (Figure 7.9C). 
7.5.5 Graft Survival and Integration 
Next we examined the capacity of scaffolds to improve the delivery of GDNF, in an 
effort to promote graft survival and integration in Parkinsonian mice. Not surprisingly, and 
as previously described,225 the inclusion of GDNF (sGDNF) within the donor cell 
preparation at the time of implantation significantly improved the number of GFP+ cells 
compared to cells alone (1188 ± 131 and 814 ± 96, respectively). Incorporation of GDNF 
within the gel (bGDNF) induced a 2-fold increase in GFP+ cell survival (1668 ± 343), 
however, presentation of GDNF on the short fibres only (iGDNF) within the gel was 
insufficient at boosting survival, and similar to in vitro findings, likely reflects the insufficient 
amount of GDNF presented to graft at the critical and vulnerable time of implantation. Most 
striking was the effect of enhanced and prolonged GDNF delivery through a combination 
of both blending within the xyloglucan gel and tethering onto short fibres (XYLO-bGDNF 
+ SF-iGDNF), which resulted in a 3.7-fold increase in GFP cells (3034 ± 413), significantly 
greater than all other methods of GDNF presentation (Figure 7.8A,D-J). GDNF 
presentation to the grafted cells commensurately increased the volume of the graft core 
(Figure 7.8B), and hence the overall density of cells within the core was not different (Figure 
7.8C) between all treatments, and again suggested that neither the physical structure of the 
scaffold nor the presentation of GDNF promoted or impeded cell migration.  
Finally, we assessed the ability of scaffold-delivered GDNF to promote the integration of 
GFP+ DA grafted neurons. Only sustained GDNF delivery enhanced graft-derived striatal 
innervation (Figure 7.9A,D,G-J). Blending GDNF into the xyloglucan gel (+XYLO-
bGDNF) resulted in a 2.1-fold increase in striatal innervation compared to cells alone (4.20 
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mm3 ± 0.59 and 2.04 mm3 ± 0.36, respectively) whilst blended plus immobilization GDNF 
(XYLO-bGDNF + SF-iGDNF) enhanced innervation by 3.1-fold (6.34mm3 ± 0.82). 
Furthermore, the dual presentation of GDNF not only enhanced graft-induced striatal 
reinnervation, but additionally the volume of innervation/GFP+ cell (Figure 7.9B) as well as 
the density of GFP+ fibres within the striatum compared to cells alone (7.4 ± 1.1 and 3.7 ± 
0.4, respectively), and all other grafts (Figure 7.9C,D’-J’). Presentation of tethered GDNF on 
short fibres alone (XYLO+SF-iGDNF) had no effect on innervation (1.15 mm3 ± 0.16). The 
presence of short fibres significantly reduced the ability for GFP+ grafted cell to innervate 
the host, whilst all other grafted cells showed similar innervation capacity, as demonstrated 
by innervation volume/GFP+ cell (Figure 7.9B).  
 
Figure 7.9: Scaffolds, incorporating GDNF, enhance innervation of grafted GFP+ neurons in the 
Parkinsonian brain. (A) Xyloglucan as well as the incorporation of GDNF within the gel (or composite 
scaffold) significantly increased the striatal volume innervated by grafted GFP+ dopaminergic neurons. (B) 
Innervation volume per grafted GFP+ cell remained unchanged across grafting conditions, with the exception 
of the presence of short fibres, which impeded fibre growth of the grafted cells. (C) Dual delivery of GDNF, 
via composite scaffolds, significantly increased the density of GFP+ fibres within the striatum. (D) 
Representative images of grafts, illustrating the extent of striatal innervation by the GFP+ grafted neurons. 
Note the increase in striatal innervation for grafts in the presence of xyloglucan and GDNF, most evidently 
GDNF delivery via composite scaffolds. (D’-J’) Photomicrographs illustrating the density of GFP+ fibres 
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100um lateral to the graft core. Note the increased density of fibres for grafts in the presence of composite 
scaffolds delivering GDNF. Data represents mean + SEM, * P < 0.05, ** P < 0.01, *** P < 0.001. 
7.6 Discussion 
Whilst proof of principal exists for the success of cell replacement therapy, variability in 
graft integration, and consequential function, remains a stumbling block that needs to be 
addressed. Extensive work has been undertaken, to better understand confounding factors 
contributing to the variability, with the ultimate goal of developing methodologies to 
improve aspects related to both the donor tissue and the host environment. While these 
efforts have resulted in stepwise improvements in grafting outcomes, little attention has been 
paid to enhancing the physical support for newly implanted stem cells/neural progenitors. 
This study provides the first evidence of the benefits of bioengineered scaffolds to enhance 
the integration of dopaminergic progenitors in an animal model of Parkinson’s disease. These 
scaffolds were demonstrated to improve both the physical and prolonged trophic support of 
progenitors in vitro and following transplantation, thereby promoting graft survival and 
striatal reinnervation of the injured brain. 
7.6.1 Physical Properties of the Host Environment 
Despite studies demonstrating the improved survival and plasticity of DA progenitors 
when implanted into a partially lesioned midbrain, where there is evidence to suggest that new 
grafted axons elect to follow host fibre bundles in vivo,207 combined with evidence for the 
important role of the ECM and adhesion molecules in establishment of neural circuits during 
development and repair,226,227 little effort has been made to enhance the physical support of 
transplanted neural progenitors within the CNS. A small number of studies have examined 
the potential benefits of co-grafting using, for example, olfactory ensheathing cells or bio-
bridges from sciatic nerve to provide substrate support for DA-enriched grafts.205,228-230 
Additionally there have been efforts to over-express the cell adhesion molecule, L1, in the 
host and/or donor tissue, to enhance functional integration.231,232 By contrast, in other 
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systems there has been significantly more attention focused on exploring the benefits of 
providing physical support for integration of grafted neurons or plasticity of host neurons 
following injury, for example to the peripheral nervous system and spinal cord. This includes 
numerous studies employing bioengineered scaffolds.233 Here we provide the first evidence 
of 3D bioengineered scaffolds supporting DA progenitors in vitro as well as their integration 
following implantation in Parkinsonian mice. In particular, the support provided by the 
xyloglucan hydrogel resulted in increased numbers of DA neurons within grafts and re-
innervation of the host striatum. Importantly, and in line with our former work,55,210 we 
demonstrate that these biomaterials are biocompatible, inducing no increase in inflammation 
following implantation into the brain (compared to cell grafts alone) and furthermore, could 
be customised to match the modulus of the rodent brain. Whilst here we demonstrate the 
capacity of scaffolds to support the integration of ectopically grafted neurons, these findings 
hold implications for homotopically transplanted cells, whereby axons of neurons implanted 
into the midbrain need to navigate over decidedly longer distances, thereby presenting a 
greater need for support, to reach their forebrain targets. Further studies are required to 
identify optimal strategies to deliver such scaffolds along the midbrain pathways with 
minimal invasiveness. These findings also raise interest regarding the development of 
alternate scaffolds that may more closely mimic neural tissue. For example, we have recently 
developed self-assembling peptide hydrogels that present a laminin epitope (a major 
constituent of the brain ECM) and have been demonstrated to support neural grafts in the 
intact brain.9,234 These newer materials may provide additional trophic benefits to the cells as 
well as possess the advantage of breaking down into naturally occurring amino acid subunits. 
7.6.2 Delivery of GDNF to Transplanted DA Progenitors  
The role of GDNF in the survival and plasticity of DA neurons is well established in vitro, 
in models of PD and following transplantation.19,218,235 Here we developed a biomaterial 
capable of prolonging the presentation of the protein to DA progenitors, by way of retention 
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within the xyloglucan hydrogel as well as sustained delivery via covalent tethering on 
electrospun short fibres. Function of the scaffold-incorporated GDNF could be confirmed 
by its ability to enhance the proportion of TH+ DA neurons in culture and promote TH+ 
DA neurite extension. Most significant was the capacity for long-term presentation in vivo 
and the influence on transplanted DA progenitors. Whilst delivery of soluble GDNF was 
sufficient to increase DA neurons within the graft (not dissimilar to blending GDNF within 
the hydrogel), such acute delivery was insufficient to impact the subsequent plasticity and 
integration of the graft. Only presentation of GDNF within the gel, or in the composite 
scaffold, influenced the volume of innervation of the host tissue by grafted DA neurons. We 
speculate that GDNF delivery via protein tethering onto PLLA short fibres alone was 
incapable of promoting enhanced graft survival due to insufficient amounts of short fibres, 
and thereby suboptimal levels of tethered GDNF, coming into contact with grafted cells to 
influence their survival. Added to this is the likelihood that tethered GDNF prevented GFP+ 
neurites existing from the graft core, but rather staying in close association with the PLLA 
short fibres present. By contrast, the composite scaffold presenting sustained GDNF release 
over weeks from the gel was complemented by persistent tethered GDNF, such that a 
synergistic effect on DA neuronal numbers and innervation was observed. Hence, here we 
present three examples of controlling the temporal delivery of a protein in vitro and in vivo; 
from minutes to hours (via soluble administration), days to weeks (via retardation within the 
gel) and weeks to months (via tethering onto short fibres). In the future, such controlled 
delivery systems could be customised for specific functional requirements for providing 
multiple proteins over differing time frames. For example, future transplantation studies may 
look towards acute delivery of cell survival factors at the time of implantation, longer delivery 
to influence cell migration and/or differentiation and persistent protein expression to 
promote plasticity of newly implanted cells. 
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7.7 Conclusion  
In summary, here we present the first evidence of bioengineered scaffolds being tailored 
to meet the many physical and trophic requirements of transplanted dopamine progenitors 
to enhance their integration into the Parkinsonian brain. Through careful selection and 
design of a composite scaffold, including prolonged neurotrophin presentation, we were able 
to improve the niche environment surrounding the implanted cells, resulting in enhanced 
survival and reinnervation of the host. The utility of such scaffolds, the incorporation of 
additional functional proteins as well as the impact on pluripotent stem cell-derived neurons, 
may impact on the future of cell therapy for the treatment of neurodegenerative disorders 
such as PD.  
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8.1 Chapter Details 
Using materials and methods explored in Chapter Seven, this chapter describes the 
successful development of the second temporally controlled growth factor delivery system, 
achieving a long delay in the release of growth factors from the SAP hydrogel. This chapter 
is also a research article manuscript in preparation by Kiara F Bruggeman, Yi Wang, 
Francesca Maclean, Clare L Parish, Richard Williams, and David R Nisbet. 
8.2 Abstract 
Tissue-specific self-assembling peptide (SAP) hydrogels designed around biologically 
relevant peptide sequences have great potential in regenerative medicine. These materials are 
often compared with electrospun nanofibre scaffold sheets, which provide larger nanofibres 
and are known to promote cell adhesion but are limited to wrapping and bandaging 
applications. Here, for the first time we describe a composite scaffold from these two classes 
of biomaterials, explicitly engineered as a system for temporally controlled drug delivery. 
Short fibres, cut from electrospun scaffolds, were mixed with our tissue-specific SAP 
hydrogel to provide a range of nanofibre sizes mimetic of that found in the extracellular 
matrix (10 – 300 nm diameter). The composite material also maintained the shear-thinning 
Chapter Eight 
Delivery System: Long (Days) Delay 
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and void filling properties of SAP hydrogels that facilitate their minimally invasive injection 
delivery and full integration with surrounding tissue. Both components were loaded with 
growth factors, important signalling molecules in tissue regeneration whose rapid 
degradation limits their clinical efficacy. The two biomaterials provided distinct growth factor 
delivery profiles: the SAP hydrogel provided a burst release, with the release rate decreasing 
over 12 hours, and the electrospun nanofibres provided a more constant, sustained delivery. 
Importantly, this second release began after a 6-day delay, to potentially allow growth factor 
delivery after subsidence of the initial immune response common after injury. This novel 
composite material combines the advantages of SAP hydrogels and electrospun nanofibres 
while also providing a superior vehicle for the stabilisation and controlled delivery of growth 
factors. This is particularly relevant for neural tissue engineering applications, such as 
traumatic brain injury, where systemic growth factor delivery is inhibited.   
8.3 Introduction 
Protein growth factors are short-lived intracellular signalling molecules used in 
nanomedicine and tissue engineering to encourage the growth of new healthy tissue. While 
their usefulness is undeniable, their relatively large size compared to conventional drug 
molecules20 and inherent instability10 make their therapeutic delivery a challenge. in vivo, 
enzymatic degradation results in very short growth factor half-lives, as low as 3 min for basic 
fibroblast growth factor (bFGF)13 and 45 min for nerve growth factor (NGF).14 Growth 
factor delivery to the brain is particularly challenging as the blood brain barrier (BBB) inhibits 
systemic delivery via the bloodstream.20 Sustained delivery can be achieved using 
intracerebroventricular (ICV) infusion, however, this is very invasive and causes iatrogenic 
injury, so much research has focused on using less invasive implantation strategies with 
nanoengineered biomaterials to support cells and provide growth factor delivery.22,36,236 
These tissue engineering scaffold materials are designed to mimic the natural extracellular 
matrix (ECM) down to the nano-level to reduce inflammation237 and promote repair and 
reconstruction. Naturally, the most abundant components of the ECM are nanofibrous 
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proteins and proteoglycan hydrogels,1 and tissue engineering materials focus on mimicking 
these elements. Electrospun materials are popular tissue engineering scaffolds due to their 
nanofibrous structure, and have been shown to promote cell attachment, differentiation, and 
proliferation.40,55 Growth factors have been incorporated into electrospun scaffolds both 
through emulsion, with the growth factor mixed into the polymer solution before 
electrospinning,238 resulting in growth factors dispersed throughout the fibres, and via 
immobilisation, with the growth factor covalently attached to the surface of fibres after 
electrospinning.31,36,192 Electrospun scaffolds have been used successfully to provide 
sustained delivery or presentation of growth factors. We have previously used immobilisation 
to provide essentially permanent presentation of growth factors, with duration dependent on 
the electrospun material degradation.31,36,192 However, electrospinning forms sheets of 
nanofibres, which are more suited for bandaging or wrapping applications than the void 
filling required for a scaffold to interface with healthy tissue surrounding a 3D injury site.40 
Self-assembling peptide (SAP) hydrogels, particularly the minimalist low molecular weight 
Fmoc-SAP systems, are not restricted by such limitations whilst also providing the fibrous 
nanoarchitecture reminiscent of the natural ECM, and hence offer the great potential as 
tissue engineering materials. They undergo thermodynamically controlled assembly to give 
1D nanofibres, 10 – 25 nm diameter, that align longitudinally to form a reversible 
supramolecular hydrogel, with the peptide sequence bioavailable on the surface of the fibre.8 
As the dominant self-assembly force is non-covalent, the material flows readily under high 
shear stress, such as when being administered via a minimally invasive needle injection, and 
then reforms in situ into a stiffer hydrogel that perfectly matches any irregularly shaped 3D 
injury site fully interfacing with surrounding healthy tissue.8 We have developed minimalist 
SAPs using recognisable peptide epitopes from biologically relevant ECM proteins to create 
tissue-specific SAPs that provide a high density of biomimetic cues in addition to the 
nanofibrous hydrogel environment.9,234 Additionally, non-covalent binding of growth factors 
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via physical adsorption to the nanofibres prevents degradation of the growth factors, and we 
have shown that stabilisation can be achieved for at least 6 weeks.239 
Both electrospun and SAP materials have been used to mimic the ECM and deliver 
growth factors and both materials have complimentary and distinct advantages. Here, we 
have developed a novel composite material using both SAP hydrogels and electrospun 
polymer nanofibres to improve ECM mimicry and move beyond simple sustained delivery 
to provide temporal control over the delivery of growth factors. 
8.4 Results and Discussion 
8.4.1 Material Development 
For this work, we used the rationally designed fluorenylmethyloxycarbonyl (Fmoc) 
capped aspartic acid-isoleucine-lysine-valine-alanine-valine (DIKVAV). The IKVAV 
sequence is a biologically recognised peptide epitope from laminin, an ECM protein common 
particularly in the central nervous system including the brain.  The N-terminal addition of 
the acidic D amino acid was used to adjust the apparent pKa of the peptide molecule to 
ensure that the pH driven self-assembly occurs at physiological pH.9 We have previously 
demonstrated the biocompatibility and utility of this SAP hydrogel in vivo via direct injection 
to the parenchyma of mouse brains.234 The peptide forms nanofibres ~10 nm in diameter 
(Figure 8.1A) and presents a macroscale supramolecular hydrogel with where the assembly 
derived stiffness is easily tuned to match the appropriate soft tissue type, an important factor 
in directing endogenous cell survival, integration and differentiation.2,240  
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Figure 8.1: Composite self-assembling peptide (SAP) hydrogel and electrospun short fibres. A-C: TEM 
(A, C) and SEM (B) micrographs of nanofibres in DIKVAV self-assembling peptide hydrogel (black arrow) 
(A), electrospun and cut short fibres (white arrow) (B) and both features highlighted in the composite material. 
Scale bars show 100 nm (black) and 1 μm (red). D-E: Photographs of DIKVAV hydrogel alone (D) and loaded 
with short fibres (E). F-G: Rheology showing storage modulus (G’) (F) and FTIR spectra (G) of DIKVAV 
hydrogel alone (black) and loaded with varying concentrations of short fibres (yellow, orange, red). Rheology 
data represent mean ± SEM (F). 
The biocompatible polymer poly(lactic acid) (PLA) was electrospun into nanofibres 
ranging ~100-2000 nm in diameter, and the scaffold was then cut by microtome into loose 
short fibres ranging ~20-100 μm long (Figure 8.1B, Section 3.2.7-3.2.8). The short fibres 
were then mixed directly by thorough vortexing into the DIKVAV hydrogel. The resultant 
composite material retained the macroscopic properties of the SAP hydrogel (Figure 8.1D-
E), specifically its injectable, shear-thinning property. On the nanoscale, the composite 
material showed the full range of nanofibres from both component materials (Figure 8.1C), 
which is more mimetic of the diverse range of nanofibre diameters found in the ECM.241 The 
addition of short fibres to the hydrogel showed little effect on the mechanical properties of 
the hydrogel (Figure 8.1F), displaying a very slight increase in stiffness with increasing short 
fibre concentration. The stability of the peptide structures was broadly retained; the FTIR 
spectra (Figure 8.1G) showed major peaks at 1630 cm-1 and minor peaks at 1690 cm-1, 
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confirming that the dominant supramolecular structure adopted within the nanofibres was 
unaffected by the addition of short fibres.61 These observations confirm the composite 
material, by retaining the desirable structural properties of its components, is capable of 
providing superior structural biomimicry than either SAP gels or electrospun scaffolds 
individually. 
8.4.2 Growth Factor Delivery 
We have previously demonstrated the ability of SAP hydrogels to stabilise and deliver 
multiple growth factors, specifically using the neurotrophic growth factor glial cell-line 
derived neurotrophic factor (GDNF) and brain derived neurotrophic factor (BDNF).239 To 
develop the composite material to provide more sophisticated control over growth factor 
delivery we first assessed the release profiles of neurotrophic growth factors from the intact 
electrospun scaffold materials alone into PBS (Figure 8.2A). We tested both common 
methods of growth factor incorporation into electrospun scaffolds, with the growth factor 
emulsion mixed directly into the polymer solution used for electrospinning (emulsion (m)) 
(Section 3.2.7), and with the growth factor covalently attached to the fibre surface after 
electrospinning (immobilised (i)) (Section 3.2.4.2). The emulsion scaffold showed a burst 
release, decreasing steeply over 12 hours and then providing a lower sustained delivery. The 
covalently immobilised scaffold showed little to no delivery into the surrounding media, 
which was expected as the growth factor was permanently immobilised onto the scaffold 
surface. The negligible amount detected may have been residual unattached growth factor or 
material degradation.  
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Figure 8.2: Growth factor incorporated electrospun materials. A: Release profiles from scaffolds with 
growth factors incorporated via emulsion (green) and immobilisation (blue) directly into PBS. Data represent 
mean ± SEM. B-G: SEM micrographs of intact scaffolds (B-D) and cut short fibres (E-G) from unmodified 
(B, E), emulsion GDNF (C, F), and immobilised BDNF (D, G). Scale bars show 2 μm. 
We also confirmed that growth factor incorporation, either by emulsion or 
immobilisation, did not disrupt the nanofibrous structure of the scaffold or short fibres 
(Figure 8.2B-G). For the composite material to work as a growth factor delivery system, with 
the electrospun short fibres contained within the SAP hydrogel, the growth factor must be 
able to leave the electrospun material to reach the surrounding environment. The release data 
demonstrates that only the emulsion growth factor shows substantial release, and that it is 
therefore more suited for use in the composite material than the immobilised growth factor. 
In isolation, the SAP and the emulsion electrospun materials loaded with GDNF both 
provided an immediate burst release diminishing over 12 hours (Figure 8.3A and Figure 8.2A 
respectively). This ‘slow’ burst delivery offered by both the SAP hydrogel alone and emulsion 
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scaffold alone offers an improvement over a solution of growth factors alone, which, 
unshielded, degrade rapidly. However, while immediate growth factor delivery can be useful 
in some contexts, delayed delivery is also very important. The therapeutic effects of  drugs 
or growth factors are optimal at varied stages of the treatment; for example, epidermal 
growth factor (EGF), which increases proliferation of neural stem/progenitor cells (NSPs), 
is best delivered initially for 7 days, followed by erythroprotein (EPO) to protect and reduce 
apoptosis in these new cells.22 In neural tissue regeneration the blood brain barrier (BBB) 
prevents systemic delivery, making controlled delivery particularly difficult to achieve in a 
non-invasive and non-iatrogenic way. Additional surgical disruption of the BBB can actually 
induce inflammation in the brain, which leads to secondary cell death.191,242 This means that 
minimally invasive temporally controlled delivery should ideally come in the form of delayed 
release from the original implanted material. To maximise the effectiveness of an implanted 
treatment strategy after injury or disease, delayed release of growth factors ensures that the 
therapeutic value of growth factors is not compromised by the initial inflammatory reaction 
after BBB breach. Concomitantly, this controlled, delayed release will not disrupt the 
inflammatory response - which has been shown to be crucial to repair243 – within the acute 
phase after brain injury, and will allow for the delivery of therapeutic factors to facilitate 
repair at a later time point, overcoming a potentially chronically persistent inflammatory 
response.    
Temporally controlled, sequential growth factor delivery is an important goal in 
regenerative medicine and was the primary motivation for the engineering of our composite 
delivery system. Emulsion growth factor loaded short fibres within a SAP hydrogel 
essentially have two sequential diffusion steps required to reach the surrounding media. They 
must diffuse first from the short fibre into the hydrogel, then from the hydrogel into the 
surrounding media. The release profile from short fibres within the composite material 
(Section 3.2.2.2) shows a 6-day delay in delivery to the surrounding media, and a more 
sustained delivery profile compared the burst release from the intact scaffold alone (Figure 
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8.3A). This is an important characteristic as it offers two temporally distinct delivery profiles, 
which is difficult to achieve in a homogeneous tissue engineering scaffold. The material can 
be designed to deliver different growth factors in an initial burst or after a delay based on 
whether they are loaded into the SAP gel or electrospun short fibre component of the 
composite.  
 
Figure 8.3: Short fibre growth factor delivery. A: Release profiles of GDNF solution (black), GDNF mixed 
with unmodified SF (grey), and mGDNF SF (green). Data show mean ± SEM. B-C: Metabolic activity of E14.5 
murine cortical neurons after 3 days of incubation with growth factor treatments. Data show mean ± SEM. 
Statistical significance determined by two-way ANOVA: *** p < 0.001, ** p < 0.01, * p < 0.05. 
We also tested the effect of the short fibres on growth factor delivery by mixing 
unmodified short fibres with GDNF solution before being loaded into the hydrogel (Figure 
8.3A). This method has been used with polymer nanoparticles to provide encapsulation free 
nanoparticle style growth factor delivery based on surface charge interactions between the 
polymer particle and the growth factor.178 This encapsulation free method offers 
simplification for single growth factor delivery, while also raising concerns about potential 
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interference in multiple growth factor systems using nano-carriers. Here we show that the 
growth factor solution exhibits the immediate slow burst profile when it is loaded into the 
hydrogel alone or when mixed with unmodified short fibres. It is likely that the encapsulation 
free effect is not observed here due to the much lower surface area to volume ratio of these 
relatively large short fibres compared to nanoparticles, which minimises the chance for 
interference from surface interactions.   
The neurotrophic growth factors used, GDNF and BDNF, are known to increase neuron 
survival/metabolic activity as measured by MTT assay.244-246 Here MTT assays were used to 
confirm the bioactivity of growth factors released from the electrospun materials with 
primary murine neurons (Figure 8.3B-C, Section 3.5.1.3, 3.5.2.8). The materials were 
incubated for 3 days before testing, allowing for degradation of free growth factor in solution. 
The emulsion short fibres showed the most significant effect on neuron metabolic activity, 
even more so than the control growth factor solution. We expect the improvement over the 
performance of the control was due to the prolonged delivery due to stabilisation from the 
short fibres. The intact emulsion scaffold showed little or no effect on the neurons, 
demonstrating the advantage of the short fibre form vs. the intact scaffold. Dispersed short 
fibres have a high surface area to volume ratio, and each fibre is able to interact with the 
solvent fully, whereas the intact scaffold has a higher density of hydrophobic polymer fibres 
to inhibit wetting of and diffusion from the interior layers of fibres. The inhomogeneous 
layered nature of intact scaffolds vs. the homogeneous dispersion of short fibres also 
contributes to the burst then sustained delivery profile observed above for the intact scaffold 
compared to the consistent delivery from the short fibres in the composite material. The 
immobilised materials, both the intact scaffold and short fibres, showed little to no effect on 
neuron metabolic activity, again because the growth factors were permanently immobilised 
to the fibres and unable to diffuse to the surrounding media and cells.  
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8.4.3 Resilience of Composite Structure 
To ensure the resilience of the composite materials, specifically to determine if the short 
fibres would remain in the gels, the SAP gels were loaded with varying concentrations of 
short fibres were gently washed in water for 7.5 hr (Section 3.4.4) using a washing procedure 
we have previously used with gold nanoparticles in SAP hydrogels.237 We found short fibres 
present and integrated into the hydrogel structure at all concentrations before and after 
washing (Figure 8.4). Importantly, we could find no visual evidence of displaced short fibres 
in the wash water under scanning electron microscopy (SEM). This is a significant result for 
a growth factor delivery vehicle in a tissue engineering material specifically, where the goal is 
the localised and long-term delivery to the extracellular environment. The resilience of the 
short fibres within the composite gel means that the growth factors will continue to be 
delivered from the implantation location only, thereby avoiding any off-target effects.  
 
Figure 8.4: Locational resilience of short fibres in hydrogel. SEM micrographs of DIKVAV hydrogel 
alone (A) and loaded with varying concentrations of short fibres before (B-D) and after (E-G) washing. Scale 
bars show 5 μm. 
We have previously tested small inorganic gold nanoparticles under the exact same 
washing conditions used here and found that they washed out readily from the SAP 
hydrogels, with complete removal of gold nanoparticles (as imaged by TEM) (Section 
5.3.2).237 The localisation of the short fibres here compares favourably to those nanoparticles. 
Intuitively, the smaller size of nanoparticles makes them more able to diffuse out of 
hydrogels. Nanoparticles in general are very popular drug delivery vehicles, as they are 
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versatile and easily functionalised. The very small size of nanoparticles makes them well 
suited for systemic and intracellular delivery systems, where small size and easy movement 
are required to allow the nanoparticle to reach its final target. Nanoparticles can be chemically 
adapted/functionalised to prevent diffusion and achieve localisation. We propose that here 
the localisation is more innate and achieved morphologically rather than chemically, which 
could be advantageous where other chemical surface modifications are required to control 
other properties (hydrophobicity, shielding layers, etc.).  
Much work has been done incorporating nanoparticles into tissue engineering scaffolds, 
as has been done here with short nanofibres. However, for incorporation into tissue 
engineering materials, we propose that the innate locational resilience of these larger 
nanofibres provides a drug delivery platform with superior long-term localisation of growth 
factor delivery. Considered with the structural biomimicry benefits of the short fibres, and 
the controlled delivery profiles, we believe that these short fibres have great potential as 
growth factor delivery vehicles in tissue engineering materials. 
8.5 Conclusion 
The novel composite material described here represents a step forward for the utility of 
both SAP hydrogels and electrospun nanofibres as tissue engineering materials. By 
combining these materials, we have demonstrated improved structural biomimicry of the 
ECM by providing a range of nanofibre sizes. The composite material also represents a novel 
growth factor delivery system capable of distinct release profiles of either a slow burst or 6-
day delayed and sustained delivery. This is a significant achievement applicable to neural 
tissue regeneration, matching the time required for the neuroinflammatory response to 
subside,247 and therefore allowing controlled growth factor delivery into a non-reactive cell 
environment to maximise therapeutic benefit.  
We propose that fine tuning of the short fibre parameters, including fibre dimensions, 
surface porosity, polymer composition, and growth factor loading could be used to also fine-
tune the release properties. Independent control of the release dose could be achieved by 
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varying the fibre loading within the hydrogel. As the system’s functionality is based on 
morphology and diffusion rather than specific chemistry, it is also inherently adaptable for 
use with other growth factors. Overall this system integrates beneficially with the SAP 
hydrogel on a material level while also providing controlled growth factor delivery.  
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9.1 Chapter Details 
This standalone chapter describes the successful development of the third temporally 
controlled growth factor delivery system, achieving stimuli-responsive control of the shape 
of the temporal release profile of growth factor from the SAP hydrogel. This chapter is also 
a research article manuscript in preparation by Kiara Bruggeman, Tina Zhang, Richard 
Williams, Antonio Tricoli, and David Nisbet. 
9.2 Abstract 
Here, we utilise a novel hybrid tissue engineering scaffold to achieve temporally controlled 
delivery of growth factors, which are important but unstable molecules used in regenerative 
medicine. Growth factors were chemically crosslinked to UV-sensitive nanoparticles, which 
were subsequently loaded into self-assembling peptide (SAP) hydrogels. We observed stimuli 
controlled delivery, where UV exposure was used to release growth factors bound to the 
nanoparticles. When the nanoparticles were incorporated within the SAP hydrogel, this UV 
trigger caused a counter-intuitive decrease in growth factor released from the hydrogel. This 
novel observation was caused by growth factor, upon release from the rapidly diffusing 
nanoparticles, instead competitively adsorbing to the SAP structures. We are the first to 
Chapter Nine 
Delivery System: Stimuli Responsive 
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report three temporally distinct release profiles from a SAP hydrogel, obtained from: 
unmodified growth factor, nanoparticle bound growth factor, and UV controlled release of 
nanoparticle bound growth factor.  This stimuli-based control allows the design of a specific 
release profile, and we used it to create a burst-free constant dose delivery profile. 
Significantly, we were able to use this approach to temporally distinguish the release profiles 
of multiple growth factors simultaneously loaded into the same hydrogel. 
9.3 Introduction 
Growth factors are important intracellular signalling protein molecules that have 
significant potential for controlling cell and tissue fate for improved regenerative medicine 
outcomes. However, as these molecules function as short-term soluble signalling molecules, 
they are rapidly secreted and consumed; their inherent instability therefore makes their 
controlled delivery a challenge.31 We have previously demonstrated that brain-derived 
neurotrophic factor (BDNF) specifically shows near total degradation after only 1 day in 
PBS,102 and growth factors are even more short-lived in vivo where enzymatic degradation is 
a factor.10 Growth factor half-lives in vivo are as low as 3 minutes for basic fibroblast growth 
factor (bFGF)13 and 45 minutes for nerve growth factor (NGF).14  
This short lifespan has a detrimental effect on the use of growth factors therapeutically, 
where their ideal delivery timeframe can occur over weeks,22 and their size and instability 
make them unsuited for systemic delivery.10 A significant design challenge lies in preventing 
growth factor degradation long enough to allow the delivery of a still functional protein 
throughout the desired timeframe only. It is important for any drug, including growth factors, 
to be delivered at the appropriate time and dose. Too much can have toxic or off-target 
effects and too little can have no effect, hence delivery must occur within a therapeutic 
concentration window.10,248 Any material strategy for controlled growth factor delivery in vivo 
must therefore ensure the long-term stabilisation of the growth factor as well as providing 
temporal control over the delivery profile. 
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Tissue engineering scaffold materials mimic the natural extracellular matrix (ECM) to 
promote tissue regeneration and degrade naturally as healthy tissue grows. An ideal growth 
factor delivery system for regenerative medicine should operate synergistically with these 
tissue engineering scaffold materials. Spatial control of growth factor delivery is achieved by 
loading them into an implanted or injected scaffold, which acts as a reservoir for diffusional 
delivery to the surrounding tissue. The goal is often to provide a consistent therapeutic 
concentration through sustained, ongoing delivery, although depending on the application 
many different delivery profiles can be required, such as rapid burst or pulsatile release.22 
Advancement of the field depends on building a library of control techniques so as to be 
able to engineer any possible combination of different release profiles of multiple drugs or 
growth factors into a single material.  
We have previously used chemical cross-linking via 4-(N-Maleimidomethyl)cyclohexane-
1-carboxylic acid 3-sulfo-N-hydroxysuccinimide ester sodium salt (SMCC) to provide a 
permanent ongoing presentation of growth factors by immobilising the growth factors to 
electrospun nanofibres in tissue engineering scaffold materials.31,36,191,192 We have also used 
this SMCC attachment to temporally control their non-permanent delivery, by attaching 
polysaccharide chains to the growth factor to delay their release from self-assembling peptide 
(SAP) hydrogel tissue engineering materials.102  
Photo triggered drug delivery from nanocarrier vehicles have been well explored, using 
light sensitive polymers as well as inorganic nanoparticles.57 They are often used 
independently but can also be incorporated into other materials, such as the photo responsive 
silica nanoparticles incorporated into hydrogel materials to provide UV-triggered drug 
delivery in a localised environment.93 In both cases, the majority of these studies focus on 
using a photo trigger to commence the release/delivery of a drug.92 The novelty of our study 
is that we use SMCC attachment to create the reverse system, in which UV light triggers a 
reduction in drug delivery rather than an increase.   
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The photocatalytic properties of titanium dioxide (TiO2) are well known, and one of the 
reasons TiO2 is a popular material for nanoparticle drug delivery systems.249 TiO2 
nanoparticles alone are acceptably biocompatible,250 and their biocompatibility can be 
improved with a biocompatible coating.251,252 We have previously demonstrated a method of 
creating TiO2 nanoparticles with a UV-sensitive lysine coating,99 which provides the 
necessary amine functional group required for growth factor attachment via SMCC. We have 
also previously explored the unique relationship between growth factors and the nanofibrous 
hydrogels formed from self-assembling peptides (SAPs).102 We have shown that growth 
factors adsorb to the SAP nanofibres,102 and that gold nanoparticles, inorganic nanoparticles 
similar to TiO2, are able to diffuse out of the SAP hydrogel readily.237  
Here, we use the SMCC attachment method and nanoparticle delivery to explore two new 
mechanisms for temporal control of delivery: attachment to a carrier nanoparticle embedded 
within a SAP hydrogel, and stimuli-responsive control of delivery from these nanoparticles. 
We report on a system in which nanoparticle bound BDNF shows greater release from the 
SAP hydrogel before UV treatment, at which point the unbound growth factor adsorbs to 
the SAP nanofibres. We also use this relationship and the UV-sensitive nanoparticles to 
induce a consistent release profile, using the UV response to counter the natural non-zero 
order delivery profile.  
9.4 Results and Discussion 
The growth factor brain derived neurotrophic factor (BDNF) was covalently attached to 
amine coated titanium dioxide (TiO2) nanoparticles via the chemical crosslinker SMCC 
(Section 3.2.4.3). After SMCC attachment the BDNF coated nanoparticles were measured 
via enzyme linked immunosorbent assay (ELISA) after repeated washing and UV exposure 
(Section 3.4.5) to assess their utility alone as photo triggered growth factor delivery vehicles. 
Repeated washing was performed to remove unbound BDNF and to test the resilience of 
the bound BDNF. The nanoparticles consistently presented more BDNF before UV 
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treatment (Figure 9.1A), while the supernatant wash solution consistently presented more 
BDNF after UV treatment (Figure 9.1B). These data indicate that the nanoparticles function 
as expected, releasing the bound BDNF into the surrounding solution only after UV 
exposure. We have previously demonstrated that the amino coating around the nanoparticles 
can be removed by UV exposure,99 and the attached BDNF is removed with it. Here, samples 
received only one UV treatment each, always performed in the last wash, to give the repeated 
washing as much chance as possible to remove the bound BDNF before the UV treatment. 
For example, the wash four samples were all washed three times without UV exposure, and 
in the fourth wash cycle samples were exposed to UV (or not for the control group). The 
high levels of BDNF in the first wash of the nanoparticles can be explained by the residual 
presence of the original BDNF reaction solution; reaction solution was removed via 
centrifugation only once before immediately commencing the washing and UV exposure 
testing. The lowest detectable BDNF release from unexposed particles was after three 
washes, which were used in further development below. The increase in BDNF detected in 
the supernatant of the fourth wash could be caused by breaking up nanoparticle 
agglomerates, or an effect of persistent mechanical washing on the bound BDNF. TEM 
micrographs (Figure 9.1C-E) show no change in nanoparticle size or morphology after 
BDNF attachment (Figure 9.1D) or UV treatment (Figure 9.1E) compared to the original 
amine coated nanoparticles (Figure 9.1C).  
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Figure 9.1: Nanoparticle growth factor attachment and UV triggered release. A-B: BDNF detected on 
nanoparticles (A) and in washing supernatant (B) with UV treatment (purple) and untreated (blue) after a 
number of washes. Each group received only one UV treatment during the latest wash (i.e.: after having already 
been washed n-1 times) and data represent mean ± SEM. C-E: TEM micrographs of amine coated 
nanoparticles (C), nanoparticle bound BDNF (D), and nanoparticle bound BDNF after UV treatment (E). 
Scale bars show 100 nm. 
The above results demonstrate the potential for this nanoparticle system to provide UV 
triggered growth factor release upon UV stimulus. Next we combined this nanoparticle 
system with our promising novel minimalist SAP hydrogels.9 Here we used Fmoc-DIKVAV 
peptide, which contains the isoleucine-lysine-valine-alanine-valine (IKVAV) sequence from 
the extracellular matrix protein laminin, modified with an additional N-terminal aspartic acid 
(D) residue to adjust the pKa properties of the molecule such that pH-driven self-assembly 
occurs at pH 7.4. These hydrogel materials have a nanofibrous morphology that provides 
structural support on a cellular level in addition to their biocompatible aqueous 
environment.61 We confirmed that incorporating nanoparticles and subsequent UV 
treatment did not disrupt the SAP hydrogel. The FTIR spectra of all gels (Figure 9.2A) show 
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a major peak at 1630 cm-1 and a minor peak at 1690 cm-1, which confirm the supramolecular 
assembly mechanism of the SAP nanofibres.9,61 Parallel plate rheology (Figure 9.2B) 
confirmed that the elastic modulus, an important factor in tissue-specific regeneration,2 
maintains largely unaffected by nanoparticle or UV treatment. While the addition of 
nanomaterial fillers often increases hydrogel stiffness, in this case it has no affect. This could 
be because the nanoparticles and SAP nanofibres are on the same scale, so the unloaded SAP 
hydrogel already has a sort of nanomaterial filler. TEM micrographs (Figure 9.2C) further 
confirm the nanofibrous structure was maintained across all hydrogels. These results confirm 
that the SAP hydrogel, a proven ECM mimetic tissue engineering material, retains its 
beneficial properties after incorporation of the nanoparticle bound growth factor pre and 
post UV treatment. 
 
Figure 9.2: SAP hydrogel characterisation with nanoparticle incorporation and UV treatment. 
Characterisation of DIKVAV hydrogel alone (black), loaded with unmodified nanoparticles (red), and loaded 
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with nanoparticle bound BDNF (green), before (blue) and after (purple) UV treatment. A: FTIR Spectra with 
faded colours showing spectra after UV treatment. B: Rheological analysis showing mean storage modulus (G’). 
C: TEM micrographs of SAP nanofibres with scale bars showing 100 nm. 
Next, to assess the effect of nanoparticle attachment on the temporally resolved delivery 
profile of a two-component system, the SAP gels were simultaneously loaded with 
nanoparticle bound BDNF (NP-BDNF) as well as unmodified GDNF (Section 3.2.2.3). The 
delivery profiles of each growth factor (Section 3.4.1) were then assessed without UV 
treatment (Figure 9.3A). As expected, the unmodified GDNF profile shows a slow burst 
delivery, with high initial delivery decreasing steadily to near zero over 12 hours. This matches 
the delivery profile we have observed from GDNF loaded alone into DIKVAV hydrogels 
(unpublished), indicating that the nanoparticles do not significantly interfere with other 
growth factors within the same system. The nanoparticle bound BDNF demonstrates a 
steady increase over 12 hours. These distinct delivery profiles from the same SAP gel 
demonstrate that the nanoparticle attachment method can be used to temporally control the 
release profile of two separate growth factors. We have previously demonstrated that SMCC 
attachment of growth factors to scaffold materials (electrospun polymer nanofibres) prevents 
their degradation while maintaining their bioactivity in vitro and in vivo, confirming bioactivity 
in vitro with BDNF,36 and in vivo with GDNF31,191 and Interleukin-10 (IL-10).192 And we have 
also demonstrated the stabilising effect of SAP hydrogels on growth factors, with BDNF 
specifically showing stabilisation out to at least 6 weeks.102 The fact that increasing amounts 
of BDNF were detected here out to 12 hours confirms that degradation is being halted and 
suggests that the nanoparticle bound BDNF would have stability similar to the nanofibre 
bound growth factors that we have published previously. All together this information 
indicates potential for nanoparticle binding as another method of temporal control of growth 
factor delivery from SAP hydrogels.  
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Figure 9.3: Relative release profiles of lone and nanoparticle bound growth factor. Release profiles 
showing the relative (percent of total) release of GDNF (green) and BDNF (blue) released at each time point 
from dually loaded SAP hydrogels. Data represent mean ± SEM. Statistical significance determined by two-
way ANOVA: **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05, ns = no statistically significant difference. 
A: Full release profiles of unmodified and nanoparticle bound growth factors without UV treatment. B-C: 
Condensed release profiles including UV treatment groups. Note statistically significant difference was found 
between each GDNF “0-6 hr” group and each “6-12 hr” groups (i.e.: 9 relationships total), and no statistically 
significant difference was found between different GDNF “0-6 hr” groups or between different GDNF “6-12 
hr” groups (B). 
Next, we explored the stimuli responsive growth factor delivery from within the dually 
loaded SAP gel. The release profile of the unmodified GDNF was changed slightly, possibly 
due to the interaction of the GDNF with newly released BDNF or the surface of the 
nanoparticles post treatment. However, this effect was small, and the total release profiles 
overall were consistent with that observed without UV treatment, indicating that this 
stimulus did not significantly affect the properties determining unbound GDNF delivery 
(Figure 9.3B). However, UV treatment significantly affected the delivery of the nanoparticle 
bound BDNF (Figure 9.3C). Over the 12-hour release profile without UV stimulus, more 
BDNF is released later in the profile. Only 36% of the total BDNF release occurred in the 
first 6 hours, with 64% released in the second half. With initial UV stimulus (i.e. UV 
treatment performed at time t = 0 hr), the release profiles were similar: 42% released in the 
first 6 hours, and 58% in the second. When the UV stimulus was applied midway (i.e. UV 
treatment performed at time t = 6 hr), however, the release profile of the BDNF changed 
more significantly, displaying a constant release rate with near equal release in the first and 
second halves (49% and 51% respectively). Counter intuitively, and interestingly, this 
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suggests that unbound BDNF is released from the bulk material more slowly than bound 
BDNF on nanoparticles. 
This interesting observation becomes more intuitive when considering the relationships 
between SAP nanofibres, growth factors, and nanoparticles, and when looking at the how 
UV treatment affects the absolute delivery profiles (Figure 9.4A). The absolute delivery 
profile (Figure 9.4A) shows the raw data, the actual amount of growth factor released (in ng) 
values used to calculate the relative profiles shown above (Figure 9.3C). The initial results 
above looking at nanoparticles alone confirm that UV treatment caused the bound BDNF 
to be released from the nanoparticles. Meanwhile, our previous work shows that growth 
factors (specifically BDNF) alone adsorb to the SAP nanofibres. We propose that the UV 
treatment of these particles when inside a SAP gel caused the BDNF to be released to the 
hydrogel, and then reversibly adsorb to the nanofibre surface, placing their release under the 
control of this adsorption interaction (Figure 9.4B). The general trend or temporal shape of 
the release observed for the untreated samples is characterised by an initial slow release, with 
an increase in release in the second half of the profile, presumably due to the diffusion of 
the nanoparticles through the system. This trend was maintained with an initial UV 
treatment, but at a lower magnitude, consistent with an incomplete detachment of BDNF 
from the nanoparticles. There may also be some photolytic degradation of the BDNF. The 
UV treatment did not change the release behaviour of the nanoparticles; it only reduced the 
amount of BDNF bound to those nanoparticles. The slight differences in the relative release 
profiles above (Figure 9.3C), with a slight shift towards earlier release from the UV treated 
gels, could be explained by factoring in a secondary release profile of unbound BDNF from 
the SAP gel, which we have shown is similar to that of unbound GDNF, characterised by a 
slow burst with more growth factor released initially.102 
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Figure 9.4: Reverse UV triggered delivery. A: Condensed release profile showing absolute amount of BDNF 
released in different UV treatments. Data represent mean ± SEM. B: Mechanism of growth factor interactions 
when bound to nanoparticles and after freed by UV treatment able to adsorb to SAP nanofibres 
Applying the UV treatment midway through the release profile allowed us to change not 
just the dose but the temporal shape of the release profile, providing a consistent dose over 
the course of the release profile by combining the first half from the relatively higher release 
rate of the untreated group followed by the second half of the relatively lower release rate of 
the UV treated group. Again, the release behaviour of the nanoparticles is unchanged, but 
UV treatment can be used to control how much growth factor those nanoparticles carry and 
when. This additional consistent dose release profile allows us to selectively induce a third 
distinct temporal release profile offered by this nanoparticle growth factor delivery system. 
The results above suggest that there is an incomplete detachment of BDNF from the 
nanoparticles, indicating that multiple UV treatments could be used to further smooth and 
control the release profile over longer periods, allowing a truly constant delivery from a 
diffusion based system. The proposed mechanism is shown in more detail below (Figure 
9.5). 
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Figure 9.5: Detailed mechanism of reverse UV-triggered release. Small green and blue circles represent 
GDNF and BDNF respectively. Large grey circles represent nanoparticles. Orange lines/thin rectangles 
represent SAP nanofibres making up the SAP hydrogel. Black arrows represent time passing only. Purple arrows 
represent UV treatment. A i: Growth factors adsorb to SAP nanofibres and release slowly from the hydrogel. 
A ii: Nanoparticles diffuse readily from the hydrogel. A iii: SAP hydrogel loaded with bout free (GDNF, green) 
and nanoparticle bound (BDNF, blue) growth factors exhibits two distinct release mechanisms. B i: The SAP 
nanofibre/growth factor interaction is unaffected by UIV treatment. B ii: UV treatment causes nanoparticle 
bound growth factor to be released into the surrounding solution as free growth factor. This release is 
incomplete, with some growth factor remaining bound. C: After UV treatment, the nanoparticles continue to 
release readily, but with a reduced amount of bound BDNF, decreasing the amount of BDNF released. The 
unbound BDNF now acts as a free growth factor and adsorbs to the SAP nanofibres, from which there is a 
small amount of release. Meanwhile, free GDNF release from the SAP nanofibres continues unaffected.    
9.5 Conclusion 
In this work, we have used TiO2 nanoparticles combined with novel SAP hydrogels to 
create a growth factor delivery system. Exploring both the effect of nanoparticle binding and 
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UV treatment we demonstrate that this system is capable of providing at least three 
temporally distinct release profiles: a steady increase, a steady decrease, and a consistent dose. 
We have demonstrated how the intuitive UV controlled growth factor release is reversed by 
interactions with SAP gels, and how the nanoparticles can be used to tune and tailor growth 
factor release profiles. We have also confirmed that neither nanoparticle incorporation nor 
UV treatment adversely effects the SAP gel properties. This is an important consideration 
when considering implementing this technology within materials with structure dependant 
design features. This system therefore shows great promise for a facile and non-intrusive 
drug delivery approach. Although UV sensitive TiO2 nanparticles were used here, the novelty 
of this system, the reverse trigger effect, depends on the combination with SAP hydrogels 
and is independent of the stimulus used to trigger release from the nanoparticles. A variety 
of stimuli-responsive nanoparticle systems for triggered drug release exist currently, using 
stimuli including infrared (IR) light, ultrasound waves, and magnetic fields.92 As such, there 
are many options for available for incorporation into this system when UV stimulus is not 
feasible. Incorporation of materials capable of second harmonic generation of UV light from 
an IR light trigger could also be used to address the issues of low penetration depth and 
cytotoxicity of UV light as a trigger.253 As a proof of concept here, we demonstrate that 
multiple aspects of temporal control over growth factor delivery are possible, and provide 
the temporally distinct delivery of multiple growth factors from a single material, an 
important goal in regenerative medicine.    
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The work described in this thesis represents a significant contribution to the field of tissue 
engineering and growth factor drug delivery. While a variety of strategies exist to incorporate 
growth factors into tissue engineering materials, there are some common drawbacks. Most 
of the existing methods focus on sustained presentation of growth factors, overcoming the 
short lifetime of these molecules but not providing the any further temporal control. We 
have established that SAP hydrogels can provide that sustained delivery, and have gone 
further developing methods of temporally controlling when that delivery occurs and the 
nature of the delivery profile.  
Current growth factor delivery strategies also often involve direct modification or 
controlled degradation of the tissue engineering material, as though the tissue engineering 
material can be either a supportive ECM mimic or a depot for sustained growth factor 
delivery, but not both. While the aim of this thesis has been to provide controlled growth 
factor delivery, an emphasis on ECM mimetic material properties has been maintained 
throughout.  The materials were first investigated in vivo without growth factors, confirming 
their relevance and efficacy as a support material. The SAP material has remained a crucial 
consideration in the development on the delivery strategies discussed here, and we have 
Chapter Ten 
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confirmed that none of the three modified delivery strategies developed significantly affect 
the important ECM mimetic characteristics of the SAP hydrogel. In fact, the composite 
material described in Chapter Eight adding short electrospun fibres to the SAP hydrogel to 
achieve a long delay represents a potential improvement to the biomimetic structural 
properties of the SAP hydrogel.  
The three proof of concept delivery strategies developed here have all been successfully 
demonstrated as means of temporally controlling growth factor delivery from SAP hydrogels. 
The short (hours) and long (days) delay methods provided barriers to the diffusion of growth 
factors out of the SAP hydrogel, delaying the start time of growth factor delivery. This is 
particularly relevant to application in brain tissue regeneration where systemic delivery is 
inhibited, so control over the timing of delivery must come in the form of controlled delayed 
between the initial material injection/implantation and the delivery or growth factors. The 
stimuli responsive method provided control over the shape of the temporal delivery profile 
rather than the starting point. The nanoparticle binding provided a distinct profile compared 
to the unbound growth factor, a gradual increase in delivered dose rather than the burst and 
gradual decrease observed from growth factors alone. The UV stimulus was also used to 
effectively smooth the delivery profile to a constant delivered dose, a burst-free sustained 
delivery.  
The short delay strategy was achieved by using electrostatic interactions between the SAP 
nanofibres and other materials. These interactions were first investigated with the SAP 
materials for delivering non-growth factor materials. Mixing the sulfonated polysaccharide, 
fucoidan, with the SAP hydrogel allowed its sustained presentation to cells and material 
characterisation revealed that the fucoidan molecules were associating closely with the SAP 
nanofibres. Similarly, the addition of a positively charged lysine residue into the SAP 
sequence was shown to increase interactions between the nanofibres and negatively charged 
viral particles. Based on these immobilising physical associations, growth factors were 
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modified by covalent attachment of the polysaccharide, chitosan, and the additional 
interactions between the chitosan and the SAP nanofibres cause the modified growth factors 
to remain in the SAP hydrogel longer. Future development of this system could focus on 
tuning the exact duration of the delay by changing the relative amount of bound chitosan, or 
by investigating other polysaccharide chains for attachment.  
The long delay strategy was achieved by combined electrospun nanofibres with the SAP 
hydrogel, creating a composite material. The use of electrospun materials for sustained 
presentation of immobilised growth factors was first investigated, including cutting the 
scaffolds into short fibres to mix into a non-SAP gel. While the growth factors presented 
maintained bioactivity, the immobilised growth factors stuck to electrospun fibres within a 
hydrogel material were not able to reach and influence cells in the surrounding environment. 
This approach was adapted with emulsion electrospinning, creating short electrospun fibres 
to act as a depot from which growth factors could slowly diffuse out, rather than an anchor 
to which they were permanently attached. The bioactivity of growth factors prepared in this 
adapted approach was confirmed, and the method successfully achieved a 6-day delay in 
growth factor delivery.  
Future work on this delivery system could see the development of multi-layered short 
fibres prepared by coaxial electrospinning to create more complex multi-component delivery 
profiles from the single material (Figure 10.1). Growth factors, or other drugs, loaded into 
the core layer could achieve a greater delay in reaching the surrounding environment, and 
unloaded shielding layers could be used as well to increase the duration of the delay. This 
approach has been demonstrated with intact electrospun scaffolds,50 and could readily be 
adapted to provide multi-layered short fibres. The high length to diameter aspect ratio (~ 
100x) of the fibres should minimise the effect of growth factors released from the ends of 
the fibres, or else post cutting treating such as layer-by-layer deposition could be used to 
create fully enclosed additional layers.  
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Figure 10.1: Multi-layered electrospun short fibre growth factor delivery vehicles. Proposed design 
approach showing (from left to right) loose short fibres, a short fibre cross section exposing the interior layers, 
and the hypothesised multi-component growth factor delivery profiles. Blue and purple layers contain distinct 
growth factors, grey layer is unloaded and provides shielding only, additionally delay the release from the core 
purple layer. 
The stimuli responsive control was achieved using UV sensitive nanoparticles and the 
same covalent chemical attachment method used to achieve a short delay and used to 
immobilise growth factors to electrospun materials. While the growth factor bound 
nanoparticles allowed displayed intuitive release behaviour, with the UV stimulus resulting 
in growth factor being released into the surrounding solution, by loading the bound 
nanoparticles into the SAP gel we were able to achieve counter intuitive stimuli responsive 
behaviour. Upon UV exposure, the bound growth factor was still released from the 
nanoparticle, however, the nanoparticles diffused more readily from the SAP hydrogel than 
unbound growth factors alone, which adsorbed to the SAP nanofibres to remain longer 
within the hydrogel. Accordingly, UV exposure reduced the growth factor release to the 
surrounding environment rather than increasing it. Using this responsivity, along with the 
known (and itself unique) release profile of the nanoparticles we were able to time the UV 
exposure to tune the shape of the release profile, achieving a delivery profile with a constant 
dose and no initial burst release. Because the release of bound particles was incomplete, 
leaving some growth factor on the nanoparticles, it is possible that repeated UV exposures 
at carefully chosen times could be used to control the shape of the release profile over an 
extended time period. 
151 
In this work, a UV-sensitive nanoparticle was used to demonstrate the counter intuitive 
stimuli responsive behaviour and release profile shape tuning. However, the UV-responsivity 
is only specific to the nanoparticles used and not to this approach to controlling growth 
factor delivery. UV light scatters readily and therefore has limited penetration depth and is 
only practical for topical treatments.92 However, stimuli responsive nanoparticle drug 
delivery is a popular field of research, with research being done on nanoparticles responding 
to variety of external stimuli, including near infrared (NIR) photo stimulation, which offers 
a greater penetration depth, as well as magnetic fields, electric fields, temperature changes, 
and ultrasound.92 Future development of this delivery strategy could see incorporation with 
other stimuli responsive nanoparticles to allow for internal application in vivo, or else 
continuing with these specific nanoparticles it could be used topical hydrogel treatments such 
as for burn wounds or as an in vitro study tool.  
Overall, this thesis described 5 distinct growth factor delivery profile options possible 
from the tissue-specific SAP hydrogels: the original slow burst/sustained profile observed 
from unmodified growth factor, short delay, long delay, the gradually increasing profile of 
nanoparticle bound growth factor, and the tuned to constant dose profile as a response to 
UV stimulus. And in all cases the modifications have been shown not to interfere with the 
delivery of unmodified growth factors. The delivery systems describe here are therapeutic 
additions to the SAP hydrogels, not replacements, they do not disrupt the SAP material and 
neither do the prevent additional growth factor delivery. 
While the focus of this thesis has been material/system development and proof of 
concept of these novel drug delivery strategies, the biological impact of any drug delivery 
system, is always an important consideration. The work described in Chapter Seven, along 
with other work outside this thesis,36,192 confirms that bioactivity of growth factors is 
maintained when modified by the SMCC chemical attachment method used here to achieve 
the short delay and stimuli responsive delivery. Direct assessment via MTT assay with murine 
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neurons in Chapter Eight demonstrated the maintained bioactivity of growth factors used in 
the emulsion electrospinning used to achieve the long delay, which has also been confirmed 
outside of this thesis.238 Concurrent with the delivery system development approaches 
described above, further biological studies should be conducted to confirm the efficacy of 
these systems in vivo.  
Currently the biological efficacy of unmodified growth factors delivered within SAPs, 
which do provide stabilisation for long-term delivery, is being assessed in ischemic brain 
injury in rats using methods described in Chapter Four and preliminary results show the 
benefit of using growth factor, in this case BDNF, and SAPs together (Figure 10.2). Cell 
transplants with both BDNF and SAP showed the best performance, in terms of both graft 
volume (Figure 10.2E) and reduced cortical atrophy (Figure 10.2F). In fact, cell transplants 
given with just BDNF were comparable to the cell grafts alone, likely due to the rapid 
degradation of BDNF early in the 36-week course experiment. However, when cells were 
delivered with SAP and BDNF, there was a statistically significant improvement compared 
to cells + SAP, indicating that the stabilising effect of the SAP allowed the BDNF growth 
factor to have a more pronounced effect on recovery. This results are very promising, and 
future studies will include similar investigation of the modified growth factor delivery systems 
discussed in this thesis in vivo. 
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Figure 10.2: BDNF growth factor + SAP efficacy in vivo at 36 weeks. A-D: representative 
photomicrographs providing a coronal view of GFP+ (red) grafts within the cortex of cells alone (A), cells + 
BDNF (B), cells + SAP (C), and cells + BDNF + SAP (D) treatment of lesioned rats. E: Graft volume. F: 
Cortical atrophy. Data represent mean ± SEM, * p < 0.05, ** p < 0.01, *** p < 0.001. 
In all three cases the novel delivery strategies described here were developed by applying 
materials and methods form other work in novel ways. There is no lack of diversity of 
materials being studied and used in tissue engineering, and the opportunities for novel 
combinations are correspondingly large. Future advancements in this field will involve the 
synergistic combinations of two or more materials, with each material contributing its own 
useful function. Appropriately, this approach to tissue engineering material development is 
itself mimetic of the ECM, an incredibly complex and specialised material able to perform 
many functions with contributions from its many constituent parts.  
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Appendix A: Supplementary Information (Chapter Six) 
Fluctuation data was calculated using the release rate data for the hourly release profile of 
BDNF and modified BDNF-Chitosan shown below. 
 
Table 1: Hourly Release Rate Data 
Time (hour) BDNF (pg/hour) BDNF-Chitosan (pg/hour) 
1 0.238854 0.427126 0.179313 0.367356 1.797767 0.356615 
2 0.375561 0.503393 85.80665 2.237672 0.983898 0.452686 
3 108.4237 54.73617 114.3919 7.825296 1.559592 3.392786 
4 39.95618 19.94937 29.85885 11.48662 6.702689 1.298517 
5 17.63363 18.53271 27.74342 41.97237 2.761074 6.432447 
6 61.5629 47.42654 51.16976 18.99239 5.674232 18.15534 
7 83.12487 66.95469 41.34791 41.66928 13.90233 3.486096 
8 43.90452 36.00312 52.99514 46.95929 2.794707 44.25023 
9 50.40296 61.11735 62.76371 52.635 26.89515 59.14041 
10 49.26989 53.52608 45.87377 58.37618 39.79055  
11 48.52583 70.86419 61.5629 50.38608 30.99872  
12 90.76646 245.6232 169.472 95.41332 71.32155  
 
From the individual time point values, the absolute changes within each sample between 
each time point were calculated (change = magnitude of ‘value at time point’ – ‘value at 
previous time point’) and an average fluctuation value was found for each sample group.  
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Table 2: Point to Point Fluctuations in Hourly Release Rate Data 
Time (hour) BDNF (pg/hour) BDNF-Chitosan (pg/hour) 
1 N/A N/A N/A N/A N/A N/A 
2 0.136707 0.076267 85.62733 1.870316 0.813869 0.096071 
3 108.0481 54.23278 28.58526 5.587625 0.575694 2.9401 
4 68.46752 34.7868 84.53306 3.66132 5.143097 2.094268 
5 22.32255 1.41666 2.115435 30.48575 3.941615 5.13393 
6 43.92927 28.89383 23.42634 22.97999 2.913158 11.72289 
7 21.56198 19.52816 9.82185 22.6769 8.228099 14.66924 
8 39.22035 30.95157 11.64723 5.290005 11.10762 40.76413 
9 6.498435 25.11423 9.76857 5.675715 24.10044 14.89019 
10 1.13307 7.591275 16.88994 5.741175 12.8954  
11 0.74406 17.33811 15.68913 7.990095 8.79183  
12 42.24063 174.759 107.9091 45.02724 40.32284  
AVERAGE 32.20934 35.88079 36.0012 14.27147 10.80306 11.53885 
 
To compare fluctuation values between BDNF and BDNF-Chitosan sample groups a 
matrix was established comparing each BDNF sample to each BDNF-Chitosan sample, and 
in each comparison, the relative change in fluctuations compared to the BDNF samples was 
calculated (change = (BDNF-Chitosan – BDNF)/BDNF). 
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Table 3: Matrix Comparison of Fluctuations in Hourly Release Rate Data 
VS BDNF-Chitosan Sample 1 Sample 2 Sample 3 
BDNF Average Fluctuation 14.27147 10.80306 11.53885 
Sample 1 32.20934 -55.69% -66.46% -64.18% 
Sample 2 35.88079 -60.23% -69.89% -67.84% 
Sample 3 36.0012 -60.36% -69.99% -67.95% 
 
From these comparative values the average change was calculated as -64.73% with a 
standard deviation of 4.98%. The negative change describes an average reduction in 
fluctuations.  
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Appendix B: Full Published Work (Chapter Four) 
A. Rodriguez, T. Wang, K. Bruggeman, C. Horgan, R. Li, R. Williams, C. Parish, D. Nisbet, 
“in vivo assessment of grafted cortical neural progenitor cells and host response to 
functionalised self-assembling peptide hydrogels and the implications for tissue repair”, 
Journal of Materials Chemistry B, 2014, vol. 2, pp. 7771-7778 - Reproduced by permission of 
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In vivo assessment of grafted cortical neural
progenitor cells and host response to
functionalized self-assembling peptide hydrogels
and the implications for tissue repair
A. L. Rodriguez,a T. Y. Wang,b K. F. Bruggeman,a C. C. Horgan,a R. Li,c R. J. Williams,cd
C. L. Parish†*b and D. R. Nisbet†*a
Tissue speciﬁc scaﬀolds formed from minimalist N-ﬂuorenylmethyloxycarbonyl self-assembling peptides
(Fmoc-SAPs) have emerged as promising biomaterials due to their ease of synthesis and capacity to self-
assemble via simple, non-covalent interactions into complex nanoﬁbrous hydrogels. However, concerns
remain over their biocompatibility and cytotoxicity for in vivo applications. Here, we demonstrate that
these Fmoc-SAPs are biocompatible in vivo and well suited as a delivery vehicle for cell transplantation.
In order to determine the eﬀect of tissue speciﬁc parameters, we designed three Fmoc-SAPs containing
varying bioactive peptide sequences derived from extracellular matrix proteins, laminin and ﬁbronectin.
Fmoc-SAPs delivering cortical neural progenitor cells into the mouse brain display a limited foreign body
response, eﬀective functionalization and low cytotoxicity for at least 28 days. These results highlight the
suitability of Fmoc-SAPs for improved neural tissue repair through the support of grafted cells and
adjacent host parenchyma. Overall, we illustrate that Fmoc-SAPs are easily engineered materials for use
as a tool in cell transplantation, where biocompatibility is key to promoting cell survival, enhancing the
graft–host interface and attenuation of the inﬂammatory response for improved tissue repair outcomes.
Introduction
Central nervous system (CNS) repair presents a signicant
challenge, given the limited regenerative capacity of neural
tissue. Currently, following insult to the CNS, treatments are
limited to pharmacotherapy or rehabilitation with the aim of
slowing disease progression and reducing secondary damage;
thereby reducing symptom severity, without actually repairing
the induced damage.1 Cell replacement therapy oﬀers an
attractive alternative, whereby cells are implanted into the site
of injury in order to regenerate and repair damaged neural
tissue, providing symptomatic relief to patients.2
Early transplantation trials have identied additional
mechanisms for repair, where graed cells have been shown to
be neuroprotective by providing trophic support to the
surrounding area, attenuating the inammatory response,
promoting endogenous stem cell neurogenesis and enhancing
angiogenesis.3–5 Biomaterials have emerged as potential
adjuncts for such tissue repair by delivering a morphological
and biochemical extracellular matrix (ECM) mimic that can
support transplanted cells at an injury site, lessening the impact
of further degeneration to surrounding tissue and ultimately
repairing the induced damage. As such, there is a need for
biocompatible, functionalized materials into which cells can be
embedded as a vector for transplantation, and once implanted
in vivo, can attenuate the inammatory response and allow the
transplanted cells to inltrate the host tissue by creating a
permissive gra–host interface.
With this in mind, an ideal biomaterial for cell trans-
plantation would improve recovery by creating a favorable
milieu for exogenous and endogenous cells.6 This would involve
controlling the inammatory response associated with the
primary insult and ensuing transplantation surgery, which
includes local astrocyte proliferation that can ultimately result
in distortion of the brain parenchyma and scarring.7 We have
previously demonstrated the potential of electrospun scaﬀolds
to modulate the inammatory response of the brain with
limited immunogenic reactivity.8 However, while these scaf-
folds were shown to mimic the ECM morphology and control
the inammatory response, their geometric constraints and
xed form does not allow them to readily interface with cells at
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the edge of a lesion site, making them less attractive for cell
transplantation within the brain.8,9
Nature utilizes supramolecular interactions to drive the self-
organization of biological macromolecules such as peptides
and proteins of the ECM.10 These principles can be used to
design synthetic peptides that can self-assemble into larger,
complex structures, reminiscent of those found within living
systems, providing a platform for the development of regener-
ative therapies.11 Peptide based materials can be rationally
designed to include features that emulate the ECM in an eﬀort
to reproduce the nanobrous network of proteins, as well as
provide control over the introduction of biochemical cues, such
as the release of growth factors and presentation of integrin
binding domains.11,12
A number of hydrogels formed from brous self-assembling
peptides (SAPs) have been developed for various in vitro and in
vivo applications.11 Signicant progress has been made by
utilizing long, highly structured peptides, such as the
commercially available RADA16, or peptide amphiphiles.13,14
However, due to their lengthy amino acid chains, these peptides
require a large number of steps to synthesize and purify –
increasing cost and complexity whilst reducing yield. Conse-
quently, considerable interest has surrounded the design of
minimalist peptide sequences (1–10 residues), as these simple
molecules retain the ability to self-assemble, whilst allowing the
incorporation of bioactive sequences. Additionally, they enable
the eﬀect of individual amino acid modications to be investi-
gated, enabling ne control over the structure, assembly
conditions and triggering mechanisms of the resulting macro-
scale hydrogel.12,15,16
A promising class of these materials is based on the
assembly of SAPs capped at the N-terminal with uo-
renylmethyloxycarbonyl (Fmoc). Fmoc-SAPs have been shown to
self-assemble into nanobers via non-covalent p–b interactions
with the peptide sequence presented on the external surface of
the brils at high density.17,18 These brils then intertwine to
form an entangled matrix hydrogel that has morphological and
mechanical similarities to many types of ECM.17,19 Fmoc-SAP
hydrogels that morphologically emulate the native ECM are of
particular interest due to their potential to eﬀectively ll a void
at the site of neural damage, readily interface with cells at the
edge of the lesion site, attenuate the inammatory response
post implantation and structurally support the surrounding
neural tissue.
Though the material characteristics and underlying self-
assembly mechanism of Fmoc-SAPs have been thoroughly
studied, investigation of their biological properties and how
cells respond to their physical and biochemical stimuli has
been limited – usually focusing on in vitro cell culture, incor-
porating the bronectin based sequence, arginine-glycine-
aspartate (RGD).15,17,19–23 Additionally, research has typically
focused on short di- and tripeptides, as the individual amino
acid contributions in longer peptide sequences tend to inhibit
spontaneous self-assembly under physiological conditions.12
We have recently published novel approaches that allow core
amino acid sequences of up to ve residues in length to be
embedded into the peptide backbone by the rational design of
additional anking residues; either through adjustment of pKa
or addition of aromatic/hydrophobic residues.12,24 Using these
methods, we have designed Fmoc-SAPs that contain peptide
sequences based on the common ECM brain protein laminin:
isoleucine-lysine-valine-alanine-valine (IKVAV) and tyrosine-
isoleucine-glycine-serine-arginine (YIGSR).
We have previously demonstrated the functionality of the
embedded peptide sequence in Fmoc-SAPs in vitro, compared to
a morphologically and chemically similar system made from a
scrambled control sequence.24 Here, we examine the eﬀect of
these Fmoc-SAPs on primary cortical neural progenitor cells in
vivo. In order to ascertain the eﬀectiveness of these laminin
peptide sequences in vivo, we also included an RGD containing
Fmoc-SAP as a control, as bronectin is known to promote cell
adhesion and is not observed in signicant amounts in the
brain, allowing us to determine the tissue specicity of the
Fmoc-SAPs.25 Importantly, for the material to be eﬀective, it
must be well tolerated by both the host and implanted cells, and
elicit a limited inammatory response with limited or no
formation of a glial scar. Therefore, the inammatory response
to these developed Fmoc-SAPs, as well as survival, migration
and integration of the transplanted cortical neural progenitor
cells were investigated in the intact brain. These results allow us
to ascertain which peptide sequence has the most benecial
eﬀect on endogenous and graed cells in vivo for future appli-
cation in the injured CNS.
Materials and methods
Solid phase peptide synthesis/mass spectrometry
Fmoc-SAPs were made using solid phase peptide synthesis
(SPPS) in a custom rotating glass reactor vessel at a 0.4 mmol
scale. Fmoc protected amino acids, hydroxybenzotriazole
(HOBt), O-benzotriazole-N,N,N0,N0-tetramethyl-uronium-hexa-
uoro-phosphate (HBTU) and Wang based resins were
purchased from GL Biochem (China). All other chemicals were
purchased from Sigma-Aldrich. Dimethylformamide (DMF) was
dried for a minimum of 2 hours prior to use with 4 A˚ molecular
sieves.
Peptide synthesis was achieved by the stepwise deprotection
of the N-terminal Fmoc group of the resin anchored amino acid
using a solution of 20% piperidine in DMF, followed by a
coupling step using a solution of the next Fmoc-amino acid in
HOBt, HBTU and N,N-diisopropylethylamine (DIPEA) in DMF.
This process of deprotection and coupling of amino acids was
repeated until the desired peptide was synthesised. The nal
Fmoc group was not removed. Deprotection and coupling of
amino acids was veried using a Kaiser test for the detection of
free amines. Once SPPS of the desired sequence was complete,
the Fmoc protected peptide and resin was washed with ethanol
and le to dry under constant vacuum for 2 days. A cleavage
solution of triuoroacetic acid (TFA), 2.5% distilled water and
2.5% triethylsilane (TES) was prepared. The resin was le to
stand in the solution for 2 hours. Following cleavage, the
peptide solution was ltered through glass wool. Excess TFA
was then evaporated using nitrogen until approximately 5 mL of
peptide solution was le. The peptide was then precipitated,
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followed by 5 washes in cold ether before being collected and
allowed to dry under constant vacuum for 2 days. The peptide
was then ground into a ne powder before being placed under
constant vacuum for a further 7 days. Mass spectrometry was
performed to verify synthesis of the desired peptide.
Fmoc-SAP gel preparation
Fmoc-SAPs were prepared at 20 mg mL1. Approximately 10 mg
of the peptide was initially dissolved in 100 mL deionized water
with 50 mL of 0.5 M sodium hydroxide (NaOH). The pH of the
peptide solution was then slowly reduced by the dropwise
addition of 0.1 M hydrochloric acid (HCl) until the pH of the
media was achieved (typically 100–150 mL). The solution was
continually vortexed throughout this process. Once a gel was
formed at appropriate pH, Hank's buﬀered saline solution
(HBSS) (Gibco) was added to make the gel up to 20 mg mL1.
The pH of the Fmoc-SAPs was measured using a microprobe pH
meter.
Fourier transform infrared spectroscopy
Fourier transform infrared spectroscopy (FTIR) was performed
using an Alpha Platinum Attenuated Total Reectance FTIR
(Bruker Optics). 30 mL of Fmoc-SAP was placed on the single
reection diamond. The pressure applicator was used to spread
the Fmoc-SAP over the crystal. Absorbance scans were taken at
0 minutes and 5 minutes, with 5 minutes showing higher
resolution.
Circular dichroism spectroscopy
Circular dichroism (CD) was completed using a Chirascan CD
Spectrometer (Applied Photophysics Limited). Fmoc-SAP solu-
tions were prepared at 1 part in 200 with deionized water. A
baseline scan for deionized water was completed and sub-
tracted from the obtained peptide CD scans. The Fmoc-SAP
solution was scanned from 350 to 170 nm at a step size of 1 and
1 nm bandwidth.
Rheology
Viscoelastic properties of the formed Fmoc-SAPs were assessed
using a Kinexus Pro+ Rheometer (Malvern). A 20 mm smooth
at plate with a solvent trap was used. The Fmoc-SAP sample
was placed on the rheometer plate at a gap size of 0.2 mm.
Oscillatory strain of 0.1% strain was used with a frequency
sweep of 0.1–100 Hz.
Atomic force microscopy
Atomic force microscopy (AFM) images of the Fmoc-SAPs were
obtained using a Multimolde 8 (Bruker BioSciences Corpora-
tion, USA). For sample preparation, 15 mL Fmoc-SAP was
applied on highly ordered pyrolytic graphite (HOPG) substrates
(SPI, USA). The tips used were scanasyst-air probes with silicon
tip on nitride lever (Bruker BioSciences Corporation, USA). The
AFM was operated in peak force QNM. Calibration of deection
sensitivity, spring constant and tip radius of probes was done
before sample imaging. Scan size was at 10 mm.
Transmission electron microscopy
Transmission electron microscopy (TEM) was performed on a
HITACHI HA7100 TEM with LaB6 lament at 100 kV. Negative
stains were performed to image the Fmoc-SAP samples. For-
mvar coated copper grids were glow discharged for 30 seconds
at 15 mA. A drop of the Fmoc-SAP sample was placed on the grid
for 30 seconds, aer which any excess was blotted oﬀ using lter
paper. The grid was then washed with a drop of water, any
excess water blotted oﬀ and the wash repeated. The grid was
then briey placed in a drop of 0.75% uranyl formate, blotted
oﬀ and placed in a second drop of uranyl formate for 20
seconds. Any excess stain solution was blotted oﬀ and the grid
was allowed to dry overnight before imaging in the TEM.
Preparation of primary cortical cells for transplantation
All procedures were conducted in accordance with the Australian
National Health and Medical Research Council's published
Code of Practice for the Use of Animals in Research and exper-
iments were approved by the Florey Institute of Neuroscience &
Mental Health animal ethics committee. All mice were housed
on a 12 hour light/dark cycle with ad libitum access to food and
water. Adult female C57BL/6 mice were used as gra recipients
while donor tissue for transplantation was obtained from time-
mated mice expressing green uorescent protein (GFP) under
the b-actin promoter. Animals were time mated overnight and
visualization of a vaginal plug on the following morning was
taken as embryonic day (E) 0.5. Embryos at E14.5 were collected
in chilled L15 media. GFP+ embryos were selected, their brains
removed and the cortices dissected to isolate GFP+ cortical
primary tissue. The cortices were incubated for 20 minutes in
0.1% DNase and 0.05% trypsin in magnesium and calcium
HBSS. The tissue was then washed gently 3 times with HBSS. The
tissue was then dissociated and the cells re-suspended in HBSS
with 0.1% DNAse at 200 000 cells per mL.
Implantation of self-assembling peptide hydrogels with cell
transplantation
Mice received implants of cells in the presence or absence of
Fmoc-SAPs (Fmoc-DIKVAV; Fmoc-FRGDF; Fmoc-DYIGSRF),
n ¼ 6 per group. Mice were anaesthetized with 5% isourane,
and the level of anesthesia maintained at 2% for the duration of
the surgery. Mice were placed in a stereotaxic frame, midline
incisions were made in the scalp and craniotomies were per-
formed overlying the striatum. Cells were mixed at a 1 : 1 ratio
with HBSS or Fmoc-SAP prior to implantation into the striatum.
A total of 2 mL (200 000 cells) were injected, using a ne glass
capillary, at the following co-ordinates: 1.0 mm anterior and
2.5 mm lateral relative to bregma, and at a depth of 3.2 mm
below the dural surface. Aer 28 days, mice were delivered a
terminal dose of barbiturate and were transcardially perfused
with warm saline followed by 4% paraformaldehyde (PFA).
Brains were removed and post-xed for 2 hours in 4% PFA
before overnight cryo-preservation in 30% sucrose solution. The
brains were then coronally sectioned at 40 mM in 12 series
before free-oating immunohistochemistry was performed.
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Immunohistochemistry
Free oating immunohistochemical procedures were per-
formed as previously described.26 Primary antibodies and dilu-
tion factors were as follows: chicken anti-GFP (GFP, 1 : 1000,
Abcam), rabbit anti-GFAP (GFAP, 1 : 800, DAKO) and mouse
anti-CD11b (1 : 100, AbD serotec). Secondary antibodies for
direct detection were used at a dilution of 1 : 200—DyLight 488
conjugated donkey anti-chicken, DyLight 550 donkey anti-
rabbit and DyLight 649 donkey anti-mouse (Jackson Immu-
noResearch). Absolute cell counts and optical density
measurements were carried out on a Leica uorescent micro-
scope (Leica CTR6000).
Assessment of gras
Graed cells, and the extent of their innervation were discern-
able by the presence of GFP+ staining. For all animals, total
number of GFP+ cell, density (GFP+ cells per mm3) and volume
of innervation (mm3) were quantied. Optical intensity was
measured at two elds of view (FOV) for comparison of inner-
vation between each group. This technique was also used for
assessment of inammation. ImageJ was used to determine the
optical intensity of the uorophore (488 for GFP; 550 for GFAP
and 649 for CD11b) in each image at each FOV. This provides a
relative comparison for the extent of innervation or elicited
inammatory response induced in each group.
Statistical analysis
One-way ANOVAs with Tukey post-hoc tests were used to identify
statistically signicant changes between groups. The data was
also transformed in order to obtain equal variance and the tests
repeated, however, this had no eﬀect on the statistical infor-
mation obtained. Statistical signicance was set at a level of
P < 0.05. Data represents mean  standard error of the mean
(SEM).
Results and discussion
Laminin and bronectin based Fmoc-SAPs form nanobrous
hydrogels at physiological pH
Three Fmoc-SAPs containing laminin and bronectin peptide
binding domains were designed and optimized for self-
assembly under physiological conditions (pH 7.4) via two
previously developed approaches.12,24 Fmoc-aspartate-isoleu-
cine-lysine-valine-alanine-valine (Fmoc-DIKVAV) and Fmoc-
aspartate-tyrosine-isoleucine-glycine-serine-arginine-phenylala-
nine (Fmoc-DYIGSRF) were designed via adjusting their pKa
with an N-terminal acidic residue, namely aspartate (Fig. 1A &
B).12 Alternatively, uncharged anking aromatic residues were
added to improve the stability of the assembly to give Fmoc-
phenylalanine-arginine-glycine-aspartate-phenylalanine (Fmoc-
FRGDF) (Fig. 1C).24
Fmoc-self-assembly occurs when individual peptide building
blocks are optimally charged, undergoing p–p stacking
between aromatic Fmoc groups and hydrogen bonding between
the pendant peptide groups, to form individual nanobers. The
short peptide chains assemble in anti-parallel b-sheets, yielding
an overall p–b assembly (Fig. 2).
To ensure the underlying non-covalent and supramolecular
interactions leading to p–b assembly were maintained with the
insertion of bioactive peptide sequences, a series of materials
characterization techniques were performed. AFM showed that
each hydrogel presented a microscale brous network broadly
Fig. 1 Chemical structure of (A) Fmoc-DIKVAV, (B) Fmoc-DYIGSRF
and (C) Fmoc-FRGDF.
Fig. 2 Schematic of Fmoc-self-assembly process with Fmoc-DIKVAV.
(A) Fmoc-DIKVAV structure as synthesized via solid-phase peptide
synthesis. (B) Aromatic Fmoc terminal groups undergo p–p stacking.
(C) The DIKVAV peptide chains undergo hydrogen bonding to form
anti-parallel b-sheets. (D) A natural twist occurs to maintain this p–b
assembly forming a hollow nanoﬁber with the DIKVAV sequence
exposed on the outside of the ﬁber. (E) The nanoﬁbers interact with
each other forming a nanoﬁbrous network as shown in (F), TEM of
resulting Fmoc-DIKVAV hydrogel (scale bar 100 nm). (G) The material
presents as a shear-thinning hydrogel.
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analogous in scale, consisting of entwined linear features
(Fig. 3A–C). TEM micrographs showed that in each case, brils
nanometers in diameter and microns in length were formed
and these appeared to orientate laterally, forming entangle-
ments (Fig. 3D–F). Though the nanobers were broadly
conserved across all three systems, a more branched architec-
ture was observed for Fmoc-DYIGSRF with bers slightly larger
in diameter than those seen for Fmoc-FRGDF and Fmoc-DIK-
VAV, potentially an eﬀect of bundling bers due to increased
relative charge (Fig. 3C & F). Though IKVAV and YIGSR are both
laminin based peptides, the observed diﬀerences in structure is
a direct result of their unique amino acid sequence, apparent
pKa of the peptide, hydrophobicity of the sequence and result-
ing charge at physiological pH.23
In order to determine the viscoelastic properties of the
hydrogels, parallel plate rheology was performed. The materials
displayed characteristic viscoelastic gel properties, namely a
storage modulus (G0) greater than the loss modulus (G0 0) with
both moduli independent of frequency (Fig. 4A–C).17 The
moduli varied across the three diﬀerent sequences, attributed
to the varying charges that appear throughout each unique
sequence and the resulting ionic interactions between the
individual brils. At the same concentration, Fmoc-DIKVAV
showed the strongest rheological properties with a G0 of 30 000
Pa (Fig. 4A). Fmoc-FRGDF and Fmoc-DYIGSRF were signi-
cantly weaker with a G0 of 100 Pa and 200 Pa respectively,
which could be a result of the morphological diﬀerences
observed (Fig. 4B & C). Importantly, the range of moduli present
is comparable to a range of so tissues and could therefore be
tuned for tissue specic applications.
Spectroscopic analyses of the Fmoc-SAP hydrogels were used
to conrm that across each sequence the underlying p–b
assembly was conserved. FTIR was used to investigate the
presence of secondary structure by monitoring intermolecular
‘peptide-like’ interactions across the amide I region (Fig. 4D).17
In each case, vibrations characteristic of this class of SAPs were
observed. Anti-parallel b-sheet formation were observed with a
major peak between 1630–1660 cm1 and aminor peak between
1690–1710 cm1.17,21 In addition, a broad feature at1650 cm1
was observed, indicative of a random coil component.21 Intra-
and supramolecular interactions were analysed using CD
(Fig. 4E). A general n–p* transition between 180 and 220 nm was
observed in each sample, indicating the formation of anti-parallel
b-sheets (Fig. 4E).27 Transitions in the range of 230–270 nm arise
due to the supramolecular alignment of individual bers and
are characteristic of Fmoc-SAPs.28 Again, the CD spectrum for
Fmoc-DYIGSRF indicates the presence of some random coil
structures. However, together with the TEM and AFM images,
the spectroscopic analysis conrms that p–b self-assembly is a
robust mechanism that allows the formation of nanobrous
structures, despite the incorporation of varying bioactive
peptide sequences, extending the peptide sequence, and
altering the hydrophobicity and charge of the peptide sequence.
Response of cortical neural progenitor cells upon
transplantation into the mouse brain using Fmoc-SAPs
Fmoc-SAPs support the survival and migration of trans-
planted cortical neural progenitor cells in the intact brain.
Following characterization of the Fmoc-SAPs, their capacity to
support cell gras in vivo was assessed in the intact brain. E14.5
cortical neural progenitor cells expressing GFP were stereotax-
ically injected into mouse brains (the striatum) in the absence
or presence of Fmoc-SAPs. The graed cells were identied by
GFP staining within the mouse brain.
A GFP+ cell count showed no statistically signicant diﬀer-
ence in survival between cells alone and cells implanted
together with Fmoc-SAPs, demonstrating that in each case the
Fmoc-SAPs were non-cytotoxic (Fig. 5A). Not surprisingly, there
was a trend for gras in the presence of Fmoc-FRGDF to have
the lowest GFP+ cell survival rate compared to Fmoc-DIKVAV
and Fmoc-DYIGSRF (Fig. 5A). This is supported by the known
Fig. 3 (A–C) AFM (scale bar 500 nm) and (D–F) TEM (scale bar 100 nm)
showing nanoﬁbrous architecture of the three Fmoc-SAPs: Fmoc-
DIKVAV, Fmoc-FRGDF and Fmoc-DYIGSRF.
Fig. 4 Rheological analysis showing characteristic viscoelastic
behavior, where G0 (circles) is greater than G0 0 (squares) for (A) Fmoc-
DIKVAV, (B) Fmoc-FRGDF and (C) Fmoc-DYIGSRF. (D) FTIR analysis of
amide I region showing characteristic peaks for antiparallel b-sheets. (E)
CD shows transition peaks at 220 nm for all the synthesized Fmoc-SAPs,
suggesting the presence of b-sheets. Transitions in the 230–270 nm
region represent supramolecular ordering and bundling of individual
ﬁbers.
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role of laminin, but not bronectin, as a major constituent of
the brain's ECM and modulator of neural diﬀerentiation and
neurite extension.29,30 This emphasizes the importance of
designing a microenvironment that is specically tuned to
cellular requirements for tissue specicity. The density of cells
within the gra core was assessed as an index of cell migration
(GFP+ cells per mm3, Fig. 5A). Similar to cell survival, gra cell
density showed no signicant diﬀerence between any groups
(Fig. 5A).
With no statistical diﬀerence observed in cell survival or
migration between gras in the presence or absence of Fmoc-
SAP, we have shown that these scaﬀolds are non-cytotoxic to
graed cells in the parenchyma. This result demonstrates the
capacity for these non-toxic materials to support cells,
potentially in a disease setting. The Fmoc-SAPs could help
rebuild tissue by supporting the surrounding parenchyma,
enhancing the gra–host interface at the lesion site to reduce
any potential for secondary degeneration whilst also
encouraging integration of transplanted cells with the host
tissue.
Graed cortical neural progenitor cells can innervate the
host brain tissue in the presence of Fmoc-SAPs. Integration of
transplanted cells within the host environment and reinnerva-
tion of damaged host tissue by transplanted cells have been
identied as key issues in clinical trials for cell replacement
therapy and are important goals in order to achieve lasting
recovery and repair of neural circuitry.31 Here, the volume of
GFP+ gra innervation was determined in animals graed with
cells in the absence or presence of Fmoc-SAPs. No statistical
diﬀerence in the level of innervation was observed between
groups (Fig. 6A). Similar to cell survival, cells in the presence of
Fmoc-FRGDF demonstrated the least capacity for innervation of
the host brain, with the smallest volume of innervation
(Fig. 6A).
Additionally, we assessed the density of GFP+ gra ber
innervation at two pre-determined elds of view (FOV1 and
FOV2) away from the edge of the gra core (Fig. 6B–D). No
signicant diﬀerence was observed between the four groups,
suggesting that the amount of neurite growth was not impeded
by the Fmoc-SAPs (Fig. 6B & C). Together, this data conrms
that implanted cells are capable of extending neurites into the
surrounding parenchyma, unhindered by the presence of Fmoc-
SAPs, highlighting their capacity as a useful tool for the delivery
of cells in cell transplantation therapy.
Implantation of Fmoc-SAPs into the intact mouse brain does
not result in glial scarring. A key concern impeding neural
plasticity following CNS injury is the formation of the glial scar.
The glial scar is comprised of reactive astrocytes and microglia
that help form a brotic scar to seal oﬀ the injury, but also
secrete inhibitory proteins that prevent axon regeneration.32–34
To further assess the biocompatibility of Fmoc-SAPs in the
brain, the inammatory microglial and astrocytic response to
the materials was investigated.
Fmoc-DIKVAV and Fmoc-DYIGSRF showed no increase in
host-derived (GFP-) astrocytes (glial brillary acidic protein;
GFAP+) compared to cells transplanted alone (Fig. 7A). Addi-
tionally, Fmoc-DIKVAV showed no increase in microglia
Fig. 5 (A) Number of GFP+ cells in the striatum 28 days after trans-
plantation (top) and cell density of implanted GFP+ cells in graft core
(bottom). Data represents mean + SEM. Photomontages of the mouse
brain illustrating GFP+ grafts in (B) the absence, and presence of (C)
Fmoc-DIKVAV, (F) Fmoc-FRGDF and (G) Fmoc-DYIGSRF. (D, E, H & I)
show high power magniﬁcation (10) of GFP+ grafts.
Fig. 6 (A) Volume of GFP+ graft innervation. (B & C) Percentage of
GFP+ ﬁbers in FOV1 and FOV2 respectively for each group, measured
as optical density. (D) Section of single brain hemisphere showing
example of ﬁelds of view (FOV) 1 (dashed line box) and 2 (solid line box)
taken from the edge of the graft core, sequentially moving outwards.
(E–J) Images of FOV2 used to measure optical density of GFP+ ﬁbers
and show ﬁber innervation. Data represents mean + SEM.
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(CD11b+) aer 28 days (Fig. 7B). These results suggest that the
host environment does not recognize these Fmoc-SAPs as
“foreign material”, with a limited immune response elicited
over the course of 28 days (Fig. 7C–R). This is signicant as
these results emphasize the biocompatibility of these materials
compared to other hydrogels, such as chitosan, that has been
shown to be phagocytized by macrophages aer 7 days in vivo
due to the elicited foreign body response.35
Aer 28 days, Fmoc-FRGDF showed a trend towards
enhanced astrocyte density compared to all other groups
(Fig. 7A). In addition, Fmoc-FRGDF showed a statistically
signicant increase in microglia recruitment (P < 0.05)
compared to cells alone and the laminin based Fmoc-SAP,
Fmoc-DIKVAV (P < 0.0001) (Fig. 7B). Again, the control RGD
sequence demonstrated the least biocompatibility for this
application, however, as validated by the high GFP+ cell counts,
the material itself is not cytotoxic (Fig. 5A). Rather, as previously
suggested, the RGD signal is not suitable for presentation to
cells in the CNS.
Previous studies have shown that Fmoc-peptides display
neuroprotective properties where Fmoc-L-leucine protected
both the mature and immature brain through the activation of
PPARg.36 In addition, Fmoc-amino acids have been reported to
have anti-inammatory properties, inhibiting the recruitment
of T-lymphocytes and neutrophils during an inammatory
response.37 In line with these ndings, here we demonstrated
that aer 28 days in vivo there was no glial scarring in the
presence of any of the Fmoc-SAPs, indicating the inherent
biocompatibility of these materials in the brain and their
capacity to attenuate the inammatory response. Importantly,
this is the rst study where Fmoc-SAPs have been used as a
vehicle for the delivery and support of cell transplants in vivo.
Their observed biocompatibility and lack of induced immune
response promotes their suitability as a tool for cell trans-
plantation in the brain.
Conclusion
Current research on Fmoc-SAPs has focused on understanding
the material properties and underlying mechanisms of self-
assembly of this system with their potential for biological
applications being limited to small in vitro proliferation assays
on cell lines. Here, we have demonstrated the utility of mini-
malist Fmoc-SAPs as biocompatible materials to support cell
transplantation in vivo. We have developed three Fmoc-SAPs,
containing varying ECM protein based peptides, for use as a
delivery vehicle for neural progenitor cells for implantation into
the intact mouse brain. The ability of the Fmoc-SAPs to main-
tain transplanted cell survival and the lack of induced immune
response suggests their potential suitability for supporting
residual host cells surrounding an injury site, as well as inte-
gration of newly transplanted cells. These results give us
condence that incorporating short amino acid sequences into
Fmoc-SAPs allows the design of materials that can be easily and
specically tuned to a particular tissue and/or cellular require-
ment and demonstrates that Fmoc-SAPs could be used as a
platform for the design of enhanced microenvironments to
promote tissue repair.
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Abstract
The local inflammatory environment of the cell promotes the growth of epithelial cancers. Therefore, controlling inflammation locally using amaterial in
a sustained, non-steroidal fashion can effectively kill malignant cells without significant damage to surrounding healthy cells. A promising class ofmaterials
for such applications is the nanostructured scaffolds formed by epitope presentingminimalist self-assembled peptides; these are bioactive on a cellular length
scale,while presenting as an easily handled hydrogel.Here,we show that the assembly process can distribute an anti-inflammatory polysaccharide, fucoidan,
localized to the nanofibers within the scaffold to create a biomaterial for cancer therapy.We show that it supports healthy cells, while inducing apoptosis in
cancerous epithelial cells, as demonstrated by the significant down-regulation of gene and protein expression pathways associated with epithelial cancer
progression. Our findings highlight an innovative material approach with potential applications in local epithelial cancer immunotherapy and drug delivery.
© 2016 Elsevier Inc. All rights reserved.
Key words: Bionanotechnology; Self-assembly; Cancer; Supramolecular materials; Hydrogels; Tissue engineering
The use of designed, nanostructured materials for the treatment
of cancers is a rapidly growing research area1 as they can
potentially mimic the tumor microenvironment.2 A promising
approach involves materials that can mediate the local tumor
environment through attenuation of the inflammatory response,3
while simultaneously providing a stable healthy extracellular
matrix (ECM) mimic to promote regeneration.4 The link between
the inflammatory response and the promotion of cancers is well
established; notably in endothelial cancers such as oral, pancreatic
and colon.5 Epidemiological studies have shown that chronic
inflammation is a significant causative factor for these cancers;
several studies showed promising anti-tumorigenic effects using
non-steroidal anti-inflammatory drugs.6 Hence, a therapeutic
opportunity lies in developing a biocompatible material that can
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achieve a spatially confined, sustained, non-steroidal and selective
suppression of the immune system.7 A range of cancer therapies
could benefit from this approach; such a material could provide an
anti-tumoral void-filling support for the surrounding healthy tissue
following surgical excision, or, alternatively, a topical treatment for
the surface of a lesion.8 Numerous examples exist of complex
hierarchical ECM assemblies, formed by the self-organization of a
range of cellularly secreted small molecules, that provide structure
and function in living systems.9 In particular, polysaccharides and
fibrous proteins assemble to form networks that support
multicellular systems and mediate cellular interactions with their
surrounding microenvironment.10 A family of sulfonated poly-
saccharides known as fucoidans have gathered increasing attention
for their inherent biocompatibility and anti-inflammatory proper-
ties both in vitro and in vivo.11 Importantly, several studies have
also indicated the anti-mitogenic effects of fucoidans as they block
cell cycle progression,12 induce apoptosis and reduce tumorige-
nicity in several cancer cell lines.13 However, the use of these
biopolymers as a therapeutic is constrained by the high solubility of
the polysaccharide chains, limiting their sustained functionality
unless encapsulated in an external carrier14 or presented on a
two-dimensional (2D) surface.15 The motivation for this work,
therefore, was to present constrained fucoidan on the surface of a
three dimensional (3D) ECM-like scaffold.
Hydrogels formed by bioinspired synthetic organic molecules
known as self-assembling peptides (SAP) are highly suitable
materials for cancer therapy,16 as they have been shown to form
nanofibrillar matrices of similar morphology17 which are functional
both in vitro18 and in vivo19 through the inclusion of bioactive and
biocompatible peptide sequences in the SAP during synthesis.20
The formation of SAP hydrogels is a thermodynamically driven
process21; control over the organization of the structures formed is
achieved through careful exploitation of assembly conditions, such
as manipulation of the molecule's specific pKa,22 biocatalysis21 or
the rate of assembly.23 Such facile control over the final structures
means that they are excellent candidates for use as tailored
multicomponent adjuvant scaffolds. Key to such applications, SAPs
have been shown to have multicomponent functionality, as the
noncovalent forces that govern their assembly can be used to
physically incorporate larger molecules such as proteins24 or
drugs25 making them an ideal candidate material for the
immobilization and functional presentation of the otherwise highly
soluble fucoidan polysaccharides as part of a self-assembledmatrix.
Methods
See Supplementary Information for full synthetic and
analytical procedures.
Co-assembled hydrogel formation
Fmoc-FRGDF (10.0 mg) along with mixtures of 2 mg
fucoidan (Marinova Pty Ltd, Cambridge, Tasmanian, Australia)
was added to separate 4 mL glass vials. Milli-Q water (400 μL;
purified by Milli-Q Advantage A10 System, Merck Millipore,
Australia) was added into each vial, then pH increased by the
addition of a minimal volume of 0.5 M NaOH while vortexing
and then neutralized to pH 7.4 via dropwise addition of 0.1 M
HCl (Asia Pacific Specialty Chemicals Ltd., Australia). Finally,
100 mM PBS (pH 7.4) was added into the solution to bring the
total volume up to 1.0 mL, and used 48 h later.
NMR studies
Fmoc-FRGDF of 2.5 mg was added to a glass vial and
dissolved in 0.5 mL of D2O. The pH was increased using freshly
prepared 0.5 M NaOD (NaOH in D2O) and vortexed until a
transparent solution was obtained. The resulting solution was
transferred to a 5 mm NMR tube. 1H, COSY, HMBC and HSQC
spectra were collected on a Bruker AVANCE III 500 MHz
FT-NMR spectrometer. 13C resonances were elucidated using both
heteronuclear multiple-bond correlation spectroscopy (HMBC) and
heteronuclear single-quantum correlation spectroscopy (HSQC).
Small-angle neutron scattering (SANS)
SANS measurements were performed on the D33 instrument
at the Institut Laue-Langevin, Grenoble, France26 in fixed
wavelength mode using a wavelength of 6 Å and a wavelength
resolution ofΔλ = 10% at detector distances of 2 m and 12 m to
cover the Q-range 0.001-0.5 Å−1. Data collected for the two
detector distances were joined using the GRASansP package,
reduced using the NIST SANS reduction macros27 and the
resultant SANS curves fit using the SASview package. A flexible
cylinder model was used to fit the data. The data for
Fmoc-FRGDF were fit using constraints on the scattering
lengths of the buffer and peptide. Kratky analysis was performed
using the NIST SANS analysis macros.27 Contrast matching to
fucoidan was performed by measuring SANS from a series of
10 mg/mL fucoidan solutions in H2O/D2Omixtures. SANS from
the chosen concentration of 21.5% confirmed that there was no
detectable scattering from the fucoidan solution. Peptide samples
were measured in sealed 1 mm path-length Hellma cells.
Cell lines and culture conditions
The human tongue squamous cell carcinoma cell line (SCC25)
cultures were obtained verified from ATCC and were maintained
in DMEM-F12 complete medium containing 10% fetal bovine
serum and 400 ng/mL hydrocortisone and penicillin/streptomycin.
The human mammary fibroblast cell line (hMFC) cultures were
maintained as described previously.18a Cell line cultures were
maintained at 37 °C with 5% CO2.
Reverse transcription and quantitative PCR
Total RNA was reverse-transcribed to generate complimentary
DNA using Superscript III (Invitrogen) following the manufac-
turer's protocol. To challenge fucoidan, cells were stimulated with
LPS (Sigma) at a concentration of 10 μg/mL in the complete
media. Differential expression of the genes examined was listed in
Supplementary Table 1. cDNA of 30 ng was used to perform
quantitative real time PCR in a 20 μL reaction using SYBRGreen
(Biorad) on a CFX connectTM Real Time PCR detection system
(Biorad). Primer oligosequences were designed using Primer3
PCR prime design tool (Whitehead Institute for Biomedical
Research, Cambridge, MA, USA) and the gene specificity was
checked using National Center for Biotechnology Information
nucleotide database. Steps followed during QPCR to generate
1398 R. Li et al / Nanomedicine: Nanotechnology, Biology, and Medicine 12 (2016) 1397–1407
amplification curves include an initial denaturing step for 3 min at
95 °C, followed by 40 cycles of 95 °C for 10 s, 60 °C for 30 s and
72 °C for 30 s. The expression of each gene in terms of fold change
was normalized to the housekeeping gene ACTB.
NFκB and CEP55 staining
SCC25 cells were treated without and with fucoidan (2 mg/mL)
for 48 h. Cellswere fixedwith paraformaldehyde and permeabilized
with 0.1% triton-X-100. Cells were blocked with 1% bovine serum
albumin (BSA) in PBS for 1 h at room temperature and further
treated with primary antibody (Rabbit polyclonal NFκB p65
antibody and Rabbit monoclonal CEP55 antibody, Abcam)
overnight at 4 °C. Cells were further incubated with anti-rabbit
Alexa Fluor 488 secondary conjugates for 1 h at room temperature.
Following several washes cells were visualized under fluorescence
microscope (Nikon).
Annexin V staining
SCC25 cells treated without and with fucoidan (2 mg/mL) for
48 h were stained with the Alexa Fluor® 488 annexin V/Dead Cell
Apoptosis Kit (Life Technologies). Cells were also counter-stained
with Hoechst dye to stain the live cells. Images were obtained
through fluorescence microscopy (Nikon Eclipse Ti-S).
Results
The formation of two-component hydrogels and evaluation of (i)
their biocompatibility and (ii) their effect on cancer cells
In order to form the scaffold to present fucoidan, we used a
biocompatible minimalist pentapeptide sequence known to assem-
ble via a π-β self-assembly mechanism, fluorenylmethoxycarbonyl
(Fmoc) FRGDF (Figure 1).17,18 Fmoc-FRGDF was synthesized
using a standard solid phase Fmoc peptide synthesismethodology to
yield a white crystalline powder (see electronic Supplementary
Information). Fucoidanwas supplied in a readily solubilized powder
of similar consistency. We mixed both powders together and
initiated self-assembly using a well-established pH switch
methodology.18a,22 The solution was then made up to a final
concentration of 10 mg/mL Fmoc-FRGDF and 2 mg/mL fucoidan
with Dulbeccos' modified Eagle medium (DMEM), and the
hydrogel was allowed to form. When this was compared to a pure
Fmoc-FRGDF hydrogel, both formed optically clear, stable
hydrogels (Supplementary Figure 1, A).
Biocompatability of the systems was measured with 3D cell
cultures of human mammary fibroblast cells as a control for healthy
tissue, and the moderately differentiated oral tongue squamous cell
carcinoma line SCC25.28 Cell viability of hMFCon the hydrogels of
Fmoc-FRGDF (0RGD) and hydrogels co-assembled with 2 mg/mL
of fucoidan (2RGD)was determined using anMTS assay up to 72 h
with no significant difference, whereas SCC25 cells showed a
reduction in the number of viable cells (Figure 2,A). A live/dead cell
assay performed at 48 h (to observe cell death mid-cycle) showed
significant numbers of dead SCC25 cells, evenly distributed
throughout the material (Figure 2, B). To observe which cells
were apoptotic, SCC25 cells were cultured for 48 h prior to staining
with Annexin V, propidium iodide and Hoechst stain to observe cell
death mid-cycle (Figure 2, C and D).
Analysis of the two component self-assembly
Four samples were prepared: (1) Fmoc-FRGDF: a hydrogel
formed by the pH triggered assembly at a concentration of 10 mg/
mL; (2) Co-Assembly: whereby 10 mg/mL Fmoc-FRGDF and
2 mg/mL fucoidan were mixed in powdered form prior to
application of a pH switch; (3) Post-Assembly: a preformed
Fmoc-FRGDF hydrogel with a solution of fucoidan added 12 h
post-assembly by mixing to the same final concentration as sample
2; and (4) Fucoidan: 2 mg/mL solution of fucoidan. As expected,
samples 1-3 formed self-supporting hydrogels, whereas sample 4
remained a solution.
We visualized the structures formed in each sample with
transmission electron microscopy (TEM) to determine the
Figure 1. Cartoon of the coassembly mechanism (A) structure of Fmoc-FRGDF, (B) cartoon schematic showing the π stacking of Fmoc and the antiparallel
interactions of the peptide which drive its assembly to fibrils that intertwine to form a scaffold, (C) structure of a fucoidan subunit, (D) co-assembly results in an
interaction of fucoidan with fibrils, resulting in the presentation of the molecule over the surface of the scaffold. (E) The addition of fucoidan post-assembly
however does not produce a surface decorated structure, instead it results in the formation of separate disordered fucoidan aggregates.
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underlying nanostructures and atomic force microscopy (AFM) to
evaluate the microstructure of the system (Figure 3). Fourier
transform infra-red spectroscopy (FTIR) was used to confirm that
the peptide-like organizationwas not disrupted. This confirmed that
the addition of fucoidan during the assembly process did not affect
the molecular packing of the peptides into the anti-parallelβ-sheets
which drive these assemblies and result in peaks at ~1630 cm−1
and ~1690 cm−1 (Figure 3, I).29 We then analyzed the chiral
organization of the structures within the samples using circular
dichroism (CD).22,24a,30 Characteristic and retained transitions
were observed in the region between 230 and 280 nm. The
mechanical properties of the hydrogel samples were then compared
by oscillatory rheometry (Figure 4, G and H). Typically,
two-component hydrogels where one component does not
otherwise self-assemble tend to yield an alternate molecular
packing, resulting in a stiffer hydrogel.31 Here though, the
characteristic frequency sweeps of this class of system were
retained, and each forms a hydrogel of comparable stiffness,
indicating that the inclusion of fucoidan (at this concentration) does
not interfere with the processes that determine the final stiffness of
the resultant hydrogels.24a,32
Interaction of fucoidan and the SAP fibrils
To determine at the availability of the peptide sequence on the
surface of the fibrils, we used 1H NMR spectroscopic analysis.
After the addition ofNaOH to solubilize the peptide (pH = 10), 1H
NMR provided a clean spectrum with narrow line widths.
However, upon gelation, the resonances associated with the
Fmoc-group and the fifth phenylalanine residue (F5) significantly
broadened and were not visible. However, the dynamic motion of
the RGDF–OH portion of the peptide is conserved in the fibrils,
and resulted in narrow line widths for this portion of the peptide
(Figure 3, K). SANS measurements of fully hydrated samples of
Fmoc-FRGDF and the co-assembled systems were performed to
investigate the nanostructures in-situ and to determine what effect
the addition of fucoidan had on fibril radius. As SANS cannot
distinguish features larger than approximately 17 nm under these
conditions, themeasurementwas found to be insensitive to average
fibril length. As SANS is sensitive to all structural features
with sufficient contrast, we performed control measurements of
2 mg/mL fucoidan alone, which in 21.5% D2O, was found to
provide conditions for negligible scattering from fucoidan. In the
samples presented here we used these conditions to observe only
the scattering from the fibrils as the contributions from fucoidan
could complicate the analysis. This approach enabled the
differences in the scattering between Fmoc-FRGDF and the
co-assembled system to be observed (Figure 3, L). Analysis of the
scattering data was performed using both a model-independent
approach and a flexible cylinder model in the SASview package
(Supplementary Information). The model-independent approach
found that fibril radius for the 0RGD sample was 48.8 ± 0.9 Å
Figure 2. Biocompatability and the effect of the material on Cancer (SCC25) and healthy (hMFC) cell fate. (A) The relative viabilities of the cells on each
scaffold over three days. SCC25 cells were seeded on the Fmoc-FRGDF hydrogel (0RGD) and 2 mg/mL fucoidan (2RGD) and incubated for 3 days. Calcein
AM staining was performed to identify live cells (green) and propidium iodide was used to identify dead cells (red). Scale bars 125 μm. A minimum of 5 fields
were captured for each treatment and number of live cells and dead cells were counted individually and percentage was calculated *P = 0.05, **P = 0.01,
***P = 0.001, ****P = 0.0001 (n = 3). (B) The distribution of SCC25 cells on day 3 on each hydrogel. (C and D) Apoptosis at 24 and 48 h. In order to
determine the mode of cell death in the SCC25 cells, we stained the cells using Annexin V (green), propidium iodide (red) and Hoechst dye (blue). Live cells are
identified by a nucleus stained only with Hoechst dye and appear only blue. Early apoptotic cells were stained green with nucleus blue and the late apoptotic cells
stained in green with a red nucleus. Scale bars 50 μm.
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with this value reducing to 35.6 ± 1.1 Å for 2RGD. Similar values
were found using model fitting with the initial fibril radius of
43.3 ± 0.1 Å, reducing to 33.7 ± 0.1 Å when the peptide was
co-assembled with fucoidan. These values are consistent with the
diameter of the previously reported subunit of these assemblies.29
The model fitting approach also indicated that there was a
densification of the fibril after co-assembly with the scattering
length density of the fibrils increasing by 9.6%.
We adapted a previously described method of gold
nanoparticle (GNP) synthesis,33 creating GNP labeled fucoidan
Figure 3. The underpinning structure and organization of the scaffold. AFM microscopy shows the structures formed by (A) Fmoc-FRGDF, (B) co-assembled
with 2 mg/mL fucoidan, (C) a solution of fucoidan (D) post-addition fucoidan (scale bar represents 1 μm). (E-F) equivalent via negatively stained TEM. (G)
Aggregates of fucoidan, which are similar to structures visible in post-addition (H), but not co-assembly (F) (scale bar represents 75 nm). (I) FTIR shows
conserved antiparallel β-sheet formation. Fucoidan solution shows no overall structure. (J) CD shows increased supramolecular ordering of Fmoc-FRGDFwhen
co-assembled. The transitions characteristic to this class of assembly are maintained across all the SAP containing samples, indicating the same chiral structure
dominates. Co-assembly increases the magnitude of the transitions indicating an increase in supramolecular ordering whereas post-assembly disrupts structure.
The solution of fucoidan has no overriding chiral signal. (K) NMR analysis shows that upon assembly Fmoc is completely removed from solution and the
N-terminal (i.e., closets to Fmoc) Phe is partially removed from the solution as the assembly forms, indicating that the RGDF portion is still in solution, and
presented on the surface of the assemblies. (L) Analysis of SANS using both a flexible cylinder model and model-independent Kratky analysis (inset) of the data
show a reduction in the fibril radius when co-assembled with fucoidan. Plots are offset for clarity.
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which can be readily visualized with TEM (Figure 4, D).
Figure 4, A-C show TEM micrographs of the nanofibrils in close
association with the GNP labeled fucoidan. Two control
hydrogels were prepared to control against possible associations
between independent gold nanoparticles and either fucoidan or
the peptide fibrils. One control hydrogel contained a mixture of
unlabeled fucoidan and the independent GNP (Figure 4, E), and
the other containing only the independent GNP (Figure 4, F). All
hydrogels were thoroughly washed with deionized water to
remove any unbound nanoparticles from the hydrogel
Figure 4. Location of fucoidan in relation to the fibrils and the effects on the final hydrogel: GNP labeled fucoidan shows co-localization along peptide fibrils
(A) pre- and (B and C) post-washing of the hydrogel indicating strong associations between fucoidan and peptide fibrils. (D) GNP labeled fucoidan in solution.
(E) Hydrogel co-assembled with unlabeled fucoidan and independent GNP shows no residual GNP post-washing. (F) Hydrogel co-assembled only with
independent GNP shows no residual GNP post-washing (scale bar represents 100 nm). (G) rheological characteristics of hydrogels. (H) Rate of the formation of
hydrogel is increased in co-assembly. (I) ITC shows increased rate of assembly with co-assembled samples (return of heat rate to 0). (J) DSC shows increased
melting temperature of co-assembled system.
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Parallel plate rheometry was used to compare the rate of
hydrogel formation.34 When the materials were analyzed after
48 h, the final modulus were comparable across a range of
frequencies and showed that the final mechanical properties of
the scaffolds were similar (Figure 4, G). A fixed frequency time
analysis showed that the co-assembled sample formed the
hydrogel more rapidly with an order of magnitude increasing in
stiffness at a specific time (Figure 4, H). Normalized isothermal
titration calorimetry (ITC) thermograms (Figure 4, I) was used
to monitor the time taken for the Fmoc-FRGDF network
formation (i.e., where the heat rate returns to zero), and the
co-assembled sample showed a rate enhancement of ca. 40% in
the latter. Differential scanning caloriometry (DSC) analyses
showed that co-assembly increased Tgel from 90.1 °C. to
94.6 °C, while the post-assembly addition did not show a
similar increase in Tgel (Figure 4, J).
Biological mechanism of the fucoidan/peptide material
Immunostaining was performed on the cells cultured at 48 h
to capture the process mid-cycle. SCC25 cells cultured on 0RGD
were further counterstained with Hoechst dye to reveal NFκβ
p65 co-localized with the nuclear stain. When the same
experiment was performed upon the 2RGD hydrogel, however,
no significant staining of NFκβ was observed.
To confirm that the material was effective at a gene
expression level, we interrogated the mRNA regulation of
genes in the NFκβ pro-inflammatory pathway using quantitative
PCR [49] (see Supplementary Information for primer se-
quences). RNA was extracted from the cells under both
conditions and quantified for the gene expression studies. We
included the pro-inflammatory cytokines interleukin (IL) 1A,
IL1B, IL6, IL8, and tissue necrotic factor (TNF), all transcribed
as a key part of the NFκβ pro-inflammatory pathway and were
therefore monitored as crucial regulators of tumorigenesis
(Figure 5, C). The time point for studying gene expression was
48 h. At this time point, most of the SCC25 cells remained viable
(~70%). In each case, there was significant downregulation in
the expression of each pro-inflammatory gene on 2RGD when
compared to the control. In order to confirm that the
downregulation of the anti-inflammatory cytokines was not
related to apoptosis, the housekeeping gene ACTB was
monitored and showed the same level of expression in both
situations. Then, to test the extent of this effect, we then
challenged the cells with LPS, as this challenge has been shown
to increase expression even if the cells were apoptotic. In each
gene analyzed, the expression in the 0RGD system showed a
significant increase, whereas the 2RGD was observed to be
similar to the unchallenged sample.
Discussion
The formation of stable, functional biomaterials that can present
biologically active sequences and molecules will play a significant
role in a range of medical applications. Self-assembly has been
shown to give rise to materials that are both biocompatible and
functional, but have not yet fully realized their potential. The use of
simple interactions between these structures and additional
functional molecules offers several advantages. The spontaneous
formation of multicomponent scaffolds with defined chemical
properties allows materials to be formed in physiological
conditions, conferring inherent biocompatibility.
To ensure that the material was biocompatible and non-toxic
toward normal cell phenotypes, primary human mammary
fibroblast cells (hMFCs) were also cultured on the SAP
hydrogels (Figure 2, A). We chose these cell lines as fibroblasts
and endothelial cancer cells have a close association in the tumor
microenvironment,35 and drugs that are solely cytotoxic also kill
fibroblasts along with the target cells, a process which actually
induces local tumorigenesis through the release of pro-cancerous
factors.5,36 In addition, the correct presentation of RGD is a
requirement for the culture of both cell types, as the SCC25 oral
cancer cells show over-expression of α5β1 integrin receptor.37
The hMFC cells showed maintained equally high viability on
both 0RGD and 2RGD, indicating that the inclusion of fucoidan
did not negatively impact the cytotoxicity of the SAP matrix.
However, the SCC25 cells showed significant numbers of dead
cells in comparison. To verify that this mechanism was
controlled apoptosis rather than necrosis, Annexin V staining
was performed. While no cells in the 0RGD hydrogel were
apoptotic, the results revealed that the majority of cells cultured
on the 2RGD hydrogels were in a late apoptotic phase, with only
a few cells found to be in the early apoptotic phase. Confident
that the fucoidan within the material contributed toward the
reduction of the number of cancer cells through the induction of
controlled apoptosis, we set out to discover the mechanism by
which it was distributed within the hydrogel. Ideally the material
would retain the functional nanostructures formed by the
Fmoc-SAP alone; however, the supramolecular ordering of
self-assembled structures has been shown to be significantly
altered in the presence of biological macromolecules such as
proteins found in serum24b and the cytosol,38 or when two or
more complementary molecules are co-assembled.31
Using TEM and AFM analyses, we observed that the
Fmoc-FRGDF formed a series of well-ordered bundles of
striated nanofibrils underpinning a fibrous matrix (Figure 3, A
and E), which were very similar to those in the co-assembled
sample, though a more pronounced bundling of fibrils was
observed (Figure 3, B and F). When the solution of fucoidan
was examined, the analysis revealed the formation of a number
of spherical structures with a diameter of ~20 nm (Figure 3, C
and G). Finally, for the post-assembled hydrogel, a mixture of
structures was observed, where spherical structures similar to
those observed in the fucoidan solution (sample 4) were
distributed at high density over the fibrillar network at both the
nano- and microscales (Figure 3, D and H).
To determine if the molecular packing of the Fmoc-SAP
within the fibrils was affected by the fucoidan, a series of
spectroscopic analyses were performed, as co-assemblies in
general have been demonstrated to promote inconsistent
alternative organizational structures.24b,38 The use of FTIR
confirmed that the addition of fucoidan during the assembly
process did not affect the molecular packing of the peptides into
the desired anti-parallel β-sheets that drive these assemblies.
Furthermore, the transitions observed via CD, shown to
represent bundling between the fibrils driven by supramolecular
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interactions, are analogous to large macromolecules.21,30
Importantly, when the co-assembled material was compared
to Fmoc-FRGDF, the wavelength of the transitions within the
spectra was unchanged, but the magnitude was increased,
suggesting that the addition of fucoidan induced increased
longitudinal ordering (Figure 3, J).30 Conversely, the magni-
tude of the transitions was diminished in the post-assembled
sample, possibly as a result of disruptions arising from the
Figure 5. Co-assembled hydrogels inhibit the expression of proinflammatory cytokines and disrupts cell division on a gene and protein level. (A) Visualization of
protein expression of fluorescent NFκβ p65 and CEP55 immunofluorescence analysis (green) in SCC25 cells localized with a nuclear counterstain of Hoechst
dye (blue) cultured on the hydrogels for 48 h. (B) NFκβ p65 in the nucleus increased with 10 μg/mL of LPS stimulation in 0RGD cultures, whereas CEP55
expression was high in SCC25 cells irrespective of stimulation with LPS. Both signals were significantly reduced in cells cultured on the 2RGD hydrogels. Scale
bars 25 μm. (C) Gene expression profiles of the pro-inflammatory cytokine response elements in LPS stimulated and non-stimulated SCC25 cells as determined
by qPCR. Interestingly, in each case, gene expression was reduced on the 2RGD hydrogels compared with 0RGD. When LPS was used to stimulate
the pro-inflammatory pathway, the expression increased significantly on 0RGD in each case, but remained comparable to the unchallenged cells on 2RGD.
*P = 0.05, **P = 0.01, ***P = 0.001, ****P = 0.0001.
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mixing process, and potentially the unbound fucoidan forming
aggregates increasing scattering in the far UV. The coassembly
did not affect the mechanical properties of the resultant
hydrogels; when the mechanical properties of the hydrogels
were studied, the characteristic frequency sweeps of this class of
system were retained, and each forms a hydrogel of comparable
stiffness. Typically, two-component hydrogels where one
component does not otherwise self-assemble tend to yield an
alternate molecular packing, resulting in a stiffer hydrogel,31
indicating that the inclusion of fucoidan (at this concentration)
does not interfere with the processes that determine the final
stiffness of the resultant hydrogels.24a,32
We hypothesized that the mechanism by which the fucoidan
in the co-assembled sample was incorporated into the fibrillar
network was through non-covalent interactions with amino
acid(s) present on the surface of the fibrils. NMR data suggest
restricted movement of the Fmoc and first phenylalanine due to
assembly into nanotubes.29 However, the dynamic motion of the
RGDF–OH portion of the peptide is conserved in the fibrils and
resulted in narrow line widths for this portion of the peptide. By
integrating 1H NMR resonances, it was concluded that b5 % of
the RGD portion of the peptide was available in solution, and
therefore available for interaction. It has been shown that a
minimum spacing of ~440 nm between RGD epitopes is
sufficient for effective cell attachment,39 and the most effective
cell interaction is achieved with well spaced clustered of
epitopes.40 As the entire fibril consists of closely packed
Fmoc-FRGDF peptides, the limited availability of the RGD
portion on the surface of the fibrils may in fact contribute to the
observed cell attachment properties.18a We then employed small
angle neutron scattering (SANS) analysis to look at the effect of
the interaction with fucoidan on the fibril morphology. Although
a slight reduction in radius is observed, the scattering fit suggests
that the morphology of the fibril is broadly retained, as opposed
to the formation of a secondary, self-sorted structure.41 This
retention of morphology coupled with an increase in density
suggests that the fucoidan interaction is allowing the SAP fibril
structure and morphology to be broadly retained, but is having an
effect on the fibrils. This co-localization was confirmed by
physically observing the location of fucoidan by labeling it with
a gold nanoparticle that could be observed via TEM. After
washing, GNP remained present only with the GNP labeled
fucoidan, where they were observed in close association with the
peptide fibrils. This indicated a strong and persistent co-localization
of the fucoidan to the fibrils.
We observed that the co-assembled sample formed more
quickly, possibly due to the bundling and co-location providing
an increased driving force for assembly. In order to analyse the
effects of this driving force on the time it takes the gel network to
form, we used parallel plate rheometry to compare the rate of
hydrogel formation.34 When the materials were analyzed after
48 h, the final modulus was comparable across a range of
frequencies, suggesting that the final mechanical properties of
the scaffolds were similar (Figure 4, G). However, a fixed
frequency time analysis showed that the co-assembled sample
formed the hydrogel more rapidly (Figure 4, H). We then
analyzed the sol–gel transition temperature (Tgel) to determine
possible effects of this stabilization on the melting temperature of
the hydrogels using a series of DSC analysis. These observations
suggest further that the co-assembly process leads to a
stabilization of the interfibrillar network. These results suggest
that the fucoidan is enhancing the stability of the fibrils in the
co-assembled system by increasing supramolecular order,30
albeit without significantly increasing its stiffness (Figure 4, G).
Confident in the structure of our material, we decided to probe
further its effect on the oral cancer cell line in further detail.
Previous studies of the SCC25 cell line in comparison with normal
human oral keratinocytes revealed significant over-expression of
the pro-inflammatory cytokine response, upregulation of the
cytokinesis promoting genes42 and, in particular, increased
expression of NFκβ useful here as an easily characterized
component of a larger inflammatory pathway.43 The uncontrolled
G2 to M cell cycle progression is essential for oral cancer
progression, and is characterized by an increase in the tumor size.43
The transcription factors associated with this pathway, PLK1 and
FOXM1, activate CEP55, a cytokinesis promoter identified as a
key marker of tumor formation and progression.44 Earlier CEP55
knockdown studies have revealed a reduction in cell proliferation
and tumorigenicity of the cancer cells.45 In addition, to further test
the material and model the highly pro-inflammatory environment
of the tumor, the cells were challenged with lipopolysaccharide
(LPS), a powerful inflammatory agent, providing a valid assay for
the progression of these cancer cell lines.46 To investigate the
mechanism inducing selective apoptotic effects in the cancer cells
observed earlier (Figure 2) we performed a series of experiments to
monitor the observed effects of the material on the protein
expression of NFκβ and CEP55 (Figure 5, A and B). When the
same experiment was performed upon the 2RGD hydrogel,
however, no significant staining ofNFκβwas observed suggesting
that the material results in a significant reduction in the protein
expression of NFκβ when compared to those stimulated by LPS.
As expected, significant CEP55 protein expression was observed
in SCC25 cells on the 0RGD hydrogel whereas the cells cultured
on 2RGD hydrogels demonstrated little or no CEP55 protein
expression, significantly this process was irrespective of stimula-
tion with LPS, indicating that cytokinesis was effectively inhibited
by the immobilized fucoidan (Figure 5, A and B). We then
confirmed these observations with gene expression studies. As
expected,whenSCC25 cellswere cultured on 0RGDwithLPS, the
response of each of the pro-inflammatory cytokines was
significantly upregulated. However, when the same conditions
were applied to the 2RGD hydrogel, there was a significant
inhibition in the transcription of each of the cytokine promoting
genes. Importantly, the expression in each of the cytokines
analyzed was significantly less than that observed in the control,
and comparable to the unchallenged 2RGD sample. NFκβ
suppresses apoptosis by inducing the expression of a number of
anti-apoptotic genes whose products include inhibitors of
apoptosis (IAPs), and TNF receptor associated factor 1 (TRAF1)
and TRAF2.47 The mechanism behind the effect of this material
could be due to the reduced activation and expression of
anti-apoptotic products which protect the cells from apoptosis by
blocking the apoptotic cascade and/or regulate other anti-apoptotic
pathways.48 We studied the materials potential as an effective
anti-mitogenic agent.12a As shown in Figure 5, C, when the
SCC25 cells were cultured on 2RGD compared to 0RGD a
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significant downregulation of CEP55 mRNA expression was
observed, again irrespective of LPS stimulation, as observed in the
protein expression studies. However, when LPS was used to
stimulate cells cultured on 0RGD hydrogel, a significant 50-fold
inhibition of the CEP55 gene was observed with the 2RGD
hydrogel. Therefore, the gene and protein data indicate that the
inclusion of fucoidan allows the hydrogel to act as a powerful
inhibitor of cytokinesis and the uncontrolled cell proliferation
associated with this type of cancer, and potentially many others.
We have shown for the first time that the self-assembly process is
able to present a bioactive macromolecule, the anti-inflammatory
polysaccharide fucoidan, so that the scaffold provides a non-toxic,
biocompatible, yet potent environment to potentially treat a range
of pro-inflammatory cancers. Future work in our laboratory will
extend this study to other cell lines, and in-vivo studies.We suggest
that this method to form materials can easily be adapted to treat a
range of other disease states. We foresee that this simple yet
powerful approach will develop further to allow researchers the
convenient fabrication of inexpensive but complex materials
which can be easily directed toward specific therapeutic outcomes.
Appendix A. Supplementary data
Supplementary data to this article can be found online at
http://dx.doi.org/10.1016/j.nano.2016.01.009.
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 ABSTRACT 
Viral vector gene delivery is a promising technique for the therapeutic administra-
tion of proteins to damaged tissue for the improvement of regeneration outcomes
in various disease settings including brain and spinal cord injury, as well as
autoimmune diseases. Though promising results have been demonstrated, 
limitations of viral vectors, including spread of the virus to distant sites,
neutralization by the host immune system, and low transduction efficiencies
have stimulated the investigation of biomaterials as gene delivery vehicles
for improved protein expression at an injury site. Here, we show how N-
fluorenylmethyloxycarbonyl (Fmoc) self-assembling peptide (SAP) hydrogels, 
designed for tissue-specific central nervous system (CNS) applications via
incorporation of the laminin peptide sequence isoleucine–lysine–valine–alanine–
valine (IKVAV), are effective as biocompatible, localized viral vector gene delivery
vehicles in vivo. Through the addition of a C-terminal lysine (K) residue, we 
show that increased electrostatic interactions, provided by the additional amine 
side chain, allow effective immobilization of lentiviral vector particles, thereby
limiting their activity exclusively to the site of injection and enabling focal gene
delivery in vivo in a tissue-specific manner. When the C-terminal lysine was 
absent, no difference was observed between the number of transfected cells, the
volume of tissue transfected, or the transfection efficiency with and without the
Fmoc-SAP. Importantly, immobilization of the virus only affected transfection 
cell number and volume, with no impact observed on transfection efficiency.
This hydrogel allows the sustained and targeted delivery of growth factors post
injury. We have established Fmoc-SAPs as a versatile platform for enhanced 
biomaterial design for a range of tissue engineering applications. 
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1 Introduction 
Viral vector gene delivery plays a significant role in 
the development of therapeutic treatments for various 
diseases including cancer, autoimmune diseases, and 
neurodegenerative diseases [1, 2]. In particular, with 
limited capacity for self-repair in the brain and spinal 
cord, the delivery of neurotrophins to damaged central 
nervous system (CNS) has shown significant poten-
tial in delaying disease progression and promoting 
regeneration [3, 4]. Neurotrophic support provided to 
cells in vivo by various growth factors and cell-signaling 
molecules (such as brain-derived neurotrophic factor 
[5], nerve growth factor [6], and glial cell-derived 
neurotrophic factor [7]) can slow progressive neuro-
degeneration in disorders including Parkinson’s disease 
and motor neuron disease. Evidence suggests that 
this approach can also limit the size of the injured 
area by protecting the surrounding parenchyma from 
secondary degeneration in acute insults such as stroke 
or traumatic brain injury, thereby improving the overall 
capacity for CNS regeneration [3]. 
Current strategies in growth factor delivery, however, 
are challenged by their short half-life, difficulty in 
penetrating the blood brain barrier, and susceptibility 
to enzymatic degradation, thereby requiring high con-
centrations of growth factors to achieve therapeutic 
benefit [8]. These limitations make the delivery of 
soluble growth factors, typically by invasive and 
cumbersome infusion kits, both inefficient and expen-
sive [9]. As a result, viral vector gene delivery has been 
investigated as a means to achieve long-term delivery 
of neurotrophic factors at a site of injury through the 
introduction of DNA into cells for localized protein 
expression [10–14]. This approach overcomes the 
challenges presented by the delivery of soluble proteins, 
by providing a targeted source of growth factors for 
the neuroprotection of cells in and surrounding the 
injury site. Though there has been success in delivering 
genetic material for targeted therapeutic protein 
expression using viral vectors [3], there is a need to 
improve this technology with a localized and efficient 
gene delivery method for future clinical applications 
[1, 15]. For this reason, the use of biomaterials as so-
phisticated tools to overcome the issues associated with 
viral vectors has garnered significant attention [1]. 
Rationally designed biomaterials are powerful tools 
for regenerative medicine [16], primarily as adjuvant 
scaffolds that mimic the physical and biochemical 
properties of the extracellular microenvironment [17], 
such as those required to support neural cells for CNS 
repair [18]. Furthermore, they can be engineered to 
incorporate viral vectors for delivery of genetic material 
through encapsulation methods, including the use  
of nanoparticles and microspheres [19, 20], and/or 
attached via chemical functionalization [21, 22]. The 
covalent and/or non-covalent attachment of viral 
vectors [23–25] encourages binding of the vector to 
the material to limit vector spread, shield the vector 
from neutralization by the host immune system, and 
increase transduction efficiency [1]. 
Previous research has demonstrated that amine 
(–NH2) moieties can enhance virus adsorption and 
cell attachment to the biomaterial surface, resulting in 
improved transduction efficiency [26]. This observation 
was attributed to the presence of positively charged 
amine (–NH3+) moieties reducing the electrostatic 
repulsion between the negatively charged membranes 
on the viral capsid and cell surface, enhancing the 
ability of the virus to attach to the cell membrane  
and deliver its genetic material [26]. Such examples 
highlight the utility of biomaterials as viral vector 
delivery vehicles. Recently, self-assembling peptides 
(SAPs) have also been demonstrated to effectively 
deliver genetic material to human mesenchymal stem 
cells in culture via recombinant adeno-associated virus 
[27]. However, the RADA16 SAP [28] used presents 
no biofunctionality, nor any capacity to immobilize 
the virus for controlled release. Here, we design a 
multifunctional biomaterial for both integrated tissue 
specificity and superior vector delivery ensuring 
improved overall tissue regenerative outcomes. 
N-Fluorenylmethyloxycarbonyl (Fmoc)-peptides are 
a class of SAPs known to self-assemble through a 
robust mechanism driven by the intermolecular sharing 
of Δ electrons between Fmoc protecting groups, and 
stabilized by the antiparallel Ά-sheet interactions of the 
protected peptide sequence, a mechanism known as 
Δ-Ά self-assembly [29]. These assemblies take the form 
of hollow fibrils, measuring ~10–30 nm in diameter and  
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microns in length, that orientate themselves longitu-
dinally into a network of interconnected bundles, 
forming a structural mimetic of the extracellular 
matrix [30]. We have shown that the mechanical 
properties of these Fmoc-SAPs can be easily tailored 
for tissue-specific applications through adjustment of 
the rate of assembly as well as the ionic concentration, 
without disturbing the nanofibrous morphology [31]. 
The biocompatibility of Fmoc-SAPs has been demon-
strated across a range of sequences, and we have 
shown that optimal biocompatibility and functionality 
of the Fmoc-SAPs requires the incorporation of 
bioactive peptide sequences [30, 32–34]. Previously, 
in a demonstration of the utility of these materials in 
a neural context, we incorporated the laminin-based 
isoleucine–lysine–valine–alanine–valine (IKVAV) 
sequence (known to promote neuron survival, neural 
differentiation, and neurite extension [35]) into an 
Fmoc-SAP system [36], as we do again here, and have 
validated its performance in vivo [34]. This capacity 
to concomitantly present a bioactive peptide sequence 
at high density for directing cell behavior while  
also providing structural support through the self- 
assembled matrix makes Fmoc-SAP scaffolds a highly 
sophisticated class of biomaterials, ideal for tissue 
engineering in the CNS. 
In this study, we hypothesized that these scaffolds 
could be used to nonspecifically immobilize viral 
vectors via reversible, noncovalent interactions between 
the SAP scaffold and the viral membrane by taking 
advantage of the chemical flexibility afforded via 
careful selection of the amino acids within the peptide 
sequence. As proof of principle, we used the pre-
viously designed Fmoc-DDIKVAV to deliver mCherry 
lentivirus in vivo, investigating its capacity for localized 
viral vector gene delivery. We subsequently improved 
on this design with the development of a second 
Fmoc-SAP, Fmoc-DDIKVAVK, engineered for the 
high-density presentation of –NH2 functional groups 
at the C-terminus of the peptide. We show that by 
increasing the electrostatic interactions available for 
binding, we can enable focal gene delivery by limiting 
viral activity to the site of the hydrogel injection. 
Such technology could hold significant potential for 
the sustained and targeted delivery of growth factors 
to aid in tissue repair.  
2 Experimental 
2.1 Solid-phase peptide synthesis 
Fmoc-SAPs were synthesized manually by solid-phase 
peptide synthesis (SPPS) as previously described  
[34]. SPPS was performed in a rotating glass reactor 
vessel at 0.4-mmol scale. Fmoc-protected amino acids, 
hydroxybenzotriazole, O-benzotriazole-N,N,N’,N’- 
tetramethyl-uronium-hexafluoro-phosphate, and Wang- 
based resins were purchased from GL Biochem (China). 
All other chemicals were purchased from Sigma- 
Aldrich. 
2.2 Fmoc-self-assembling peptide hydrogel 
preparation 
To prepare the Fmoc-SAP hydrogels, 10 mg of peptide 
was dissolved in 100 ΐL deionized water and 75 ΐL 
0.5 M sodium hydroxide (NaOH). Hydrochloric acid 
(HCl, 0.1 M) was then used to reduce the pH of the 
peptide solution. HCl was added drop-wise until the 
solution reached ~pH 7.4 and formed a self-supporting 
hydrogel. The final volume of HCl added varied 
between 100 and 150 ΐL. Finally, the gel was made 
up to a final concentration of 20 mg/mL by addition 
of phosphate-buffered saline (PBS). The solution was 
vortexed throughout the entire procedure.  
2.3 Transmission electron microscopy (TEM) 
TEM images were obtained using a HITACHI HA7100 
TEM. A LaB6 filament at 100 kV was used. Negative 
stains were performed to image the Fmoc-SAP samples 
as previously described [34].  
2.4 Atomic force microscopy (AFM) 
AFM was performed using a MultiMode 8 (Bruker 
BioSciences Corporation, USA) operated in peak force 
QNM with a scan size of 10 ΐm. Highly ordered 
pyrolytic graphite (HOPG) substrates (SPI, USA) were 
used for sample preparation. Fmoc-SAP hydrogel 
(15 ΐL) was applied to the HOPG substrates. Scanasyst- 
air probes with silicon tip on nitride lever (Bruker 
BioSciences Corporation) were used. 
2.5 Fourier transform infrared (FTIR) spectroscopy 
For FTIR spectroscopy, 30 ΐL of Fmoc-SAP hydrogel 
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sample at 20 mg/mL was placed on the single reflec-
tion diamond. An Alpha Platinum Attenuated Total 
Reflectance FTIR (Bruker Optics) was used to obtain 
scans from 1,550–1,750 cmƺ1, corresponding to the 
amide I region. A background scan of deionized water 
was subtracted from the hydrogel data. 
2.6 Circular dichroism (CD) 
Fmoc-SAP hydrogels, prepared as described above at 
20 mg/mL, were diluted at 1:200 in deionized water 
for CD. Approximately 400 ΐL was placed in the 
cuvette. Deionized water was used as the background 
scan and subtracted from the hydrogel CD data. All 
scans were taken from 350 to 170 nm at a step size  
of 1 and 1-nm bandwidth by using a Chirascan CD 
Spectrometer (Applied Photophysics Limited). 
2.7 Rheology 
A Kinexus Pro+ Rheometer (Malvern) was used to 
assess the viscoelastic properties of the previously 
prepared Fmoc-SAP hydrogels at 20 mg/mL with a 
20-mm rough flat plate and solvent trap geometry. 
Approximately 200 ΐL of the hydrogel sample was 
placed on the geometry. A frequency sweep was 
performed from 0.1–100 Hz using an oscillatory strain 
of 0.1% at a 0.2-mm gap size. 
2.8 Determination of lentiviral release and 
immobilization 
To determine successful immobilization of the mCherry 
lentivirus, release of mCherry lentivirus from the two 
Fmoc-SAP hydrogels was compared. Samples (100 ΐL) 
of Fmoc-SAP hydrogels at 20 mg/mL were mixed with 
1 ΐL of mCherry lentivirus (titer at 9.28 × 1010 copies/mL; 
GeneCopoeia) and placed in a 96-well plate. PBS 
(200 ΐL) was placed on top of the gel, and the plate 
was placed in an incubator (37 °C, 5% CO2). The PBS 
was then collected and replaced with fresh PBS every 
24 h for 5 days. The PBS supernatant was stored in a 
freezer until ready for analysis by an enzyme-linked 
immunosorbent assay (ELISA). An HIV Type 1 p24 
Antigen ELISA 2.0 kit (ZeptoMetrix) was used to 
measure the amount of mCherry released. The ELISA 
was performed as per the manufacturer’s instructions. 
2.9 Implantation of mCherry virus with Fmoc-SAP 
The Florey Institute of Neuroscience and Mental 
Health animal ethics committee approved all animal 
experiments with procedures conducted in accordance 
with the Australian National Health and Medical 
Research Council’s published Code of Practice for the 
Use of Animals in Research. Adult Swiss mice were 
housed with a 12-h light/dark cycle and ad libitum 
access to food and water. Mice received stereotaxic 
implants of mCherry lentivirus alone (n = 6) or 
mCherry virus in the presence of Fmoc-DDIKVAV 
(n = 6) or Fmoc-DDIKVAVK (n = 6). Isoflurane (5%) was 
used to induce anesthesia, and 2% isoflurane was 
maintained for the duration of surgery. Mice were 
placed into a stereotaxic frame and a craniotomy 
performed for microinjections into the underlying 
striatum (coordinates: anterior +1.0 mm and lateral 
ƺ2.3 mm, relative to Bregma). A fine-pulled micro-
pipette coupled to a Hamilton syringe was used to 
inject virus or virus with Fmoc-SAP at a depth of 
3.2 mm below the dura surface. For control animals, 
1 ΐL of mCherry (109 UI/mL) was diluted in 1 ΐL sterile 
PBS and the total 2-ΐL suspension was implanted. 
Alternatively, the virus was mixed at a 1:1 ratio with 
either of the Fmoc-SAPs. After 21 days, mice were 
killed by an overdose of sodium pentobarbitone 
(100 mg/kg) and transcardially perfused with warm 
saline followed by 4% paraformaldehyde (PFA). After 
removal, mouse brains were post-fixed for 2 h in 4% 
PFA. Following fixation, brains were cryopreserved 
in a 30% sucrose solution overnight. The brains  
were coronally sectioned (40 ΐm at a 1:12 series)  
and immunohistochemistry against red fluorescent 
protein (rabbit anti-RFP, 1:1000, Rockland, USA) was 
performed to amplify the mCherry signal, using 
previously described methods [37]. Cell counts for 
mCherry virally infected cells (mCherry+), transduction 
volume, and density measurements were performed 
on a Leica microscope (Leica CTR6000) using LAS 
software. One-way ANOVAs with Tukey’s post-hoc 
tests were used to identify statistically significant 
changes between groups. Statistical significance was 
set at P < 0.05. Data represent the mean ± standard 
error of the mean (SEM). 
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3 Results and discussion 
3.1 Material characterization of the lysine- 
functionalized self-assembling peptide 
An initial titration was performed to investigate any 
shifts in the apparent pKa of the newly derived Fmoc- 
DDIKVAVK resulting from the addition of a K residue 
at the C-terminus, and the effect this could have on the 
pH of gelation (Fig. 1(a)) [36]. Although the addition 
of the K residue was observed to shift the pKa (from 
~7.0 to ~7.8), it indicated that self-assembly of this 
SAP could take place under physiological conditions 
(pH ~7.4). This was confirmed when both Fmoc- 
DDIKVAV and Fmoc-DDIKVAVK formed clear, self- 
supporting hydrogels at pH ~7.4 using the pH switch 
method previously described (Fig. 1(b)) [34]. 
The mechanical properties of both hydrogels were 
compared using parallel plate rheometry. Here, both 
gels demonstrated viscoelastic properties characteristic 
of previously described Fmoc-SAP hydrogels, where 
the storage modulus (G’) is greater than the loss 
modulus (G”) and shows only a weak dependence on  
frequency (Figs. 1(c) and 1(d)) [36]. Fmoc-DDIKVAVK 
appeared to be a slightly stronger material than Fmoc- 
DDIKVAV (G’ = 10,500 and 6,500 Pa, respectively), 
most likely the consequence of increased electrostatic 
interactions. The higher pKa Fmoc-DDIKVAVK 
required more HCl addition to achieve gelation at 
physiological pH. The positively charged lysine groups 
attract negatively charged chloride ions from solution, 
which themselves attract further lysine groups attached 
to other fibrils. This increased electrostatic interaction 
enables stronger supramolecular interactions between 
the aligned fibrils, increasing the effective points of 
entanglement and resulting in a more rigid nano-
fibrous network [31]. 
AFM demonstrated that a microscale network was 
formed by both hydrogels, confirming that although 
the addition of a K residue shifted the pKa slightly, 
self-assembly of the nanofibrous structures that 
underpinned the hydrogel was maintained at phy-
siological pH (Figs. 2(a) and 2(d)). This modification 
in supramolecular ordering was further visualized 
using TEM, with Fmoc-DDIKVAVK exhibiting a higher  
 
Figure 1 Fmoc-DDIKVAVK forms a hydrogel under physiological conditions. (a) Titration curve for Fmoc-DDIKVAV (open circles) 
and Fmoc-DDIKVAVK (closed circles) showing a slight shift in pKa (Fmoc-DDIKVAV: dashed line; Fmoc-DDIKVAVK: solid line) that 
correlates with the expected pH range of self-assembly. (b) An inversion test demonstrates the gelation of the two Fmoc-SAPs using a 
pH switch. Rheological analysis for (c) Fmoc-DDIKVAV and (d) Fmoc-DDIKVAVK. Closed circles = G'; open circles = G". 
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degree of alignment of the nanofibers compared to 
the more branched arrangement of Fmoc-DDIKVAV 
(Figs. 2(b) and 2(e)). 
Finally, the effect of the addition of a K residue  
on the Δ-Ά assembly mechanism was characterized 
spectroscopically, using FTIR and CD. The FTIR spectra 
showed major peaks at 1,630 cmƺ1 and minor peaks  
at 1,690 cmƺ1, representative of antiparallel Ά-sheets 
formed by hydrogen bonding between the peptide 
sequences (Fig. 2(g)) [36]. The CD spectra further 
supported the FTIR data, with a transition at 200 nm 
indicative of Ά-sheets in both Fmoc-DDIKVAV and 
Fmoc-DDIKVAVK (Fig. 2(h)) [29]. Importantly, the  
wavelength of the minima was not affected but 
increased in magnitude, indicating that the addition 
of the K residue did not affect the intermolecular Δ-Ά 
interactions, but did promote increased supramole-
cular ordering of the fibrils, as observed by TEM and 
AFM [36]. 
3.2 Assessment of virus retention in self-assembling 
hydrogels 
Satisfied that the additional K residue was not 
adversely impinging on the assembly process, we 
proceeded to evaluate the material as a viral vector 
gene delivery vehicle. We blended lentiviruses into  
 
Figure 2 Microscopy images of Fmoc-SAPs show the nanofibrous structure of the gels, with spectroscopy confirming that the
underlying ʌ-ȕ self-assembly mechanism is maintained with the addition of a K residue. A cumulative release profile confirms lentivirus
immobilization in the presence of K. Fmoc-DDIKVAV nanofibrous network shown in (a) AFM image and (b) TEM image. (c) TEM 
image of lentivirus (green) embedded within the branched arrangement of the individual fibers, inset shows lentivirus alone. (d)–(f)
Corresponding images for Fmoc-DDIKVAVK. Scale for AFM = 1 ȝm, TEM = 200 nm. (g) FTIR and (h) CD for Fmoc-DDIKVAV (solid 
line) and Fmoc-DDIKVAVK (dashed line). (i) A cumulative release profile for Fmoc-DDIKVAVK (closed circles) and Fmoc-DDIKVAV 
(open circles) over 5 days. 
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preformed Fmoc-SAP hydrogels, and subsequently 
allowed them to reform gels at room temperature. 
Initial TEM images showed the lentiviral particles 
(80–100 nm in diameter) visibly embedded within the 
nanofibrous assembly of both Fmoc-SAPs (Figs. 2(c) 
and 2(f)). To investigate the retention of the lentiviral 
particles within the Fmoc-SAP scaffolds, and whether 
increased retention was induced by the additional 
positively charged residue, the release of the virus 
from the gels (in a static, physiological environment) 
was measured using an HIV-1 p24 antigen ELISA. 
Measured absorbance values were interpolated using 
a calibration curve of standard concentrations within 
the detection limits of the instrument and data above or 
below these limits were approximated as the minimum 
or maximum of the detection range, respectively. 
Fmoc-SAP hydrogels (100 ΐL) were again mixed 
with the lentivirus and placed in a 96-well plate with 
200 ΐL of PBS placed on top of each gel-virus sample. 
The plate was left in an incubator (37 °C, 5% CO2) and 
200 ΐL of PBS was removed and replaced every 24 h 
for 5 days. The isolated supernatant at each time 
point was analyzed with ELISA. The results showed  
an increase in lentiviral particle retention in the 
K-functionalized peptide hydrogel compared to 
Fmoc-DDIKVAV over 5 days, as revealed by the 
reduced detection of HIV-1 p24 (viral particles) in the 
supernatant (Fig. 2(i)). This result indicates that the 
addition of a positively charged K residue resulted in 
effective immobilization of the majority of the viral 
particles within the Fmoc-DDIKVAVK hydrogel (Fig. 3). 
This is important for the broad applicability of this 
method. Here, we have used a lentiviral vector as proof 
of concept; however, immobilization via electrostatic 
interactions with the negatively charged viral capsule 
could be utilized for any viral capsule such as adeno- 
and retroviruses.  
3.3 In vivo assessment of self-assembling hydrogels 
as viral vector gene delivery vehicles 
Upon confirmation of viral vector immobilization  
in Fmoc-DDIKVAVK hydrogels, we investigated the 
capacity of the Fmoc-SAP to localize viral vector 
delivery in vivo. mCherry lentivirus was loaded into 
the Fmoc-DDIKVAV and Fmoc-DDIKVAVK hydrogels, 
prior to stereotaxic injection into the mouse brain 
 
Figure 3 Charge-based immobilization of lentivirus within Fmoc self-assembling peptides is achieved through peptide functionalization
with a K residue. When a K residue is added to the laminin-based self-assembling peptide sequence, Fmoc-DDIKVAV, the positive charges
from the –NH2 side groups immobilize the lentiviral vector via electrostatic interactions. This results in retention of the vector within the
nanofibrous Fmoc-SAP network resulting in localized gene delivery to cells at the injection site. When no K is present, the virus is released
from the Fmoc-SAP hydrogel. (TEM scale bar = 200 nm) 
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(striatum) and compared to delivery of virus alone. 
The Fmoc-SAP hydrogels were injected at a con-
centration of 10 mg/mL, and the amount of viral 
vector-mediated transfection was assessed after three 
weeks. A cell count of transduced (mCherry+) cells 
showed that delivery of the lentivirus in the absence 
of the Fmoc-SAPs resulted in the highest number of 
transduced cells with a statistically significant difference 
in the level of transduction between the Fmoc- 
DDIKVAVK and both of the other groups (Fig. 4(a)). 
Additionally, a difference in volume of the mCherry+ 
area was observed with Fmoc-DDIKVAVK having 
the least mCherry coverage (Fig. 4(b)). There was  
no significant difference observed in the density of 
mCherry+ cells at the site of delivery between the 
three groups (Fig. 4(c)). Importantly, this result indicates 
that the capacity for transfection by the mCherry 
lentivirus was not compromised by the Fmoc-SAP 
hydrogels but simply achieved localized DNA delivery 
to the microenvironment surrounding the material 
without affecting the tropism of the virus. In parti-
cular, the introduction of a K residue resulted in the 
most focal delivery due to immobilization of the 
mCherry virus (Fig. 4(d)). This is noteworthy, as we 
have enhanced the properties of this sophisticated 
minimalist Fmoc-SAP system for our desired appli-
cation in viral vector gene delivery for the CNS. The 
development of this adjuvant scaffold now offers the 
potential to deliver biologically relevant DNA (via 
viral vectors within SAPs) directly at the edge of a 
lesion (for example, post-traumatic brain injury or 
stroke) to enhance cell survival within the penumbra,  
 
Figure 4 (a) Focal delivery of the mCherry lentivirus within an Fmoc-DDIKVAVK gel significantly reduced the number of mCherry+ 
cells in the host striatum. (b) Similarly, the volume of mCherry+ cells within the striatum was reduced with the addition of a K residue,
demonstrating the ability of Fmoc-DDIKVAVK to immobilize the lentivirus and subsequently localize delivery of genetic material.
(c) Consequently, the density of the mCherry+ cells was similar across all groups, demonstrating that the transduction efficiency of
the delivered virus was not compromised by the presence of the Fmoc-SAPs. Data represent the mean + SEM. *P < 0.05, **P < 0.01. 
Chromogenic stain of mCherry+ cells in the mouse brain, illustrating the transduction efficiency following (d) direct viral vector delivery,
(e) viral vector delivery with Fmoc-DDIKVAV, and (f) viral vector delivery with Fmoc-DDIKVAVK. Note the reduced volume of 
transduction with the addition of a K residue (5× magnification) (d’)–(f’), high-power (20×) images of (d)–(f), illustrating transduced 
mCherry. 
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reducing its size and encouraging reinnervation. 
Delivery within the Fmoc-SAP hydrogel will also 
avoid neurite misrouting, antibody neutralization, and 
immune responses that increase as a result vector 
diffusion, as our scaffold will protect the virus from 
the host immune response through localized delivery. 
In addition to Fmoc-SAP’s ability to support cells 
through its nanofibrous architecture, provide high- 
density presentation of bioactive peptides to direct 
cell behavior, and capacity for injection into a void, 
making intimate contact with the surrounding tissue, 
the designed hydrogel can now limit the spread of 
the viral vector to non-target tissues and deliver the 
desired genetic material to cells, providing long-term 
protein expression for therapeutic benefit. 
4 Conclusion 
Though viral vectors have emerged as useful tools 
for the delivery of genetic material, there is a need for 
a delivery mechanism that will shield the viral vector 
from the host immune system to improve transduction 
efficiency and achieve localized long-term therapeutic 
protein expression. In this work, we established the 
suitability of Fmoc-SAPs to focally deliver a viral 
vector into the brain without compromising the 
infectivity of the virus. The addition of a K residue 
demonstrated that the additional –NH2 groups 
resulted in immobilization of the virus within the 
material, achieving localized transduction of the cells 
surrounding the injected Fmoc-SAP. With the added 
versatility of tissue specification through the high- 
density presentation of the laminin-based IKVAV 
sequence, such a material holds exciting promise as a 
valuable tool for continuing advances in gene therapy, 
particularly viral vector gene delivery for tissue 
engineering of the CNS. 
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Background:Tethering proteins onto bioengineered scaffolds enables longterm delivery, however protein stability, release
kinetics, and functionality over time remains unknown.
Results: Tethered proteins remain stable and functional for several months, capable of activating intracellular signaling path-
ways and influencing cell fate.
Conclusion: Tethered proteins are stable and functional long-term.
Significance: Such knowledge may have implications for promoting tissue repair.
Various engineering applications have been utilized to deliver
molecules and compounds in both innate and biological set-
tings. In the context of biological applications, the timely deliv-
ery of molecules can be critical for cellular and organ function.
As such, previous studies have demonstrated the superiority of
long-termproteindelivery, bywayof protein tethering ontobio-
engineered scaffolds, compared with conventional delivery of
soluble protein in vitro and in vivo. Despite such benefits little
knowledge exists regarding the stability, release kinetics, lon-
gevity, activation of intracellular pathway, and functionality of
these proteins over time. By way of example, here we examined
the stability, degradation and functionality of a protein, glial-
derived neurotrophic factor (GDNF), which is known to influ-
enceneuronal survival, differentiation, andneuritemorphogen-
esis. Enzyme-linked immunosorbent assays (ELISA) revealed
that GDNF, covalently tethered onto polycaprolactone (PCL)
electrospun nanofibrous scaffolds, remained present on the
scaffold surface for 120 days, with no evidence of protein leach-
ing or degradation. The tethered GDNF protein remained func-
tional and capable of activating downstream signaling cascades,
as revealed by its capacity to phosphorylate intracellular Erk in a
neural cell line. Furthermore, immobilization of GDNF protein
promoted cell survival and differentiation in culture at both 3
and 7 days, further validating prolonged functionality of the
protein, well beyond the minutes to hours timeframe observed
for soluble proteins under the same culture conditions. This
study provides important evidence of the stability and function-
ality kinetics of tethered molecules.
Soluble proteins in their natural physiological environment
execute their function and are then degraded by enzymes, oxi-
dation, hydrolysis, and other reactions over relatively short
periods of time, thereby losing their original bio-functionality.
As such, repeated synthesis and delivery from the local environ-
ment is required for ongoing activity (1).When soluble proteins
are extrinsically introduced in vivo to influence cellular
responses (e.g. to promote tissue repair or influence disease
progression) they are also only present for short periods of time
(typically minutes to hours), due to diffusion into the local
physiological environment and degradation. Hencemethods of
ongoing delivery must be employed which typically rely on the
use of cumbersome catheters and infusion pumps. Conse-
quently there is increasing interest to develop improved meth-
odologies to enable the stable delivery of molecules and pro-
teins, and to ensure these factors can be administered in
temporally and spatially appropriate manners.
Work by us andothers has already demonstrated that protein
immobilization onto bioengineered scaffolds can provide
means to control the localization of biologicalmolecules, create
longer lasting stimuli, and can be controlled by way of substrata
(scaffold) degradation. We demonstrated that when tethered
onto electrospun nanofibrous scaffolds both brain-derived
neurotrophic factor (BDNF)4 and glial-cell derived neu-
rotrophic factor (GDNF) were capable of promoting neural
stem cell proliferation and influencing differentiation in vitro to
a greater extent than culturing cells in the presence of soluble
protein (2, 3). Furthermore, we showed that tethered GDNF
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maintained long-term biofunctionality in vivo, supporting the
survival, differentiation, and integration of transplanted neural
stem cells for up to 28 days (3). Work by others has similarly
demonstrated the benefit of tethered proteins. By way of exam-
ple, photochemically bound nerve growth factor on micropo-
rous poly(2-hydroxyethylmethacrylate) was shown to encour-
age neurite outgrowth of PC12 cells (4); methacrylamide
chitosan immobilized with rat interferon- promoted neural
differentiation of adult neural stem/progenitor cells (5, 6); and
tethered epidermal growth factor (EGF) on poly(methyl meth-
acrylate)-graft-poly(ethylene oxide) significantly enhanced
mesenchymal stem cell (MSC) spreading and survival com-
pared with saturating concentrations of soluble EGF (7).
Despite evidence for the benefit of immobilized proteins, lit-
tle attention has been paid to the amount of protein tethered to
biomaterial surfaces, stability and longevity of tethered pro-
teins, protein degradation rate, the release kinetics of tethered
molecules, activation of intracellular signaling pathway, or the
duration of functionality of the protein. Here we investigated
the stability of a tethered protein, GDNF, its activation of
intracellular signaling pathway, and its functionality using
primary cultures isolated from the developing ventral mid-
brain, enriched with dopaminergic neurons. GDNF has been
shown to promote the survival, differentiation, and neurite
growth, most notably of dopaminergic neurons in vitro and in
vivo (8, 9). GDNF has additionally been shown to delay degen-
eration of dopaminergic neurons in Parkinsonian animals as
well as promote the survival and integration of these neurons
following transplantation into animal models of the disease
(10–13). GDNF therefore represents an example whereby pro-
longed protein delivery could have a significant impact on stem
cell populations in vitro, disease progression and disease treat-
ment. Our findings demonstrated long-term presence and
functionality of GDNF, with no evidence of degradation or
leaching, thereby highlighting the potential benefit of tethered
molecules in applications such as tissue repair where prolonged
exposure to trophic proteins is likely to be of benefit.
EXPERIMENTAL PROCEDURES
Synthesis of Electrospun Scaffolds—Electrospun fibers were
produced from polycaprolactone (PCL, Mn 70–90k, Sigma
Aldrich), dissolved in a 3:1 (v/v) solution of chloroform (Chem-
Supply) and methanol (Chem-Supply), respectively. A home
built electrospinner consisting of a syringe pump (KD-100, KD
Scientific, Holliston) and an adjustable DC voltage power sup-
ply (Model RR 50-1.25R/230/DDPM, Gamma High Voltage
Research, Ormond Beach, FL) was employed. Spinning was
performed at room temperature using a 20 kV voltage, a
21-gauge needle, a 2 ml/h flow rate, and a 13 cm working dis-
tance. The duration of electro-spinning and collection onto a
spinning mandrel resulted in two-dimensional (100 um) and
three-dimensional (250–300 m thick) scaffolds, as confirmed
by scanning electron microscopy and previously reported (2).
After collection, the scaffolds were dried in a vacuum oven at
37 °C overnight (Labec Laboratory Equipment, Australia) and
stored in a desiccator prior to use. The scaffolds were then
aminolysed by immersion in 0.05 M ethylenediamine (ED,
Sigma Aldrich), diluted in 2-propanol (Merck Pty, Australia)
for 15 min at room temperature with moderate stirring. The
samples were subsequently washed three times with ice-cold
distilled water, and sterilized in 70% ethanol for 15 min.
Scanning Electron Microscopy—To validate scaffold struc-
ture and assembly, samples were coated with 2 nm of plati-
num by sputtering at 20 mA for 1 min. A scanning electron
microscope was then used to visualize the morphology of the
electrospunmaterials (ZeissUltra Plus FE-S.E., 7.5maperture
at 3 kV). A working distance of 3.4 mm and magnification of
4950 was employed.
Confirmation of Aminolysation—Scaffolds treated with ED
(Sigma Aldrich Pty Ltd) were dissolved in 100 l of tetrahydrofu-
ran and 100 l of PBS, and reacted with 100 l of fluorescamine
(Molecular Probes, 10 mg/ml in acetone). The fluorescence was
detectedusing aplate readerwith ex/em390/475–490 nm. For
the standard curve amine concentrations included 1.49 106,
1.12  106, 7.45  107, 1.49  107, 7.45  10 8, 1.49 
108, 7.45 109, and 0 mol/g of ED in PBS.
Protein Tethering on PCL Scaffolds—For immobilization of
GDNF onto PCL scaffolds, 4-(N-maleimidomethyl) cyclo-
hexane-1-carboxylic acid 3-sulfo-N-hydroxy-succinimide ester
sodium salt (sulfo-SMCC, Sigma Aldrich) was used as a cross-
linker. A 2.5 mg/ml sulfo-SMCC solution in PBS was gently
shaken for an hour at room temperature and then filtered (0.22
mm filter). The PCL scaffolds, after treatment with ED, were
immersed in the prepared sulfo-SMCC solution for 2 h at room
temperature with gentle agitation, then transferred to a recom-
binant human GDNF solution (4 mg/ml; R & D Systems) over-
night at 4 °C. To ensure that GDNF protein was attached and
not simply absorbed onto the scaffolds some scaffolds were
vortexed in PBS for minutes following protein immobilization.
Amounts of tethered protein, stability, and functionality were
compared between: PCL scaffolds (PCL), PCL scaffolds teth-
ered with GDNF (PCL_iGDNF), and PCL scaffolds tethered
with GDNF and vortexed (PCL_iGDNF(v)). GDNF was addi-
tionally tethered to aminolysed scaffolds in the presence of arti-
ficial cerebrospinal fluid (aCSF) to confirm stability and func-
tion in a biologically relevant fluid.
Enzyme-linked Immunoabsorbent Assay—Enzyme-linked
immunoabsorbent assays (ELISA)were performed as described
previously (3). In brief, PCL scaffolds,  GDNF attachment,
were incubated in 1mg/ml of goat anti-GDNF antibody (R &D
Systems) containing 5% donkey serum in PBST (PBS contain-
ing 0.05%Tween-20) for 2 h at room temperature. The scaffolds
were washed three times in PBST before being immersed in
anti-goat horseradish peroxidase (HRP, 1:2000 in PBST solu-
tion containing 2% donkey serum) for 1 h. After three washes in
PBST, scaffolds were placed in a 96-well plate where the bound
HRP activity was assessed by color development using TMB
microwell peroxidase system (R &D Systems). 30l of 1 MHCl
was added to each well to stop the reaction, and the absorbance
(at 450 nm) was measured with a microtiter plate reader
(SpectraMax). A standard curve for GDNF was performed
(0–10,000 pg/ml) from which the amount of bioavailable teth-
ered GDNF protein per scaffold could be determined and com-
pared across treatments. To determine the stability of tethered
GDNF over time, scaffold samples were collected immediately
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after protein attachment (day 0) and at 3, 7, 14, 28, and 120 days
after attachment and storage in PBS and aCSF.
To assess whether tethered proteins were susceptible to pro-
teolytic degradation of tethered proteins we treated iGDNF
scaffolds with 0.25% trypsin (Invitrogen) for 10 min and com-
pared the amount of GDNF present on PCL to non-trypsin-
treated iGDNF scaffolds. Collected scaffolds and supernatant
were stored at 80 °C until determination of protein levels by
sandwich ELISA.
BET Surface Area Analysis of PCL Scaffolds—Brunauer-
Emmett-Teller (BET) surface area analysis was performed
using a micromeritics TriStar II surface area and porosity
instrument to determine the surface area of the scaffolds (14),
and subsequently the amount of GDNF tethered onto the PCL
surface. 45 mg of untreated polymer scaffold was loaded into a
dry 0.95-cm diameter sample tube and degassed under vacuum
(0.15–0.3mbar) at room temperature for 7 days on amicrome-
ritics VacPrep 061 sample degas system. The degassed sample
mass was determined to be 43 mg. The sample tube was then
loaded into the instrument for adsorption analysis of nitrogen
gas in a liquid nitrogen bath. The specific surface area was
determined to be 3.0050 m2/g. The weight of the punch biop-
sies (0.6 cm in diameter) on which GDNF was attached, and
cells cultured, was 0.80 mg so the absolute surface area was
0.0008 g 3.0050 m2/g 0.0024 m2 24 cm2.
Immunoblotting—The dopaminergic neural stem cell line,
SN4741, was cultured in DMEM, 10% FBS, L-glutamine (2mM),
penicillin/streptomycin (50 units/ml), and glucose (0.6%). For
analysis of intracellular GDNF signaling, 100,000 cells were
seeded onto 12-well plates or PCL scaffolds. At 70% confluency
the cells were changed into serum-free media with or without
GDNF (soluble or immobilized). A standard curve of GDNF
treatment (0, 3, 10, 30, 100 ng/ml), using the same cell line, was
performed in parallel to quantify the levels of GDNF activity.
Cells were stimulated with soluble GDNF (sGDNF, 30 ng/ml)
for 60 min or 3 days, and tethered GDNF (iGDNF) for 1 day or
3 days prior to being lysed in ice-cold buffer containing 20 mM
Tris-Cl, pH 7.5, 150 mM NaCl, 1% Triton X-100, 1% protease
inhibitor mixture (Sigma), 50 mMNaF, and 0.2 mMNa3VO4 for
20 min on ice. Lysates were centrifuged at 14,000 rpm for 20
min at 4 °C to collect supernatants. Protein was quantified
using the bicinchoninic acid assay kit (Pierce) using bovine
serum albumin standards.
Protein (50 g) was electrophoresed through 12.5% SDS-
polyacrylamide gels and transferred to Immobilon PVDF-FL
membrane (Millipore).Membranes were blockedwith 5% skim
milk in Tris-buffered saline with Tween-20 (TBST), pH 8.0, for
30min and incubated withmouse pErk1,2 (1:2,000, #9106, Cell
Signaling Technology) and rabbit total Erk1,2 (1:1,000, #9102,
Cell SignalingTechnology) antibodies in 3%BSA inTBSTover-
night at 4 °C. Blots were washed 3 in TBST for 10 min and
incubated with IRDYe 680 and 800CW-conjugated secondary
antibodies (1:10,000) followed by 3 washes in TBST for 10
min and detected using the Odyssey Classic infrared imaging
system. Membranes were then stripped and re-probed with
mouse anti -actin (1:5000, Sigma). Blots were quantified by
taking the ratio of pErk/Erk bands and subtracting background
intensity.
Microdissection and Culturing of Ventral Midbrain
Progenitors—All procedures were conducted in accordance
with the Australian National Health and Medical Research
Council’s published Code of Practice for the Use of Animals in
Research, and experiments were approved by the Florey Neu-
roscience Institute animal ethics committee. C57BL/6 mice
were housed on a 12 h light/dark cycle with ad libitum access to
food and water. Cells used for in vitro culturing were obtained
frommice thatwere timemated overnight, with visualization of
a vaginal plug on the followingmorning taken as embryonic day
(E) 0.5. Ventral midbrain (VM) tissue was isolated at mouse
embryonic day 11.5 (E11.5).
Pregnant mice (E11.5) were anesthetized with isoflurane
prior to cervical dislocation. The collected embryos were
immersed in chilled L15 medium (Invitrogen), the brains
removed and ventral midbrain microdissected. Subsequently
the tissue fragments were incubated in 0.1% DNase and 0.05%
trypsin (in magnesium and calcium free Hank’s buffered saline
solution, HBSS) for 15 min followed by three gentle washes in
HBSS. Finally, the tissue fragments were dissociated in N2
media consisting of a 1:1 mixture of F12 and MEM supple-
mented with 15 mM HEPES buffer, 1 mM glutamine, 6 mg/ml
glucose (Sigma-Aldrich), 1.5mg/ml bovine serumalbumin, and
1% N2 supplement (all purchased from Invitrogen). Cells were
seeded at a density of 175,000 cells/cm2 onto either poly-D-
lysine-coated coverslips (in the presence or absence of soluble
GDNF, 30 ng/ml) or PCL scaffolds ( immobilizedGDNF) and
incubated at 37 °C in 5% CO2 for 3 and 7 days. After 3 days and
7 days, the cells were fixed with 4% paraformaldehyde for 20
min, washed, and stored in PBS containing 0.025% sodium
azide until the time of immunocytochemistry.
Immunocytochemistry—Fixed cultures were incubated over-
night in the following primary antibodies (diluted in 0.3% Tri-
ton X and 5% donkey serum): mouse anti- tubulin (TUJ1,
1:1500, Promega, neuronal marker), and rabbit anti-tyrosine
hydroxylase (TH, 1:400 Pelfreeze, rate-limiting enzyme in dop-
amine synthesis and marker of dopaminergic neurons). Cul-
tures were then washed for 10 min in PBS before the secondary
antibodies were subsequently added and incubated for an hour
at room temperature. Secondary antibodies (1:300 in PBS con-
taining 0.3% Triton X and 2% of goat/donkey serum) were as
follows: DyLight 488 donkey anti-rabbit (Jackson Immuno-
Research), DyLight 549 donkey anti-mouse (Jackson immuno-
Research). Afterwashing in PBS,Hoechst (1:1000 in PBS, nuclei
marker) was applied for 5 min, followed by two washes. The
samples were then slide mounted (Dako) and imaged using a
fluorescence microscope.
Statistical Analysis—For all ELISAs, Western blots, and cell
cultures 3 independent experiments were performed with
three coverslips or scaffolds included for each condition in each
experiment. For assessments of cell viability and differentia-
tion, 10 fields of view per coverslip or scaffold were imaged
using a Zeiss200 inverted microscope (images captured at 20x
magnification). All data are expressed asmean S.D. Student’s
t-tests or one-way ANOVAs with Tukey post-hoc tests were
used to show significant differences between groups with the
level of significance set at 0.05.
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RESULTS AND DISCUSSION
Because of the high surface area to volume ratio, tuneable
surface chemistry and biomimetic environment, electrospun
scaffolds have been applied as a delivery system of biological
molecules to influence cell behavior in vitro and in vivo (15, 16).
As proof of principle, we previously demonstrated that the
three-dimensional structure of electrospunPCL scaffolds could
be exploited to deliver neurotrophins BDNF andGDNF in vitro
to influence cell survival, proliferation, and differentiation (2,
3). Furthermore, implantation of GDNF functionalized scaf-
folds promoted the engraftment of neural transplants for up to
28 days (3). However in these former studies, and others like it
exploring the benefits of tethered proteins, there remains insuf-
ficient knowledge pertaining to the amount of immobilized
protein on the scaffold surface, the stability of the tethered pro-
tein, activation of intracellular signaling pathway, or the bio-
functionality of the molecules over time. In the present study
we examined the stability of immobilized GDNF on electro-
spun PCL scaffolds over 120 days (at 37 °C) and the biological
effects on primary neurons in cultures. Specifically, we exam-
ined the ability of tethered GDNF protein to activate intracel-
lular signaling pathways and to promote survival and dopamin-
ergic differentiation of ventral midbrain cells for up to 7 days in
culture.
Confirmation of Protein Immobilization and Maintained
Presentation without Degradation—The electrospun PCL scaf-
foldswere treatedwith ethylenediamine (ED) to produce amine
groups on the fiber surface for protein (GDNF) attachment
via a crosslinker, succinimidyl 4-(N-maleimidomethyl)-cyclo-
hexane-1-carboxylate (SMCC) (2). The amount of fluores-
camine on the scaffolds after aminolysationwasmeasured to be
1.2  1011 mol/g. Subsequent GDNF attachment onto the
scaffolds (24 cm2), via SMCC crosslinking, was confirmed by
ELISA. Results showed significant levels of GDNF on the scaf-
fold (PCL_iGDNF; 975 115 pg), comparedwith PCL scaffolds
alone (75 45 pg; reflective of background readings) or in the
absence of the SMCC crosslinker (PCL_sGDNF, 180  30 pg;
reflective of physically absorbed GDNF into the scaffold), Fig.
1A. Furthermore we confirmed the benefit of utilizing 3D scaf-
folds, with significantly more (5-fold) GDNF attachment that
observed on 2D PCL electrospun scaffolds (data not shown). In
light of BET analysis, demonstrating a total surface area of 24
cm2 for the 0.6 cm diameter PCL scaffold inserts used for pro-
tein attachment, and a total of 975  115 pg GDNF on the
scaffold, we were able to estimate a total of 41 pg of tethered
GDNF per cm2 of PCL scaffolds.
To confirm that themajority of the protein was tethered, and
not absorbed onto the scaffolds, we vortexed the scaffolds that
had been immobilized with GDNF to shake off any protein
embedded but not tethered to the PCL fibers. Under these con-
ditions, no significant difference was seen in GDNF levels on
PCL_iGDNF and PCL_iGDNF with vortexing (PCL_iGDNF:
975  115 pg, and PCL_iGDNF(v): 650  60 pg, respectively,
Fig. 1A), indicating that the majority of the protein was cova-
lently attached.
To examine the stability of tethered GDNF on scaffolds, the
immobilized scaffoldswere immersed in PBS for up to 120 days,
with PCL scaffold samples collected at day 0 (i.e. upon comple-
tion of protein immobilization), day 3, 7, 14, 28, and 120 days
and supernatant collected at days 1, 3, 7, and 14 days. All sam-
ples were stored at80 °C prior to performing ELISAs. Impor-
tantly, we confirmed that freezing of scaffolds had no effect on
the stability of the protein, with no significant difference
observed in the amount of tethered protein at day 0 from fresh
versus frozen PCL_iGDNF samples (975  115 pg and 810 
100 pg, respectively, Fig. 1, A and B). Examination of
PCL_iGDNF scaffolds, with or without vortexing, showed no
significant difference in GDNF concentration over time (day 0,
3, 7, 14, 28, or 120 days), demonstrating that the protein
remained tethered on the scaffold without degradation for at
least 120 days (Fig. 1B) and thereby highlighting the potential
application of these scaffolds for long-term protein presenta-
tion. Tethered GDNF stability was additionally confirmed in
artificial cerebrospinal fluid (aCSF), with no difference in the
level of GDNF present at 1 and 7 days, or from stability in PBS
conditions (data not shown). Under these various culturing
conditions, the degradation of covalently attached proteins is
likely to occur through surface erosion of the electrospun scaf-
fold. Hence, based upon our previous work, we anticipate pro-
FIGURE 1. Confirmation of protein tethering and stability on electrospun nanofibers. A, immobilization of GDNF on PCL scaffolds (iGDNF) significantly
increases the presentation of protein in culture. The majority of protein was covalently attached as reflected by vortexing to remove excess absorbed protein
(iGDNF(v)). B, amount of GDNF presents on scaffolds at 0, 3, 7, and 14 days after attachment without vortexing (black bars) and at 0, 3, 7, 14, 28, and 120 days
after attachment with vortexing (white bars). No significant decrease was observed in the amount of GDNF on the scaffolds over time, indicative of protein
stability. C, small amount of GDNF was absorbed onto the scaffolds at the time of tethering, which leached from the biomaterial within the first day, and
subsequently degraded. D, treatment of iGDNF scaffolds with trypsin had no effect on the amount of GDNF protein present compared with iGDNF alone,
indicating that tethered GDNF was resistant to proteolysis. Data represent mean S.E. *, p 0.05; **, p 0.01; ***, p 0.001; one-way ANOVA with Tukey
post-hoc test.
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teins are likely to remain present in culture in excess of 12
months (17).
Results from the supernatant revealed that any absorbed pro-
tein leached from the scaffoldwithin 24 h (225 75 pg, Fig. 1C),
andwas comparable to the difference observed between iGDNF
(PCL_iGDNF: 819  100 pg, Fig. 2B) and vortexed iGDNF
(PCL_iGDNF(v): 515  50 pg, Fig. 1B). Interestingly, GDNF
was onlymarginally detectable in the supernatant at 3, 7, and 14
days, indicating that the protein measured in the supernatant
after 24 h had likely degraded, and thereby further highlighting
the benefit of protein tethering for biological applications.
Under biological setting proteases are responsible for the
degradation of soluble proteins. To determine whether immo-
bilized proteins may be susceptible to proteolytic degradation
we treated iGDNF scaffolds with the protease trypsin and com-
pared the amount of GDNF present to non-trypsinized iGDNF
scaffolds. Results showed no significant difference in the
amount of GDNF present following trypsin treatment, indi-
cating that our tethered proteins were resistant to proteoly-
sis (Fig. 1D).
Here we demonstrate the ability to covalently tether GDNF
onto the surface of electrospun PCL scaffolds using the sulfo-
SMCC protein crosslinking reaction. This linking is dependent
on the protein of interest possessing sulfhydryls (thiols, -SH),
which readily react with the maleimide group within the sulfo-
SMCCat pH6.5–7.5.However, it is still possible formaleimides
to react with amines, such as those found on the N terminus of
a protein or peptide (18). At pH	 7.5 the reactivity of maleim-
ides to amines begins to increase and as our reactions were
conducted in PBS (pH 7.4) the same chemistry can be used to
tether a protein that does not possess a free sulfhydryl group,
although the reaction will be slower. However, it should be
noted that hydrolysis of the maleimide group is a possibility
during such a conjugation. In this regard, the ability to tether a
particular proteinmay therefore be dependent on the structure
of the protein to be tethered (i.e. the binding affinity of the
maleimide). Furthermore, while it may be possible to attach a
number of different proteins using this approach it will also be
important to ensure that such crosslinking does not interfere
with the cellular accessibility of the protein surface. In this
regard it may be necessary to assess other crosslinkers for pro-
tein attachment.
The Biofunctionality of Tethered GDNF on Cultured Neurons—
Next we investigated the bio-functionality of tethered GDNF
on aneural stemcell line in culture.Using the dopaminergic cell
line (SN4741), known to express theGDNF receptors, c-ret and
GFRa1, we examined the ability of tethered GDNF to induce
intracellular phosphorylation of ErK1 and ErK2, key compo-
nents of the GDNF-ErK signaling pathway. Comparable levels
of total ErK1 and 2 could be detected in cells cultured on both
PCL and PCL_iGDNF. However, the presence of GDNF signif-
icantly increased the phosphorylation of ErK (Fig. 2A), indicat-
ing that tethered GDNF was capable of mediating intracellular
GDNF signaling. Quantification of band density revealed a sig-
nificant (4.4-fold) increase in the ratio of phospho-ErK to total
ErK following culturing on tethered GDNF, Fig. 2B. Next we
examined the duration of functionality of tethered GDNF.
While soluble GDNF (30 ng/ml) significantly increased pErK
levels after 1 h of stimulation, by 3 days in culture pErK levels
were not significantly different to untreated cultures, reflective
of degradation of the GDNF protein. By comparison, tethered
GDNF resulted in a significant increase in pErK levels at 1 day
and was maintained for 3 days in culture (Fig. 2, C and D).
GDNF has been demonstrated to be sufficient to promote cell
survival, differentiation, and neurite growth of both rodent and
human primary, neural, and pluripotent stem cells (19–26).
FIGURE 2. Phosphorylation of intracellular ERK confirms functionality and longevity of tethered GDNF. A, culturing of SN4741 neural cells on
PCLiGDNF, but not PCL alone, resulted in phosphorylation of intracellular Erk determined by immunoblot analysis, indictive of intracellular signaling in
response toGDNFpresentation.B, ratio of phospho-ERK/total ERK level. TetheredGDNF results in a 4.4-fold increase inpERK/ERK level comparedwith culturing
on PCL. C and D, phospho-ERK levels were significantly elevated after 1 h of stimulation of SN4741 cells with soluble GDNF, but returned to basal levels within
3 days. By contrast culturing cells on iGDNF resulted in maintained elevated pERK levels (at 1 and 3 days in culture). Data represent mean S.E. *, p 0.05, **,
p 0.01; ***, p 0.001, Student’s t test and one-way ANOVA.
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These functions of GDNF have been additionally supported by
increased phosphorylation of Erk. However to achieve these
effects commonly requires repeated protein delivery, particu-
larly in in vivo contexts. Here we demonstrate tethered protein
is capable of activating intracellular Erk to a similar magnitude.
Importantly however, the temporal expression and ability to
maintain signaling (i.e. phospho-Erk levels) is sustainable, and
may therefore present a superior method to prolong functional
protein delivery for in vitro and in vivo applications.
Finally we examined the ability of tetheredGDNF to not only
induce an intracellular response, but also provide a prolonged
effect on neural progenitors in culture. Here we demonstrate
that soluble GDNF (added at the time of cell seeding) increased
cell survival (and proportion of TH dopaminergic neurons) at
3 days, however viability significantly diminished thereafter to
levels not different from untreated controls (Fig. 3, A and B),
presumably reflecting insignificant GDNF levels in the media
beyond this time. By contrast, tethering GDNF onto the scaf-
fold surface significantly increased andmaintained cell survival.
After 3 days in culture, we demonstrated that tethered GDNF
significantly improved the viability of VM cells (Hoechst
labeled non-pyknotic nuclei) in culture compared with cells
cultured on PDL coated plastic (56.37%  0.96 and 44.04% 
1.78, respectively), or PCL scaffolds alone (46.74% 2.86), Fig.
3. Similarly immobilized GDNF enhanced the number of tyro-
sine Hydroxylase immunoreactive (TH) dopaminergic cells
in culture, Fig. 3, B, K–N. After 7 days, cells cultured in the
presence of immobilized GDNF showed no decrease in cell via-
bility or the proportion of dopaminergic neurons compared
with 3 days in culture, demonstrating maintained activity of
FIGURE 3. GDNF immobilization enhances cell viability and differentiation. A, GDNF protein tethering, with or without vortexting, significantly increased
the viability and (B) proportion of tyrosine hydroxylase-immunoreactive (TH) cells in ventral midbrain cultures, compared with soluble GDNF (sGDNF, at 7
days) and culturing under control conditions (PDL-coated plastic, control or PCL scaffolds, PCL). Black bars: 3 days in vitro (DIV), white bars: 7 DIV. Prolonged
culturing (7DIV) resulted in a significant decrease in cell viability and TH cells, effects that could be prevented by maintained presentation of GDNF in culture.
C–F, representative photomicrographs of Hoechst-labeled nuclei,G–J, TUJ neurons, K–N, TH dopaminergic neurons, andO—R, merged images of VM cells
cultured on PDL-coated plastic (control), PCL, PCL with immobilized GDNF (PCL_iGDNF), and PCL with immobilized GDNF and vortexed (PCL_iGDNF(v)). Data
represent mean S.E. *, p 0.05, **, p 0.01, ***, p 0.001. #, p 0.05; ##, p 0.01, 7 days in culture significantly different from same condition at 3 days in
culture (p 0.05). One-way ANOVA with Tukey post-hoc test.
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GDNF, while cells cultured on PCL alone showed significantly
reduced viability over time (Fig. 3). These findings demonstrate
the benefits of maintained presentation and functionality of
tethered protein.
The development of assays to provide long-term presenta-
tion ofmolecules is important for increasing our understanding
of physiological processes. Most in vitro studies focused on
understanding the role of a given molecule in development,
adult homeostasis, or disease rely on application of soluble pro-
teins in culture; effects that are rapid and transient and often do
not reflect the ongoing presentation of a protein that typically
occurs in nature. In addition to providing amore relevant assay
to understand these basal and pathophysiological functions, the
use of tethered proteins can also aid in the development of new
treatments. For example, long term delivery of GDNF in vivo,
by way of protein tethering onto bioengineered scaffolds, such
as microspheres, could be exploited to stall disease progres-
sion in PD, or promote the survival and integration of newly
transplanted dopaminergic neurons for patients. The devel-
opment of such protein/molecule tethering technologies will
be dependent on ongoing validation of protein/molecule sta-
bility and function, using methodologies such as those
described here.
CONCLUSION
Protein immobilization on the surface of tissue engineering
scaffolds has been investigated for their potential to influence
cellular responses in vitro and in vivo. While the benefits of
tethered proteins have been recognized for some years now,
there has been a notable lack of research concentrating on their
stability and bio-functionality kinetics. Here we demonstrate,
by way of GDNF as an example, that tethered proteins on elec-
trospun scaffolds are stable for prolonged periods of time (with
no evidence of degradation), activate intracellular signaling cas-
cades, andmaintain cellular effects (GDNF influencing cell via-
bility and differentiation). These findings hold significant
potential for the use of biomaterials in presenting and main-
taining the activity of proteins in vitro and in vivo, and may
impact on the ability to enhance tissue repair.
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a b s t r a c t
The nanoﬁbrillar structures that underpin self-assembling peptide (SAP) hydrogels offer great potential
for the development of ﬁnely tuned cellular microenvironments suitable for tissue engineering.
However, biofunctionalisation without disruption of the assembly remains a key issue. SAPS present
the peptide sequence within their structure, and studies to date have typically focused on including a sin-
gle biological motif, resulting in chemically and biologically homogenous scaffolds. This limits the utility
of these systems, as they cannot effectively mimic the complexity of the multicomponent extracellular
matrix (ECM). In this work, we demonstrate the ﬁrst successful co-assembly of two biologically active
SAPs to form a coassembled scaffold of distinct two-component nanoﬁbrils, and demonstrate that this
approach is more bioactive than either of the individual systems alone. Here, we use two bioinspired
SAPs from two key ECM proteins: Fmoc-FRGDF containing the RGD sequence from ﬁbronectin and
Fmoc-DIKVAV containing the IKVAV sequence from laminin. Our results demonstrate that these SAPs
are able to co-assemble to form stable hybrid nanoﬁbres containing dual epitopes. Comparison of the
co-assembled SAP system to the individual SAP hydrogels and to a mixed system (composed of the
two hydrogels mixed together post-assembly) demonstrates its superior stable, transparent, shear-
thinning hydrogels at biological pH, ideal characteristics for tissue engineering applications.
Importantly, we show that only the coassembled hydrogel is able to induce in vitro multinucleate myo-
tube formation with C2C12 cells. This work illustrates the importance of tissue engineering scaffold func-
tionalisation and the need to develop increasingly advanced multicomponent systems for effective ECM
mimicry.
Statement of Signiﬁcance
Successful control of stem cell fate in tissue engineering applications requires the use of sophisticated
scaffolds that deliver biological signals to guide growth and differentiation. The complexity of such pro-
cesses necessitates the presentation of multiple signals in order to effectively mimic the native extracel-
lular matrix (ECM). Here, we establish the use of two biofunctional, minimalist self-assembling peptides
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(SAPs) to construct the ﬁrst co-assembled SAP scaffold. Our work characterises this construct, demon-
strating that the physical, chemical, and biological properties of the peptides are maintained during
the co-assembly process. Importantly, the coassembled system demonstrates superior biological perfor-
mance relative to the individual SAPs, highlighting the importance of complex ECM mimicry. This work
has important implications for future tissue engineering studies.
 2016 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
1. Introduction
The successful application of biomaterials to tissue engineering
requires the fabrication of carefully controlled physical and chem-
ical properties presented on biologically relevant scales to promote
cellular regeneration. The most promising candidates for tissue
engineering should provide a three-dimensional (3D) microenvi-
ronment with support for cells as well as biochemical cues to pro-
mote and regulate cell behaviour such as cell adhesion, migration,
proliferation and differentiation [1–3]. These biomaterials must
also exhibit little or no immune response, and be biocompatible
and non-cytotoxic after degradation [1,4]. These requirements pre-
sent signiﬁcant challenges in the design of tissue engineering
materials, and provide the design inspiration for materials that
can be applied to cell regeneration and repair.
Nanostructured 3D matrix scaffolds are some of the most
promising and important biomaterials that have been applied to
tissue engineering [4,5]. Developing design rules for these materi-
als allows them to be purpose-built to provide a suitable cellular
microenvironment that mimics the native ECM [1,2,4,6]. A variety
of scaffolds have been investigated, including electrospun nanoﬁ-
bres [7–9], biologically derived and synthetic hydrogel scaffolds
[10–16], and self-assembling peptide (SAP) hydrogel scaffolds
[4,17,18].
SAP hydrogel scaffolds are a novel class of biomimetic materials
consisting of structure forming low molecular weight peptide
sequences [19,20]. SAP hydrogel scaffolds have proven to be partic-
ularly promising due to their inherent biocompatibility, tuneable
mechanical and chemical properties, ability to ﬁll irregularly
shaped voids, and their porous, nanoﬁbrous structure, making
them ideal candidates for applications in regenerative medicine
[4,21,22].
Recently, the potential of minimalist SAP systems for biomedi-
cal applications has gained much interest, due to their short length
and ability to present biochemical cues at high densities through
careful control of the amino acid sequence, allowing functionality
to be included without sacriﬁcing structure [17,21,23]. Under-
standing the mechanisms underpinning the structural formation
of one group of these systems, ﬂuorenylmethyloxycarbonyl (Fmoc)
SAPs, has enabled the introduction of such biochemical cues via
spontaneous assembly [23,24]. Here, under appropriate conditions,
the Fmoc groups interact through p-p stacking, forming the back-
bone of the Fmoc-SAP structure, and the pendant peptides align
through hydrogen bonding to form a network of stabilising b-
sheets (Fig. 1) [25–27]. These assemblies subsequently stack to
form nanotubes with the peptide sequence exposed at high density
within beta strands [23,26,28]. Individual nanotubes then align
longitudinally, resulting in the spontaneous formation of nanoﬁbre
bundles decorated with the peptide sequence of interest constitut-
ing the hydrogel scaffold [21]. The minimalist nature of Fmoc-SAP
systems is advantageous as they are relatively inexpensive and
quick to produce [21,24]. In addition, the Fmoc moiety itself has
been shown to possess anti-inﬂammatory properties, a valuable
property for the development of adjuvant scaffolds in cellular
applications [29]. While a recent in vitro study has indicated the
cytotoxicity of degradation products from high concentrations of
Fmoc-F and Fmoc-FF due to the poor stability of these systems
[30], and the possible formation of aggregates and nanocrystalline
structures [31,32]; these studies, and recent work by our group
have highlighted the need for optimisation and functionalization,
thereby making these systems suitable for attachment based cell
culture in vitro [33], and neural stem cell transplantation and viral
vector delivery in vivo [34].
Another promising advantage of Fmoc-based SAP systems over
other, longer SAP systems is their heightened potential for biofunc-
tionalisation. Previously, biofunctionalisation of non-Fmoc pep-
tides (such as RADA16) and peptide amphiphiles (PA), achieved
through capping with short bioactive sequences (epitopes), has
shown some promise in eliciting an improved cellular response
in vitro and in vivo [17,35–37]. The capping of PAs with IKVAV in
particular has seen selective promotion of cell differentiation, neu-
rite extension, and neural differentiation, as well as reduced devel-
opment of astrocytes (an inﬂammatory cell within the central
nervous system (CNS)), indicating the formation of an appropriate
cellular microenvironment for tissue engineering, in this case
within the CNS [17,38–40]. While these results are promising,
the relative size of the bioactive epitope to the PAs results in an
inherently low-density presentation of the epitope [21,40,41].
What is more, work on biofunctionalised PAs has shown that den-
sity, rather than dimensionality, of the biofunctional epitope pre-
sentation plays a more important role in cell differentiation and
is likely to play a wider role in the biofunctionality of the intro-
duced material [35,42].
Our previous research has focused on the high-density presen-
tation of RGD and IKVAV epitopes (Fig. 2a & b) [21,43,44]. The
laminin-derived IKVAV and the ﬁbronectin-derived RGD sequences
are common components of the mammalian ECM [21,42,45]. These
Fmoc peptides have been rationally designed to form SAP hydro-
gels at physiological pH [21], allowing for control of various cellu-
lar processes including survival, adhesion, differentiation,
migration and proliferation [4]. Incorporation of these sequences
has enabled us to develop an Fmoc-SAP scaffold that more closely
mimics the ECM, both physically and chemically. However, while
biofunctionalisation of SAP scaffolds represents a signiﬁcant
advancement in the development of cell scaffold materials, cellular
control is somewhat limited in this instance by the presentation of
a single biochemical cue [42].
The combination of multiple signals in a single, homogenous
scaffold offers the potential for a synergistic effect on cellular
response through the improved spatial and chemical arrangement
of multiple bioactive signals [46]. A range of co-assembled sys-
tems, mixed, and self-sorting have been reported [22,47–50], how-
ever, bioactive co-assembly has only previously been investigated
in PA systems, with limited success [46], and in an Fmoc-SAP sys-
tem where a non-gelating Fmoc-RGD molecule was used to deco-
rate ﬁbrils of Fmoc-FF [51]. In each case, the mechanism by
which the SAPs molecularly pack into the ﬁbres is not well under-
stood and the design of such co-assembled systems continues to
prove challenging [52].
Here, we present a ﬁrst step towards the development of truly
co-assembled minimalist bioactive Fmoc-SAP scaffolds for the
high-density presentation of multiple biochemical cues, in this
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Fig. 1. Self-assembly of a minimalist Fmoc-SAP. Individual SAPs consist of an Fmoc group (grey) attached to the end of a short amino acid chain (red). Under appropriate
conditions, the Fmoc groups then stack together while the peptides align, wrapping around to form a SAP nanoﬁbre. These nanoﬁbres then bundle together to form a hydrogel
scaffold. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 2. (a, b) Structural formulae for the bioactive Fmoc-SAP sequences, (a) Fmoc-FRGDF, (b) Fmoc-DIKVAV with (a’ & b’) corresponding TEM images (scale = 200 nm). (c) p-b
Co-assembly process where peptides are mixed prior to gelation and co-assembled via a pH switch method. (d) In contrast, the mixed assembly process results from the
mixing of two previously prepared gels, giving rise to an inhomogeneous hydrogel.
C.C. Horgan et al. / Acta Biomaterialia 38 (2016) 11–22 13
case presenting both RGD and IKVAV in a single, co-assembled SAP
system. In order to conﬁrm the successful formation of co-
assembled structures, we characterised the assembly process
across all length scales; the molecular packing using Fourier trans-
form infrared spectroscopy (FTIR), circular dichroism (CD) spec-
troscopy, and small-angle X-ray scattering (SAXS); the structures
at longer length scales by transmission electron microscopy
(TEM); and the bulk mechanical properties of the hydrogels by rhe-
ological measurements. We considered various co-assembled com-
binations of our two individual Fmoc-SAPs (Fmoc-FRGDF and
Fmoc-DIKVAV) and distinguished the resulting co-assembled
hydrogel structures (Fig. 2c) from both single Fmoc-SAP and paral-
lel mixed Fmoc-SAP systems (Fig. 2d) to show that a unique
homogenous nanoﬁbrous hydrogel was obtained. Crucially, biolog-
ical characterisation of these scaffolds demonstrated the superior
biofunctionality of the co-assembled system over our other SAP
systems, demonstrating the synergistic potential of simultaneously
presenting multiple bioactive epitopes.
2. Materials and methods
2.1. Solid phase peptide synthesis (SPPS)
Fmoc-FRGDF and Fmoc-DIKVAV SAPs were made using solid
phase peptide synthesis (SPPS) [53] in a custom rotating glass reac-
tor vessel at a 0.4 mmol scale as described in [44]. Fmoc protected
amino acids, Hydroxybenzotriazole (HOBt), O-Benzotriazole-N,N,
N0,N0-tetramethyl-uronium-hexaﬂuoro-phosphate (HBTU) and
Wang based resins were purchased from GL Biochem (China). All
other chemicals were purchased from Sigma-Aldrich. Dimethylfor-
mamide (DMF) was dried for a minimum of 2 h prior to use with
4 Å molecular sieves.
2.2. Single Fmoc-SAP hydrogel preparation
Peptide hydrogels were prepared at concentrations of 10 and
20 mg/mL using a method analogous to that described in [44],
using 1.0 phosphate buffered saline (PBS) solution rather than
Hank’s buffered saline solution to take the hydrogels to the appro-
priate concentrations. Mass spectrometry was performed to con-
ﬁrm the desired peptide sequence was synthesised
(Supplementary Fig. 1).
2.3. Mixed Fmoc-SAP hydrogel preparation
The mixed Fmoc-SAP hydrogel consisted of two different single
Fmoc-SAP hydrogels, Fmoc-FRGDF and Fmoc-DIKVAV. In each case,
the single Fmoc-SAP hydrogels were prepared as detailed above.
The mixed Fmoc-SAP hydrogel was then prepared through the
combination of the single Fmoc-SAP hydrogels over vortex.
Fmoc-SAP hydrogels were combined in volumetrically equal ratios,
with vortex mixing used to produce a single, heterogeneous
hydrogel.
2.4. Co-Assembled Fmoc-SAP hydrogel preparation
The co-assembled Fmoc-SAP hydrogel was prepared in a similar
manner to the single Fmoc-SAP hydrogels, however the single pep-
tide used in hydrogel preparation was replaced with two different
peptides, Fmoc-FRGDF and Fmoc-DIKVAV. These peptides were
combined in equal mass ratios to a total mass of 5 mg. Hydrogel
formation was then achieved as detailed in Section 2.2 above.
2.5. Transmission electron microscopy
Negative stain TEM was performed using a 125 kV Hitachi
H7100FA electron microscope with a LaB6 cathode as described
in [44]. Nanoﬁbre dimension and statistical analyses were per-
formed as detailed in Section 3.
2.6. Titration
50 lL of 1 M NaOH was added dropwise to a vial containing
10 mg of peptide while mixed over vortex. Next, 200 lL of DI
H2O was similarly added dropwise over vortex. The pH of the solu-
tion was measured using an Oaktron pH 700 micro pH electrode
(Thermo Scientiﬁc). 10 lL of 0.2 M HCl was added dropwise over
vortex until the hydrogel solution reached pH 3. pH was measured
after addition of each 10 lL of HCl.
2.7. Rheology
Rheological analysis was performed using a Kinexus
Pro + Rheometer (Malvern). Approximately 0.5 mL of hydrogel
sample was placed on a ﬂat plate geometry with solvent trap
(Upper Geometry: PU20 SR1351 SS, Lower Geometry: PLS55
C0177 SS). A gap distance of 0.2 mm was used and multiple fre-
quency sweeps were performed for frequencies ranging from 0.1
to 100 Hz with a 0.1% strain at a constant temperature of 25 C.
2.8. Fourier transform infrared spectroscopy
FTIR was completed using an Alpha Platinum ATR FTIR (Bruker
Optics). 100 lL of peptide hydrogel was placed on the single reﬂec-
tion diamond and the pressure applicator used to adequately
spread hydrogel over crystal surface. Absorbance scans of the
amide I region (1550–1750 cm1) were obtained for each peptide,
and a background buffer scan subtracted.
2.9. Circular dichroism
CD was completed using a Chirascan CD Spectrometer (Applied
Photophysics Limited) from 180 nm to 320 nm with a step size of
0.5 and a 1 nm bandwidth as described in [44]. The resulting data
was averaged and smoothed post-acquisition using software pro-
vided by Chirascan prior to analysis. Hydrogels were diluted 1 in
200 with de-ionized water to reduce scattering [23].
2.10. Small angle X-ray scattering
SAXS was performed using the SAXS/WAXS beamline at the
Australian Synchrotron. Measurements were taken using two dif-
ferent camera lengths: 900 mm and 7000 mmwith an X-ray wave-
length of 1.0332 Å. These camera lengths enabled the scattering
vector (q) to be measured across the range 0.008 –0.7 Å1. The
diffraction pattern was recorded on a Pilatus 1 M detector
(170 mm  170 mm, effective pixel size of 172 l  172 lm), and
processed using the Australian Synchrotron ScatterBrain software.
Hydrogel samples were prepared, as detailed above, two days
prior to testing and stored in eppendorf vials. Prior to sample expo-
sure, PBS backgrounds were loaded into 1.5 mm glass capillaries
and sealed to prevent evaporation. Capillaries were then loaded
into a custom mount designed to enable movement of the capillar-
ies in two dimensions. Two 5-s exposures were taken for each sam-
ple background using the two different camera lengths. PBS
backgrounds were then removed from the capillaries and replaced
with hydrogel samples. Capillaries were then resealed and
remounted for measurement. Multiple 5-s exposures were taken
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for each sample on the two different camera lengths at different
positions along the capillary length.
Repeated measurements for each sample on each camera length
were averaged and the PBS background subtracted using Scat-
terBrain. q calibration was performed using air shot scattering
curves, though the use of capillaries prevented standard intensity
normalisation. To circumvent this issue, intensity normalisation
was performed relative to a known scattering curve for de-fatted
human serum albumin (DFHSA) at a protein concentration of
1 mg/mL. Due to weak scattering at higher q values, the back-
ground was scaled by 0.9 prior to subtraction from the sample
scattering data. Data for each sample on the two different camera
lengths were then combined using IgorPro, though data at the
lower q range (obtained using the 7000 mm camera length)
showed a linear scattering curve for all samples (likely due to
aggregation) and so was discarded. Analysis of the scattering
curves for each sample was performed across the q range 0.01–
0.3 Å1. The intensity of the x-rays scattered from each sample, I
(q), was then compared to a number of theoretical form factors, F
(q), which result from the particle geometry. I(q) can be described
as the product of the number density of scattered objects (np), the
form factor (F(q)), and the structure factor (S(q) = 1, for our dilute
system), which describes interparticle interactions (Eq. (1)).
IðqÞ ¼ npFðqÞSðqÞ ð1Þ
I(q) for each of our samples was compared to form factor mod-
els provided by the National Institutes of Standards and Technol-
ogy (NIST) for use in conjunction with IgorPro, with the quality
of the ﬁt estimated using a chi-squared test [54]. These models
included calculations of np, though structure factors had to be cal-
culated separately. While structure factors are widely used to gen-
erate higher quality models of X-ray scattering intensity, IgorPro
applies an average structure factor approximation, which rests on
the assumption of homogeneous, monodisperse, spherical parti-
cles. As our samples consist of inhomogeneous, polydisperse,
non-spherical particles, the use of an average structure approxima-
tion is inappropriate. Though structure factors for our samples
could be calculated using polymer reference interaction site model
(PRISM) theory, high-quality ﬁts were obtained without the reli-
ance on structure factors and they have hence been excluded from
our calculations of I(q) [55,56].
2.11. Cell culture
Sterile hydrogels for each of the single, mixed, and co-
assembled peptide systems were prepared similar to the non-
sterile hydrogel method previously detailed. However, the sterile
hydrogels were prepared in sterile conditions with PBS replaced
by high glucose Dulbecco’s Modiﬁed Eagle Medium (DMEM) (Life
Technologies, Melbourne, Australia) with 10% of fetal bovine serum
(FBS). 400 lL of each hydrogel was then transferred to a 24-well
plate and placed under UV light for 30 min for sterilisation prior
to seeding with C2C12 mouse myoblasts, a skeletal muscle precur-
sor cell line and commonly used model of myogenesis and skeletal
muscle regeneration [57].
C2C12 skeletal muscle cells were maintained in high glucose
Dulbecco’s modiﬁed Eagle medium (DMEM) (Life Technologies,
Melbourne, Australia) containing 10% fetal bovine serum (FBS), at
37 C with 5% CO2. 10,000 cells in 200 lL of cell culture media were
then seeded onto each hydrogel system, with 3 independent exper-
iments performed in duplicate for each hydrogel system.
2.12. DAPI and Actin Staining
Following 48 h in culture, C2C12 cells seeded on the four
Fmoc-SAP systems were stained with the nuclear stain DAPI (Life
Technologies Australia Pty. Ltd., VIC, Australia) and Phalloidin
(Life Technologies Australia Pty. Ltd., VIC, Australia) an F-actin
stain. Brieﬂy, the upper media in each well was carefully
aspirated and 200 lL of 4% paraformaldehyde (PFA, ProSciTech
Pty. Ltd. QLD, Australia) was added and left at room temperature
for 20 min to ﬁx the cells and the gels. Then PFA was aspirated
and the cells and gels were washed with 200 lL of PBS. Next,
200 lL of 0.1% Triton  100 (ProSciTech Pty. Ltd., QLD, Australia)
in PBS was added into each well and maintained at room temper-
ature for 15 min to permeabilise the cells. Then the cells were
stained with 200 lL of the mixture of DAPI and rhodamine
phalloidin solution (Life Technologies Australia Pty. Ltd., VIC,
Australia) (diluted 200 and 100 times, respectively) at room
temperature for 60 min. DAPI and Rhodamine phalloidin were
used according to manufacturer’s instructions. Stained cells were
observed under a ﬂuorescent microscope (Nikon) at 20. Three
independent experiments in duplicate were performed for each
hydrogel system.
3. Statistical methods
Nanoﬁbre dimensions for each hydrogel were calculated based
on TEM images using ImageJ. A selection of 10 width measure-
ments across different nanoﬁbres were taken from each of two
images, corresponding to different samples of each peptide
system, and a two-tailed T-test used to compare the mean width
values between co-assembled and mixed systems. Nanoﬁbre
widths measured were then compared to the diameters measured
using SAXS.
Nanoﬁbre diameters were similarly modelled using SAXS, with
mean and standard deviation values calculated from the optimal
ﬁtting model using Igor Pro. A two-tailed T-test was used to com-
pare the mean width values between co-assembled and mixed
systems.
4. Results
4.1. Titration
Titration of the single and co-assembled Fmoc-SAP systems
(Fig. 3a) was employed to determine the pKa of the dual peptide
system as a predictor of gelation behaviour. The titration curves
for the single and co-assembled Fmoc-SAP systems displayed mul-
tiple pKa shifts (inﬂection points on the curves in as seen in Fig. 3a),
between pH 7 and pH 9, with the titration curve for the co-
assembled FRGDF-DIKVAV appearing as an average of the titration
curves of the constituent single SAPs, Fmoc-FRGDF and Fmoc-
DIKVAV.
4.2. Transmission electron microscopy
Nanoﬁbrous structure formation and the network bundling for
the mixed and co-assembled FRGDF-DIKVAV system was con-
ﬁrmed with negatively stained TEM (Fig. 3b & c). As expected,
the Fmoc-SAPs yielded nanoﬁbres with consistent morphology
and diameters, with the characteristic nanoscale assemblies
observed for each of the single Fmoc-SAP systems also prominent
in the TEM micrographs of the mixed and co-assembled systems.
The co-assembled system contained nanoﬁbres with width dimen-
sions of 13.1 nm ± 2.2 nm (mean ± standard deviation) (Fig. 3c),
statistically signiﬁcantly different (p = 0.000014) from the mixed
system nanoﬁbres of 9.6 nm ± 2.0 nm (Fig. 3b). The mixed system
nanoﬁbres display similar widths to both the FRGDF and DIKVAV
systems, with width dimensions of 9.2 nm ± 1.4 nm and
C.C. Horgan et al. / Acta Biomaterialia 38 (2016) 11–22 15
9.5 nm ± 1.2 nm respectively. Importantly, these results corrobo-
rate the nanoﬁbre diameters measured using SAXS (Table 1).
4.3. Rheology
Fig. 4 shows the storage moduli (G’) and loss moduli (G”) of the
single, mixed, and co-assembled Fmoc-SAP systems as a function
of applied frequency (Hz). All hydrogels displayed viscoelastic gel
behaviour; with the storage moduli values higher than the loss
moduli values with the range of frequencies measured. Viscoelastic
behaviour remained essentially constant for each of the SAP sys-
tems at 25 C and 37 C (with minor differences displayed for the
mixed and co-assembled SAP systems across the two
temperatures).
For the single Fmoc-SAP systems, the G’ value of Fmoc-DIKVAV
was at 104 Pa (Fig. 4b), in the appropriate range for application to
tissue engineering, while the moduli for Fmoc-FRGDF were much
lower (Fig. 4a). The G’ value of the mixed FRGDF-DIKVAV system
(Fig. 4c) was similar to that of single Fmoc-DIKVAV, whereas the
ratio of G”/G’ (the tan d value) was similar to that of the single
Fmoc-FRGDF system at 0.1–0.13 between 0.1 and 1 Hz. In contrast,
the moduli for co-assembled FRGDF-DIKVAV showed a 20%
reduction relative to Fmoc-DIKVAV, but the tan d was maintained
(Fig. 4d).
4.4. Fourier transform infrared spectroscopy
FTIR spectra of each of the single, mixed, and co-assembled
SAP systems are shown in Fig. 5a. In each case, a major peak at
approximately 1630 cm1 and a minor peak at approximately
1690 cm1.
4.5. Circular dichroism
CD spectra for the single and mixed SAP systems display local
maximum bands at approximately 190 nm and/or local minimum
bands at approximately 218 nm (Fig. 5b). However, the CD spec-
trum for the co-assembled system is inverted, displaying local
minimum bands between 190 nm and 200 nm.
4.6. Small angle X-ray scattering
SAXS was used to determine a physical model of the nanoﬁbres
formed by each of the different SAP systems and identify differ-
ences between the nanoﬁbres formed for each system. To deter-
mine the most suitable form factor model for our systems,
different models were ﬁtted to the experimental SAXS data, using
ﬁtting algorithms included in the NIST IgorPro software (Fig. 6).
TEM images were used to guide initial parameter values for the
cylinder diameter and length, while the scattering length densities
were adjusted to account for the use of these models for SAXS data.
In each case, the optimal ﬁt was achieved using the hollow cylinder
with polydisperse radius form factor model (Fig. 6). The theoretical
form factor model ﬁt to the experimental data for each of the pep-
tide systems enabled the physical properties of the peptide nanoﬁ-
bres to be determined (Table 1). In the single and mixed systems,
the peptide nanoﬁbres exhibit similar core and shell thicknesses
of around 20–25 Å, and similar lengths, on the order of 3000 Å.
However, for the co-assembled system, the mean core radius was
increased to 29.7 Å and the radial shell thickness to 51.9 Å, closely
agreeing with the nanoﬁbre diameters observed in the TEM images
(Fig. 3b and c). Statistical comparison of the nanoﬁbre diameters
modelled using SAXS demonstrated a statistically signiﬁcant
Fig. 3. (a) Titration curves showing shifts in pKa for the individual peptides and FRGDF-DIKVAV combination. TEM images of (b) mixed and (c) co-assembled SAP hydrogels
conﬁrming nanoﬁbre formation (scale = 200 nm).
Table 1
Hollow cylinder with polydisperse radius form factor model parameters for different peptide systems.
Parameter FRGDF DIKVAV Mixed FRGDF-DIKVAV Co-Assembled FRGDF-DIKVAV
Length (Å) 3015 2979 2900 3315
Mean Core
Radius (Å) 24.25 20.65 23.40 29.71
Radial Shell Thickness (Å) 29.52 28.17 27.06 51.88
Radial Polydispersity 0.06 0.10 0.19 0.12
SLD Core (Å2) 1.31  105 1.33  105 1.36  105 1.28  105
SLD Shell (Å2) 9.94  106 9.91  106 9.94  106 9.76  106
SLD Solvent (Å2) 9.52  106 9.49  106 9.54  106 9.49  106
Chi-Squared (v2) *4.40 1.62 1.88 1.02
* Though the v2 value here is high, this ﬁt showed the best v2 value for FRGDF (see Supplementary Table 1).
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increase (>75%) in core radius and shell thickness between the co-
assembled nanoﬁbres and those of the mixed and single SAP sys-
tems (p < 0.0001 in each case), as opposed to the average of the
two observed in self-sorted systems [58].
4.7. Bioavailability investigation of Fmoc-SAP systems through 3D cell
culture
3D cell cultures on the mouse skeletal muscle precursor cell
line, C2C12 myoblasts, were performed for each of the SAP sys-
tems. Following 48 h of culture, myoblasts were visualised with
DAPI (nuclear stain) and rhodamine phalloidin (F-actin stain)
staining (Fig. 7). In each case seeded cells migrated into the gel
matrix, rather than remaining on the surface, indicating the
Fmoc-SAP hydrogels promoted C2C12 migration. Cells seeded onto
the Fmoc-FRGDF hydrogel (Fig. 7a) were mostly mononuclear, with
some multinucleated cells formed. In addition, limited cell spread-
ing was observed. For the Fmoc-DIKVAV hydrogel (Fig. 7b) on the
other hand, a much greater degree of cell spreading was observed,
with many multinuclear cells formed, a few of which were begin-
ning to elongate into myotube-like structures. The co-assembled
FRGDF-DIKVAV hydrogel (Fig. 7d) displayed an even more remark-
able effect on cell morphology, with numerous multinuclear cell
clusters observed, as well as elongated multinucleated myotubes,
which stained intensely for F actin. Unfortunately, the opacity of
the mixed FRGDF-DIKVAV system (Fig. 7c) prevented clear imaging
of the cells in the hydrogel, though it is clear that fewer myotube-
shaped cells have formed in this system than the co-assembled
system.
5. Discussion
This study has demonstrated the capacity of minimalist, func-
tionalised Fmoc-SAPs to undergo co-assembly to form stable,
nanoﬁbrous hydrogel networks with enhanced biofunctionality.
Physical and chemical characterisation of the co-assembled
Fmoc-SAP systems indicate that the underlying assembly
architecture is maintained during the co-assembly process, but
that the nanoﬁbrous network formed is physically and chemically
distinct from the single and mixed Fmoc-SAP systems.
Nanoﬁbrous architecture formation and pH-dependent gelation
by the co-assembled Fmoc-SAP system was conﬁrmed through
titration, TEM, and rheology characterisation studies. The pH
switch-triggered self-assembly of Fmoc-SAPs is determined by
the pKa of the peptide, which, in turn, is dependent on the compo-
sition of the peptide chain [21]. The peptide sequences of both
Fmoc-SAPs was designed to allow assembly at physiological pH.
The assembly of the Fmoc-SAPs is driven by the achievement of
local thermodynamic minima to form a metastable structure
[59]. Self-Sorted systems are usually achieved by having a differ-
ence in pKa to allow the preferential assembly of one or the other
of the component [50]. In this case, however, the pKa of each fmoc-
SAP has been designed in order to achieve assembly under physio-
logical conditions and are closely matched. In each case, pKa shifts
between pH 7 and pH 9 indicate the ability of the system to form a
stable hydrogel at physiological pH (7.4), as was experimentally
conﬁrmed previously [21], with these results indicating the
retained capacity of the Fmoc-SAPs within the co-assembled sys-
tem to form a hydrogel under physiological conditions with no sig-
niﬁcant shifts.
TEM imaging of the nanoﬁbrous networks demonstrated hydro-
gel formation in each case and that co-assembly resulted in nanos-
cale morphologies similar to the individual assemblies (Fig. 3c),
rather than allowing a secondary type of structure to form [60].
Importantly, morphological differences were observed between
the hydrogel-mixed and co-assembled FRGDF-DIKVAV systems,
suggesting that the method of combination plays a role in deter-
mining the overall network structure.
Morphological differences between the mixed and co-
assembled Fmoc-SAP systems were also apparent through differ-
ences in the elastic moduli for each system. The rheological prop-
erties of hydrogels are controlled by a number of parameters,
including nanoﬁbre stiffness, concentration, branching and num-
ber/type of entanglements [61]. Differences in the rheological
Fig. 4. Rheological data for single Fmoc-SAP sequences (a) FRGDF, (b) DIKVAV with comparison to (c) mixed and (d) co-assembled systems at 25 C (black) and 37 C (grey)
(G’ = circles; G” = squares).
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properties of each of the Fmoc-SAP systems therefore enable us to
distinguish between the mixed and co-assembled systems. For the
mixed system, the similarity of the G’ value to that of Fmoc-
DIKVAV and the similarity of the tan d value to Fmoc-FRGDF sug-
gests that the two Fmoc-SAPs co-existed as two separate non-
interactive networks and both contributed to the overall rheologi-
cal properties of the mixed system, which has been observed with
other co-assembled systems [49]. On the other hand, the distinct
moduli for the co-assembled system with a tan d value similar to
Fmoc-DIKVAV suggests that co-assembled FRGDF-DIKVAV is a
cooperative system with modiﬁcation to the ﬁbril interaction,
which inﬂuenced the type/number of entanglements formed, indi-
cating a single aggregated structure exists as opposed to a cooper-
ative network of two distinct components.
For successful in vivo applications as adjuvant cell scaffolds, it is
essential that the hydrogel scaffold closely mimics the native ECM
both in terms of the chemical signal presented and the physical
support provided [40]. The elastic moduli of neural tissue ranges
from 102 to 103 Pa while the moduli for connective and muscle tis-
sues are 104 Pa [62]. As such, Fmoc-SAP hydrogels with elastic
moduli in these ranges have the potential to act as adjuvant
ECM-mimetic cell scaffolds with appropriate properties for tissue
engineering applications [63]. Importantly, these results indicate
that the moduli of the co-assembled system are in the appropriate
range for application to tissue engineering.
Spectroscopic analysis of the Fmoc-SAP systems demonstrates
that the assembly is consistently driven by Fmoc- interactions, sta-
bilised by a range of hydrogen bonds in a hierarchical assembly
[26], supported by the structural similarities observed between
the nanoﬁbrous networks [64]. However, spectral differences
between the co-assembled Fmoc-SAP system and the mixed and
single Fmoc-SAP systems provide further evidence for the distinct
nanoﬁbrous structure formed through co-assembly.
In each case, the FTIR and CD spectra indicate the organisation
of the molecules into a dominant structural ordering. However, the
CD spectrum for the co-assembled system is inverted, a result of
the p-p⁄ Cotton effect from the Fmoc moiety, implying an opposite
chirality of the co-assembled system with respect to the other
peptide systems [65,66]. In addition, broad transitions in the
230–270 nm region for each of the systems (arising from numer-
ous p-p⁄ transitions) indicate the supramolecular alignment of
the peptide nanoﬁbres into a hydrogel scaffold [21]. The large tran-
sitions for the single Fmoc-FRGDF and Fmoc-DIKVAV hydrogels in
this region indicate a high degree of ﬁbre bundling [43]. The same
effect is observed for the mixed and co-assembled SAP systems,
though co-assembled FRGDF-DIKVAV displays smaller transitions
relative to both the single and mixed SAP systems. This could be
due to a reduced number of ﬁbrils present due to a single popula-
tion of heterogeneous structures.
Transitions present in the 180–220 nm region of the CD spectra
for the single and mixed systems indicate the presence of b-sheets.
On the other hand, the co-assembled FRGDF-DIKVAV system dis-
played a unique CD spectrum in this region, demonstrating an
absorption shift of the minima from 218 to 205 nm, and a greatly
reduced maxima 190 nm. This effect possibly arises from the
novel interaction of aromatic and the carboxyl groups induced dur-
ing the heterogeneous molecular packing of the penta- and
hexapeptides [67], providing a means to spectroscopically distin-
guish the co-assembled system from the mixed system.
SAXS modelling of each Fmoc-SAP system provided further evi-
dence that the underlying p-b architecture was maintained during
co-assembly, resulting in the formation of unique, multicompo-
nent nanoﬁbres. Previous SAXS investigation of b-peptide oligo-
mers indicated a good ﬁt to a form factor model of a hollow
cylinder with polydisperse radius to solutions of b-peptide oligo-
mers, suggesting that simple cylindrical models can provide suit-
able ﬁts for b-peptide solutions [68]. High quality ﬁtting to this
model was achieved for each of our Fmoc-SAP systems, aligning
with previously observed model ﬁtting for b-peptide oligomer
solutions [68,69]. However, in our case, high quality ﬁts were
obtained without the need for associated structure factors.
Modelling of each of the Fmoc-SAP systems highlighted key dif-
ferences between each of the assemblies, in particular distinguish-
ing the co-assembled nanoﬁbres from the other Fmoc-SAP systems.
The distinct radial parameters observed for the co-assembled sys-
tem (an increase in radial shell thickness of greater than 75% rela-
tive to the other peptide systems) are likely a result of larger,
alternate packing than the formation of two self-sorted structures,
modelled here by the mixed system [43]. The interaction of the
two differently shaped and charged peptide sequences, requiring
an increase in the radial shell thickness in order to achieve packing
stability. Importantly, this suggests that the two SAPs are incorpo-
rated into a single structure, rather than forming a self-sorted
heterogeneous system consisting of two separate homogeneous
structures that would demonstrate properties closer to those of
the mixed hydrogel [58]. This result supports the rheological mea-
surements, where the co-assembled system was much weaker
than the mixed or the Fmoc-DIKVAV systems, but stronger than
the Fmoc-FRGDF, suggesting a distinct structure composed of the
co-operative individual Fmoc-SAPs. The polydispersity in the cylin-
der (nanoﬁbre) radius provides further conﬁrmation of the forma-
tion of homogenous structures, with polydispersity values ranging
between 0.06 and 0.12 for the single and co-assembled systems,
indicating minimal variation in the cylinder radius along its length.
Fig. 5. (a) FTIR and (b) CD spectra for single, mixed, and co-assembled SAP hydrogels.
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Fig. 6. (a) Scattering data obtained using SAXS for FRGDF (blue) showing various cylindrical models ﬁtted to data including cylinder (green), cylinder with polydisperse radius
(purple), hollow cylinder (black), ﬂexible cylinder (orange) and hollow cylinder with polydisperse radius (red). The hollow cylinder with polydisperse radius is the best ﬁt for
our SAXS data as highlighted in (b) at higher Q values for FRGDF. Similar ﬁts were obtained using this model for (c) DIKVAV, (d) mixed and (e) co-assembled hydrogel systems
(blue = SAXS experimental data; red = hollow cylinder with polydisperse radius model). For all cylindrical model ﬁts for DIKVAV, DIKVAV/FRGDF mixed and co-assembled
systems see Supplementary Fig. 2. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
Fig. 7. DAPI/Rodamine phalloidin staining of C2C12 myoblasts maintained in high glucose DMEM plus 10% FBS at 48 h post seeding onto hydrogels of (a) Fmoc-FRGDF,
(b) Fmoc-DIKVAV, (c) mixed FRGDF-DIKVAV, and (d) co-assembled FRGDF-DIKVAV (scale = 50 lm).
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However, as expected for the mixed system, the polydispersity
value increases to 0.19, suggesting a greater degree of inhomo-
geneity arising from the presence of two separate populations of
ﬁbrils.
C212 cell cultures demonstrated the enhanced bioactivity of the
co-assembled Fmoc-SAP system relative to both the single and the
mixed Fmoc-SAP systems, highlighting the beneﬁt of incorporating
multiple bioactive epitopes into a single nanoﬁbrous network.
C212 cells are known to proliferate as myoblasts but will withdraw
from the cell cycle and fuse to form multinucleated myotubes
under appropriate cell conditions [70]. Laminin-based substrates
have been shown to support proliferation and myogenic differenti-
ation of myoblasts [71], while ﬁbronectin-based substrates have
also demonstrated their ability to drive myogenesis [72]. Our
results demonstrate the afﬁnity of these cells for our laminin-
and ﬁbronectin-based SAP systems, with a clear preference for
the co-assembled Fmoc-SAP system containing both laminin- and
ﬁbronectin-derived epitopes. Importantly, this result also demon-
strates the advantages for the co-assembled SAP system relative
to the mixed SAP system, with clearer gel formation, which has
practical implications for the use of this co-assembled SAP system
in tissue engineering applications.
Together, the results of these characterisation studies demon-
strate the capacity of minimalist Fmoc-SAP systems to undergo
co-assembly. While these results do not offer extensive insight into
the exact molecular mechanisms that enable co-assembly in this
system, we demonstrate, through the incorporation of bioactive
epitopes, our functionalised Fmoc-SAPs offer superior biological
performance in the co-assembled system over both the single
and mixed systems. These results therefore illustrate the potential
for application of co-assembled Fmoc-SAP systems to tissue engi-
neering applications.
The co-assembly of Fmoc-SAPs however, offers additional ben-
eﬁts in the design and control of tissue engineering scaffolds
through modulation of physical parameters. Our results for the
co-assembled FRGDF-DIKVAV indicated gelation behaviour that
lies between its constituent Fmoc-FRGDF and Fmoc-DIKVAV SAPs
indicating a potential mechanism through which the gelation
behaviour of co-assembled Fmoc-SAP systems can be tailored. Sim-
ilarly, the rheological properties for co-assembled FRGDF-DIKVAV
represent an intermediate between the weakest gel, Fmoc-
FRGDF, and the strongest, Fmoc-DIKVAV. This range of material
properties suggests an as yet unidentiﬁed opportunity for control-
ling the stiffness of Fmoc-SAP hydrogels, where the combination of
Fmoc-SAPs in particular ratios (data not shown) could achieve the
tuning required for select tissue engineering applications. Further
modulation of hydrogel properties could be achieved through co-
assembly, with SAXS results indicating an increase in ﬁbre diame-
ter relative to the other SAP systems. This increase in nanoﬁbre
width highlights the potential for co-assembly to permit greater
control over ﬁbril morphology, which has not been previously
attained in other SAP systems. Through altering the relative ratios
of the different SAPs present in the co-assembled system, we can
potentially alter the nanoﬁbre width, allowing us to selectively
tune ﬁbril morphology for tissue-speciﬁc ECMs.
Future studies on co-assembled Fmoc-SAPs can investigate both
the enhanced bioactivity of the system as well as the potential
mechanisms for control of the physical properties of the resultant
hydrogel. For example, recent work on co-assembly in non-
functionalised Fmoc-SAPs has indicated the importance of stabi-
lization offered by neighbouring benzyl groups [52]. Such work
may soon enable further co-assembled systems to be designed
and developed. If successful, such studies could enable tissue engi-
neering scaffolds to be tailored for tissue- or application-speciﬁc
uses, enabling clinicians to select from a library of systems for indi-
vidual patients or conditions.
6. Conclusions
In summary, novel co-assembled Fmoc-SAP systems were
developed with the potential to present multiple bioactive epi-
topes and synergistically provide appropriate physical and chemi-
cal cues for cellular regeneration and repair. We demonstrate that
two signals can be included into a nanoﬁbrillar SAP hydrogel by
mixing two preformed gels, or by co-assembling two distinct SAPs.
In particular, we show for the ﬁrst time the successful co-assembly
of multiple bioactive SAP sequences into a single nanoﬁbre scaf-
fold. This process enables us to produce a tuneable biomaterial that
can include multiple bioactive sequences in precisely deﬁned
ratios. Importantly, the observed increase in the width of the co-
assembled nanoﬁbres demonstrates a potential avenue for the tun-
ing of ﬁbril morphology through the co-assembly of multiple SAP
systems, indicating the capacity for co-assembly to enable tuning
of biomimetic SAP scaffolds to the ECM of particular tissues. This
study similarly demonstrates the distinct biochemical properties
of a co-assembled system for the concomitant presentation of
unique signals to individual muscle precursor cells (C2C12 myo-
blasts) stimulating distinct cellular behaviours with regards to cell
spreading and the formation of elongated, multinucleated
myotube-like structures. This co-assembled system therefore pro-
vides a platform for a tuneable biomimetic material for future
in vitro and in vivo tissue engineering applications.
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